AU2015299173A1 - 2-(morpholin-4-yl)-l,7-naphthyridines - Google Patents
2-(morpholin-4-yl)-l,7-naphthyridinesInfo
- Publication number
- AU2015299173A1 AU2015299173A1 AU2015299173A AU2015299173A AU2015299173A1 AU 2015299173 A1 AU2015299173 A1 AU 2015299173A1 AU 2015299173 A AU2015299173 A AU 2015299173A AU 2015299173 A AU2015299173 A AU 2015299173A AU 2015299173 A1 AU2015299173 A1 AU 2015299173A1
- Authority
- AU
- Australia
- Prior art keywords
- pyrazol
- naphthyridine
- morpholin
- methylmorpholin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C3-C5-cycloalkyl Chemical group 0.000 claims description 464
- 150000001875 compounds Chemical class 0.000 claims description 265
- 239000000203 mixture Substances 0.000 claims description 201
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 188
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 144
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 103
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 101
- 239000001257 hydrogen Substances 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 239000011780 sodium chloride Substances 0.000 claims description 55
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 51
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 39
- 125000001559 cyclopropyl group Chemical compound [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 38
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 38
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 37
- 125000004076 pyridyl group Chemical group 0.000 claims description 37
- 125000001153 fluoro group Chemical group F* 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 35
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 33
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 26
- 125000000335 thiazolyl group Chemical group 0.000 claims description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 24
- 125000003277 amino group Chemical group 0.000 claims description 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 24
- 125000002816 methylsulfanyl group Chemical compound [H]C([H])([H])S[*] 0.000 claims description 24
- 125000001544 thienyl group Chemical group 0.000 claims description 24
- 125000003386 piperidinyl group Chemical group 0.000 claims description 23
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 23
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 21
- 125000004193 piperazinyl group Chemical group 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 125000002883 imidazolyl group Chemical group 0.000 claims description 19
- 125000002971 oxazolyl group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 125000000999 tert-butyl group Chemical compound [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000005842 heteroatoms Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000000069 prophylaxis Effects 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000000959 isobutyl group Chemical compound [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 13
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 12
- 125000000175 2-thienyl group Chemical compound S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 12
- 230000003463 hyperproliferative Effects 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 11
- 150000001204 N-oxides Chemical class 0.000 claims description 11
- 125000004482 piperidin-4-yl group Chemical compound N1CCC(CC1)* 0.000 claims description 11
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 235000019253 formic acid Nutrition 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 230000001085 cytostatic Effects 0.000 claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 5
- 230000001472 cytotoxic Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 239000000546 pharmaceutic aid Substances 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000004177 diethyl group Chemical compound [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000003725 azepanyl group Chemical group 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004497 pyrazol-5-yl group Chemical compound N1N=CC=C1* 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 150000003936 benzamides Chemical compound 0.000 claims 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- 150000002989 phenols Chemical compound 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical compound [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- 125000004800 4-bromophenyl group Chemical compound [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical compound [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 150000001448 anilines Chemical compound 0.000 claims 2
- 150000002466 imines Chemical compound 0.000 claims 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- QRWKOEQJCVOTKP-UHFFFAOYSA-N pyridin-2-amine Chemical compound NC1=C=CC=C[N]1 QRWKOEQJCVOTKP-UHFFFAOYSA-N 0.000 claims 2
- 125000003396 thiol group Chemical compound [H]S* 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical compound NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical compound [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical compound [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- VCGTXINEJSPRPB-LLVKDONJSA-N C[C@H]1N(CCOC1)C1=NC2=C(N=CC=C2C(=C1)C=1C(=NNC=1)C(F)(F)F)C1=CC=NN1 Chemical compound C[C@H]1N(CCOC1)C1=NC2=C(N=CC=C2C(=C1)C=1C(=NNC=1)C(F)(F)F)C1=CC=NN1 VCGTXINEJSPRPB-LLVKDONJSA-N 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- SBGFNEBPRPMVKW-UHFFFAOYSA-N OCC1=C2C=CN=C(C3=CC=NN3)C2=NC(=C1)N1CCOCC1 Chemical compound OCC1=C2C=CN=C(C3=CC=NN3)C2=NC(=C1)N1CCOCC1 SBGFNEBPRPMVKW-UHFFFAOYSA-N 0.000 claims 1
- 150000003869 acetamides Chemical compound 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 150000001912 cyanamides Chemical compound 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000369 oxido group Chemical compound [*]=O 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical compound N1CC(CCC1)* 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical compound N1=CN=CC(=C1)* 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 description 213
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 165
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 133
- 239000000243 solution Substances 0.000 description 96
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 82
- 238000006243 chemical reaction Methods 0.000 description 78
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 67
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 62
- 239000012074 organic phase Substances 0.000 description 61
- 235000019439 ethyl acetate Nutrition 0.000 description 56
- 239000011541 reaction mixture Substances 0.000 description 55
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 53
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 52
- 229940093499 ethyl acetate Drugs 0.000 description 52
- 229910001868 water Inorganic materials 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 50
- 210000004027 cells Anatomy 0.000 description 48
- 239000007787 solid Substances 0.000 description 48
- 230000002829 reduced Effects 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 229910052786 argon Inorganic materials 0.000 description 41
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 34
- 239000000741 silica gel Substances 0.000 description 34
- 229910002027 silica gel Inorganic materials 0.000 description 34
- 239000002904 solvent Substances 0.000 description 33
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 31
- 238000007792 addition Methods 0.000 description 31
- 239000007864 aqueous solution Substances 0.000 description 31
- 229910000024 caesium carbonate Inorganic materials 0.000 description 31
- 239000002585 base Substances 0.000 description 29
- 125000006239 protecting group Chemical group 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 125000004432 carbon atoms Chemical group C* 0.000 description 26
- 230000000875 corresponding Effects 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
- 229910052938 sodium sulfate Inorganic materials 0.000 description 25
- 235000011152 sodium sulphate Nutrition 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 235000017557 sodium bicarbonate Nutrition 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 23
- 238000010626 work up procedure Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 21
- 239000003960 organic solvent Substances 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 20
- 230000001681 protective Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 231100000277 DNA damage Toxicity 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 229910052763 palladium Inorganic materials 0.000 description 16
- 239000004698 Polyethylene (PE) Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 108060006202 ATM Proteins 0.000 description 13
- 102100000648 ATM Human genes 0.000 description 13
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 13
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 13
- 235000015320 potassium carbonate Nutrition 0.000 description 13
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 13
- 230000001131 transforming Effects 0.000 description 13
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 12
- 238000009835 boiling Methods 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000001184 potassium carbonate Substances 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 11
- 150000002430 hydrocarbons Chemical group 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 238000000844 transformation Methods 0.000 description 10
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- 125000004429 atoms Chemical group 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 239000006196 drop Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- KSZMBXHYSQDICN-UHFFFAOYSA-N methyl 3-amino-2-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(Cl)=C1N KSZMBXHYSQDICN-UHFFFAOYSA-N 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 230000002194 synthesizing Effects 0.000 description 8
- 150000003568 thioethers Chemical class 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- 102000001253 Protein Kinases Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000002378 acidificating Effects 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000006555 catalytic reaction Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 230000003000 nontoxic Effects 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000028617 response to DNA damage stimulus Effects 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1H-1,8-naphthyridin-2-one Chemical compound C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 description 6
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 6
- 239000004166 Lanolin Substances 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- 108091000081 Phosphotransferases Proteins 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 150000001642 boronic acid derivatives Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 229920001888 polyacrylic acid Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- PIZNQHDTOZMVBH-UHFFFAOYSA-N thionylimide Chemical compound N=S=O PIZNQHDTOZMVBH-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000008648 triflates Chemical class 0.000 description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 5
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 5
- 102100019730 TP53 Human genes 0.000 description 5
- 101710026335 TP53 Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 150000002366 halogen compounds Chemical class 0.000 description 5
- 239000008079 hexane Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000000155 isotopic Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920001690 polydopamine Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 125000005555 sulfoximide group Chemical group 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- 150000005057 1,7-naphthyridines Chemical class 0.000 description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-Butanol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- 210000001508 Eye Anatomy 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N Pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940032147 Starch Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000006880 cross-coupling reaction Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cells Anatomy 0.000 description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 238000006418 Brown reaction Methods 0.000 description 3
- 102100006400 CSF2 Human genes 0.000 description 3
- 102100006435 CSF3 Human genes 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- 229940052303 Ethers for general anesthesia Drugs 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-Methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001409 amidines Chemical class 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 201000011231 colorectal cancer Diseases 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical class O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000001023 inorganic pigment Substances 0.000 description 3
- 229910000460 iron oxide Inorganic materials 0.000 description 3
- 235000013980 iron oxide Nutrition 0.000 description 3
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000005054 naphthyridines Chemical class 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000001850 reproductive Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- SHXCUQHMQIBOAR-UHFFFAOYSA-N 1,2,3$l^{2}-dioxaborolane Chemical compound [B]1CCOO1 SHXCUQHMQIBOAR-UHFFFAOYSA-N 0.000 description 2
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical group C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 2
- NKYFJZAKUPSUSH-UHFFFAOYSA-N 1-bromo-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(Br)=C1 NKYFJZAKUPSUSH-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 2
- FMKOJHQHASLBPH-OUBTZVSYSA-N 2-iodopropane Chemical compound CC([13CH3])I FMKOJHQHASLBPH-OUBTZVSYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100017902 ATRIP Human genes 0.000 description 2
- 108060000722 ATRIP Proteins 0.000 description 2
- 108010026410 Ado-Trastuzumab Emtansine Proteins 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- 229920002301 Cellulose acetate Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229960002152 Chlorhexidine Acetate Drugs 0.000 description 2
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 229940116364 Hard Fat Drugs 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 206010020243 Hodgkin's disease Diseases 0.000 description 2
- 206010020718 Hyperplasia Diseases 0.000 description 2
- PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 2
- SKRDXYBATCVEMS-UHFFFAOYSA-N Isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 229940039717 Lanolin Drugs 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- CZFNISFYDPIDNM-UHFFFAOYSA-N N,N-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 2
- 229910003813 NRa Inorganic materials 0.000 description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 2
- 101700061400 PRKDC Proteins 0.000 description 2
- 102100003225 PRKDC Human genes 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 229940075579 Propyl Gallate Drugs 0.000 description 2
- 108010027643 Replication Protein A Proteins 0.000 description 2
- 102000018780 Replication Protein A Human genes 0.000 description 2
- 229960005055 SODIUM ASCORBATE Drugs 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 108009000491 Small cell lung cancer Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 229960003885 Sodium Benzoate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 229940075582 Sorbic Acid Drugs 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- NQSIKKSFBQCBSI-UHFFFAOYSA-N Tetrapropylammonium perruthenate Chemical compound [O-][Ru](=O)(=O)=O.CCC[N+](CCC)(CCC)CCC NQSIKKSFBQCBSI-UHFFFAOYSA-N 0.000 description 2
- 240000000280 Theobroma cacao Species 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960002622 Triacetin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 210000001635 Urinary Tract Anatomy 0.000 description 2
- 230000001594 aberrant Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- DRGVLUZIGUIMLB-UHFFFAOYSA-N acetic acid;rhodium Chemical compound [Rh].[Rh].CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O DRGVLUZIGUIMLB-UHFFFAOYSA-N 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000005764 cacao Nutrition 0.000 description 2
- 235000005767 cacao Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 125000005469 ethylenyl group Chemical group 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical class CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic Effects 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960005301 pentazocine Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960001663 sulfanilamide Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 2
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960004906 thiomersal Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 125000005490 tosylate group Chemical group 0.000 description 2
- QCRXMFTZTSTGJM-UHFFFAOYSA-N triacetyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(=O)OC(=O)CC(O)(C(=O)OC(C)=O)CC(=O)OC(C)=O QCRXMFTZTSTGJM-UHFFFAOYSA-N 0.000 description 2
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 description 1
- OUFPJVWVFXZKOX-UHFFFAOYSA-N (2-fluoro-4-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=C(B(O)O)C(F)=C1 OUFPJVWVFXZKOX-UHFFFAOYSA-N 0.000 description 1
- DHQMUJSACXTPEA-UHFFFAOYSA-N (2-methoxypyridin-4-yl)boronic acid Chemical compound COC1=CC(B(O)O)=CC=N1 DHQMUJSACXTPEA-UHFFFAOYSA-N 0.000 description 1
- MSQFFCRGQPVQRS-UHFFFAOYSA-N (2-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1B(O)O MSQFFCRGQPVQRS-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- CATMPQFFVNKDEY-DGCLKSJQSA-N (2R)-2-amino-5-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid Chemical compound C1=CC=C2C(C[C@@H](NC(=O)CC[C@@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-DGCLKSJQSA-N 0.000 description 1
- UELYDGOOJPRWGF-SRQXXRKNSA-N (2R,3R)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol Chemical compound C1=C(C(F)(F)F)C(O[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)[S@](=N)(=O)C2CC2)=N1 UELYDGOOJPRWGF-SRQXXRKNSA-N 0.000 description 1
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2R,3R,4R,5S)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2R,3R,4R,5S)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- VPAWVRUHMJVRHU-VGDKGRGNSA-N (2R,4R)-N,N-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- XXXSJQLZVNKRKX-YQRDHHIGSA-N (2S)-6-amino-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-3-[[2-[2-[(2S,5S,8S,11R,14S,17S)-14-(4-aminobutyl)-5-benzyl-8-[(4-hydroxyphenyl)methyl]-11-(1H-indol-3-ylmethyl)-4-methyl-3,6,9,12,15,18-hexaoxo-17-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl] Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)C(=O)N(C)[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)C(C)C)C1=CC=C(O)C=C1 XXXSJQLZVNKRKX-YQRDHHIGSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 1
- MDKHWJFKHDRFFZ-PHDIDXHHSA-N (3R,5R)-3,5-dimethylmorpholine Chemical compound C[C@@H]1COC[C@@H](C)N1 MDKHWJFKHDRFFZ-PHDIDXHHSA-N 0.000 description 1
- SFWWGMKXCYLZEG-YFKPBYRVSA-N (3S)-3-methylmorpholine Chemical compound C[C@H]1COCCN1 SFWWGMKXCYLZEG-YFKPBYRVSA-N 0.000 description 1
- GDFGTRDCCWFXTG-ZIFCJYIRSA-N (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline Chemical compound C1=CC=C2C[C@H]3N(CCC)C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]3CC2=C1O GDFGTRDCCWFXTG-ZIFCJYIRSA-N 0.000 description 1
- MDKHWJFKHDRFFZ-OLQVQODUSA-N (3S,5R)-3,5-dimethylmorpholine Chemical compound C[C@H]1COC[C@@H](C)N1 MDKHWJFKHDRFFZ-OLQVQODUSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- LMUASBOUSAMURX-UHFFFAOYSA-N (4-ethylsulfanylphenyl)boronic acid Chemical compound CCSC1=CC=C(B(O)O)C=C1 LMUASBOUSAMURX-UHFFFAOYSA-N 0.000 description 1
- FYJDSWBEPMIWEC-UHFFFAOYSA-N (4-propan-2-ylsulfanylphenyl)boronic acid Chemical compound CC(C)SC1=CC=C(B(O)O)C=C1 FYJDSWBEPMIWEC-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
- OBWIRUCBMIYFBP-UHFFFAOYSA-N (6-methylsulfonylpyridin-3-yl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=N1 OBWIRUCBMIYFBP-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- SSNHGLKFJISNTR-FWUPRJFYSA-N (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical class OC1=CC(CCCCC)=CC(O)=C1C1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-FWUPRJFYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
- PCZHWPSNPWAQNF-LMOVPXPDSA-K 2-[[(2S)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron Chemical compound [Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)N(CC(O)=O)CC([O-])=O)C=C1 PCZHWPSNPWAQNF-LMOVPXPDSA-K 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N 2-[[2-[bis(2-hydroxyethyl)amino]-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- QCWJONLQSHEGEJ-UHFFFAOYSA-N 2-[bis(2-ethoxyethyl)phosphanyl]ethyl-bis(2-ethoxyethyl)phosphane Chemical compound CCOCCP(CCOCC)CCP(CCOCC)CCOCC QCWJONLQSHEGEJ-UHFFFAOYSA-N 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- HTIZLJISEUYGSA-UHFFFAOYSA-N 2-chloro-1,8-naphthyridine Chemical class C1=CC=NC2=NC(Cl)=CC=C21 HTIZLJISEUYGSA-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- YHPMRWZVIQTSFZ-UHFFFAOYSA-N 3,5-difluoro-2-(2-fluorophenyl)pyridine Chemical compound FC1=CC(F)=CN=C1C1=CC=CC=C1F YHPMRWZVIQTSFZ-UHFFFAOYSA-N 0.000 description 1
- YVWATSXVUOJOIG-UHFFFAOYSA-N 3,6-dihydro-2H-pyran-4-ylboronic acid Chemical compound OB(O)C1=CCOCC1 YVWATSXVUOJOIG-UHFFFAOYSA-N 0.000 description 1
- XYWJNTOURDMTPI-UHFFFAOYSA-N 3-(1H-benzimidazol-1-ium-2-yl)propanoate Chemical compound C1=CC=C2NC(CCC(=O)O)=NC2=C1 XYWJNTOURDMTPI-UHFFFAOYSA-N 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N 3-(3-methylsulfonyloxypropylamino)propyl methanesulfonate Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- TYEXNVNUZXJNBN-YYADALCUSA-N 3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid Chemical compound O=C1C(N\N=C/2C(C(=CC=C\2)C=2C=C(C=CC=2)C(O)=O)=O)=C(C)NN1C1=CC=C(C)C(C)=C1 TYEXNVNUZXJNBN-YYADALCUSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- CURYRIVJTBNEGU-UHFFFAOYSA-L 3-bromo-1-[12-(3-bromopropanoyl)-3,12-diaza-6,9-diazoniadispiro[5.2.5^{9}.2^{6}]hexadecan-3-yl]propan-1-one;dichloride Chemical compound [Cl-].[Cl-].C1CN(C(=O)CCBr)CC[N+]21CC[N+]1(CCN(CC1)C(=O)CCBr)CC2 CURYRIVJTBNEGU-UHFFFAOYSA-L 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- ICPOKTZORRQGLK-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group C[C](C)C=C ICPOKTZORRQGLK-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- BDOSWBBKOSGKAV-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(S(C)(=O)=O)C=C1 BDOSWBBKOSGKAV-UHFFFAOYSA-N 0.000 description 1
- KKLCYBZPQDOFQK-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1 KKLCYBZPQDOFQK-UHFFFAOYSA-N 0.000 description 1
- IZMZHRJBBYCHOO-UHFFFAOYSA-N 4,5-didehydro-3H-thiophene Chemical group [CH]1CC#CS1 IZMZHRJBBYCHOO-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- GKEOOUFCVWEWHA-UHFFFAOYSA-N 4-chloro-1,6-naphthyridine Chemical compound C1=NC=C2C(Cl)=CC=NC2=C1 GKEOOUFCVWEWHA-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N 5-Chloro-6-[(2-Iminopyrrolidin-1-Yl)Methyl]Pyrimidine-2,4(1h,3h)-Dione Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N 5-chloro-4-hydroxy-1H-pyridin-2-one Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 101710036216 ATEG_03556 Proteins 0.000 description 1
- 108009000368 ATR Signaling Proteins 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 229960001686 Afatinib Drugs 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229960004343 Alendronic acid Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229940043215 Aminolevulinate Drugs 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anethole trithione Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 229950006323 Angiotensin ii Drugs 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 229960005348 Antithrombin III Drugs 0.000 description 1
- 108090000935 Antithrombin-III Proteins 0.000 description 1
- 102000004411 Antithrombin-III Human genes 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229950005725 Arcitumomab Drugs 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N Arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N BBR-2778 Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 108010067213 Basiliximab Proteins 0.000 description 1
- 229950011276 Belotecan Drugs 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N Belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N Bis(trimethylsilyl)amine Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N Bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 108010013795 Brentuximab Vedotin Proteins 0.000 description 1
- 229960000455 Brentuximab vedotin Drugs 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- DMFGMZOCUXJFAO-UHFFFAOYSA-N CC1(OB(OC1(C)C)C1=CC(=CC=C1)S(=O)(=NC(=O)OCC)C)C Chemical compound CC1(OB(OC1(C)C)C1=CC(=CC=C1)S(=O)(=NC(=O)OCC)C)C DMFGMZOCUXJFAO-UHFFFAOYSA-N 0.000 description 1
- NIDVAWNDFBVEDZ-UHFFFAOYSA-N CC1(OB(OC1(C)C)C1=CC=C(C=C1)S(=O)(=NC(=O)OCC)C)C Chemical compound CC1(OB(OC1(C)C)C1=CC=C(C=C1)S(=O)(=NC(=O)OCC)C)C NIDVAWNDFBVEDZ-UHFFFAOYSA-N 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- 108060006647 CHEK2 Proteins 0.000 description 1
- MHNNVDILNTUWNS-XYYAHUGASA-N CHEMBL2104994 Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 description 1
- 101700030325 CHKB Proteins 0.000 description 1
- 102100016705 COL18A1 Human genes 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N Cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 229960001921 Calcium levofolinate Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229950001178 Capromab Drugs 0.000 description 1
- 229940105305 Carbon Monoxide Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000010027 Carcinoma, Intraductal, Noninfiltrating Diseases 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229950001357 Celmoleukin Drugs 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FLASNYPZGWUPSU-SICDJOISSA-N Chitosan Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H](O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](N)[C@H]2O)CO)[C@H](N)[C@H]1O)CO)NC(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N FLASNYPZGWUPSU-SICDJOISSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N Chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 229960000724 Cidofovir Drugs 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovirum Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229950002550 Copanlisib Drugs 0.000 description 1
- 229950006799 Crisantaspase Drugs 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N Cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N DME dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N Degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960002272 Degarelix Drugs 0.000 description 1
- 108010043242 Denosumab Proteins 0.000 description 1
- 229950010726 Depreotide Drugs 0.000 description 1
- 229960000605 Dexrazoxane Drugs 0.000 description 1
- 229950000758 Dianhydrogalactitol Drugs 0.000 description 1
- 229950007457 Dibrospidium Chloride Drugs 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N Diethyl sulfate Chemical group CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N Dimethyl sulfate Chemical group COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- 229950000549 Elliptinium acetate Drugs 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 229950011487 Enocitabine Drugs 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N Enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 229950002973 Epitiostanol Drugs 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 229960003388 Epoetin alfa Drugs 0.000 description 1
- 229950005185 Epoetin zeta Drugs 0.000 description 1
- 229950006835 Eptaplatin Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960003399 Estrone Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 229950011548 FADROZOLE Drugs 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960002258 Fulvestrant Drugs 0.000 description 1
- 230000035521 G2 Phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229960003823 Gadoteric acid Drugs 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K Gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- HBEAOBRDTOXWRZ-UHFFFAOYSA-K Gadoversetamide Chemical compound [Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC HBEAOBRDTOXWRZ-UHFFFAOYSA-K 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 108010091266 Gemtuzumab Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 Granisetron Drugs 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Hiestrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 229960004931 Histamine Dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N Histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N Homoharringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N Hydrazoic acid Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- 102100005044 IL11 Human genes 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 229950006971 Incadronic acid Drugs 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N Incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- VDJHFHXMUKFKET-WDUFCVPESA-N Ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229950000038 Interferon alfa Drugs 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 229960001388 Interferon-beta Drugs 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- YLPBXIKWXNRACS-UHFFFAOYSA-N Iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N Iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 241001397173 Kali <angiosperm> Species 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 210000001117 Keloid Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000000244 Kidney Pelvis Anatomy 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N L-Histidyl-L-seryl-L-a-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-a-glutamylglycyl -L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leu Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N Lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N Lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 229960003918 Levothyroxine Sodium Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100000918 MAPK14 Human genes 0.000 description 1
- 101710026141 MIH1 Proteins 0.000 description 1
- 229950010718 MOPIDAMOL Drugs 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 229960003951 Masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 229950009246 Mepitiostane Drugs 0.000 description 1
- 229960004635 Mesna Drugs 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229960004469 Methoxsalen Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950004962 Miriplatin Drugs 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
- 229950007699 Mogamulizumab Drugs 0.000 description 1
- 229960004715 Morphine Sulfate Drugs 0.000 description 1
- 229960005195 Morphine hydrochloride Drugs 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N N',N'-dimethyl-N-(1-nitroacridin-9-yl)propane-1,3-diamine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N N,N-dimethyl-2H-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- LXCIHXPVYQKJAG-UHFFFAOYSA-N N-[aziridin-1-yl-(2-methylaziridin-1-yl)phosphoryl]-N-prop-2-enylprop-2-en-1-amine Chemical compound CC1CN1P(=O)(N(CC=C)CC=C)N1CC1 LXCIHXPVYQKJAG-UHFFFAOYSA-N 0.000 description 1
- USVVENVKYJZFMW-UHFFFAOYSA-L N-carboxylatoiminocarbamate Chemical compound [O-]C(=O)N=NC([O-])=O USVVENVKYJZFMW-UHFFFAOYSA-L 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N Nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 Naltrexone Drugs 0.000 description 1
- 229950010676 Nartograstim Drugs 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 229950007221 Nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960004918 Nimorazole Drugs 0.000 description 1
- MDJFHRLTPRPZLY-UHFFFAOYSA-N Nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
- 229950010203 Nimotuzumab Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N Nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010019706 Nivolumab Proteins 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000261 Non-homologous end joining Proteins 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 229960004534 ORGOTEIN Drugs 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229960002450 Ofatumumab Drugs 0.000 description 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229950001550 Orilotimod Drugs 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 229950000193 Oteracil Drugs 0.000 description 1
- 206010063834 Oversensing Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N Oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 229960002404 Palifermin Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N Palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- GRHYHJAAOJVRSZ-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2N=C3[CH]C(OC(F)F)=CC=C3N=2)=C1OC GRHYHJAAOJVRSZ-UHFFFAOYSA-N 0.000 description 1
- 229960001373 Pegfilgrastim Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N Pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 229950003332 Perflubutane Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N Perfluorobutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229950009351 Perfosfamide Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N Phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N Phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 229960004403 Pixantrone Drugs 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N Plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 Plerixafor Drugs 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 101700030467 Pol Proteins 0.000 description 1
- 229950008282 Poliglusam Drugs 0.000 description 1
- 229920000081 Polyestradiol phosphate Polymers 0.000 description 1
- 229960001298 Polyestradiol phosphate Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960004293 Porfimer Sodium Drugs 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N Pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- SXTZYIWTRUTYCY-UHFFFAOYSA-N Rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2N=C3[CH]C=CC=C3N=2)=C1C SXTZYIWTRUTYCY-UHFFFAOYSA-N 0.000 description 1
- 229950011613 Racotumomab Drugs 0.000 description 1
- 229950004043 Radotinib Drugs 0.000 description 1
- 239000005464 Radotinib Substances 0.000 description 1
- DUPWHXBITIZIKZ-UHFFFAOYSA-N Radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 229950008933 Refametinib Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 230000036191 S Phase Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102100001186 SCT Human genes 0.000 description 1
- 229950001403 SIZOFIRAN Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229940043230 Sarcosine Drugs 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229950007308 Satumomab Drugs 0.000 description 1
- 229960002101 Secretin Drugs 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 229940010747 Sodium Hyaluronate Drugs 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229960000912 Stanozolol Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N Sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 102100020224 TACR3 Human genes 0.000 description 1
- 101710026034 TACR3 Proteins 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N Tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N Tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 229960003102 Tasonermin Drugs 0.000 description 1
- 229950001699 Teceleukin Drugs 0.000 description 1
- 229950000864 Technetium (99mTc) nofetumomab merpentan Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- 229960004113 Tetrofosmin Drugs 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N Thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 108010066702 Thyrotropin Alfa Proteins 0.000 description 1
- 229960003087 Tioguanine Drugs 0.000 description 1
- 229960002952 Tipiracil Drugs 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960004380 Tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960003962 Trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- GCPXMJHSNVMWNM-UHFFFAOYSA-N Trihydroxyarsenite(Iii) Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N Trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N Trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N Trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N Vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N XANTHOTOXIN Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Yamafur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 229950009233 Zinostatin stimalamer Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N Zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- YCPOZVAOBBQLRI-PHDIDXHHSA-N [(2R,3R)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-PHDIDXHHSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4R,5R)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl-oxo-[1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 229940089792 ado-trastuzumab emtansine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 229960002616 ancestim Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 108091004612 arcitumomab Proteins 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- NHHWJSXMTZIPES-UHFFFAOYSA-N bistriflylimide anion Chemical compound FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F NHHWJSXMTZIPES-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- 229960005331 calcium folinate Drugs 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960003996 chlormadinone Drugs 0.000 description 1
- 229960001411 chlormethine Drugs 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- LRCTTYSATZVTRI-UHFFFAOYSA-L cyclohexane-1,2-diamine;platinum(4+);tetradecanoate Chemical compound [Pt+4].NC1CCCCC1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O LRCTTYSATZVTRI-UHFFFAOYSA-L 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- JQUMOJMZTXDLIN-UHFFFAOYSA-N dilithium;butane Chemical compound [Li+].[Li+].CCC[CH2-].CCC[CH2-] JQUMOJMZTXDLIN-UHFFFAOYSA-N 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- DRFILBXQKYDTFW-JIWRMXRASA-L disodium;2-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxylatomethylamino)-3-oxopropyl]disulfanyl]propanoyl]amino]acetate Chemical compound [Na+].[Na+].OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC([O-])=O)CSSC[C@@H](C(=O)NCC([O-])=O)NC(=O)CC[C@H](N)C(O)=O DRFILBXQKYDTFW-JIWRMXRASA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 108010063231 eculizumab Proteins 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950007539 elliptinium Drugs 0.000 description 1
- 229960001069 eltrombopag Drugs 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 229960004579 epoetin beta Drugs 0.000 description 1
- 108010002601 epoetin beta Proteins 0.000 description 1
- 108010030868 epoetin zeta Proteins 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- BARDROPHSZEBKC-OITMNORJSA-N fosaprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NC(=O)N(P(O)(O)=O)N1 BARDROPHSZEBKC-OITMNORJSA-N 0.000 description 1
- 229960002891 fosaprepitant Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZPDFIIGFYAHNSK-YYLIZZNMSA-K gadobutrol Chemical compound C1C[N+]2(CC([O-])=O)CC[N+]3(CC([O-])=O)CC[N+]4([C@@H](CO)[C@@H](O)CO)[Gd-]32[N+]1(CC([O-])=O)CC4 ZPDFIIGFYAHNSK-YYLIZZNMSA-K 0.000 description 1
- 229960003411 gadobutrol Drugs 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- 229960002059 gadoversetamide Drugs 0.000 description 1
- 229960001547 gadoxetic acid Drugs 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004859 glucarpidase Drugs 0.000 description 1
- 108010049491 glucarpidase Proteins 0.000 description 1
- 108010068227 glutoxim Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 239000002815 homogeneous catalyst Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 108010061572 ibritumomab tiuxetan Proteins 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229950007467 indisetron Drugs 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 229960002993 ingenol mebutate Drugs 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 201000008255 invasive lobular carcinoma Diseases 0.000 description 1
- 229960003795 iobenguane (123I) Drugs 0.000 description 1
- 229960004108 iobitridol Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950001783 levofolinic acid Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 229960005033 methyl aminolevulinate Drugs 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960001980 metirosine Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010007997 mogamulizumab Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- XCKKIKBIPZJUET-VYKNHSEDSA-N morphine hydrochloride Chemical compound Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XCKKIKBIPZJUET-VYKNHSEDSA-N 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- LSNOAQQZECGQNS-UHFFFAOYSA-N morpholine-2-carboxamide Chemical compound NC(=O)C1CNCCO1 LSNOAQQZECGQNS-UHFFFAOYSA-N 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 108010043585 nimotuzumab Proteins 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 108010045555 obinutuzumab Proteins 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 108010052070 ofatumumab Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010026276 pembrolizumab Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 108010042024 pertuzumab Proteins 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 201000008199 pleuropulmonary blastoma Diseases 0.000 description 1
- 229940034049 polysaccharide-K Drugs 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960000214 pralatrexate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229950000989 procodazole Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000005470 propylenyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 229960000924 quinagolide Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- 108010020302 racotumomab Proteins 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 108010026911 ramucirumab Proteins 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001846 repelling Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 101710004466 rgy Proteins 0.000 description 1
- 101710030364 rgy1 Proteins 0.000 description 1
- 101710030359 rgy2 Proteins 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 229950002433 roniciclib Drugs 0.000 description 1
- 229960003021 samarium (153Sm) lexidronam Drugs 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-F samarium-153(3+);N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine Chemical compound [153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-F 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950002350 secretin human Drugs 0.000 description 1
- 229960000714 sipuleucel-T Drugs 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JMHCCAYJTTWMCX-QWPJCUCISA-M sodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 JMHCCAYJTTWMCX-QWPJCUCISA-M 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- SARBMGXGWXCXFW-GJHVZSAVSA-M sodium;2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl [(2R)-2,3-di(hexadecanoyloxy)propyl] phosphate;hydrate Chemical compound O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O SARBMGXGWXCXFW-GJHVZSAVSA-M 0.000 description 1
- FWYUJENICVGSJH-UHFFFAOYSA-M sodium;2-[bis[2-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]-2-oxoethyl]amino]acetate Chemical compound [Na+].CC1=NC=C([N+]([O-])=O)N1CCOC(=O)CN(CC([O-])=O)CC(=O)OCCN1C([N+]([O-])=O)=CN=C1C FWYUJENICVGSJH-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- 229950010130 tamibarotene Drugs 0.000 description 1
- 229960005126 tapentadol Drugs 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 108010072399 technetium Tc 99m-nofetumomab merpentan Proteins 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 229960000902 thyrotropin alfa Drugs 0.000 description 1
- 108010078548 tocilizumab Proteins 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940026752 topical Sulfonamides Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- PUMSLVXNEXVCIC-UHFFFAOYSA-N tributyl(prop-1-en-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C(C)=C PUMSLVXNEXVCIC-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 101700070144 tyr-3 Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Description
2-(Morpholin-4-yl)-l,7-naphthyridines
Field of application of the invention
The invention relates to substituted 2-(morpholin-4-yl)-l,7-naphthyridine compounds, a process for their production and the use thereof.
BACKGROUND OF THE INVENTION The integrity of the genome of eukaryotic cells is secured by complex signaling pathways, referred to as the DNA damage response (DDR), and multiple DNA repair mechanisms. Upon recognizing DNA damage activation of the DDR pathways results in cell cycle arrest, suppression of general translation, induction of DNA repair, and, finally, in cell survival or cell death. Proteins that directly recognize aberrant DNA structures, such as the MRE11-Rad50-Nbsl complex recognizing DNA double strand breaks by binding to double-stranded DNA ends, or RPA (replication protein A) binding to single stranded DNA, recruit and activate the most upstream kinases of the DDR pathway, ATM (ataxia-telangiectasia mutated), ATR (ATM-and Rad3-related, UniProtKB/Swiss- Prot Q13535), and DNA-PKcs (DNA-dependent protein kinase). Whereas ATM is primarily activated by DNA double strand breaks, and DNA-PKcs is mainly involved in non-homologous end joining process of DNA repair, ATR responds to a broad spectrum of DNA damage, including double-strand breaks and lesions derived from interference with DNA replication. Major components of downstream signaling of ATM include Chk2 and p53, whereas ATR signaling involves Chkl and cdc25. Knockout of the ATR gene in mice is embryonically lethal and ATR knockout cells develop chromosome breaks and undergo apoptosis [E.J. Brown, D. Baltimore: ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14,
397-402, 2000]. In contrast, ATM is not essential for cell survival although ATM knockout cells are hypersensitive to ionizing radiation and agents which cause DNA double-strand breaks.
ATR, which forms a complex with ATRIP (ATR-interacting protein, UniProtKB/Swiss-Prot Q8WXE1) is mainly activated by long stretches of single-stranded DNA which are generated by the
continuing DNA unwinding activity of helicases upon stalled replication. This replication stress with stalled replication forks may be induced by ultraviolet light, certain chemotherapeutic drugs, hydroxyurea, or aberrant oncogenic signaling resulting in increased replication initiation or origin firing. Activation of ATR results in inhibition of the cell cycle in S or G2 phase via the Chkl-cdc25 pathway and in suppression of late origin firing. The cell gains time to resolve the replication stress and, eventually, to restart replication after the source of stress has been removed. As the ATR pathway ensures cell survival after replication stress it potentially contributes to resistance to chemotherapy. Thus inhibition of ATR kinase activity could be useful for cancer treatment.
In oncogene-driven tumor cells (e.g. Ras mutation/upregulation, Myc upregulation, CyclinE overexpression) increased replication stress has been observed as compared to healthy normal cells. ATR suppression in Ras oncogene driven cells was reported to result in substantial tumor cell killing [O. Gilad, BY Nabet, et al.: Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 70, 9693-9702, 2010]. Although ATM and ATR are principally activated by different types of DNA damage their signaling includes some cross-talk thus that they can, at least partially, substitute for each others function. This finding suggests some tumor-cell selectivity of pharmaceutical inhibition of ATR. A healthy normal cell, which has ATM and ATR pathways in parallel, arrests in Gl phase of the cell cycle upon induced DNA damage even in presence of an ATR inhibitor. In contrast, a tumor cell which most often deficient in ATM and/or p53 signaling relies on the ATR pathway and undergoes cell death in presence of an ATR inhibitor. This suggests that ATR inhibitors may be used for the treatment of tumors with deficient ATM signaling and/or p53 function.
Details of DDR signaling and the functional role of ATM and ATR were recently reviewed in: E.
Fokas, R. Prevo et al.: Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treatment Rev 40, 109-117, 2014. J.M. Wagner & S.H. Kaufmann: Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals 3, 1311-1334, 2010. D. Woods & J.J. Tuchi:
Chemotherapy induced DNA damage response. Cancer Biol. Thera. 14, 379-389, 2013. A.
Marechal & L. Zou: DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect.
Biol. 5, a012716, 2013. M.K. Zeman & K.A. Cimprich: Causes and consequences of replication stress. Nat. Cell Biol. 16, 2-9, 2014. S. Llona-Minguez, A. Hoglund et al.: Chemical strategies for development of ATR inhibitors. Exp. Rev. Mol. Med. 16, elO, 2014.
Some inhibitors of ATR kinase are known (J. Med. Chem. 2013, 56, 2125-2138; Exp. Rev. Mol.
Med. 16, elO, 2014; WO2010054398A1; WO2010071837A1; WO2010073034A1;
WO2011143399A1; WO2011143419A1; WO2011143422A1; WO2011143423A2;
WO2011143425A2; WO2011143426A1; WO2011154737A1; WO2011163527A1;
WO2012138938A1; WO2012178123A1; WO2012178124A1; WO2012178125A1;
WO2013049719A1; WO2013049720A1; WO2013049722A1; WO2013049859A1;
WO2013071085A1; WO2013071088A1; WO2013071090A1; WO2013071093A1;
WO2013071094A1; WO2013152298A1; WO2014062604A1; WO2014089379A1;
WO2014143240).
WO 0058307 describe aryl fused 2,4-disubstituted pyridines as NK3 receptor ligands. However, no 1,7-naphthyridine compounds are exemplified.
WO 2006039718 describe aryl nitrogen-containing bicyclic compounds for the prophylaxis and treatment of protein kinase mediated diseases. However, no 1,7-naphthyridine compounds are exemplified.
WO 2008017461 and the Journal of Medicinal Chemistry 2011, 54(22), 7899-7910 describe 1,7- naphthyridine derivatives as p38 MAP kinase inhibitors. The 8-position of the 1,7-naphthyridine derivatives is substituted with a phenyl ring. No 1,7-naphthyridine compounds are exemplified, which are substituted with a heteroaryl group in the 8-position of the 1,7-naphthyridine.
There is a need for the development of AT inhibitors for treating diseases, in particular hyperproliferative diseases. The problem to be solved by the present invention is to provide further compounds which inhibit ATR. It was found, surprisingly, that 2-(Morpholin-4-yl)-l,7- naphthyridines of general formula (I) or (lb) inhibit ATR.
In accordance with a first aspect, the present invention covers compounds of general formula (I)
(I) in which:
represents a group selected from
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C6-alkenyl, C3-C6-cycloalkyl, 3- to 10-membered heterocycloalkyl,
4- to 10-membered heterocycloal kenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)N R7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10,
-SiR10R R12, -(PO)(OR7)2, -(PO)(OR7)R10 0r -(PO)(R10)2,
wherein each Ci-C6-alkyl, Ci-C6-alkoxy, 3- to 10-membered heterocycloal koxy, C2-C6- alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-C6-alkyl optionally substituted one or more times with hydroxyl or phenyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, C3-C5-cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, -NR8(CO)OR7,
-N R8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10,
-N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, _(po)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl;
wherein each 4- to 10-membered heterocycloal kenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl; R3, R4 represent, independently from each other, hydrogen or methyl;
R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, C3-C6-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen; or
R7 and R8 together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci-C6-alkyl, Ci-C6-haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S; represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally
substituted, one or more times, independently from each other, with R13; R10 represents Ci-C4-alkyl; or
R9 and R10 together, in case of -N=(SO)R9R10 group, represent a 5- to 8-membered
heterocycloalkyl group; R11 represents hydrogen, Ci-C4-alkyl, -(CO)OR7, -(CO)NR7R8 or CN;
R12 represents hydrogen or Ci-C4-alkyl;
R13 represents halogen, OH, -NR7R8, CN, N02, Ci-Ce-alkyl, Ci-C5-haloalkyl, Ci-C5-alkoxy, Ci-C5- haloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, -(CO)OR7 or -(CO)NR7R8;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
The terms as mentioned in the present text have the following meanings:
The term "halogen atom", "halo-" or "Hal-" is to be understood as meaning a fluorine, chlorine, bromine or iodine atom.
The term "Ci-C6-alkyl" is to be understood as meaning a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms, e.g. a methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, 2-methylbutyl, 1- methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neo-pentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl group, or an isomer thereof. Particularly, said group has 1, 2, 3 or 4 carbon atoms ("Ci-C4-alkyl"), e.g. a methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl group, more particularly 1, 2 or 3 carbon atoms ("Ci-C3-alkyl"), e.g. a methyl, ethyl, n-propyl or iso-propyl group.
The term "Ci-C6-haloalkyl" is to be understood as meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "Ci-C6-alkyl" is defined supra, and in which one or more hydrogen atoms is replaced by a halogen atom, in identically or differently, i.e. one halogen atom being independent from another. Particularly, said halogen atom is F. Said Ci-C6- haloalkyl group is, for example, -CF3, -CHF2, -CH2F, -CF2CF3 or -CH2CF3.
The term "Ci-C4-hydroxyal kyl" is to be understood as meaning a linear or branched, saturated,
monovalent hydrocarbon group in which the term "Ci-C4-alkyl" is defined supra, and in which one or more hydrogen atoms is replaced by a hydroxy group, e.g. a hydroxymethyl, 1-hydroxyethyl, 2- hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 2,3-dihydroxypropyl, 1,3- dihydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, l-hydroxy-2- methyl-propyl group.
The term "Ci-C6-alkoxy" is to be understood as meaning a linear or branched, saturated, monovalent, hydrocarbon group of formula -O-alkyl, in which the term "alkyl" is defined supra, e.g. a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, iso-pentoxy, or n-hexoxy group, or an isomer thereof. Particularly, said "Ci-C6-alkoxy" can contain 1, 2, 3, 4 or 5 carbon atoms, (a "Ci-C5-alkoxy"), preferably 1, 2, 3 or 4 carbon atoms ("Ci-Gralkoxy").
The term "Ci-C5-haloalkoxy" is to be understood as meaning a linear or branched, saturated, monovalent Ci-C6-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom. Particularly, said halogen atom is F. Said Ci-Ce-haloalkoxy group is, for example, -OCF3, -OCHF2, -OCH2F, -OCF2CF3, or -OCH2CF3.
The term "C2-C6-alkenyl" is to be understood as meaning a linear or branched, monovalent hydrocarbon group, which contains one or more double bonds, and which has 2, 3, 4, 5 or 6 carbon atoms or 2, 3 or 4 carbon atoms ("C2-C4-alkenyl), particularly 2 or 3 carbon atoms ("C2-C3- alkenyl"), it being understood that in the case in which said alkenyl group contains more than one double bond, then said double bonds may be isolated from, or conjugated with, each other. Said alkenyl group is, for example, a vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (E)-but- 2-enyl, (Z)-but-2-enyl, (E)-but-l-enyl, (Z)-but-l-enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (E)-pent-l-enyl, (Z)-pent-l-enyl, hex-5-enyl, (E)-hex-4-enyl, (Z)- hex-4-enyl, (E)-hex-3-enyl, (Z)-hex-3-enyl, (E)-hex-2-enyl, (Z)-hex-2-enyl, (E)-hex-l-enyl, (Z)-hex-l- enyl, isopropenyl, 2-methylprop-2-enyl, l-methylprop-2-enyl, 2-methylprop-l-enyl, (E)-l- methylprop-l-enyl, (Z)-l-methylprop-l-enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1- methylbut-3-enyl, 3-methylbut-2-enyl, (E)-2-methylbut-2-enyl, (Z)-2-methylbut-2-enyl, (E)-l- methylbut-2-enyl, (Z)-l-methylbut-2-enyl, (E)-3-methylbut-l-enyl, (Z)-3-methylbut-l-enyl, (E)-2- methylbut-l-enyl, (Z)-2-methylbut-l-enyl, (E)-l-methylbut-l-enyl, (Z)-l-methylbut-l-enyl, 1,1- dimethylprop-2-enyl, 1-ethylprop-l-enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3- methylpent-4-enyl, 2-methylpent-4-enyl, l-methylpent-4-enyl, 4-methylpent-3-enyl, (E)-3- methylpent-3-enyl, (Z)-3-methylpent-3-enyl, (E)-2-methylpent-3-enyl, (Z)-2-methylpent-3-enyl,
(E)-l-methylpent-3-enyl, (Z)-l-methylpent-3-enyl, (E)-4-methylpent-2-enyl, (Z)-4-methylpent-2- enyl, (E)-3-methylpent-2-enyl, (Z)-3-methylpent-2-enyl, (E)-2-methylpent-2-enyl, (Z)-2- methylpent-2-enyl, (E)-l-methylpent-2-enyl, (Z)-l-methylpent-2-enyl, (E)-4-methylpent-l-enyl, (Z)-4-methylpent-l-enyl, (E)-3-methylpent-l-enyl, (Z)-3-methylpent-l-enyl, (E)-2-methylpent-l- enyl, (Z)-2-methylpent-l-enyl, (E)-l-methylpent-l-enyl, (Z)-l-methylpent-l-enyl, 3-ethylbut-3- enyl, 2-ethylbut-3-enyl, l-ethylbut-3-enyl, (E)-3-ethylbut-2-enyl, (Z)-3-ethylbut-2-enyl, (E)-2- ethylbut-2-enyl, (Z)-2-ethylbut-2-enyl, (E)-l-ethyl but-2-enyl, (Z)-l-ethylbut-2-enyl, (E)-3-ethylbut-
1- enyl, (Z)-3-ethylbut-l-enyl, 2-ethylbut-l-enyl, (E)-l-ethylbut-l-enyl, (Z)-l-ethylbut-l-enyl, 2- propylprop-2-enyl, l-propylprop-2-enyl, 2-isopropyl prop-2-enyl, l-isopropylprop-2-enyl, (E)-2- propylprop-l-enyl, (Z)-2-propylprop-l-enyl, (E)-l-propylprop-l-enyl, (Z)-l-propylprop-l-enyl, (E)-
2- isopropylprop-l-enyl, (Z)-2-isopropylprop-l-enyl, (E)-l-isopropylprop-l-enyl, (Z)-l- isopropylprop-l-enyl, (E)-3,3-dimethylprop-l-enyl, (Z)-3;3-dimethylprop-l-enyl, 1-(1,1- dimethylethyl)ethenyl, buta-l,3-dienyl, penta-l,4-dienyl, hexa-l,5-dienyl, or methylhexadienyl group. Particularly, said group is vinyl or allyl. The term "C3-Ci0-cycloalkyl" is to be understood as meaning a saturated, monovalent, mono-, or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms ("C3-Ci0-cycloalkyl"). Said C3-Ci0-cycloalkyl group is for example, a monocycl ic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon ring, e.g. a perhydropentalenylene or decalin ring. Particularly, said ring contains 3, 4, 5 or 6 carbon atoms ("C3-C5-cycloalkyl"), preferably cyclopropyl.
The term "3- to 10-membered heterocycloalkyi" is to be understood as meaning a saturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from C(=0), O, S, S(=0), S(=0)2, N a, in which Ra represents a hydrogen atom, or a Ci-C6-alkyl or Ci-C6-haloalkyl group ; it being possible for said heterocycloalkyi group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom.
Particularly, said 3- to 10-membered heterocycloalkyi can contain 2, 3, 4, or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "3- to 6-membered heterocycloalkyi"), more particularly said heterocycloalkyi can contain 4 or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "5- to 6-membered heterocycloalkyi").
Particularly, without being limited thereto, said heterocycloalkyi can be a 4-membered ring, such
as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, or a 6-membered ring, such as
tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl, or a 7-membered ring, such as a diazepanyl ring, for example. Optionally, said heterocycloal kyi can be benzo fused. Preferably, the 3- to 6-membered heterocycloalkyi is a tetrahydrofuranyl, tetrahydropyranyl or piperazinyl.
Said heterocycloalkyi can be bicyclic, such as, without being limited thereto, a 5, 5-membered ring, e.g. a hexahydrocyclopenta[c] pyrrol-2(lH)-yl ring, or a 5, 6-membered bicyclic ring, e.g. a hexahydropyrrolo[l,2-a]pyrazin-2(lH)-yl ring. As mentioned supra, said nitrogen atom-containing ring can be partial ly unsaturated, i.e. it can contain one or more double bonds, such as, without being limited thereto, a 2,5-dihydro-lH- pyrrolyl, 4H-[l,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[l,4]thiazinyl ring, for example, or, it may be benzo-fused, such as, without being limited thereto, a dihydroisoquinolinyl ring, for example. The term "3- to 10-membered heterocycloalkoxy" of formula -O-heterocycloalkyl, in which the term "heterocycloalkyi" is defined supra, is to be understood as meaning a saturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from C(=0), O, S, S(=0), S(=0)2, NRa, in which Ra represents a hydrogen atom, a Ci-C6-alkyl or Ci-C6-haloalkyl group and which is connected to the rest of the molecule via an oxygen atom, e.g. a pyrrolidineoxy,
tetrahydrofuraneoxy or tetrahydropyranoxy.
The term "4- to 10-membered heterocycloalkenyl" is to be understood as meaning an unsaturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from C(=0), O, S, S(=0), S(=0)2, NRa, in which Ra represents a hydrogen atom, or a Ci-C5-alkyl or Ci-Ce-haloalkyl group ; it being possible for said heterocycloalkenyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Examples of said heterocycloalkenyl may contain one or more double bonds, e.g. 4H-pyranyl, 2H-pyranyl, 3,6-dihydro-2H-pyran-4-yl, 3,6-dihydro-2H-thiopyran-4-yl, l,2,3,6-tetrahydropyridin-4-yl, 3H-diazirinyl, 2,5-dihydro-lH- pyrrolyl, [l,3]dioxolyl, 4H-[l,3,4]thiadiazinyl, 2,5-dihydrofuranyl, 2,3-dihydrofuranyl, 2,5- dihydrothiophenyl, 2,3-dihydrothiophenyl, 4,5-dihydrooxazolyl, 4H-[l,4]thiazinyl or 5,6- dihydroimidazo[l,2-a]pyrazin-7(8H)-yl group or it may be benzo fused.
The term "heteroaryl" is understood as meaning a monovalent, monocyclic- , bicyclic- or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms (a "5- to 14-membered heteroaryl" group), 5 or 6 or 9 or 10 ring atoms (a "5- to 10-membered heteroaryl" group) or particularly 5 or 6 ring atoms ("5- to 6-membered heteroaryl" group), and which contains at least one heteroatom which may be identical or different, said heteroatom being such as oxygen, nitrogen or sulfur, and in addition in each case can be benzocondensed. Particularly, heteroaryl is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl etc., and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, etc.; or azocinyl, indolizinyl, purinyl, etc., and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthpyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl, oxepinyl or lH-pyrrolo[2,3-b]pyridin-4-yl, etc. .
In general, and unless otherwise mentioned, the heteroarylic or heteroarylenic radicals include all the possible isomeric forms thereof, e.g. the positional isomers thereof. Thus, for some illustrative non-restricting example, the term pyridinyl or pyridinylene includes pyridin-2-yl, pyridin-2-ylene, pyridin-3-yl, pyridin-3-ylene, pyridin-4-yl and pyridin-4-ylene; or the term thienyl or thienylene includes thien-2-yl, thien-2-ylene, thien-3-yl and thien-3-ylene.
The term "Ci-C5", as used throughout this text, e.g. in the context of the definition of "Ci-C5-alkyl", "Ci-Ce-haloalkyl", "Ci-C5-alkoxy", or "Ci-C5-haloalkoxy" is to be understood as meaning an al kyl group having a finite number of carbon atoms of 1 to 6, i.e. 1, 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term "Ci-C6" is to be interpreted as any sub-range comprised therein, e.g. Ci-C6 , C2-C5 , C3-C4 , Ci-C2 , Ci-C3 , Ci-C4 , Ci-C5 particularly Ci-C2 , Ci-C3 , Ci-C4 , Ci-C5, Ci- C5 more particularly Ci-C4 ; in the case of "Ci-C5-haloalkyl" or "Ci-C5-haloalkoxy" even more particularly Ci-C2.
Similarly, as used herein, the term "C2-C6", as used throughout this text, e.g. in the context of the definitions of "C2-C6-alkenyl" and "C2-C6-alkynyl", is to be understood as meaning an alkenyl group or an alkynyl group having a finite number of carbon atoms of 2 to 6, i.e. 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term "C2-C6" is to be interpreted as any sub-range comprised therein, e.g. C2-C6 , C3-C5 , C3-C , C2-C3 , C2-C , C2-C5 particularly C2-C3.
Further, as used herein, the term "C3-C5", as used throughout this text, e.g. in the context of the definition of "C3-C5-cycloalkyl", is to be understood as meaning a cycloalkyl group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term "C3-C5" is to be interpreted as any sub-range comprised therein, e.g. C3-C6 , C4-C5 , C3-C5 , C3-C , C -C6, C5-C6 ; particularly C3-C6.
Further, as used herein, the term "C2-C ", as used throughout this text, e.g. in the context of "C2-C4-alkenyl" is to be understood as meaning a al kenyl group having a finite number of carbon atoms of 2 to 4, i.e. 2, 3 or 4 carbon atoms. It is to be understood further that said term "C2-C4" is to be interpreted as any sub-range comprised therein, e.g. C2-C , C2-C3 , C3-C . The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
Ring system substituent means a substituent attached to an aromatic or nonaromatic ring system which, for example, replaces an available hydrogen on the ring system.
As used herein, the term "one or more", e.g. in the definition of the substituents of the compounds of the general formulae of the present invention, is understood as meaning "one, two, three, four or five, particularly one, two, three or four, more particularly one, two or three, even more particularly one or two".
The invention also includes all suitable isotopic variations of a compound of the invention. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature. Examples of isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), C, 13C, 14C, 15N, "0, 180, 32P, 33P, 33S, 34S, 35S, 36S, 18F, 36CI, 82Br, 123l, 124l, 129l and 131l, respectively. Certain isotopic variations of a compound of the invention, for example, those in which one or more radioactive isotopes such as 3H or 14C are incorporated, are useful in drug
and/or substrate tissue distribution studies. Tritiated and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents.
Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.
By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The compounds of this invention may contain one or more asymmetric centre, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the ( ) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric centre, and diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
The compounds of the present invention may contain sulphur atoms which are asymmetric, such as an asymmetric sulphoxide or sulphoximine group, of structure:
, for example, in which * indicates atoms to which the rest of the molecule can be bound.
Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the
present invention.
Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.
The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by
chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
In order to limit different types of isomers from each other reference is made to lUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976).
The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. R- or S- isomers, or E- or Z-isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
Further, the compounds of the present invention may exist as tautomers. For example, any compound of the present invention which contains a pyrazole moiety as a heteroaryl group for example can exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, or a triazole moiety for example can exist as a 1H tautomer, a 2H tautomer, or a
4H tautomer, or even a mixture in any amount of said 1H, 2H and 4H tautomers, namely :
1 H-tautomer 2H-tautomer
1 H-tautomer 2H-tautomer 4H-tautomer
The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio. Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.
The present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and co-precipitates.
The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, may exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates.
Further, the compounds of the present invention can exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or can exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy.
The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic
acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts/' J. Pharm. Sci. 1977, 66, 1-19.
A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, persulfuric, 3-phenylpropionic, picric, pivalic, 2-hydroxyethanesulfonate, itaconic, sulfamic, trifluoromethanesulfonic, dodecylsulfuric, ethansulfonic, benzenesulfonic, para-toluenesulfonic, methansulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, hemisulfuric, or thiocyanic acid, for example.
Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1,6- hexadiamine, ethanolamine, gl ucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, l-amino-2,3,4-butantriol. Additionally, basic nitrogen containing groups may be quaternised with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides ; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate ; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
Those skilled in the art will further recognise that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, al kali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
The present invention includes all possible salts of the compounds of the present invention as
single salts, or as any mixture of said salts, in any ratio.
Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio. When radicals in the compounds of the present invention are substituted, the radicals may be mono- or polysubstituted, unless specified otherwise. In the context of the present invention, all radicals which occur more than once are defined independently of one another. Substitution by one, two or three identical or different substituents is preferred.
In the context of the present invention, the term "treatment" or "treating" includes inhibition, retardation, checking, alleviating, attenuating, restricting, reducing, suppressing, repelling or healing of a disease (the term "disease" includes but is not limited a condition, a disorder, an injury or a health problem), or the development, the course or the progression of such states and/or the symptoms of such states. The term "therapy" is understood here to be synonymous with the term "treatment". The terms "prevention", "prophylaxis" or "preclusion" are used synonymously in the context of the present invention and refer to the avoidance or reduction of the risk of contracting, experiencing, suffering from or having a disease or a development or advancement of such states and/or the symptoms of such states.
The treatment or prevention of a disease may be partial or complete. In another embodiment, the present invention covers compounds of general formula (I)
(I) in which:
R1 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)NR7R8,
-(S02)R9, -(SO)R9, -SR9, -(S02)NR7R8, -NR7(S02)R9, -((SO)=N R )R10, -N=(SO)R9R10,
-SiR10R R12, -(PO)(OR7)2, -(PO)(OR7)R10 or -(PO)(R10)2,
wherein each Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy,
C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-Ce-alkyl, 3- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkenyl, phenyl, -(CO)OR7, -(CO)N R7R8, -NR7(CO)R10, -NR8(CO)OR7, -NR8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -(PO)(OR7)2,
-(PO)(OR7)R10, -(PO)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl;
wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl;
R3, R4 represent, independently from each other, hydrogen or methyl; R7, R8 represent, independently from each other, hydrogen or Ci-C6-alkyl; or
R7 and R8 together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci-C5-alkyl, Ci-C5-haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;
R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally
substituted, one or more times, independently from each other, with R13; represents Ci-C4-alkyl; or
R9 and R10 together, in case of -N=(SO)R9R10 group, represent a 5- to 8-membered
heterocycloalkyl group;
R11 represents hydrogen, d-C4-alkyl, -(CO)OR7, -(CO)NR7R8 or CN;
R12 represents hydrogen or Ci-C4-alkyl; R13 represents halogen, OH, -NR7R8, CN, N02, Ci-Ce-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy,
Ci-Ce-haloalkoxy, C2-C6-alkenyl, C3-C6-cycloalkyl, -(CO)OR7 or -(CO)NR7R8;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In accordance with another embodiment the present invention covers compounds of general formula (I), supra, in which :
R1 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; represents hydrogen, fluoro, chloro, CN, Ci-C4-alkyl, Ci-C4-alkoxy, 3- to 6-membered heterocycloalkoxy, C2-C -alkenyl, C3-C5-cycloalkyl, 3- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkenyl, phenyl, 5- to 6-membered heteroaryl, -(CO)NR7R8, -(S02)R9, -SR9, -((SO)=NR )R10, -N=(SO)R9R10,
wherein each Ci-C -alkyl, Ci-C -alkoxy, 3- to 6-membered heterocycloalkoxy,
C2-C -alkenyl, C3-C5-cycloal kyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, is optionally substituted, one or more times, independently from each other, with fluoro, chloro, OH, -NR7R8, Ci-C4-alkyl, 5-membered heterocycloalkyl, phenyl, -NR8(CO)OR7, -(S02)R9, -((SO)=NR )R10, -(PO)(OR7)2 or with a 5- to 6-membered heteroaryl group which is optionally substituted, one or more times, with Ci-C -alkyl; wherein each 4- to 6-membered heterocycloalkenyl is optionally substituted, one or more times, independently from each other,with Ci-C -alkyl; represent, independently from each other, hydrogen or methyl;
R7, R8 represent, independently from each other, hydrogen or Ci-C4-alkyl; R9 represents Ci-C4-alkyl; R10 represents Ci-C4-alkyl; or
R9 and R10 together, in case of -N=(SO)R9R10 group, represent a 6-membered heterocycloalkyl group;
R11 represents hydrogen, d-C4-alkyl, -(CO)OR7; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In accordance with another embodiment the present invention covers compounds of general formula (lb)
(lb) in which R1, R2, R4, R7, R8, R9, R10, R11, R12 and R13 are as defined for the compound of general formula (I) supra or infra.
I n accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents hydrogen, fluoro, chloro, CN, methyl, Ci-C -alkoxy, C2-C3-alkenyl, cyclopropyl, 3- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkenyl, phenyl,
pyridinyl, thiazolyl, -(S02)R9, -SR9, -((SO)=NR")R10, -N=(SO)R9R10, wherein each methyl, Ci-C -alkoxy, C2-C3-alkenyl, cyclopropyl, 3- to 6-membered
heterocycloalkyl, phenyl, pyridinyl or thiazolyl is optionally substituted, one or more times, independently from each other, with fluoro, chloro, OH, -N R7R8, methyl, 5-membered heterocycloal kyl, -NR8(CO)OR7, -(S02)R9, -((SO)=NR )R10, -(PO)(OR7)2, or with a group selected from :
wherein * indicates the point of attachment of said group with the rest of the molecule; wherein each 4- to 6-membered heterocycloalkenyl is optionally substituted, one
or more times, with methyl;
R4 represents hydrogen or methyl;
R7, R8 represent, independently from each other, hydrogen or Ci-C4-alkyl; R9 represents Ci-C4-alkyl; R10 represents Ci-C4-alkyl; or
R9 and R10 together, in case of -N=(SO)R9R10 group, represent a 6-membered heterocycloalkyl group;
R11 represents hydrogen, methyl, -(CO)OR7; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
I n accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule; represents hydrogen, fluoro, chloro, CN, methyl, cyclopropyl, C2-C3-alkenyl,
Ci-C4-alkoxy, 3- to 10-membered heterocycloalkyi, 4- to 10-membered heterocycloalkenyl, 5- to 10-membered heteroaryl, phenyl, -NR7R8 , -N=(SO)R9R10, -((SO)=NR )R10, -(S02)R9, -SR9,
wherein each methyl, C2-C3-alkenyl, Ci-C4-alkoxy, 3- to 10-membered heterocycloalkyi, 5- to 10-membered heteroaryl, phenyl is optionally substituted, one or more times, independently from each other, with fluoro, chloro, OH, -NR7R8, Ci-C4-alkyl, cyclopropyl, Ci-C6-haloalkyl, Ci-C4-alkoxy, Ci-C4-hydroxyalkyl, benzyl, 5- to 6- membered heterocycloalkyi, -N R8(CO)OR7, -(S02)R9, -((SO)=NR )R10, -(PO)(OR7)2 or with a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; wherein each 4- to 10-membered heterocycloal kenyl is optionally substituted, one or more times, with methyl;
R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, cyclopropyl or optionally halogenated phenyl; R9 represents Ci-C4-alkyl;
R10 represents Ci-C4-alkyl; or
R9 and R10 together, in case of -N=(SO)R9R10 group, represent a 6-membered heterocycloalkyi group;
R11 represents hydrogen, methyl, -(CO)OR7;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents CN, d-C4-alkoxy, -(S02)R9, -SR9, cyclopropyl, -NR7R8 , -N=(SO)R9R10, phenyl,
5- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl ,
wherein each Ci-C4-alkoxy, phenyl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkyl is optionally substituted, one or more times, independently from each other, with fluoro, chloro, -NR7R8, Ci-C4-alkyl, cyclopropyl, Ci-C5-haloalkyl, Ci-C4-alkoxy, Ci-C -hydroxyalkyl, benzyl, 5- to 6-membered heterocycloalkyl, -NR8(CO)OR7, -(S02)R9, -((SO)=N R )R10;
R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, cyclopropyl or optionally halogenated phenyl;
R9 represents Ci-C -alkyl;
R10 represents Ci-C -alkyl; or
R9 and R10 together, in case of -N=(SO)R9R10 group, represent a 6-membered heterocycloalkyl group;
R11 represents hydrogen; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents CN, methoxy, ethoxy, propoxy, butyloxy, isopropoxy, methylsulfanyl,
cyclopropyl, -NR7R8, (4-oxido-l,4 4-oxathian-4-ylidene)amino, phenyl, pyridinyl, thiazolyl, lH-pyrrolo[2,3-b]pyridinyl, pyrrolyl, thienyl, pyrazolyl, 1,2-oxazolyl, imidazolyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-thiopyranyl, piperidinyl, piperazinyl,
5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl, methanesulphonyl,
wherein each ethoxy, propoxy, butyloxy, phenyl, pyridinyl, thiazolyl, pyrroly, thienyl, pyrazolyl, 1,2-oxazolyl, imidazolyl, piperidinyl or piperazinyl is optionally substituted, one or more times, independently from each other, with fluoro, chloro, -NR7R8, methyl, ethyl, 2,2,-dimethylethyl, cyclopropyl, trifluoromethyl, methoxy, hydroxymethyl, benzyl, piperazinyl, -NR8(CO)OR7, methanesulphonyl, -((SO)=NR )R10;
R7, R8 represent, independently from each other, hydrogen, methyl, 2,2-dimethylethyl,
2,2-dimethylpropyl, cyclopropyl or fluorophenyl;
R10 represents methyl;
R11 represents hydrogen; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the
molecule;
R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)N R7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10,
-SIR10R R12, -(PO)(OR7)2, -(PO)(OR7)R10 or -(PO)(R10)2,
wherein each Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy,
C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-Ce-alkyl optionally substituted with hydroxyl or phenyl, Ci -haloalkyl, Ci -alkoxy, -cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, NR8(CO)OR7, -N R8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)NR7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl; wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl;
R3, R4 represent, independently from each other, hydrogen or methyl;
R7, R8 represent, independently from each other, hydrogen, Ci-C5-alkyl, C3-C5-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen; or
R7 and R8together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci -alkyl, Ci -haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;
R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13;
R10 represents Ci-C -alkyl; or
R9 and R10together, in case of -N=(SO)R9R10 group, represent a 5- to 8-membered
heterocycloalkyl group;
R represents hydrogen, Ci-C4-alkyl, -(CO)OR7, -(CO) NR7R8 or CN; R12 represents hydrogen or Ci-C4-alkyl;
R13 represents halogen, OH, -N R7R8, CN, N02, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy, Ci-Ce- haloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, -(CO)OR7 or -(CO)N R7R8.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents hydrogen, halogen, -N R7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C6-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)N R7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -N R7(S02)R9, -((SO)=N R )R10, -N=(SO)R9R10, trimethylsily, triethylsilyl, triisopropylsilyl, dimethylphenylsilyl, isopropyldimethylsilyl, tert- butyldiphenylsilyl, tert-butyldimethylsilyl, -(PO)(OR7)2, -(PO)(OR7)R10 o r -(PO)(R10)2, wherein each Ci-C6-alkyl, Ci-C6-alkoxy, 3- to 10-membered heterocycloalkoxy,
C2-C6-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -N R7R8, Ci-C5-alkyl optionally substituted with hydroxyl or phenyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, C3-C6-cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)N R7R8, -N R7(CO)R10, N R8(CO)OR7, -N R8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -N R7(S02)R9, -((SO)=N R )R10, -N =(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl; wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl;
R3, R4 represent, independently from each other, hydrogen or methyl;
R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, C3-C5-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen; or
R7 and R8together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci-C6-alkyl, Ci-C6-haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;
R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13;
R10 represents Ci-C4-alkyl; or
R9 and R10together, in case of -N =(SO)R9R10 group, represent a 5- to 8-membered
heterocycloalkyl group;
R represents hydrogen, d-C4-alkyl, -(CO)OR7, -(CO) NR7R8 or CN;
R12 represents hydrogen or Ci-C -alkyl; R13 represents halogen, OH, -N R7R8, CN, N02, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy, Ci-C6- haloalkoxy, C2-C6-alkenyl, C3-C6-cycloalkyl, -(CO)OR7 or -(CO)N R7R8.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule; represents hydrogen, halogen, -N R7R8, CN, Ci-C6-alkyl, Ci-C4-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C -alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, -(CO) N R7R8, -(S02)R9, -(SO)R9,
-SR9, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, _(PO)(Rio)2;
wherein each Ci-C6-alkyl; Ci-C4-alkoxy, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with
halogen, OH, amino, -N R7R8,
Ci-C4-alkyl optionally substituted with hydroxyl or phenyl,
Ci-C2-haloalkyl, Ci-C3-alkoxy, C3-C6-cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, -NR8(CO)OR7, -(S02)R9, -SR9,
-N R7(S02)R9, -((SO)=NR )R10, -(PO)(OR7)2, -(PO)(OR7)R10, or with a heteroaryl group;
wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, independently from each other, with methyl;
R4 represents hydrogen or methyl;
R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, C3-C5-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen;
R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13;
R10 represents Ci-C4-alkyl; or
R9 and R10together, in case of -N=(SO)R9R10 group, represent a 5- to 8-membered
heterocycloalkyl group;
R represents hydrogen, Ci-C4-alkyl, -(CO)OR7, -(CO)NR7R8 or CN;
R13 represents halogen, OH or Ci-C6-alkoxy.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which R1 represents:
wherein * indicates the point of attachment of said group with the rest of the
molecule; represents hydrogen, chloro,-amino, propylamino, dimethylamino, methyl(propyl)amino, methyl(2-methyl propyl (amino, 2,2-dimethyl propyl (methyl (amino,
cyclopropyl(methyl)amino, methyl(phenyl)amino, CN, methyl, ethyl, propan-2-yl, 3-methylbutan-2-yl, pentan-3-yl, hexan-2-yl, 3,3-dimethylbutan-2-yl, methoxy, ethoxy, propoxy, butoxy, 2-methyl-propan-l-yloxy, propan-2-yloxy,
(2-oxotetrahydrofuran-3-yl)oxy, propenyl, cyclopropyl, cyclohexyl, azetidinyl,-pyrrolidinyl,
2- oxo-l, 3-oxazolidin-2-one, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 2-oxo-pyrrolidin-l-yl, 2-oxo-piperidin-l-yl,
3- oxo-piperazin-l-yl, 2-oxo-l,3-oxazinan-3-yl, l-oxidotetrahydro-2H-thiopyran-4-yl, l,l-dioxidotetrahydro-2H-thiopyran-4-yl, l,l-dioxido-l,2-thiazolidin-2-yl,
5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl, 3-oxa-8-azabicyclo[3.2.1]oct-8-yl, l,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, (3a ,6aS)-tetrahydro-lH-furo[3,4-c]pyrrol- 5(3H)-yl, (lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, l,l-dioxido-l-thia-6- azaspiro[3.3]hept-6-yl72,5-dihydro-lH-pyrrol-l-yl, 3,6-dihydro-2H-pyran-4-yl, l,2,5,6-tetrahydropyridin-3-yl, l,2,3,6-tetrahydropyridin-4-yl,
3.6- dihydro-2H-thiopyran-4-yl, phenyl, l,3-dihydro-2H-isoindol-2-yl, 3,4-dihydroquinolin- l(2H)-yl, 3,4-dihydroisoquinolin-2(lH)-yl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, 2-oxo-l,2-dihydropyridin-
4- yl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, lH-pyrrolo[2,3-b]pyridin-4-yl,
6.7- dihydro-5H-pyrrolo[l,2-a]imidazol-3-yl, -(CO)NH2, methylsulfonyl, ethylsulfonyl, propan-2-ylsulfonyl, phenylsulfonyl, methylsulfinyl, ethylsulfinyl, propan-2-ylsulfinyl, phenylsulfinyl, methylsulfanyl, ethylsulfanyl, propan-2-ylsulfanyl, phenylsulfanyl, -N=(SO)dimethyl, -N=(SO)diethyl,
wherein * indicates the point of attachment of said group with the rest of the molecule, -(PO)(0-methyl)27— (PO)(0-ethyl)methyl, -(po)(0-2-methylpropyl)methyl,
-(PO)(0-ethyl)2-methylpropyl, -(PO)dimethyl, -(PO)diethyl,
wherein each methyl, ethyl, propan-2-yl, 3-methylbutan-2-yl, pentan-3-yl, hexan-2-yl, 3,3-dimethylbutan-2-yl, methoxy, ethoxy, propoxy, 2-methyl-propan-l-yloxy, butoxy, cyclopropyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 3-oxo-piperazin-l-yl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, indolyl,
is optionally substituted, one or more times, independently from each other, with fluoro, chloro, bromo, OH, amino, -NH-cyclopropyl, dimethylamino, methyl, ethyl, propan-l-yl, propan-2-yl, 2-methylpropyl, ieri-butyl, hydroxymethyl, 2-hydroxyethyl, 2-methyl-2-hydroxypropan-l-yl, 2-hydroxypropan-2-yl, benzyl, fluoroethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, isopropoxy, methoxymethyl, cyclopropyl, cyclobutyl , tetrahydrofuranyl, tetrahydropyranyl, phenyl, -(CO)O-methyl, (CO)O-iert-butyl, -(CO)NH2, -(CO)NH-methyl,
-(CO)NH-iert-butyl, -(CO)dimethylamino, -(CO)piperidin-l-yl,
-(CO)NH-cyclopropyl, -NH(CO)methyl, -NH(CO)0-tert-butyl, methylsulfonyl, ethylsulfonyl, propan-2-ylsulfonyl, phenylsulfonyl, methylsulfanyl, -(S02)N 7 8, NH(S02)methyl,-((SO)=NH)methyl, -((SO)=NH)ethyl, -((SO)=NH)propan-2-yl,
-((SO)=N-methyl)methyl, -((SO)=N-(CO)0-ethyl)methyl, -((SO)=N-(CN))methyl, -((SO)=N-(CO)NH-ethyl)methyl, -(PO)(0-methyl)2,-(PO)(OH)(0-methyl) or with furanyl or pyrazolyl,
wherein each l,2,5,6-tetrahydropyridin-3-yl, l,2,3,6-tetrahydropyridin-4-yl is optionally substituted, one or more times, independently from each other, with methyl;
R4 represents hydrogen or methyl.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents 2,2-dimethylpropyl(methyl)amino, cyclopropyl(methyl)amino,
methyl(phenyl)amino, 3-methylbutan-2-yl, cyclopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidinyl, piperazinyl, 5,6-dihydroimidazo[l,2-a]pyrazin- 7(8H)-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyridinyl, lH-pyrrolo[2,3-b]pyridin-4-yl or 6,7-dihydro-5H-pyrrolo[l,2- a]imidazol-3-yl,
wherein each 3-methylbutan-2-yl, cyclopropyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl or pyridinyl is optionally substituted, one or two or three times, independently from each other, with
fluoro, chloro, OH, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, hydroxymethyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, -(CO)O-methyl, methylsulfonyl, methylsulfanyl or -((SO)=NH)methyl;
R4 represents methyl.
In accordance with another embodiment the present invention covers compounds of general formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule; represents tetrahydro-2H-thiopyran-4-yl, piperidinyl, 5,6-dihydroimidazo[l,2-a]pyrazin 7(8H)-yl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, pyridinyl or 6,7-dihydro-5H-pyrrolo[l,2- a]imidazol-3-yl,
wherein each piperidinyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl or pyridinyl is optionally substituted, one or two times, independently from each other, with fluoro, amino, methyl, ethyl, propan-2-yl, hydroxymethyl, methoxy, cyclopropyl, methylsulfonyl, methylsulfanyl or -((SO)=NH)methyl;
R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (lb), in which R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents 2,2-dimethylpropyl(methyl)amino, cyclopropyl(methyl)amino,
methyl(phenyl)amino, 3-methylbutan-2-yl, cyclopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidin-4-yl, piperazin-l-yl, 5,6-dihydroimidazo[l,2- a]pyrazin-7(8H)-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, 1H- pyrazol-4-yl, thiophen-2-yl, thiophen-3-yl, lH-imidazol-5-yl, l,2-oxazol-5-yl, l,3-thiazol-5- yl, pyridine-3-yl, pyridine-4-yl, lH-pyrrolo[2,3-b]pyridin-4-yl or 6,7-dihydro-5H- pyrrolo[l,2-a]imidazol-3-yl,
wherein each 3-methylbutan-2-yl, cyclopropyl, piperidin-4-yl, piperazin-l-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, thiophen-2-yl, thiophen-3-yl, lH-imidazol- 5-yl, , l,2-oxazol-5-yl, l,3-thiazol-5-yl, pyridine-3-yl or pyridine-4-yl is optionally substituted, one or two or three times, independently from each other, with
fluoro, chloro, OH, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, hydoxymethyl, benzyl, 2-fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, -(CO)O-methyl, methylsulfonyl, methylsulfanyl or -((SO)=NH)methyl;
R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (lb), in which R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents tetrahydro-2H-thiopyran-4-yl, piperidin-4-yl, 5,6-dihydroimidazo[l,2-a]pyrazin 7(8H)-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, l,2-oxazol-5-yl, 1,3-thiazol- 5-yl, pyridine-3-yl, 6,7-dihydro-5H-pyrrolo[l,2-a]imidazol-3-yl, wherein each piperidin-4-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, 1,2- oxazol-5-yl, pyridine-3-yl is optionally substituted, one or two times, independently from each other, with
fluoro, OH, amino, methyl, ethyl, propan-2-yl, hydoxymethyl, 2-fluoroethyl, methoxy, cyclopropyl, ethylsulfonyl, methylsulfanyl ,-((SO)=NH)methyl, R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents phenyl, pyrazolyl, thiophenyl or pyridinyl,
wherein each phenyl, pyrazolyl, thiophenyl or pyridinyl is optionally substituted, one or two times, independently from each other, with
fluoro, chloro, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, methylsulfonyl,
methylsulfanyl, -((SO)=NH)methyl,
R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl, thiophen-2-yl, thiophen-3-yl or
pyridine-3-yl, pyridine-4-yl,
wherein each phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl, thiophen-2-yl, thiophen-3-yl, pyridine-3-yl or pyridine-4-yl,is optionally substituted, one or two times, independently from each other, with
fluoro, chloro, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, methylsulfonyl, methylsulfanyl, -((SO)=NH)methyl,
R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (lb), in which
R1 represents:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl or pyridine-3-yl,
wherein each phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl or pyridine-3-yl,is optionally substituted, one or two times, independently from each other, with
fluoro, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, methylsulfonyl, methylsulfanyl, -((SO)=NH)methyl,
R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in
which R1 represents a group selected from
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another embodiment the present invention relates to compounds of formula (I) or (lb) which R1 represents a group selected from
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R1 represents
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R2 represents hydrogen, fluoro, chloro, CN, Ci-C4-alkyl, Ci-C4-alkoxy, 3- to 6-membered heterocycloalkoxy, C2-C4-alkenyl, C3-C5-cycloal kyl, 3- to 6-membered heterocycloalkyl, 4- to 6- membered heterocycloalkenyl, phenyl, pyridinyl, thiazolyl, -(CO)NR7R8, -(S02)R9, -SR9,
-((SO)=NR )R10, -N=(SO)R9R10,
wherein each Ci -alkyl, Ci -alkoxy, 3- to 6-membered heterocycloal koxy, -alkenyl, -cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, pyridinyl or thiazolyl is optionally substituted, one or more times, independently from each other, with
fluoro, chloro, OH, -N R7R8, Ci-C4-alkyl, 5-membered heterocycloalkyl, phenyl,
-N R8(CO)OR7, -(S02)R9, -((SO)=NR )R10, -(PO)(OR7)2 or a group selected from :
wherein * indicates the point of attachment of said group with the rest of the molecule;
wherein each 4- to 6-membered heterocycloalkenyl is optionally substituted, one or more times, with Ci-C4-alkyl .
In another embodiment, the present invention relates to compounds of formula (I) or (lb), in which R2 represents hydrogen, fluoro, chloro, CN, Ci-C4-alkyl, Ci-C4-alkoxy, 3- to 6-membered heterocycloalkoxy, C2-C3-alkenyl, C3-C5-cycloal kyl, 3- to 6-membered heterocycloalkyl, 4- to 6- membered heterocycloalkenyl, phenyl, pyridinyl, thiazolyl, -(CO)NR7R8, -(S02)R9, -SR9,
-((SO)=NR )R10, -N=(SO)R9R10, wherein each Ci-C4-alkyl, Ci-C -alkoxy, 3- to 6 -membered heterocycloal koxy, C2-C - alkenyl, C3-C5-cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, pyridinyl or thiazolyl is optionally substituted, one or more times, independently from each other, with fluoro, chloro, OH, -NR7R8, Ci-C -alkyl, 5-membered heterocycloalkyl, phenyl, -NR8(CO)OR7, -(S02)R9, -((SO)=NR )R10, -(PO)(OR7)2 or a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; wherein each 4- to 6-membered heterocycloalkenyl is optionally substituted, one or more times, independently from each other, with Ci-C -alkyl. I n another embodiment the present invention relates to compounds of general formula (I) or (lb), in which R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10- membered heterocycloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered
heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, -(CO)OR7,
-(CO)NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -N R7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -SiR10R"R12, -(PO)(OR7)2, -(PO)(OR7)R10 or -(PO)(R10)2,
wherein each Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-C5-alkyl optionally substituted with hydroxy or phenyl, Ci- Ce-haloalkyl, Ci-C5-alkoxy, C3-C5-cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, -NR8(CO)OR7, -NR8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)NR7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl;
wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R2 represents CN, methoxy, ethoxy, propoxy, butyloxy, isopropoxy, methylsulfanyl, cyclopropyl, -NR7R8 , (4-oxido-l,4 4-oxathian-4-ylidene)amino, phenyl, pyridinyl, thiazolyl, lH-pyrrolo[2,3-b]pyridin-4-yl, pyrrolyl, thienyl, pyrazolyl, 1,2-oxazolyl, imidazolyl,
tetrahydro-2H-pyranyl, 3,6-dihydro-2H-thiopyranyl, piperidinyl, piperazinyl,
5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl, methanesulphonyl, -((SO)=NR )R10,
wherein each ethoxy, propoxy, butyloxy, phenyl, pyridinyl, thiazolyl, pyrroly, thienyl, pyrazolyl, 1,2-oxazolyl, imidazolyl, piperidinyl or piperazinyl is optionally substituted, one or more times, independently from each other, with fluoro, chloro, -NR7R8, methyl, ethyl, 2,2,-dimethylethyl, cyclopropyl, trifluoromethyl, methoxy, hydroxymethyl, benzyl, piperazinyl, -NR8(CO)OR7, methanesulphonyl, S-methylsulfonimidoyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R2 represents hydrogen, chloro,-amino, propylamino, dimethylamino, methyl(propyl)amino, methyl (2-methyl propyl (amino, 2, 2-dimethyl propyl (methyl)amino, cyclopropyl (methyl (amino, methyl(phenyl)amino, CN, methyl, ethyl, propan-2-yl, 3-methylbutan-2-yl, pentan-3-yl, hexan-2- yl, 3,3-dimethylbutan-2-yl, methoxy, ethoxy, propoxy, butoxy, 2-methyl-propan-l-yloxy, propan- 2-yloxy, (2-oxotetrahydrofuran-3-yl)oxy, propenyl, cyclopropyl, cyclohexyl, azetidinyl,-pyrrolidinyl, 2-oxo-l,3-oxazolidin-2-one, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 2-oxo-pyrrolidin-l-yl, 2-oxo-piperidin-l-yl, 3-oxo-piperazin-l- yl, 2-oxo-l,3-oxazinan-3-yl, l-oxidotetrahydro-2H-thiopyran-4-yl, l,l-dioxidotetrahydro-2H- thiopyran-4-yl, l,l-dioxido-l,2-thiazolidin-2-yl, 5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl, 3-oxa- 8-azabicyclo[3.2.1]oct-8-yl, l,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, (3aR,6aS)-tetrahydro-lH-
furo[3,4-c]pyrrol-5(3H)-yl, (lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, l,l-dioxido-l-thia-6- azaspiro[3.3]hept-6-yl72,5-dihydro-lH-pyrrol-l-yl, 3,6-dihydro-2H-pyran-4-yl, 1,2,5,6- tetrahydropyridin-3-yl, l,2,3,6-tetrahydropyridin-4-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, l,3-dihydro-2H-isoindol-2-yl, 3,4-dihydroquinolin-l(2H)-yl, 3,4-dihydroisoquinolin-2(lH)-yl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, 2-oxo-l,2-dihydropyridin-4-yl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, 1H- pyrrolo[2,3-b]pyridin-4-yl, 6,7-dihydro-5H-pyrrolo[l,2-a]imidazol-3-yl, -(CO)NH2, methylsulfonyl, ethylsulfonyl, propan-2-ylsulfonyl, phenylsulfonyl, methylsulfinyl, ethylsulfinyl, propan-2- ylsulfinyl, phenylsulfinyl, methylsulfanyl, ethylsulfanyl, propan-2-ylsulfanyl, phenylsulfanyl, -N=(SO)dimethyl, -N=(SO)diethyl,
wherein * indicates the point of attachment of said group with the rest of the molecule,
-(PO)(0-methyl)2HPO)(0-ethyl)methyl, -(PO)(0-2-methylpropyl)methyl,
-(PO)(0-ethyl)2-methylpropyl, -(PO)dimethyl, -(PO)diethyl,
wherein each methyl, ethyl, propan-2-yl, 3-methylbutan-2-yl, pentan-3-yl, hexan-2-yl,
3,3-dimethylbutan-2-yl, methoxy, ethoxy, propoxy, 2-methyl-propan-l-yloxy, butoxy, cyclopropyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,
3-oxo-piperazin-l-yl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, indolyl,
is optionally substituted, one or more times, independently from each other, with fluoro, chloro, bromo, OH, amino, -NH-cyclopropyl, dimethylamino, methyl,
ethyl, propan-l-yl, propan-2-yl, 2-methylpropyl, tert-butyl, hydroxymethyl, 2-hydroxyethyl, 2-methyl-2-hydroxypropan-l-yl, 2-hydroxypropan-2-yl, benzyl, fluoroethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, isopropoxy, methoxymethyl, cyclopropyl, cyclobutyl , tetrahydrofuranyl, tetrahydropyranyl, phenyl, -(CO)O-methyl, (CO)O-tert-butyl, -(CO)NH2, -(CO)NH-methyl,
-(CO)NH-tert-butyl, -(CO)dimethylamino, -(CO)piperidin-l-yl, -(CO)NH-cyclopropyl, -NH(CO)methyl, -NH(CO)0-tert-butyl, methylsulfonyl, ethylsulfonyl, propan-2-ylsulfonyl, phenylsulfonyl, methylsulfanyl, -(S02)N 7 8, NH(S02)methyl,-((SO)=NH)methyl, -((SO)=NH)ethyl, -((SO)=NH)propan-2-yl, -((SO)=N-methyl)methyl, -((SO)=N-(CO)0-ethyl)methyl, -((SO)=N-(CN))methyl,
-((SO)=N-(CO)NH-ethyl)methyl, -(PO)(0-methyl)2,-(PO)(OH)(0-methyl) or with furanyl, pyrazolyl,
wherein each l,2,5,6-tetrahydropyridin-3-yl, l,2,3,6-tetrahydropyridin-4-yl is optionally substituted, one or more times, independently from each other, with methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents 2,2-dimethylpropyl(methyl)amino, cyclopropyl(methyl)amino,
methyl(phenyl)amino, 3-methylbutan-2-yl, cyclopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidinyl, piperazinyl, 5,6-dihydroimidazo[l,2-a]pyrazin-
7(8H)-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyridinyl, lH-pyrrolo[2,3-b]pyridin-4-yl, 6,7-dihydro-5H-pyrrolo[l,2- a]imidazol-3-yl,
wherein each 3-methylbutan-2-yl, cyclopropyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyridinyl, is optionally substituted, one or two or three times, independently from each other, with
fluoro, chloro, OH, amino, methyl, ethyl, propan-l-yl, propan-2-yl, tert-butyl, hydroxymethyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, -(CO)O-methyl, methylsulfonyl, methylsulfanyl, -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents tetrahydro-2H-thiopyran-4-yl, piperidinyl, 5,6-dihydroimidazo[l,2-a]pyrazin- 7(8H)-yl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, pyridinyl, 6,7-dihydro-5H-pyrrolo[l,2-
a]imidazol-3-yl,
wherein each piperidinyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, pyridinyl,
is optionally substituted, one or two times, independently from each other, with
fluoro, amino, methyl, ethyl, propan-2-yl, hydroxymethyl, methoxy, cyclopropyl, methylsulfonyl, methylsulfanyl, -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents 2,2-dimethylpropyl(methyl)amino, cyclopropyl(methyl)amino,
methyl(phenyl)amino, 3-methylbutan-2-yl, cyclopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidin-4-yl, piperazin-l-yl, 5,6-dihydroimidazo[l,2- a]pyrazin-7(8H)-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, 1H- pyrazol-4-yl, thiophen-2-yl, thiophen-3-yl, lH-imidazol-5-yl, l,2-oxazol-5-yl, l,3-thiazol-5- yl, pyridine-3-yl, pyridine-4-yl, lH-pyrrolo[2,3-b]pyridin-4-yl or 6,7-dihydro-5H- pyrrolo[l,2-a]imidazol-3-yl,
wherein each 3-methylbutan-2-yl, cyclopropyl, piperidin-4-yl, piperazin-l-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, thiophen-2-yl, thiophen-3-yl, lH-imidazol- 5-yl, l,2-oxazol-5-yl, l,3-thiazol-5-yl, pyridine-3-yl or pyridine-4-yl is optionally substituted, one or two or three times, independently from each other, with
fluoro, chloro, OH, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, hydoxymethyl, benzyl, 2-fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, -(CO)O-methyl, methylsulfonyl, methylsulfanyl or -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents tetrahydro-2H-thiopyran-4-yl, piperidin-4-yl, 5,6-dihydroimidazo[l,2-a]pyrazin- 7(8H)-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, l,2-oxazol-5-yl, 1,3-thiazol- 5-yl, pyridine-3-yl or 6,7-dihydro-5H-pyrrolo[l,2-a]imidazol-3-yl,
wherein each piperidin-4-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, l,2-oxazol-5-yl or pyridine-3-yl is optionally substituted, one or two times, independently from each other, with
fluoro, OH, amino, methyl, ethyl, propan-2-yl, hydoxymethyl, 2-fluoroethyl, methoxy, cyclopropyl, ethylsulfonyl, methylsulfanyl or -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of general formula (I) or (lb), in which R2 represents 5- to 6-membered heteroaryl, which is optionally substituted, one or two times, independently from each other, with fluoro, chloro, methyl, ethyl, 2,2,-dimethylethyl,
cyclopropyl, trifluoromethyl, methoxy, benzyl or methanesulphonyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents phenyl, pyrazolyl, thiophenyl or pyridinyl,
wherein each phenyl, pyrazolyl, thiophenyl or pyridinyl is optionally substituted, one or two times, independently from each other, with
fluoro, chloro, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, methylsulfonyl,
methylsulfanyl or -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl, thiophen-2-yl, thiophen-3-yl,
pyridine-3-yl or pyridine-4-yl,
wherein each phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl, thiophen-2-yl, thiophen-3-yl, pyridine-3-yl or pyridine-4-yl is optionally substituted, one or two times, independently from each other, with
fluoro, chloro, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, methylsulfonyl,
methylsulfanyl or -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which
R2 represents phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl or pyridine-3-yl,
wherein each phenyl, lH-pyrazol-4-yl, lH-pyrazol-5-yl or pyridine-3-yl is optionally substituted, one or two times, independently from each other, with
fluoro, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, methylsulfonyl,
methylsulfanyl or -((SO)=NH)methyl.
In another embodiment the present invention relates to compounds of general formula (I) or (lb), in which R2 represents 5-membered heteroaryl, which is optionally substituted, one or two times, independently from each other, with chloro, methyl, ethyl, 2,2,-dimethylethyl, cyclopropyl, trifluoromethyl, benzyl, methanesulphonyl.
In another embodiment the present invention relates to compounds of general formula (I) or (lb), in which R2 represents pyridinyl, thiazolyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, wherein each
pyridinyl, thiazolyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl is optionally substituted, one or two times, independently from each other, with fluoro, chloro, methyl, ethyl, 2,2,-dimethylethyl, cyclopropyl, trifluoromethyl, methoxy, benzyl, methanesulphonyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R2 represents a group
wherein * indicates the point of attachment of said group with the rest of the molecule; wherein R2a represents Ci-C4-alkyl and R2b represents Ci-C4-alkyl, C3-C5-cycloalkyl or a 5- to 6-membered heterocycloalkyl group, wherein each Ci-C4-alkyl is optionally substituted, independently from each other, one or more times, with fluoro, or
R2a and R2b represent together a C3-C5-cycloalkyl group or a 5- to 6-membered heterocycloalkyl group.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R2 represents a group
wherein * indicates the point of attachment of said group with the rest of the molecule; wherein R2a represents methyl and R represents Ci-C4-alkyl, C3-C6-cycloalkyl or a 5- to 6-membered heterocycloalkyl group or
R2a and R2b represent together a C3-C5-cycloalkyl group or a 5- to 6-membered heterocycloalkyl group.
In another embodiment the present invention relates to compounds of formula (I), in which R3 represents methyl and R4 represents H.
In another embodiment the present invention relates to compounds of formula (I), in which R3 represents H and R4 represents methyl. In another embodiment the present invention relates to compounds of formula (I), in which R3
represents H and R4 represents H.
In another embodiment the present invention relates to compounds of formula (I) , in which R3 represents methyl and R4 represents methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R4 represents H or methyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R4 represents H.
In a preferred embodiment the present invention relates to compounds of formula (I) or (lb), in which R4 represents methyl. In another preferred embodiment the present invention relates to compounds of formula (I) or (lb), in which R4 represents methyl in the absolute configuration R.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R7represents hydrogen and R8 represents hydrogen.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R7represents hydrogen and R8 represents Ci-C4-alkyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R7represents Ci-C4-alkyl and R8 represents Ci-C4-alkyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R9 represents methyl, ethyl, propyl or phenyl optionally substituted with R13. In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R10 represents methyl, ethyl or propyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R represents hydrogen, methyl, ethyl or -(CO)OR7.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R12 represents hydrogen, methyl, ethyl or propyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R2 represents a -SiR10R R12 group, wherein R10, R , R12 represent, independently from each
other, Ci-C4-alkyl, phenyl or benzyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which 2 represents a -SiR10R R12 group selected from trimethylsily, triethylsilyl, triisopropylsilyl, dimethylphenylsilyl, isopropyldimethylsilyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl. In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R10, R , R12 represent, independently from each other, Cl-C4-alkyl, phenyl or benzyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R10, R11, R12 represent, independently from each other, methyl, ethyl, propyl, isopropyl, tert- butyl, phenyl or benzyl. In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R10, R , R12 represent, independently from each other, methyl, ethyl, isopropyl, tert-butyl, or phenyl.
In another embodiment the present invention relates to compounds of formula (I) or (lb), in which R10, R , R12 represent, independently from each other, methyl, ethyl, or phenyl. In a further embodiment the invention relates to compounds of formula (I) or (lb), according to any of the above-mentioned embodiments, in the form of or a stereoisomer, a tautomer, an N- oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
It is to be understood that the present invention relates to any sub-combination within any embodiment or aspect of the present invention of compounds of general formula (I) or (lb), supra. More particularly still, the present invention covers the title compounds of general formula (I) or (lb), which are disclosed in the Example section of this text, infra.
In accordance with another aspect, the present invention covers methods of preparing compounds of the present invention, said methods comprising the steps as described below in the schemes 1 to 6 and/or the Experimental Section. In particular, the present invention covers a method to prepare compounds of general formula 5,
characterized in that compounds of general formula 4, in which R3 and R4 have the same meaning as defined for the compounds of general formula (I) or (lb) are reacted in an organic solvent at a temperature between -20°C and the boiling point of the solvent, preferably between -5°C and 30°C, using a strong base to obtain compounds of general formula (5).
The preparation of compounds of general formula 5 can be performed in an aprotic organic solvent, preferably in tetrahydrofuran or N,N-dimethylformamide.
Preferred strong bases which can be used for the preparation of compounds of general formula 5 are LiHMDS, KHMDS, NaHMDS or LDA. In particular, the present invention covers a method to prepare compounds of general formula 8,
characterized in that compounds of general formula 7, in which R1, R3 and R4 have the same meaning as defined for the compounds of general formula (I) or (lb) are reacted in an organic solvent at a temperature between -20°C and the boiling point of the solvent, preferably between - 5°C and 30°C, using a strong base to obtain compounds of general formula (8).
The preparation of compounds of general formula 8 can be performed in an aprotic organic solvent, preferably in tetrahydrofuran or N,N-dimethylformamide.
Preferred strong bases which can be used for the preparation of compounds of general formula 8 are LiHMDS, KHMDS, NaHMDS or LDA. In accordance with a further aspect, the present invention covers intermediate compounds which
are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula
in which 3 and R4 are as defined for the compound of general formula (I) or (lb) supra.
In accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 8,
in which R1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra.
In accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 9,
in which R3 and R4 are as defined for the compound of general formula (I) or (lb) supra.
In accordance with a further aspect, the present invention covers intermediate compounds which
are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 11,
11 in which 1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra.
I n accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 12,
in which R1, R3 and R4 are as defined for the compound of general formula (I) or (lb), supra, and X is chloro, bromo or iodo.
In accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 15,
15 in which 1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra.
In accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 16,
16 in which R1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra.
In accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (lb), particularly in the methods described herein. In particular, the present invention covers compounds of general formula 39,
39 in which Y represents OH, -0-S02-CF3, CI, Br, I, SH or -S02CI, preferably OH, -0-S02-CF3 or CI. In accordance with a further aspect, the present invention covers intermediate compounds which
are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of formula
(also referred to as 4,4,5,5-tetramethyl-(3-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)phenyl)- 1,3,2-dioxaborolan).
In accordance with a further aspect, the present invention covers intermediate compounds which are useful in the preparation of compounds of the present invention of general formula (I) or (lb), particularly in the methods described herein. In particular, the present invention covers compounds of formula
(also referred to as 4,4,5,5-tetramethyl-(4-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)phenyl)- 1,3,2-dioxaborolane).
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 5,
5
in which R3 and R4 are as defined for the compound of general formula (I) or (lb) supra, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 8,
in which R1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 9,
9 in which R3 and R4 are as defined for the compound of general formula (I) or (lb) supra, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 11,
11
in which 1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 12,
in which R1, R3 and R4 are as defined for the compound of general formula (I) or (lb), supra, and X is chloro, bromo or iodo, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 15,
in which R1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 16,
16
in which 1, R3 and R4 are as defined for the compound of general formula (I) or (lb) supra, for the preparation of a compound of general formula (I) or (lb) as defined supra.
In accordance with yet another aspect, the present invention covers the use of the intermediate compounds of general formula 39,
in which Y represents OH, -0-S02-CF3, CI, Br, I, SH or -S02CI, preferably OH, -0-S02-CF3 or CI for the preparation of a compound of general formula (I) or (lb) as defined supra.
The compounds of general formula (I) or (lb) according to the invention show a valuable spectrum of action which could not have been predicted. They are therefore suitable for use as medicaments for the treatment and/or prophylaxis of diseases in humans and animals.
In particular, said compounds of the present invention have surprisingly been found to effectively inhibit ATR kinase and may therefore be used for the treatment or prophylaxis of diseases mediated by ATR kinase, in particular hyperproliferative diseases.
The present invention relates to a method for using the compounds and/or pharmaceutical compositions of the present invention, to treat diseases, in particular hyperproliferative diseases. Compounds can be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and/or cell division, and/or produce apoptosis. This method comprises administering to a mammal in need thereof, in particular a human, an amount of a compound of this invention which is effective to treat the disease. Hyperproliferative diseases include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those diseases also include lymphomas, sarcomas, and leukaemias.
Examples of breast cancer include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
Examples of cancers of the respiratory tract include, but are not limited to small-cell and non- small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
Examples of brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as
neuroectodermal and pineal tumour.
Tumours of the male reproductive organs include, but are not limited to prostate and testicular cancer. Tumours of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
Tumours of the digestive tract include, but are not limited to anal, colon, colorectal, oesophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
Tumours of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
Examples of liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal,
nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell. Lymphomas include, but are not l imited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T- cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
Leukemias incl ude, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
These diseases have been well characterized in humans, but also exist with a similar etiology in
other mammals, and can be treated by administering compounds or pharmaceutical compositions of the present invention.
The present invention relates to the treatment of hyperproliferative diseases with deficient ATM sinaling and/or p53 function, in particular of lung carcinoma, in particular small-cell lung cancer, colorectal cancer, bladder cancer, lymphomas, gliomas, and ovarian cancer.
In particular, the present invention relates to the treatment of lung carcinoma, in particular small- cell lung cancer, colorectal cancer, bladder cancer, lymphomas, in particular diffuse large B-cell lymphoma (DLBC) and mantle cell lymphoma (MCL), prostate cancer, in particular castration- resistant prostate cancer, gliomas, and ovarian cancer The present invention further provides for the use of the compounds of general formula (I) or (lb) and/or of the pharmaceutical compositions of the present invention for the production of a medicament for the treatment and/or prophylaxis of diseases, especially of the aforementioned diseases, in particular of a hyperproliferative disease.
A further subject matter of the present invention is the use of the compounds of general formula (I) or (lb) and/or of the pharmaceutical compositions of the present invention in the manufacture of a medicament for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
The present invention furthermore relates to the compounds of general formula (I) or (lb) for use in a method for the treatment and/or prophylaxis of a disease, in particular of a hyper- proliferative disease.
The present invention further provides a method for treatment and/or prophylaxis of diseases, especially the aforementioned diseases, in particular of a hyperproliferative disease, using an effective amount of the compounds of general formula (I) or (lb) and/or of the pharmaceutical compositions of the present invention. The present invention further provides the compounds of general formula (I) or (lb) and/or of the pharmaceutical compositions of the present invention for use in the treatment and/or prophylaxis of diseases, especially of the aforementioned diseases, in particular of a hyperproliferative disease.The present invention further provides the compounds of general formula (I) or (lb) and/or of the pharmaceutical compositions of the present invention for use in a method for treatment and/or prophylaxis of the aforementioned diseases, in particular of a hyperproliferative
disease.
The present invention further provides a pharmaceutical composition comprising the compound of general formula (I) or (lb), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, with one or more excipient(s), in particular pharmaceutically suitable excipients, which are inert and nontoxic. Conventional procedures for preparing such pharmaceutical compositions in appropriate dosage forms can be utilized.
The present invention furthermore relates to pharmaceutical compositions, in particular medicaments, which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient, and to their use for the above mentioned purposes.
Pharmaceutically acceptable excipients are non-toxic, preferably they are non-toxic and inert. Pharmaceutically acceptable excipients include, inter alia, · fillers and excipients (for example cellulose, microcrystalline cellulose, such as, for example, Avicel®, lactose, mannitol, starch, calcium phosphate such as, for example, Di- Cafos®),
• ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols),
· bases for suppositories (for example polyethylene glycols, cacao butter, hard fat)
• solvents (for example water, ethanol, Isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins),
• surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyle sulphate, lecithin, phospholipids, fatty alcohols such as, for example, Lanette®, sorbitan fatty acid esters such as, for example, Span®, polyoxyethylene sorbitan fatty acid esters such as, for example, Tween®, polyoxyethylene fatty acid glycerides such as, for example, Cremophor®, polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers such as, for example, Pluronic®),
• buffers and also acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine)
• isotonicity agents (for example glucose, sodium chloride),
• adsorbents (for example highly-disperse silicas)
• viscosity-increasing agents, gel formers, thickeners and/or binders (for example polyvinyl pyrrol idon, methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids such as, for example, Carbopol®, alginates, gelatine),
• disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate such as, for example, Explotab®, cross- linked polyvinylpyrrolidon, croscarmellose-sodium such as, for example, AcDiSol®),
• flow regulators, lubricants, glidant and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas such as, for example, Aerosil®),
• coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example polyvinylpyrrolidones such as, for example, Kollidon®, polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®),
• capsule materials (for example gelatine, hydroxypropylmethylcellulose),
• synthetic polymers (for example polylactides, polyglycolides, polyacrylates, polymethacrylates such as, for example, Eudragit®, polyvinylpyrrolidones such as, for example, Kollidon®, polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers),
• plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate),
• penetration enhancers,
• stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate),
• preservatives (for example parabens, sorbic acid, thiomersal, benzal konium chloride, chlorhexidine acetate, sodium benzoate),
• colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide),
• flavourings, sweeteners, flavour- and/or odour-masking agents.
Further excipients and procedures are described in the following references, each of which is incorporated herein by reference: Powell, M.F. et al., "Compendium of Excipients for Parenteral Formulations" PDA Journal of Pharmaceutical Science & Technology 1998, 52(5), 238-311 ;
Strickley, .G "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1" PDA Journal of Pharmaceutical Science & Technology 1999, 53(6), 324-349 ; and Nema, S. et al., "Excipients and Their Use in Injectable Products" PDA Journal of Pharmaceutical Science & Technology 1997, 51(4), 166-171. The present invention furthermore relates to a pharmaceutical combination, in particular a medicament, comprising at least one compound according to the invention and at least one or more further active ingredients, in particular for the treatment and/or prophylaxis of the above mentioned diseases.
The present invention further provides a pharmaceutical combination comprising:
one or more active ingredients selected from a compound of general formula (I) or (lb), and one or more active ingredients selected from antihyperproliferative, cytostatic or cytotoxic substances for treatment of cancers.
The term "combination" in the present invention is used as known to persons skilled in the art and may be present as a fixed combination, a non-fixed combination or kit-of-parts. A "fixed combination" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein, for example, a first active ingredient and a second active ingredient are present together in one unit dosage or in a single entity. One example of a "fixed combination" is a pharmaceutical composition wherein a first active ingredient and a second active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a "fixed combination" is a pharmaceutical combination wherein a first active ingredient and a second active ingredient are present in one unit without being in admixture.
A non-fixed combination or "kit-of-parts" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein a first active ingredient and a second active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the first active ingredient and the second active ingredient are present separately. The components of the non-fixed combination or kit-of-parts may be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.
The compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutically active ingredients where the combination causes no unacceptable adverse effects. The present invention relates also to such
pharmaceutical combinations. For example, the compounds of this invention can be combined with known chemotherapeutic agents and/or anti-cancer agents, e.g. anti-hyper-proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof. Other indication agents include, but are not limited to, anti-angiogenic agents, mitotic inhibitors, alkylating agents, anti-metabolites, DNA-intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, toposisomerase inhibitors, biological response modifiers, or anti-hormones.
For example, the compounds of the present invention can be combined with known
antihyperproliferative, cytostatic or cytotoxic substances for treatment of cancers. Examples of suitable antihyperproliferative, cytostatic or cytotoxic combination active ingredients include:
1311-chTNT, abarelix, abiraterone, aclarubicin, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alemtuzumab, Alendronic acid, alitretinoin, altretamine, amifostine,
aminoglutethimide, Hexyl aminolevulinate,amrubicin, amsacrine, anastrozole, ancestim, anethole dithiolethione, angiotensin II, antithrombin III, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, axitinib, azacitidine, basiliximab, belotecan, bendamustine, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, bosutinib, brentuximab vedotin, busulfan, cabazitaxel, cabozantinib, calcium folinate, calcium levofolinate, capecitabine, capromab, carboplatin, carfilzomib, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, ceritinib, cetuximab, chlorambucil, chlormadinone, chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, copanlisib , crisantaspase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, dabrafenib, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dexrazoxane, dibrospidium chloride, dianhydrogalactitol, diclofenac, docetaxel, dolasetron, doxifluridine, doxorubicin, doxorubicin + estrone, dronabinol, eculizumab, edrecolomab, elliptinium acetate, eltrombopag, endostatin, enocitabine, enzalutamide, epirubicin, epitiostanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin, erlotinib, esomeprazole, estradiol, estramustine, etoposide, everolimus, exemestane, fadrozole, fentanyl, filgrastim, fluoxymesterone, floxuridine, fludarabine, fluorouracil, flutamide, folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoteric acid meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, Glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony
stimulating factor, histamine dihydrochloride, histrelin, hydroxycarbamide, 1-125 seeds, lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, interferon alfa, interferon beta, interferon gamma, iobitridol, iobenguane (1231), iomeprol, ipilimumab, irinotecan, Itraconazole, ixabepilone, lanreotide, lapatinib, lasocholine, lenalidomide, lenograstim, lentinan, letrozole, leuprorelin, levamisole, levonorgestrel, levothyroxine sodium, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melarsoprol, melphalan, mepitiostane, mercaptopurine, mesna, methadone, methotrexate, methoxsalen,
methylaminolevulinate, methylprednisolone, methyltestosterone, metirosine, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, mogamulizumab, molgramostim, mopidamol, morphine hydrochloride, morphine sulfate, nabilone, nabiximols, nafarelin, naloxone + pentazocine, naltrexone, nartograstim, nedaplatin, nelarabine, neridronic acid, nivolumabpentetreotide, nilotinib, nilutamide, nimorazole, nimotuzumab, nimustine, nitracrine, nivolumab, obinutuzumab, octreotide, ofatumumab, omacetaxine mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, orilotimod, oxaliplatin, oxycodone, oxymetholone, ozogamicine, p53 gene therapy, paclitaxel, palifermin, palladium-103 seed, palonosetron, pamidronic acid, panitumumab, pantoprazole, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab, pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentazocine, pentostatin, peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone + sodium hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib , regorafenib, risedronic acid, rhenium-186 etidronate, rituximab, romidepsin, romiplostim, romurtide, roniciclib , samarium (153Sm) lexidronam, sargramostim, satumomab, secretin, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, tamibarotene, tamoxifen, tapentadol, tasonermin, teceleukin, technetium (99mTc) nofetumomab merpentan, 99mTc- HYNIC-[Tyr3]-octreotide, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine + tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombopoietin, tryptophan, ubenimex, valatinib,
valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin.
In a preferred embodiment the pharmaceutical combination of the present invention comprises a compound of general formula (I) or (lb), and
one or more active ingredients selected from carboplatin and cisplatin.
Generally, the use of antihyperproliferative, cytostatic or cytotoxic combination active ingredients in combination with a compound or pharmaceutical composition of the present invention will serve to:
(1) yield better efficacy in reducing the growth of a tumor or even eliminate the tumor as compared to administration of either agent alone,
(2) provide for the administration of lesser amounts of the administered chemotherapeutic agents,
(3) provide for a chemotherapeutic treatment that is well tolerated in the patient with fewer deleterious pharmacological complications than observed with single agent chemotherapies and certain other combined therapies,
(4) provide for treating a broader spectrum of different cancer types in mammals, especially humans,
(5) provide for a higher response rate among treated patients,
(6) provide for a longer survival time among treated patients compared to standard chemotherapy treatments,
(7) provide a longer time for tumor progression, and/or
(8) yield efficacy and tolerability results at least as good as those of the agents used alone, compared to known instances where other cancer agent combinations produce antagonistic effects.
In addition, the compounds of general formula (I) can also be used in combination with radiotherapy and/or surgical intervention.
In a further embodiment of the present invention, a compound of the present invention may be used to sensitize a cell to radiation. That is, treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA
damage and cell death than the cell would be in the absence of any treatment with a compound of the invention. In one aspect, the cell is treated with at least one compound of the invention.
Thus, the present invention also provides a method of killing a cell, wherein a cell is administered one or more compounds of the invention in combination with conventional radiation therapy. The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of the invention prior to the treatment of the cell to cause or induce cell death. In one aspect, after the cell is treated with one or more compounds of the invention, the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell.
In another embodiment of the present invention, a cell is killed by treating the cell with at least one DNA damaging agent. That is, after treating a cell with one or more compounds of the invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell. DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g., cisplatinum), ionizing radiation (X-rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents.
In another embodiment, a cell is killed by treating the cell with at least one method to cause or induce DNA damage. Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage. By way of a non-limiting example, a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell.
In one aspect of the invention, a compound of the invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell. In another aspect of the invention, a compound of the invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell. In yet another aspect of the invention, a compound of the invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun.
In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo.
The compounds of general formula (I) or (lb) can act systemically and/or locally. For this purpose, they can be administered in a suitable manner, for example by the oral, parenteral, pulmonal,
nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic route, or as an implant or stent.
The compounds of general formula (I) or (lb) can be administered in administration forms suitable for these administration routes. Suitable administration forms for oral administration are those which release the compounds of general formula (I) or (lb) in a rapid and/or modified manner, work according to the prior art and contain the compounds of general formula (I) or (lb) in crystalline and/or amorphous and/or dissolved form, for example tablets (uncoated or coated tablets, for example with enteric or retarded-dissolution or insoluble coatings which control the release of the compound of general formula (I) or (lb)), tablets or films/wafers which disintegrate rapidly in the oral cavity, films/lyophilizates, capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
Parenteral administration can be accomplished with avoidance of an absorption step (for example by an intravenous, intraarterial, intracardial, intraspinal or intralumbal route) or with inclusion of an absorption (for example by an intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal route). Suitable administration forms for parenteral administration include injection and infusion formulations in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders.
For the other administration routes, suitable examples are pharmaceutical forms for inhalation or inhalation medicaments (including powder inhalers, nebulizers), nasal drops, solutions or sprays; tablets, films/wafers or capsules for lingual, sublingual or buccal administration, films/wafers or capsules, suppositories, ear or eye preparations (for example eye baths, ocular insert, ear drops, ear powders, ear-rinses, ear tampons), vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (for example patches), milk, pastes, foams, dusting powders, implants, intrauterine coils, vaginal rings or stents.
The compounds of general formula (I) or (lb) can be converted to the administration forms mentioned. This can be done in a manner known per se, by mixing with pharmaceutically suitable excipients . These excipients include carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersing or wetting agents (for
example sodium dodecylsulphate, polyoxysorbitan oleate), binders (for example
polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g. antioxidants, for example ascorbic acid), dyes (e.g. inorganic pigments, for example iron oxides) and flavour and/or odour correctants.
Pharmaceutically acceptable excipients are non-toxic, preferably they are non-toxic and inert. Pharmaceutically acceptable excipients include, inter alia: fillers and excipients (for example cellulose, microcrystalline cellulose, such as, for example, Avicel®, lactose, mannitol, starch, calcium phosphate such as, for example, Di-Cafos®),
• ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols),
• bases for suppositories (for example polyethylene glycols, cacao butter, hard fat)
• solvents (for example water, ethanol, Isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins),
• surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyle sulphate, lecithin, phospholipids, fatty alcohols such as, for example, Lanette®, sorbitan fatty acid esters such as, for example, Span®, polyoxyethylene sorbitan fatty acid esters such as, for example, Tween®, polyoxyethylene fatty acid glycerides such as, for example, Cremophor®, polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers such as, for example, Pluronic®),
• buffers and also acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine)
• isotonicity agents (for example glucose, sodium chloride),
• adsorbents (for example highly-disperse silicas)
• viscosity-increasing agents, gel formers, thickeners and/or binders (for example polyvinyl pyrrol idon, methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids such as, for example, Carbopol®, alginates, gelatine),
• disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate such as, for example, Explotab®, cross- linked polyvinylpyrrolidon, croscarmellose-sodium such as, for example, AcDiSol®),
• flow regulators, lubricants, glidant and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas such as, for example, Aerosil®),
coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example polyvinylpyrrolidones such as, for example, Kollidon®, polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®),
capsule materials (for example gelatine, hydroxypropylmethylcellulose),
synthetic polymers (for example polylactides, polyglycolides, polyacrylates, polymethacrylates such as, for example, Eudragit®, polyvinylpyrrolidones such as, for example, Kollidon®, polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers),
plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate),
penetration enhancers,
stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate), preservatives (for example parabens, sorbic acid, thiomersal, benzal konium chloride, chlorhexidine acetate, sodium benzoate),
colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide),
flavourings, sweeteners, flavour- and/or odour-masking agents.
The present invention further provides medicaments which comprise at least one compound of general formula (I) or (lb), typically together with one or more inert, nontoxic, pharmaceutically suitable excipients, and the use thereof for the aforementioned purposes.
Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of hyperproliferative diseases by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known active ingredients or medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed,
the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
The total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day. Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing. In addition, "drug holidays" in which a patient is not dosed with a drug for a certain period of time, may be beneficial to the overall balance between pharmacological effect and tolerability. A unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.
In spite of this, it may be necessary to deviate from the amounts specified, specifically depending on body weight, administration route, individual behaviour towards the active ingredient, type of formulation, and time or interval of administration. For instance, less than the aforementioned minimum amount may be sufficient in some cases, while the upper limit mentioned has to be exceeded in other cases. In the case of administration of greater amounts, it may be advisable to divide them into several individual doses over the day.
The percentages in the tests and examples which follow are, unless indicated otherwise,
percentages by weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data for liquid/liquid solutions are based in each case on volume.
Syntheses of Compounds (Overview): The compounds of the present invention can be prepared as described in the following section. The schemes and the procedures described below illustrate general synthetic routes to the compounds of general formula (I) of the invention and are not intended to be limiting. It is clear to the person skilled in the art that the order of transformations as exemplified in the schemes can be modified in various ways. The order of transformations exemplified in the schemes is therefore not intended to be limiting. In addition, interconversion of any of the substituents can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups, cleavage of protecting groups, exchange, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art. These transformations include those which introduce a functionality which allows for further interconversion of substituents. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example P.G.M. Wuts and T.W. Greene in "Protective Groups in Organic Synthesis", 4th edition, Wiley 2006). Specific examples are described in the subsequent paragraphs. Further, it is possible that two or more successive steps may be performed without work-up being performed between said steps, e.g. a "one-pot" reaction, as is well-known to the person skilled in the art.
The syntheses of the 2-(morpholin-4-yl)-l,7-naphthyridine derivatives according to the present invention are preferably carried out according to the general synthetic sequence, shown in schemes 1-6.
Scheme 1: Route for the preparation of compounds of general formula 8, wherein R1, R3 and R4 have the meaning as given for general formula (I), supra and R has the meaning as alkyl. In addition, the substituents R1 can bear a protecting group and the interconversion of any of the substituents R1 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups or cleavage of protecting groups. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.
The starting material methyl 3-amino-2-chloropyridine-4-carboxylate 3 (CAS No: 173435-41-1) is commercially available or can be prepared according to a literature procedure (see Journal of Heterocyclic Chemistry, 38(1), 99-104; 2001). Step 1 -» 2 (Scheme 1)
Amide formation
In the first step (scheme 1), morpholine derivative 1 (which is commercially available or described in the literature) can be converted to the corresponding acetamide 2 using an acetylating agent. The starting morpholine could either be used as a salt (e.g. HCI salt) or as the free amine. For example the morpholine 1 can be acetylated using acetyl chloride in an organic solvent such as dichloromethane in the presence of a base such as K2C03. The acetylation can also be performed using acetic anhydride in pyridine. Alternatively, acetic acid, a base and an activating reagent generating an active ester in situ in an organic solvent can be used for the transformation. For a review see: C.A.G.N. Montalbetti and V. Falque Tetrahedron 2005, 61, 10827-10852 and references therein).
Step 3 -> 4 (Scheme 1) Amidine formation
Methyl 3-amino-2-chloropyridine-4-carboxylate 3 is reacted with morpholine amide of furmula 2 in an amidine forming reaction to give compounds of the general formula 4. Typically the reaction is performed with POCI3 neat or in an organic solvent at a temperature range between 0°C and the boiling point of the selected solvent. Preferably a halogenated solvent such as chloroform, DCE or DCM is used for the reaction.
Step 4 -> 5 (Scheme 1)
Naphthyridine formation The amidines of formula 4 can be converted to the corresponding 2-(morpholin-4-yl)-l,7- naphthyridines of formula 5. Typically the reaction is performed in an organic solvent at a temperature between -20°C and the boiling point of the selected solvent using a strong base. Preferably Li HMDS, KHMDS, NaHMDS or LDA are used as base.
Step 5 -> 8 (Scheme 1)
Palladium catalyzed reaction with boronic acids
The chloronaphthyridines of formula 5 can be reacted with a boronic acid derivative 1-B(O )2 to give a compound of formula 8. The boronic acid derivative may be a boronic acid (R = -H) or an ester of the boronic acid, e.g. its isopropyl ester (R = -CH(CH3)2), preferably an ester derived from pinacol in which the boronic acid intermediate forms a 2-aryl-4,4,5,5-tetramethyl-l,3,2- dioxaborolane (R-R = -C(CH3)2-C(CH3)2-). The NH groups of the heterocycle R1 of the boronic acid derivatives may be masked by any suitable protecting group (see Green, Wuts, "Protective groups in organic synthesis" 1999, John Wiley & Sons and references cited therein). The corresponding protective group may be removed at any suitable step of the synthesis. Preferably THP
(tetrahydropyranyl), BOC (ieriButoxycarbonyl) or PMB (pora-Methoxybenzyl) are used as protective groups during the synthesis.
The coupling reaction is catalyzed by palladium catalysts, e.g. by Pd(0) catalysts like
tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4], tris(dibenzylideneacetone)di-palladium(0) [Pd2(dba)3], or by Pd(ll) catalysts like dichlorobis(triphenylphosphine)-palladium(ll) [Pd(PPh3)2CI2], palladium(ll) acetate and triphenylphosphine or by [1,1'- bis(diphenylphosphino)ferrocene] palladium dichloride.
The reaction is preferably carried out in a mixture of a solvent like 1,2-dimethoxyethane, dioxane, DMF, DME, THF, or isopropanol with water and in the presence of a base l ike potassium carbonate, sodium bicarbonate or potassium phosphate.
(review: D.G. Hall, Boronic Acids, 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, ISBN 3- 527-30991-8 and references cited therein).
The reaction is performed at temperatures ranging from room temperature (i.e. approx. 20°C) to the boiling point of the respective solvent. Further on, the reaction can be performed at temperatures above the boiling point using pressure tubes and a microwave oven. The reaction is preferably completed after 1 to 36 hours of reaction time.
The steps for the synthesis sequence giving rise to naphthyridines of formula 8 may be also interchanged using similar reaction conditions for each step as described above. For example: 3 ^ 6 ^ 7 ^ 8
10
Scheme 2: Route for the preparation of compounds of general formula 10 and 11, wherein R1, R3 and R4 have the meaning as given for general formula (I), supra and R has the meaning as alkyl. In addition, the substituents R1 can bear a protecting group and the interconversion of any of the substituents R1 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups or cleavage of protecting groups. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.
Step 8 -> 10 (Scheme 2)
Transformation of hydroxy to chloro substituent
In the next step, the hydroxy-naphthyridine of formula 8 is converted to the corresponding chloro-naphthyridine 10. This reaction is typically performed using POCI3 without any additional solvent. The reaction is typically carried out at elevated temperatures.
The steps for the synthesis sequence giving rise to naphthyridines of formula 10 may also be interchanged using similar reaction conditions for each step as described above. For example:
5 -> 9 -> 10
Step 8 -> 11 (Scheme 2) Triflate formation
The hydroxy-naphthyridine of the general formula 8 can be converted to the corresponding triflate of formula 11. Typically the hydroxy-naphthyridine 8 is reacted with a triflating reagent such as for example N-Phenylbis(trifluoromethanesulfonimide) with or without a base in an organic solvent such as for example dichloromethane.
Scheme 3: Route for the preparation of compounds of general form ula 12, 13, 18, 19 and 20, wherein R1, R3, R4, R7, R8 and R9 have the meaning as given for general formula (I), supra and R" has the meaning as Ci-C6-alkyl or 3- to 10-membered heterocycloalkyl. In addition, the substituents R1 can bear a protecting group and the interconversion of any of the substituents R1 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups or cleavage of protecting groups. Appropriate
protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.
Step 8 -» 12 (Scheme 3)
Conversion of hydroxy to halogen (F, Br, CI, I)
The transformation of hydroxy-naphthyridine 8 to a halogen compound of formula 12 can be performed (for halogen = CI) for example using chlorinating reagents such as trichlorophosphate with or without an organic solvent. Typically the reactions are performed at elevated temperatures. For halogen = Br reagents such as phosphorus tribromide or phosphorus oxytribromide can be used. For halogen = F see for example J. of Org. Chem., 2013, 78, 4184 - 4189. For halogen = I see for example Journal of Organic Chemistry, 2009, 74, 5111 - 5114 and references therein.
Step 8 -> 13 (Scheme 3) Conversion of hydroxy to ethers
Hydroxy-naphthyridines of formula 8 can be converted to the corresponding ether of general formula 13, in which " is Ci-C6-alkyl or 3- to 10-membered heterocycloalkyl. The reaction is performed using halides (preferably CI, Br or I), tosylates, mesylates or triflates. This reaction is performed in a solvent such as for example acetonitrile, DMF or a 1:1 mixture of methanol and water. The reaction is performed in the presence of a base such as for example CSCO3 or K2CO3.
The reaction is performed at temperatures ranging from room temperature to the boiling point of the respective solvent. Furthermore, the reaction can be performed at temperatures above the boiling point under pressure. The reaction is preferably completed after 1 to 16 hours.
Alternatively, the ether of general formula 13 can be synthesized via a Mitsunobu reaction from an alcohol in the presence of a phosphine (such as for example triphenyl phoshine) and an azodicarboxylate (e.g. diisopropyl azodicarboxylate) in a solvent such as for example THF.
Step 8 -> 15 (Scheme 3)
Conversion of hydroxy to thiol
For the conversion of hydroxy-naphthyridines of formula 8 to thiols of formula 15 for example Lawesson's reagent or diphosphorus pentasulfide in an organic solvent can be used. Typically these reactions are run at elevated temperatures.
Step 15 -» 20 (Scheme 3) Conversion of thiol to sulfonamide
Thiols of general formula 15 can be converted to the corresponding sulfonamides 20 via the intermediate sulfonylchlorides of formula 16 in analogy to literature procedures. For example see European J. of Medicinal Chemistry 2013, 60, 42-50 and references therein.
Step 15 -» 17 (Scheme 3) Conversion of thiol to thioether
Thiols of formula 15 can be alkylated to the corresponding thioethers 17. The reaction is performed using alkyl halides (preferably CI, Br or I), tosylates, mesylates, or triflates. This reaction is performed in a solvent such as for example acetonitrile, DMF or a 1:1 mixture of methanol and water. The reaction is performed in the presence of a base such as for example CsC03 or K2C03. The reaction is performed at temperatures ranging from room temperature to the boiling point of the respective solvent. Furthermore, the reaction can be performed at temperatures above the boiling point under pressure. The reaction is preferably completed after 1 to 16 hours.
Step 17 -» 18 (Scheme 3) Conversion of thioether to sulfoxide
Thioethers of formula 17 can be oxidized to the corresponding sulfoxides 18. Typically an oxidizing reagent in an organic solvent is used (for example 3-chloro-benzenecarboperoxoic acid in dichloromethane).
Step 17 -» 19 (Scheme 3) Conversion of thioether to sulfone
Thioethers of general formula 17 can be oxidized to the corresponding sulfoxides 19. Typically an oxidizing reagent in an organic solvent is used (for example 3-chloro-benzenecarboperoxoic acid in dichloromethane).
Scheme 4: Route for the preparation of compounds of general form ula 17, 19, 21, 23, 24, 26 and 27, wherein R1, R3, R4, R7, R8 and R9 have the meaning as given for general formula (I), supra. The group A represents C2-C6-alkenyl, C5-C5-cycloalkenyl or 4- to 10-membered heterocycloalkenyl and
the group D represents C2-C5-alkyl, C5-C5-cycloalkyl or 4- to 10-membered heterocycloalkyl. In addition, the substituents 1 can bear a protecting group and the interconversion of any of the substituents R1 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups or cleavage of protecting groups. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.
Step 12 -» 17 (Scheme 4) Conversion to Thioether
Halogen compounds of the general formula 12 can be converted to the corresponding thioethers of general formula 17 by nucleophilic substitution with thiols. Typically a base such as for example KOtBu, NaH, caesium carbonate, potassium carbonate in an organic solvent such as for example ieri-butanol, DMSO or DMF are used. Typically the reaction is performed at elevated temperature. See for example: Journal of Medicinal Chemistry, 2008 , 51, 3466 - 3479 and references therein.
Step 11 or 12 -> 21 (Scheme 4)
C-N cross coupling reaction or nucleophilic substitution Halogen compounds of general formula 12 or triflates of general formula 11 can be converted to the corresponding amines 21 by a C-N cross coupling reaction. Typically a metal catalyst, a ligand and a base in an organic solvent is used. For a recent review see for example: Chem. Soc. Rev., 2013, 42, 9283 or "Metal-Catalyzed Cross-Coupling Reactions (2 Volume Set)", 2004 by Armin de Meijere (Editor), Frangois Diederich (Editor) and literature references therein. Alternatively halogen compound of general formula 12 can be converted to the corresponding amines 21 via a nucleophilic substitution reaction. Typically nucleophilic amines in combination with a base (for example triethylamine, HCinig's base, potassium carbonate) in an organic solvent (for example iPrOH, DCM, DMSO, DMF) are used. See for example: Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5502 - 5505 and references therein.
Step 11 or 12 -> 22 (Scheme 4) Hydrocarbonylation
Halogen compounds of general formula 12 or triflates of general formula 11 can be converted to the corresponding esters 22 by a metal catalyzed carbonylation reaction. Typically
carbonmonoxide and a palladium catalyst with or without a ligand (for example: palladium acetate / l,3-bis-(diphenylphosphino)propane; bis-triphenylphosphine-palladium(ll) chloride / - triphenylphosphine), an alcohol as nucleophile (for example: methanol, ethanol) in an organic solvent (for example: DMF, methanol, ethanol) is used. See for example: Journal of Medicinal Chemistry, 2008, 51, 1649 - 1667 or Synthesis, 2001, 7, 1098 - 1109 and references therein. Step 22 -» 23 (Scheme 4)
Amide formation
Esters of general formula 22 can be converted to the corresponding amides of general formula 23. Typically an amine is reacted in combination with a base (as for example sodium hydroxide or magnesium methanolate) in a solvent (as for example methanol, isopropanol, water).
Alternatively the ester 22 can be reacted with an amine and n-butyllithium or trimethylaluminum in an organic solvent (such as for example THF, toluene) to form amides of formula 23. See for example Chem. Commun., 2008, 1100-1102 and references therein.
Alternatively the ester of general formula 22 can be hydrolyzed to the corresponding carboxylic acid (using for example KOH, water, methanol as ester hydrolysis conditions) and reacted further to the corresponding amides 23 under classical amide coupling conditions. For a review for amide coupling conditions using the free carboxylic acid and an amine in combination with an activating agent see for example Chem. Soc. Rev., 2009, 38, 606-631 and references therein.
Step 11 or 12 -> 24 (Scheme 4)
Nitrile formation Halogen comounds of general formula 12 or triflates of general formula 11 can be converted to the corresponding nitriles 24. Typically a palladium catalyst and a ligand (such as for example 1,1'- bis-(diphenylphosphino)ferrocene / tris-(dibenzylideneacetone)dipalladium(0) ), zinc (II) cyanide in solvent (such as for example Ν,Ν-dimethyl acetamide / water) is used. See for example Tetrahedron Letters, 2006, 47, 3303 - 3305 and references therein.
Step 11 or 12 -> 25 (Scheme 4) C-C cross coupling reaction
Halogen comounds of general formula 12 or triflates of general formula 11 can be reacted with a boronic acid derivative A-B(OR)2 to give a compound of formula 25. The group A represents Ci-C6- alkyl, C2-C6-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloal kyl,
4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl. The boronic acid derivative may be a boronic acid (R = -H) or an ester of the boronic acid, e.g. its isopropyl ester (R = -CH(CH3)2), preferably an ester derived from pinacol in which the boronic acid intermediate forms a 2-aryl- 4,4,5,5-tetramethyl-l,3,2-dioxaborolane (R-R = -C(CH3)2-C(CH3)2-). The group A of the boronic acid derivatives may be masked by any suitable protecting group (see Green, Wuts, "Protective groups in organic synthesis" 1999, John Wiley & Sons). The corresponding protective group may be removed at any suitable step of the synthesis.
The coupling reaction is catalyzed by palladium catalysts, e.g. by Pd(0) catalysts like
tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4], tris(dibenzylideneacetone)di-palladium(0) [Pd2(dba)3], or by Pd(ll) catalysts like dichlorobis(triphenylphosphine)-palladium(ll) [Pd(PPh3)2CI2], palladium(ll) acetate and triphenylphosphine or by [1,1'- bis(diphenylphosphino)ferrocene] palladium dichloride.
The reaction is preferably carried out in a mixture of a solvent like 1,2-dimethoxyethane, dioxane, DMF, DME, THF, or isopropanol with water and in the presence of a base l ike potassium carbonate, sodium bicarbonate or potassium phosphate.
(review: D.G. Hall, Boronic Acids, 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, ISBN 3- 527-30991-8 and references cited therein).
The reaction is performed at temperatures ranging from room temperature to the boiling point of the solvent. Further on, the reaction can be performed at temperatures above the boiling point under pressure. The reaction is preferably completed after 1 to 36 hours.
Step 25 -» 26 (Scheme 4)
Hydrogenation of double bond
U nsaturated derivatives of formula 25 (wherein the group A represents C2-C6-alkenyl, C5-C6- cycloalkenyl, 4- to 10-membered heterocycloal kenyl). can be hydrogenated to the corresponding
saturated derivatives of general formula 26 (wherein the group D represents C2-C5-alkyl, C5-C5- cycloalkyl, 4- to 10-membered heterocycloalkyi). Typically hydrogen (at atmospheric or elevated pressure) is used in combination with a heterogeneous or homogeneous catalyst such as for example palladium on charcoal in an organic solvent such as ethyl acetate, methanol or acetic acid.
Step 12 -» 27 (Scheme 4) Dehalogenation reaction
Halides of general formula 12 can be dehalogenated for example by a hydrogenation reaction to obtain naphthyridines of general formula 27. Typically hydrogen (at atmospheric or elevated pressure), a base as for example triethylamine and a heterogeneous metal catalyst such as for example palladium on activated carbon in an organic solvent such as for example ethanol, ethyl acetate, acetic acid is used.
Step 11 or 12 -> 19 (Scheme 4)
Sulfonylation reaction A halide of general formula 12 or a triflate of general formula 11 can be converted to the corresponding sulfone of general formula 19 by reaction with an alkyl sulfinic acid sodium salt or aryl sulfinic acid sodium salt with a base such as for example 4-(N,N-dimethlyamino)pyridine or pyridine in an organic solvent as for example Ν,Ν-dimethyl-formamide. Typically the reaction is performed at elevated temperature. The reaction can also be mediated by copper (see for example European Journal of Medicinal Chemistry, 2004 , vol. 39, 735 - 744).
18 31 38
Scheme 5: Route for the preparation of compounds of general form ula 38, wherein R1, R3, R4, R9 and R have the meaning as given for general formula (I), supra. In addition, the substituents R1
can bear a protecting group and the interconversion of any of the substituents R1 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups or cleavage of protecting groups. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.
Step 18 -» 31 (Scheme 5)
Sulfoximine formation
Sulfoxide 18 is converted to the corresponding sulfoximine 31 in a two step procedure. Typically, the sulfoxide 18 is converted to a protected sulfoximine intermediate using a described procedure (Org. Lett., 2004, 6, 1305-1307 and references therein). Deprotection to the sulfoximine to 31 is performed using a base such as for example K2C03 in methanol. Additional options to convert the sulfoxide 18 to an unprotected sulfoximine 31 are the use of hydrazoic acid prepared in situ (e.g. ChemMedChem, 2013, 8, 1021) or the use of 0-(mesitylenesulfonyl)hydroxylamine (MSH) (e.g. J. Org. Chem., 1973, 38, 1239.
Step 31 -> 38 (Scheme 5)
Functionalization of the sulfoximine nitrogen
Functionalization of the nitrogen of sulfoximines of general formula 31 can be performed using previously described methods: N-unprotected sulfoximines of formula 31 may be reacted to give N-functionalized derivatives of formula 38. There are multiple methods for the preparation of N- functionalized sulfoximines by functionalization of the nitrogen of the sulfoximine group:
- Alkylation: see for example: a) U. Lucking et al, US 2007/0232632; b) C.R. Johnson, J. Org. Chem. 1993, 58, 1922; c) C. Bolm et al, Synthesis 2009, 10, 1601.
- Reaction with isocyanates: see for example: a) V.J. Bauer et al, J. Org. Chem. 1966, 31, 3440; b) C. R. Johnson et al, J. Am. Chem. Soc. 1970, 92, 6594; c) S. Allenmark et al, Acta Chem. Scand. Ser.
B 1983, 325; d) U. Lucking et al, US2007/0191393.
- Reaction with chloroformiates: see for example: a) P.B. Kirby et al, DE2129678; b) D.J. Cram et al, J. Am. Chem. Soc. 1974, 96, 2183; c) P. Stoss et al, Chem. Ber. 1978, 111, 1453; d) U. Lucking et al, WO2005/37800.
- Reaction with bromocyane: see for example: a) D.T. Sauer et al, Inorganic Chemistry 1972, 11, 238; b) C. Bolm et al, Org. Lett. 2007, 9, 2951; c) U. Lucking et al, WO 2011/29537.
Scheme 6: Route for the preparation of compounds of general form ula 32, 33, 34, 35, 36 and 37,
wherein 1, R3, R4, R7, R8, R9, R10, R and R12 have the meaning as given for general formula (I), supra. In addition, the substituents R1 can bear a protecting group and the interconversion of any of the substituents R1 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups or cleavage of protecting groups. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.
Step 11 -» 32 (Scheme 6) A triflate of general formula 11 can be converted to the corresponding sulfonamide 32 under palladium catalysis in analogy to literature procedures. For example see J. Am. Chem. Soc, 2009, 131, 16720 - 16734 and references therein.
Step 11 -> 33 (Scheme 6)
A triflate of general formula 11 can be converted to the corresponding sulfoximines 33 under palladium catalysis in analogy to literature procedures. For example see US2001/144345.
Step 11 -» 34 (Scheme 6)
A triflate of general formula 11 can be converted to the corresponding sililated compound 34 under palladium catalysis in analogy to literature procedures. For example see Org. Lett. 2007, 9, 3785-3788 and references therein. Step 11 -» 35 (Scheme 6)
A triflate of general formula 11 can be converted to the phosphonate 35 under palladium catalysis in analogy to literature procedures. For example see US2008/9465
Step 11 -> 36 (Scheme 6)
A triflate of general formula 11 can be converted to the phosphinate 36 under palladium catalysis in analogy to literature procedures. For example see Adv. Synth. Cat., 2013, 355, 1361 - 1373 and references therein.
Step 11 -» 37 (Scheme 6)
A triflate of general formula 11 can be converted to the phosphine oxide 37 under palladium
catalysis in analogy to literature procedures. For example see US2007/4648
EXPERIMENTAL SECTION
The following table lists the abbreviations used in this paragraph, and in the examples section. Boc ieri-butyloxycarbonyl
BuLi Butyllithium
cone. concentrated
DCE Dichloroethane
DCM Dichloromethane
DMAP N,N-Dimethylaminopyridine
DME Dimethoxyethane
DMF Dimethylformamide
DMSO Dimethyl sulfoxide
EA Ethyl acetate
EtOAc Ethyl acetate
EtOH Ethanol
HPLC, LC high performance liquid chromatography
h hour
LiHMDS Lithium bis(trimethylsilyl)amide
KHMDS Potassium bis(trimethylsilyl)amide
KOtBU Potassium tert-butoxide
min minute
LCMS, LC-MS, LC/MS Liquid chromatography-mass spectrometry
LDA Lithium diisopropylamide
MS mass spectroscopy
NMR nuclear magnetic resonance
NMO N-metylmorpholine-N-oxide
NaHMDS Sodium bis(trimethylsilyl)amide
PE Petrol ether
Pd(dppf)CI2 [l, -Bis-diphenylphosphino-ferrocene]palladium(ll) dichloride Rac Racemate
Rf Retardiation factor
Rt Retention time
sat. saturated
rt, RT Room temperature
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TLC thin-layer chromatography
Chemical names were generated using ACD/Name Batch Version 12.01 or Autonom 2000.
All reagents, for which the synthesis is not described in the experimental part, are either commercially available or synthesized as described in literature references.
Analytical Methods
LC-MS Method 1:
column: Ascentis Express C18, 2.7 μιη, 3 cm x 2.1 mm
column temp.: 30 °C
injection volume: Ι μΙ
detection: MM-ES + APCI +DAD (254 nm)
fragment. potential: 50 V
mass range : 80-800 m/z
mobile phase A: water / 0.1% formic acid
mobile phase B: methanol / 0.1% formic acid
system time delay: 0.2 min
gradient:
LC-MS Method 2:
MS instrument type: Micromass Quatro Micro; HPLC instrument type: Agilent 1100 Series; UV DAD; column: Chromolith Flash RP-18E 25-2 mm; mobile phase A: 0.0375% TFA in water, mobile
phase B: 0.01875% TFA in acetonitrile; gradient: 0.0 min 100% A -> 1.0 min 95% A ->3.0 min 95% A -> 3.5 min 5% A -> 3.51 min 5% A -> 4.0 min 95% A; flow rate: 0.8 ml/min; col umn temp: 50 °C; UV detection: 220 nm & 254 nm. LC-MS Method 3:
System : MS (LBA639)
Binary Solvent Manager
Sample Manager
Organizer
Column Manger
PDA
ELSD
I njection volume: Ι μΙ
Column: Acquity UPLC BEH C18 1.7 50x2. lmm
Eluent Al: H20 + 0,l%Vol. HCOOH (99%)
A2: H20 + 0,2%Vol. NH3 (32%)
Bl: Acetonitril
Flow rate: 0,8 ml/min
Temperature: 60°C
Eluent Gradient Al + Bl: 0-1.6 min 1-99% Bl; 1.6-2.0 min
LC-MS Method 4:
I nstrument MS: Waters ZQ; Instrument HPLC: Waters UPLC Acquity; Column : Acquity BEH C18 (Waters), 50mm x 2.1mm, 1.7μιτι; eluent A: water +0,lvol% formic acid, eluent B: acetonitrile (Lichrosolv Merck); gradient: 0.0 min 99% A-1.6min 1% A-1.8 min 1%A - 1.81 min 99% A - 2.0min 99 % A; temperature: 60°C; flow: 0.8 mL/min; UV-Detection PDA 210-400nmnm - plus fixed wavelength 254 nm; MS ESI (+),Scan region 170-800 m/z
Preparative HPLC
Autopurifier: acidic conditions
System: Waters Autopurificationsystem: Pump 2545, Sample Manager 2767, CFO,
DAD 2996, ELSD 2424, SQD
Column: XBrigde C18 5 μητι 100 x 30 mm
Solvent: A = H20 + 0.1% Vol. HCOOH (99%)
B = MeCN
Gradient: 0.00 - 0.50 min 5% B, 25 ml/min
0.51 - 5.50 min 10-100% B, 70 ml/min
5.51 - 6.50 min 100% B, 70 mL/min
Temperature: T
Solution: max. 250 mg / max. 2.5 mL DMSO or DMF
Injection: 1 x 2.5 ml
Detection: DAD scan range 210-400 nm
MS ESI+, ESI-, scan range 160-1000 m/z
Autopurifier: basic conditions
System: Waters Autopurificationsystem: Pump 2545, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD
Column: XBrigde C18 5 μηι 100 x 30 mm
Solvent: A = H20 + 0.2% Vol. NH3 (32%)
B = MeCN
Gradient: 0.00 - 0. 50 min 5% B, 25ml/min
0.51 - 5.50 min 10-100% B, 70ml/min
5.51 - 6.50 min 100% B, 70ml/min
Temperature: RT
Solution: max. 250 mg / max. 2.5 mL DMSO or DMF
Injection: 1 x 2.5 ml
Detection: DAD scan range 210-400 nm
MS ESI+, ESI-, scan range 160-1000 m/z
Preparation of Intermediates
lntermediate-1
Step a:
methyl-2-chloro-3-[l-morpholin-4-yleth-(£)-ylideneamino]isonicotinate
Under argon and at a temperature of 0°C, 2.44 ml (25.40 mmol) of phosphorus oxychloride were added to a solution of 2.17 ml (18.8 mmol) of /V-acetylmorpholine in 12 ml of absolute dichloroethane. The yellow solution was stirred at room temperature for 30 min. 1.75 g (9.39 mmol) of methyl 3-amino-2-chloroisonicotinate were then added. The mixture was stirred at 80°C for 3 h. Dichloroethane was distilled off. Without work-up, the residue was purified by column chromatography [Puriflash silica gel 60 (80 g, 30 μιη); ethyl acetate/methanol 1:1, (300 ml)]. In this manner, methyl 2-chloro-3-[l-morpholin-4-yleth-(f)-ylideneamino]isonicotinate was obtained in a yield of 2.5 g (89% of theory) as a yellow oil. :H NM (400 MHz, CDCI3): δ [ppm] = 1.79-1.84 (2H), 2.14 (3H), 3.66-67 (4H), 3.88-3.91 (4H), 3.93 (3H), 7.77 (1H), 8.56 (2H).
Step b:
8-chloro-2-(morpholin-4-yl)-[l,7]naphthyridin-4-ol
Under argon and at 0°C, 20.1 ml (20.1 mmol) of lithium bis(trimethylsilyl)amide were added dropwise to a solution of 2.0 g (6.7 mmol) of methyl 2-chloro-3-[l-morpholin-4-yleth-(£)- ylideneamino]isonicotinate in 20 ml of dry /V,/V-dimethylformamide. The mixture was then stirred at room temperature for 3 h. For work-up, 2 ml of water were added and the mixture was concentrated. The residue was chromatographed [Puriflash silica gel 60 (80 g, 30 μιτι), ethyl acetate/methanol 1:1 (500 ml)]. 1.16 g (65% of theory) of 8-chloro-2-morpholin-4-yl- [l,7]naphthyridin-4-ol were isolated as a light-yellow solid. 1H NMR (400 MHz, DMSO): δ [ppm] = 3.63-3.65 (4H), 3.72-3.74 (4H), 6.62 (1H), 7.73 (1H), 7.98 (1H), 11.62 (1H). lntermediate-2
2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-ol
Under argon, 244 mg (0.30 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1) and 650 mg (2.00 mmol) of caesium carbonate were added to a suspension of 556 mg (2.00 mmol) of l-(tetrahydropyran-2-yl)-5-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolane-2-yl)-lH-pyrazole and 266 mg (1.00 mmol) of 8-chloro-2-morpholin-4-yl- [l,7]naphthyridin-4-ol in 4.0 ml of absolute 1,4-dioxane. The reaction mixture was stirred at 80°C for 16 h. The brown reaction solution was purified via column chromatography [silica gel 60 (30 g); ethyl acetate (200 ml)]. In this manner, 206 mg (54% of theory) of 2-morpholin-4-yl-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-ol were isolated as a yellow oil. LCMS (method 1): m/z: [M+H]+ = 382.3, t = 3.0 min. lntermediate-3
2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin
trifluoromethanesulphonate
Under argon, 25 μΙ (0.15 mmol) of diisopropylethylamine were added to a solution of 28 mg (0.07 mmol) of 2-morpholin-4-yl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4- ol and 39 mg (0.11 mmol) of W-phenylbis(trifluoromethanesulphonimide) in 3.0 ml of absolute dichloromethane. The reaction mixture was stirred at room temperature for 16 h. The brown reaction solution was purified via column chromatography [silica gel 60 (12 g, 30 μιη); ethyl acetate (100 ml)]. 34 mg (88% of theory) of 2-morpholin-4-yl-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate were isolated as a yellow oil. 1H NMR (400 MHz, CDCI3): δ [ppm] = 1.48-1.52 (1H), 1.63-1.71 (2H), 2.04-2.10 (2H), 2.48-2.54 (1H), 3.62-3.75 (4H), 3.80-3.83 (4H), 3.92 (1H), 6.04-6.06 (1H), 6.96 (1H), 7.10 (1H), 7.26 (1H), 7.61
(1H), 7.69 (1H), 8.53 (1H). lntermediate-4
4,8-dichloro-2-(morpholin-4-yl)-[l,7]naphthyridine
3 g (11.3 mmol) of 8-chloro-2-(morpholin-4-yl)-[l,7]naphthyridin-4-ol were suspended in 10 ml (107 mmol) of phosphorus oxychloride, and the mixture was stirred at 95°C for 3 h. A clear brown solution was formed. For work-up, the mixture was, with ice-cooling, carefully adjusted to pH 8 using 5N sodium hydroxide solution. This aqueous phase was extracted three times with in each case 50 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The resulting brown solid was triturated with 10 ml of methanol, filtered off and then dried. This gave 2.48 g (77% of theory) of 4,8-dichlori-2- (morpholin-4-yl)-[l,7]naphthyridine as a light-brown solid. LC-MS (method 1): m/z: [M+H]+ = 284.2, , = 3.53 min. lntermediate-5
4 hloro-2-(morpholin-4-yl)-8-[2-(tetrah dropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
Under argon, 813 mg (0.7 mmol) of tetrakis(triphenylphosphine)palladium(0) and 2.92 g (21.1 mmol) of potassium carbonate were added to a suspension of 2 g (7.04 mmol) of 4,8-dichloro-2-(morpholin-4-yl)-[l,7]naphthyridine and 2.94 g (10.56 mmol) of l-(tetrahydro-2H- pyran-2-yl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole in 30 ml of dimethoxyethane and 3 ml of water. The reaction mixture was stirred at 100°C for 2 h. For workup, 20 ml of sodium bicarbonate solution were added to the mixture. The precipitated solid was filtered off and washed with 5 ml of water. This gave 2 g (71% of theory) of 4-chloro-2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow solid.
LC-MS (method 1): m/z: [M+H]+ = 400.3, , = 3.62 min. lntermediate-6
8-chloro-4-isopropoxy-2-(morpholin-4-yl)-l,7-naphthyridine
A suspension of 8-Chloro-2-(morpholin-4-yl)-[l,7]naphthyridin-4-ol (2.66 g, 10 mmol), 2- iodopropane (2 ml, 20 mmol) and potassium carbonate (1.66 g, 12 mmol) in acetonitrile (100 ml) were stirred for 8 hours at 85°C. The reaction mixture was allowed to cool to ambient temperature, the solvent was distilled off under reduced pressure and the residue was dissolved in water (30 ml) and dichloromethane (50 ml). The layers were separated and the aqueous phase was extracted with dichloromethane (3x 30 ml). The combined organic phases were dried over sodium sulphate and the solvent distilled off under reduced pressure.
The residue was crystallized from methanol (10 ml) and dried. The title compound was obtained in 2g as white solid. 1H-NMR (400 MHz, DMSO-d6): δ [ppm]= 1.38 (6H), 3.67 - 3.82 (8H), 4.99 - 5.12 (1H), 6.83 (1H), 7.68 (1H), 7.99 (1H). lntermediate-7
Step a:
l-((ff)-3-methylmorpholin-4-yl)ethano
12.8 g (127 mmol) of (/?)-3-methylmorpholine and 52.7 g (381 mmol) of potassium carbonate were suspended in 300 ml of dichloromethane, the mixture was stirred at room temperature for 30 min, 19.9 g (254 mmol) of acetyl chloride were added and the mixture was stirred at room temperature for 18 h. The conversion was monitored by NMR. For work-up, the precipitated solid was filtered off with suction and washed with 200 ml of dichloromethane. The mother liquor was concentrated to dryness. 17.19 g (95% of theory) of l-[(/?)-3-methylmorpholin-4-yl]ethanone were
isolated as a yellow oil. :H NM (400 MHz, CDCI3): δ [ppm] = 1.23-1.35 (3H), 2.04-2.08 (3H), 2.98 (1/2H), 3.40-3.49 (2H), 3.53-3.60 (1H), 3.66-3.69 (1H), 3.79 (1/2H), 3.87 (1H), 4.24 (1/2H), 4.56 (1/2H). Step b:
methyl 2 hloro-3-[l-((/?)-3-methylmorpholin-4-yl)eth-(£)-ylideneamino]isonicotinate
Under argon and at a temperature of 0°C, 17.1 ml (188 mmol) of phosphorus oxychloride were added to a solution of 9.00 g (62.8 mmol) of l-[(/?)-3-methylmorpholin-4-yl]ethanone in 78 ml of absolute 1,2-dichloroethane. The yellow solution was stirred at room temperature for 30 min. 11.7 g (62.8 mmol) of methyl 3-amino-2-chloroisonicotinate were then added. The mixture was stirred at 80°C for 1 h, at room temperature overnight and on the next day at 80°C for another 5 h. The 1,2-dichloroethane was distilled off. For work-up, the mixture was taken up in 200 ml of dichloromethane and 100 ml of water, sodium carbonate was added slowly and a little at a time with vigorous stirring (pH = 9) and the mixture was extracted three times with in each case 250 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness under reduced pressure. In this manner, methyl 2-chloro-3-[l-((/?)-3- methylmorpholin-4-yl)eth-(f)-ylideneamino]isonicotinate was obtained in a yield of 19.5 g (100% of theory) as a brown oil which was used without further purification in the next step. H NMR (400 MHz, CDCI3): δ [ppm] = 1.37 (3H), 1.78 (3H), 3.35 (1H); 3.58 (1H), 3.72-3.75 (3H), 3.83 (3H), 3.95 (1H), 4.28 (1H), 7.52 (1H), 8.01 (1H). LC-MS (method 1): Rt = 0.23 min; MS (ESI/APCIpos) m/z = 312.2 [M+H]+.
Step c:
8-chloro-2-((/?)-3-methylmorpholin- -yl)-[l,7]naphthyridin-4-ol
Under argon and at 0°C, a solution of 31.4 g (187 mmol) of lithium bis(trimethylsilyl)amide dissolved in 250 ml of dry tetrahydrofuran was added dropwise over a period of 15 min to a solution of 19.5 g (62.8 mmol) of methyl 2-chloro-3-[l-((/?)-3-methylmorpholin-4-yl)eth-(f)- ylideneamino]isonicotinate in 600 ml of dry tetrahydrofuran. The mixture was then stirred at room temperature for 3 h. For work-up, 50 ml of water were carefully added and the mixture was concentrated to dryness under reduced pressure. The residue was taken up in 600 ml of saturated ammonium chloride solution and extracted four times with in each case 200 ml of dichloromethane/isopropanol (4:1). The combined organic phases were dried over sodium sulphate, filtered and, under reduced pressure, concentrated to dryness. The residue was recrystallized from 250 ml of acetonitrile (7.56 g). The mother liquor was concentrated and the residue was recrystallized again from 125 ml of acetonitrile (3.65 g). 11.2 g (64% of theory, 1st fraction, clean) and 2.63 g (14% of theory, 2nd fraction, about 90% pure, concentrated mother liquor) of 8-chloro-2-((/?)-3-methylmorpholin-4-yl)-[l,7]naphthyridin-4-ol were isolated as a yellow-orange solid. H NM (400 MHz, DMSO-d5): δ [ppm] = 1.21 (3H), 3.18 (1H), 3.49 (1H), 3.65 (1H), 3.77 (1H), 3.98 (1H), 4.15 (1H), 4.41 (1H), 6.59 (1H), 7.72 (1H), 7.97 (1H), 11.59 (1H). LC-MS (method 1): R, = 3.05 min; MS (ESI/APCIpos) m/z = 280.2 [M+H]+. lntermediate-8
4,8-dichloro-2-[(3R)-3-methylmorpholin-4-yl]-l,7-naphthyridine
0.50 g (1.8 mmol) of 8-chloro-2-[(3R)-3-methylmorpholin-4-yl]-l,7-naphthyridin-4-ol were suspended in 1.6 ml (17 mmol) of phosphorus oxychloride, and the mixture was stirred at 95°C for 3 h. The reaction was cooled to room temperature and then placed in an ice bath. The reaction was carefully quenched by dropwise addition of NaOH (3N) until pH 9. The aqueous phase was extracted 3 times with CH2CI2. The organic layer was dried (silicon filter) and concentrated under reduced pressure. The crude mixture was then stirred with MeOH and filter. The solid was dried under reduced pressure at 40°C. The desired compound was obtained without further purification. 1H-NMR (300MHz, DMSO-d5): δ [ppm]= 1.25 (3H), 3.19 - 3.31 (1H), 3.50 (1H), 3.61 - 3.69 (1H), 3.74 - 3.81 (1H), 3.99 (1H), 4.29 (1H), 4.57 - 4.67 (1H), 7.77 - 7.81 (2H), 8.14 (1H). LC-MS (Method 3): m/z: [M+H]+ = 299, R, = 1.24 min.
lntermediate-9
2-[((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H^yrazol-3-yl]-[l,7]naphthyridm 4-ol
Under argon, 146 mg (0.18 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1) and 2.33 g (7.15 mmol) of caesium carbonate were added to a suspension of 500 mg (1.79 mmol) of 8-chloro-2-((/?)-3-methylmorpholin-4-yl)- [l,7]naphthyridin-4-ol and 746 mg (2.68 mmol) of l-(tetrahydropyran-2-yl)-5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolane-2-yl)-lH-pyrazole in 7.5 ml of absolute 1,4-dioxane. The reaction mixture was stirred at 90°C for 16 h. The brown reaction solution was purified via column chromatography [silica gel 60 (30 g); ethyl acetate (200 ml)] . In this manner, 506 mg (72% of theory) of 2-[(/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridin-4-ol were isolated as a yellow oil. LCMS (method 1): m/z: [M+H]+ = 396.3,
lntermediate-10
2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate
Under argon a solution of 4.81 g (11.74 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-ol, 6.43 g (18 mmol)
N-Phenylbis(trifluoromethanesulfonimide) and 4.18 ml (24 mmol) Ν,Ν-Diisopropylethylamin in 100 ml absolute dichloromethane was stirred for 3 days at room temperature. The solvent was distilled off under reduced pressure and the residue was chromatographed twice [silica gel 60 (400 g); dichlormethane / methanol, 98 : 2/ ethyl acetate]. The title compound was obtained in 2.6 g (42 % of theory) as yellow solid. LC-MS (method 1): m/z: [M+H]+ = 528.2, t = 4.00 min.
Intermediate-ll
Step a:
l-((S)-3-methylmorpholin-4-yl)ethanone
12.8 g (127 mmol) of (S)-3-methylmorpholine and 52.7 g (381 mmol) of potassium carbonate were suspended in 300 ml dichloromethane, the mixture was stirred at room temperature for 30 min, 19.9 g (254 mmol) of acetyl chloride were added with ice bath cooling and the mixture was stirred at room temperature for 7 d. The potassium carbonate was filtered off with suction and washed. With ice bath cooling, 43 ml (248 mmol) of /V,/V-diisopropylethylamine were added to the mother liquor, and the mixture was stirred at room temperature for 1 h. The solution was washed three times with in each case 200 ml of water, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure. 9.39 g (69% of theory) of l-((S)-3- methylmorpholin-4-yl)ethanone were isolated as a brown oil. 1H NMR (400 MHz, CDCI3): δ [ppm] = 1.23-1.35 (3H), 2.04-2.08 (3H), 2.98 (1/2H), 3.40-3.49 (2H), 3.53-3.60 (1H), 3.66-3.69 (1H), 3.79 (1/2H), 3.87 (1H), 4.24 (1/2H), 4.56 (1/2H).
Step b:
methyl 2 hloro-3-[l-((S)-3-methylmorpholin-4-yl)eth-(£)-ylideneamino]isonicotinate
Under argon and at a temperature of 0°C, 18.3 ml of (197 mmol) of phosphorus oxychloride were added to a solution of 9.39 g (65.6 mmol) of l-((S)-3-methylmorpholin-4-yl)ethanone in 83 ml of
absolute 1,2-dichloroethane. The yellow solution was stirred at room temperature for 30 min. 12.37 g (65.6 mmol) of methyl 3-amino-2-chloroisonicotinate were then added. The mixture was stirred at 80°C for 5 h. The 1,2-dichloroethane was distilled off. For work-up, the mixture was taken up in 200 ml of dichloromethane and 100 ml of water, with vigorous stirring, by slowly adding, a little at a time, solid sodium carbonate, the pH was adjusted to pH = 9 and the mixture was then extracted three times with in each case 250 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated under reduced pressure. In this manner, methyl 2-chloro-3-[l-((S)-3-methylmorpholin-4-yl)eth-(f)- ylideneamino]isonicotinate was obtained in a yield of 19.2 g (94% of theory) as a brown oil which was reacted further without further purification. :H NM (400 MHz, CDCI3): δ [ppm] = 1.37 (3H), 1.78 (3H), 3.35 (1H); 3.58 (1H), 3.72-3.75 (3H), 3.83 (3H), 3.95 (1H), 4.28 (1H), 7.52 (1H), 8.01 (1H). LC-MS (method 1): R, = 0.23 min; MS (ESI/APCIpos) m/z = 312.2 [M+H]+.
Step c:
8-chloro-2-((S)-3-methylmorpholin- -yl)-[l,7]naphthyridin-4-ol
Under argon at 0°C, a solution of 30.8 g (184 mmol) of lithium bis(trimethylsilyl)amide, dissolved in 250 ml of dry tetrahydrofuran, was added dropwise over a period of 15 min to a solution of 19.2 g (61.5 mmol) of methyl 2-chloro-3-[l-(S)-3-methylmorpholin-4-yl)eth-(E)- ylideneamino]isonicotinate in 600 ml of dry tetrahydrofuran. The mixture was then stirred at room temperature for 3 h. For work-up, 50 ml of water were carefully added and the mixture was concentrated under reduced pressure. The residue was taken up in 600 ml of saturated ammonium chloride solution and extracted four times with in each case 200 ml of dichloromethane/isopropanol (4:1). The combined organic phases were dried over sodium sulphate, filtered and, under reduced pressure, concentrated to dryness. The residue was recrystallized from 250 ml of acetonitrile (5.7 g). The mother liquor was concentrated and the residue was recrystallized again from 125 ml of acetonitrile (5.0 g). 10.7 g (62% of theory, 1st fraction, clean) and 4.53 g (24% of theory, 2nd fraction, about 90% pure, concentrated mother liquor) of 8-chloro-2-((S)-3-methylmorpholin-4-yl)-[l,7]naphthyridin-4-ol were isolated as a brown solid. :H NMR (400 MHz, DMSO-d5): δ [ppm] = 1.21 (3H), 3.18 (1H), 3.49 (1H), 3.65 (1H), 3.76 (1H),
3.98 (1H), 4.15 (1H), 4.40 (1H), 6.60 (1H), 7.72 (1H), 7.97 (1H), 11.6 (1H). LC-MS (method 1): , = 3.05 min; MS (ESI/APCIpos) m/z = 280.2 [M+H]+.
Step d:
2-((S)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H^yrazol-3-yl]-[l,7]naphthyridin 4-ol
Under argon, 583 mg (0.75 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1) and 9.31 g (28.6 mmol) of caesium carbonate were added to a suspension of 2.00 g (7.15 mmol) of 8-chloro-2-((S)-3-methyl-morpholin-4-yl)-[l,7]naphthyridin- 4-ol and 2.98 g (10.7 mmol) of l-(tetrahydropyran-2H-pyran-2-yl)-lH-pyrazol-5-boronic acid pinacol ester in 80 ml of absolute 1,4-dioxane. The reaction mixture was degassed three times and stirred at 85°C for 3 h. Since, according to LC/MS, conversion was incomplete and there was no further conversion (starting materiahproduct about 40:60), another 2 g of l-(tetrahydropyran- 2H-pyran-2-yl)-lH-pyrazole-5-boronic acid pinacol ester, 200 mg of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1) and 3 g of caesium carbonate were added to the reaction solution and the mixture was stirred at 85°C for 1 h. The solvent was distilled off and 100 ml of saturated ammonium chloride solution were added to the residue. The aqueous phase was extracted four times with in each case 100 ml of dichloromethane/isopropanol 4:1. The combined organic phases were dried over sodium sulphate and then concentrated to dryness under reduced pressure. The residue was chromatographed [silica gel 60 (2 x 80 g, 50 μητι); dichloromethane/methanol 96:4 to 90:10]. This gave 402 mg (13% of theory) of 2-((S)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridin-4-ol as a brown solid. H NMR (400 MHz, DMSO-d5): δ [ppm] = 1.18 (3H), 1.44- 1.61 (3H), 1.91-2.00 (2H), 2.32-2.40 (1H), 3.09-3.18 (1H), 3.21-3.28 (1H), 3.45 (1H), 3.60-3.76 (3H), 3.91-4.02 (2H), 4.30 (1H), 6.09 (1H), 6.59 (1H), 6.91 (1H), 7.59 (1H), 7.77 (1H), 8.33 (1H), 11.46 (1H). LC-MS (method 1): R, = 3.08 min; MS (ESI/APCIpos) m/z = 396.2 [M+H]+. lntermediate-12
8-chloro-2-[(3/?)-3-methylmorpholin-4-yl]-4-(propan-2-yloxy)-l,7-naphthyridine
2.96 g (21.5 mmol) of potassium carbonate were added to a solution of 5 g (18 mmol) of 8-chloro- 2-(morpholin-4-yl)-[l,7]naphthyridin-4-ol and 3.57 ml (36 mmol) of 2-iodopropane in 50 ml of dry acetonitrile. The suspension was stirred at 85°C for 2 h. The course of the reaction was monitored by LCMS. 100 ml of water were added to the mixture. The aqueous phase was extracted three times with in each case 50 ml ethyl acetate. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (80 g, 30 μηη); ethyl acetate (500 ml)]. 4 g (70% of theory) of 8-chloro-2-[(3/?)-3-methylmorpholin-4-yl]- 4-(propan-2-yloxy)-l,7-naphthyridine were obtained as a beige solid. LC-MS (method 1): m/z: [M+H]+ = 322.2, t = 3.79 min. lntermediate-13
Step a:
4,8-dichloro-2-(morpholin-4-yl)-[l,7]naphthyridine
3 g (11.3 mmol) of 8-chloro-2-(morpholin-4-yl)-[l,7]naphthyridin-4-ol were suspended in 10 ml (107 mmol) of phosphorus oxychloride, and the mixture was stirred at 95°C for 3 h. A clear brown solution was formed. For work-up, the mixture was, with ice-cooling, carefully adjusted to pH 8 using 5N sodium hydroxide solution. This aqueous phase was extracted three times with in each case 50 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The resulting brown solid was triturated with 10 ml of methanol, filtered off and then dried. This gave 2.48 g (77% of theory) of 4,8-dichlori-2- (morpholin-4-yl)-[l,7]naphthyridine as a light-brown solid. LC-MS (method 1): m/z: [M+H]+ = 284.2, R, = 3.53 min.
Step b:
4 hloro-2-(morpholin-4-yl)-8-[2- tetrahydropyran-2-yl)-2H^yrazol-3-yl]-[l,7]naphthyridine
Under argon, 813 mg (0.7 mmol) of tetrakis(triphenylphosphine)palladium(0) and 2.92 g (21.1 mmol) of potassium carbonate were added to a suspension of 2 g (7.04 mmol) of 4,8-dichloro-2-(morpholin-4-yl)-[l,7]naphthyridine and 2.94 g (10.56 mmol) of l-(tetrahydro-2H- pyran-2-yl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole in 30 ml of dimethoxyethane and 3 ml of water. The reaction mixture was stirred at 100°C for 2 h. For work- up, 20 ml of sodium bicarbonate solution were added to the mixture. The precipitated solid was filtered off and washed with 5 ml of water. This gave 2 g (71% of theory) of 4-chloro-2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 400.3, R, = 3.62 min. lntermediate-14
Step a:
l-[(3R,5S)-3,5-dimethylmorpholin-4-yl]
(3R,5S)-3,5-Dimethylmorpholine (0.50 g, 4.3 mmol, 1 eq.) was solubilized in pyridine (8.6 mL, 0.11 mol, 25 eq.) and acetic anhydride (4.0 mL, 42 mmol, 10 eq.) was added. The reaction was stirred for 16 hours at room temperature. The reaction mixture was then concentrated under reduced pressure and the desired product was obtained in 95% yield (0.64 g). :H NMR (400 MHz, DMSO- d6) δ ppm: 1.22 (6H), 2.00 (3H), 3.44 (2H), 3.65 (2H), 4.00 (2H). LC-MS (Method 3): m/z: [M+H]+ = 158, Rt = 0.57 min.
Step b:
methyl 2-chloro-3-[(EHl-[(3R,5S)-3 -dimethylmorpholin-4-yl]ethylidene}amino] isonicotinate
l-[(3R,5S)-3,5-Dimethylmorpholin-4-yl]ethanone (0.54 g, 3.4 mmol, 2.3 eq.) was solubilized in DCE (2.7 mL) and the reaction mixture was cooled to 0°C. POCI3 (0.46 mL, 4.3 mmol, 3.3 eq.) was added slowly and the reaction was warmed up to rt. After 30 minutes, methyl 3-amino-2- chloroisonicotinate (0.28 g, 1.5 mmol, 1 eq.) was added in one portion and the mixture was stirred at 80°C. After 6 hours, the reaction was cooled to room temperature and the solvent was removed under reduced pressure. The crude mixture was diluted with CH2CI2 and washed three times with sat. NaHCC>3. The organic phase was dried (MgSC ) and concentrated under reduced pressure. The crude mixture was purified by flash chromatography (gradient: 100% hexane to 100% EtOAc). The desired product was obtained in 58% yield (0.28 g). H NMR (400 MHz, DMSO- d6) δ ppm: 1.29 (3H), 1.33 (3H), 1.77 (3H), 3.56 (2H), 3.72 (2H), 3.77 (3H), 4.06 - 4.24 (2H), 7.56 (1H), 8.01 (1H). LC-MS (Method 3): m/z: [M+H]+ = 326, R, = 0.85 min.
Step c:
8 hloro-2-[(3R,5S)-3,5-dimethylmorpholin-4-yl]-4-isopropoxy-l,7-naphthyridine
Methyl 2-chloro-3-[(E)-{l-[(3R,5S)-3,5-dimethylmorpholin-4-yl]ethylidene}amino] isonicotinate (0.28 g, 0.86 mmol, 1 eq.) was solubilised in dry THF (6 mL) under inert atmosphere (Argon). The reaction mixture was cooled to 0°C and a solution of LiHMDS (1.0 M in THF, 2.5 mL, 2.6 mmol, 3 eq.) was added slowly. The reaction mixture was stirred for 16 h at room temperature. The reaction was quenched with H20 and concentrated under reduced pressure. The crude 8-chloro- 2-[(3R,5S)-3,5-dimethylmorpholin-4-yl]-l,7-naphthyridin-4-ol (0.36 g) was used in the next step without further purification. CH3CN (10 mL) was added to 8-chloro-2-[(3R,5S)-3,5-
dimethylmorpholin-4-yl]-l,7-naphthyridin-4-ol (0.20 g, 0.68 mmol, 1 eq.). 2-lodopropane (0.13 mL, 1.4 mmol, 2 eq.) and K2C03 (0.14 g, 0.81 mmol, 1.2 eq.) were sequentially added to the suspension. The reaction mixture was stirred at 85°C for 16h. The reaction was cooled to room temperature and diluted with EtOAc and washed three times with H20. The organic phase was dried (MgS04) and concentrated under reduced pressure. The desired product was obtained without further purification in 60 % yield over two steps. 1H-NM (400MHz, DMSO-de): <5 [ppm] : 1.31 (6H), 1.39 (6H), 3.64 (2H), 3.83 (2H), 4.54 (2H), 5.04 (1H), 6.66 (1H), 7.68 (1H), 7.97 (1H). LC- MS (Method 3): m/z: [M+H]+ = 336, Rt = 1.39 min. lntermediate-15
Step a:
l-[(3R,5R)-3,5-dimethylmorpholin-4-yl]
(3R,5R)-3,5-Dimethylmorpholine (0.50 g, 4.3 mmol, 1 eq.) was solubilized in pyridine (8.6 mL, 0.11 mmol, 25 eq.) and acetic anhydride (4.0 mL, 0.42 mmol, 10 eq.) was added. The reaction was stirred for 16 hours at room temperature. The reaction mixture was then concentrated under reduced pressure and the desired product was obtained in quantitative yield. H NMR (400 MHz, DMSO-c/5) δ ppm: 1.26 (6H), 2.00 (3H), 3.43 - 3.59 (2H), 3.83 - 3.97 (4H). LC-MS (Method 3): m/z: [M+H]+ = 158, R, = 0.56 min.
Step b:
methyl 2-chloro-3-[(EHl-[(3R,5R)- -dimethylmorpholin-4-yl]ethylidene}amino] isonicotinate
l-[(3R,5R)-3,5-Dimethylmorpholin-4-yl]ethanone (0.70 g, 4.4 mmol, 2.3 eq.) was solubilized in DCE (10 mL) and the reaction mixture was cooled to 0°C. POCI3 (0.59 mL, 6.4 mmol, 3.3 eq.) was added slowly and the reaction was warmed up to rt. After 30 minutes, methyl 3-amino-2- chloroisonicotinate (0.36 g, 1.9 mmol, 1 eq.) was added in one portion and the mixture was
stirred at rt. After 48 hours, the reaction was quenched with sat. NaHC03 and extracted three times with CH2CI2. The organic phase was dried (MgS04) and concentrated under reduced pressure. The crude mixture was purified by flash chromatography (gradient: 100% hexane to 100% EtOAc). The desired product was obtained in 18% yield (0.12 g). :H NM (400 MHz, DMSO- d6) δ ppm: 1.26 (3H), 1.33 (3H), 1.79 (3H), 3.55 (2H), 3.77 (3H), 3.89 - 4.00 (4H), 7.54 - 7.58 (1H), 8.02 - 8.06 (1H).
Step c:
8 hloro-2-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-4-isopropoxy-l,7-naphthyridine
Methyl 2-chloro-3-[(E)-{l-[(3R,5R)-3,5-dimethylmorpholin-4-yl]ethylidene}amino]isonicotinate (0.12 g, 0.36 mmol, 1 eq.) was solubilised in dry THF (2.5 mL) under inert atmosphere (Argon). The reaction mixture was cooled to 0°C and a solution of LiHMDS (1.0 M in THF, 1.1 mL, 1.1 mmol, 3 eq.) was added slowly. The reaction mixture was stirred for 16 h at room temperature. The reaction was quenched with H2O and concentrated under reduced pressure The crude 8-chloro-2- [(3R,5R)-3,5-dimethylmorpholin-4-yl]-l,7-naphthyridin-4-ol (0.36 g) was used in the next step without further purification. CH3CN (6.8 mL) was added to 8-chloro-2-[(3R,5R)-3,5- dimethylmorpholin-4-yl]-l,7-naphthyridin-4-ol (0.14 g, 0.46 mmol, 1 eq.). 2-lodopropane (0.10 mL, 0.90 mmol, 2 eq.) and K2C03 (74 mg, 0.55 mmol, 1.2 eq.) were sequentially added to the suspension. The reaction mixture was stirred at 85°C for 48 h. The reaction was cooled to room temperature and diluted with H20, extracted three times with CH2CI2 and washed with sat. NaCI. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The desired product was obtained without further purification in 52% yield over two steps (81 mg). H-NM (400MHz, DMSO-dg): <5 [ppm] : 1.26 (6H), 1.39 (6H), 3.58 - 3.64 (2H), 3.99 - 4.04 (2H), 4.17 - 4.25 (2H), 4.97 - 5.07 (1H), 6.85 (1H), 7.73 (1H), 8.06 (1H). LC-MS (Method 3): m/z: [M+H]+ = 336, R, = 1.38min. lntermediate-16
Step a:
l-bromo-3-(methylsulfinyl)benzene
To a solution of (3-bromophenyl)(methyl)sulfane (50.0 g, 0.246 mol) in CH3CN (500 mL) was added FeCI3 (1.2 g, 1 A mmol) with stirring. After the addition, the mixture was stirred at room temperature for 10 min and then cooled to 0 °C. Η5Ι06 (62.0 g, 0.212 mol) was added in portions and then the mixture was stirred at 0 °C for 1 h. TLC (PE: EA = 3: 1, Rf = 0.4) showed the most of starting material was consumed. The reaction mixture was quenched by the addition of saturated aqueous NH4CI (1.0 L) and extracted with EA (300 mL x 3). The combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure to give l-bromo-3-(methylsulfinyl)benzene (55.0 g) as yellow oil, which was used directly in the next step without further purification.
-3-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)
To a suspension of l-bromo-3-(methylsulfinyl)benzene (55.0 g, 0.251 mol), ethyl carbamate (45.0 g, 0.505 mol), MgO (40.3 g, 1.0 mol) and Rh2(OAc)4 (2.6 g, 7.6 mmol) in DCM (600 mL) was added Phl(OAc)2 (122.0 g, 0.378 mol) carefully under N2. The mixture was stirred at room temperature for 5 days. TLC (PE: EA = 1: 1, f = 0.8) showed the most of starting material was consumed. The mixture was filtered and the filtrate was concentrated under reduced pressure to give the crude compound, which was chromatographed on silica gel (PE: EA = 20: 1-5: 1) to give l-bromo-3-(N- (ethoxycarbonyl)-S-methylsulfonimidoyl)benzene (55.0 g, 81.4% of theory) as white solid. 1H NMR (400 MHz, CDCI3): δ = 8.15 - 8.14 (1H), 7.94 - 7.92 (1H), 7.81 - 7.80 (1H), 7.51 - 7.47 (1H), 4.13 - 4.08 (2H), 3.32 (3H), 1.25 (3H).
Step c:
4A5,5-tetramethyl-(3-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)phenyl)-l,3,2-dioxaborolane
To a solution of l-bromo-4-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)benzene (55.0 g, 0.18 mol) in anhydrous dioxane (600 mL) was added 4,4,4',4l,5,5,5l,5'-octamethyl-2,2l-bi( l,3,2- dioxaborolane) (53.0 g, 0.209 mol), KOAc (35.3 g, 0.34 mol) and Pd(dppf)CI2 (4.0 g, 5A7 mmol ) under N2. After the addition, the mixture was stirred at 80 °C for 4 h. TLC (PE: EA = 1: 1, f = 0.6) showed the most of starting material was consumed. The mixture was filtered and to the filtrate was added CH3COOH (20.0 g, 0.33 mol) and Pinacol (30.0 g, 0.253 mol). The resulting mixture was stirred at room temperature for 18 h. The mixture was concentrated and chromatographed on silica gel (PE: EA = 20: 1-5: 1) to give the crude, which was washed by PE/EA (100 mL x 2, PE: EA = 1: 10) to give 4,4,5, 5-tetramethyl-(3-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl) phenyl)-l,3,2- dioxaborolane (35.0 g, 55.2% of theory) as white solid. H N MR (400 MHz, MeOD-d4): δ = 8.40 (1H), 8.09 - 8.07 (1H), 7.61 - 7.58 (1H), 4.13 - 4.07 (2H), 3.32 (3H), 1.35 ( 12H), 1.25 - 1.22 (3H). LC- MS method 2: (ES-API) m/z = 272.0 (M+H-82)+. lntermediate-17
Step a:
l-bromo-4-(methylsulfinyl)benzene
To a solution of (3-bromophenyl)(methyl)sulfane ( 100.0 g, 0.492 mol) in CH3CN (500 mL) was
added FeCI3 (2.4 g, 14.8 mmol) with stirring. After the addition, the mixture was stirred at room temperature for 10 min and then cooled to 0 °C. H5I05 (124.2 g, 0.545 mol) was added in portions and the mixture was stirred at 0 °C for 1 h. TLC (PE : EA = 5 : 1, Rf = 0.2) showed the most of starting material was consumed. The reaction mixture was quenched by the addition of saturated aqueous NH4CI (1.0 L) and extracted with EA (300 mL x 4). The organic layers were washed with brine (300 mL), dried over Na2SC>4 and concentrated. The residue was purified by chromatography on silica gel (PE/EA = 20: 1 ~ 5: 1) to give l-bromo-4-(methylsulfinyl)benzene (103.0 g, 95.5% of theory) as a white solid. Step b
l-bromo-4-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)benzene
To a suspension of l-bromo-4-(methylsulfinyl)benzene (100.0 g, 0.456 mol), ethyl carbamate (77.0 g, 0.864 mol), MgO (73.4 g, 1.821 mol) and Rh2(OAc)4 (4.7 g, 10.63 mmol) in DCM (1.5 L) was added Phl(OAc)2 (221.5 g, 0.688 mol) carefully under N2. The mixture was stirred at room temperature for 7 days. TLC (PE : EA = 1 : 1, f = 0.7) showed the most of starting material was consumed. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (PE/EA = 20: 1 ~ 5: 1) to give l-bromo-4- (N-(ethoxycarbonyl)-S-methylsulfonimidoyl)benzene (95.0 g, 68.0% of theory) as a white solid. H NMR (400 MHz, CDCI3): δ = 7.87 - 7.85 (2H), 7.76 - 7.74 (2H), 4.13 - 4.08 (2H), 3.30 (3H), 1.28 - 1.22 (3H).
Step c:
4A5,5-tetramethyl-(4-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)phenyl)-l,3,2-dioxaborolane
To a solution of l-bromo-4-(N-(ethoxycarbonyl)-S-methylsulfonimidoyl)benzene (95.0 g, 0.310 mol) in anhydrous dioxane (1.5 L) was added 4,4,4',4l,5,5,5l,5'-octamethyl-2,2l-bi(l,3,2- dioxaborolane) (95.0 g, 0.374 mol), KOAc (61.0 g, 0.622 mol) and Pd(dppf)CI2 (7.0 g, 9.57 mmol ) under N2. After the addition, the mixture was stirred at 80 °C for 18 h. The mixture was filtered and to the filtrate was added CH3COOH (18.0 g, 0.30 mol) and pinacol (18.0 g, 0.152 mol). The mixture was stirred at room temperature for 18 h. The mixture was concentrated and the residue was first purified by chromatography on silica gel (PE/EA = 20: 1 ~ 5: 1) and then washed by EA/PE (100 mL x 2, EA/PE = 1: 10) to give the title compound (87.0 g, 79.5% of theory) as a white solid. H NM (400 MHz, MeOD-d4): δ = 8.04 - 7.97 (4H), 4.13 - 4.06 (2H), 3.30 (3H), 1.36 (12H), 1.25 - 1.21 (3H). LC-MS method 2: (ES-API) m/z = 272.1 (M+H-82)+. lntermediate-18
4 hloro-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine
lntermediate-8 (0.5 g, 1.7 mmol), l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole (0,47 g, 1.7 mmol) and PdCI2(PPh3)2 (0.12 g, 0,17 mmol) were solubilisend in DME (15 mL). Potassium carbonate (2.5 mL, 5,0 mmol, 2M aq. Solution) was added and the reaction was heated for 10 minutes under microwave irradiation at 130°C. The reaction mixture was dried by filtration through a silicon filter and concentrated under reduced pressure. The crude material was purified by Flash column chromatography (Hexane\ethyl acetate). The
title compound was obtained in 45% yield (0.5 g).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.21 (dd, 3H), 1.40 - 1.64 (m, 3H), 1.90 - 2.03 (m, 2H), 2.30 - 2.39 (m, 1H), 3.15 - 3.28 (m, 2H), 3.41 - 3.52 (m, 1H), 3.57 - 3.78 (m, 3H), 3.92 - 3.99 (m, 1H), 4.12 (t, 1H), 4.44 - 4.54 (m, 1H), 5.99 - 6.09 (m, 1H), 6.92 (dd, 1H), 7.62 (s, 1H), 7.76 (d, 1H), 7.83 (d, 1H), 8.49 (d, 1H).
Preparation of the compounds of the present invention
Example 1
4-[(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S- methylsulphoximide
Step a:
4-[(2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- yl]phenyl-/V-ethoxycarbon l-S-methylsulphoximide
Under argon, 48 mg (0.06 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 761 mg (2.34 mmol) of caesium carbonate were added to a suspension of 300 mg (0.58 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 413 mg (1.17 mmol) of pinacol ester in 7.5 ml of absolute dioxane. The reaction mixture was stirred at 100°C for 3 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μιτι); ethyl acetate (100 ml)]. This gave 280 mg (81% of theory) of 4-[(2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-W-ethoxycarbonyl-S- methylsulphoximide as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 591.3, Rt = 3.43 min.
Step b:
4-[(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S- methylsulphoximide
185 mg (0.31 mmol) of 4-[(2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide were dissolved in 20 ml of ethanol, and 4 ml of (8 mmol) of 2N hydrochloric acid were added. After 1 h, LCMS showed complete removal of the protective group. Ethanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. This gave 158 mg (99% of theory) of 4-[(2-(Morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]-naphthyridine-4- yl]phenyl-N-ethoxycarbonyl-S-methylsulphoximide as a colourless solid, m.p. 230-232°C. 1H NM (400 MHz, DMSO-ds): δ [ppm] = 1.12-1.15 (3H), 3.56 (3H), 3.80 (8H), 3.91-4.00 (2H), 7.33-7.35 (1H), 7.42 (1H), 7.57 (1H), 7.65 (1H), 7.88-7.90 (2H), 8.15-8.17 (2H), 8.35-8.36 (1H), 13.40 (1H). LCMS (method 1): m/z: [M+H]+ = 507.3, R, = 2.93 min.
Example 2
4-[(2-(Morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S-methylsulphoximi^
158 mg (0.312 mmol) of 4-[(2-(morpholin-4-yl)-8-[-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide were suspended in 10 ml of sodium methoxide (33%), and the mixture was stirred at 60°C for 30 min. For work-up, 20 ml of water were added and the mixture was then extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated. The solid formed was triturated with 5 ml of methanol, filtered off and dried. This gave 88 mg (65% of theory) of 4- [(2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S-methylsulphoximide as a yellow solid, m.p. 271-273°C. H NM (400 MHz, DMSO-d5): δ [ppm] = 3.17 (3H), 3.80 (8H), 4.35 (1H), 7.35-7.37 (1H), 7.42 (1H), 7.54 (1H), 7.65 (1H), 7.79-7.82 (2H), 8.12-8.14 (2H), 8.34-8.35 (1H), 13.40 (1H). LC-MS (method 1): m/z: [M+H]+ = 435.3, R, = 2.62 min.
Example 3
4-[6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
4-[6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
Under argon, 16 mg (0.019 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 100 mg (0.20 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 78 mg (0.39 mmol) [6- (methylsulfonyl)pyridin-3-yl]boronic acid in 1.4 ml dioxane and 254 mg (0.78 mmol) caesium carbonate. The mixture was stirred at 110 °C for 4 hours. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and the crude product (168 mg) was used without further purification.
Step b:
4-[6-(methylsulfonyl)pyridin-3-yl]- -(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
0.37 ml (0.73 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 165 mg crude 4-[6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine in 1.5 ml methanol and the reaction mixture was stirred at room
temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC (Autopurifier: acidic conditions) to give 9 mg (0.02 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 3.40 (3H), 3.82 (8H), 7.38 (1H), 7.43 (1H), 7.66 (1H), 7.70 (1H), 8.26 (1H), 8.36 (1H), 8.40 (1H), 9.01 (1H), 13.42 (1H).
Example 4
4-(3,6-dihydro-2H^yran-4-yl)-2-(morpholin-4-yl)-8-(lH^yrazol-3-yl)-[l,7]naphthyridine
Step a:
4-(3,6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 40 mg (0.05 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 635 mg (1.95 mmol) of caesium carbonate were added to a suspension of 250 mg (0.49 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 205 mg (0.97 mmol) of 3,6-dihydro-2H-pyran-4-boronic acid and pinacol ester in 5.0 ml of absolute dioxane. The reaction mixture was stirred at 110°C for 4 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μιτι); ethyl acetate (100 ml)]. This gave 55 mg (25% of theory) of 4- (3,6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 448.4, t = 3.43 min. Step b:
4-(3,6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 50 mg (0.11 mmol) of 4- (3;6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine. After one hour of stirring at room temperature, the trifluoroacetic acid was distilled off and the residue was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (25 g, 30 μιη); ethyl acetate (100 ml)]. This gave 15 mg (37% of theory) of 4-(3;6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l;7]naphthyridine as a yellow solid, m.p. 233-235°C. H NM (400 MHz, DMSO): δ [ppm] = 3.76-3.78 (10H), 3.90-3.92 (2H), 4.29-4.31 (2H), 5.99 (1H), 7.38 (2H), 7.61 (1H), 7.66-7.67 (1H), 8.35-8.36 (1H), 13.35 (1H). LC- MS (method 1): m/z: [M+H]+ = 364.3, R, = 2.71 min.
Example 5
4-[4-(N,S-dimethylsulfonimidoyl)phenyl]-2-[morpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[4-(N,S-dimethylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
2-[Morpholin-4-yl]-4-[4-(S-methylsulfonimidoyl)phenyl]-8-[l-(tetrahydro-2
pyrazol-5-yl]-l,7-naphthyridine (83 mg, 0.16 mmol, 1 eq.) was solubilized in THF (3 mL) and NaH (60% in mineral oil, 15 mg, 0.38 mmol, 2.4 eq). The reaction mixture was stirred for 30 minutes at rt and iodomethane (35 μΐ, 0.56 mmol, 3.5 eq.) was added. The reaction was stirred for 16 hours at rt and then quenched by addition of H2O. The aqueous phase was extracted 3 times with CH2CI2 and the organic phase was dried (MgSC ), filtered and concentrated under reduced pressure. The crude material was purified by preparative HPLC (basic) and the desired compound was obtained in 63% yield (57 mg). 1H-NM (400MHz, DMSO-d5): δ [ppm] : 1.40 - 1.66 (3H), 1.92 - 2.05 (2H), 2.34 - 2.45 (1H), 2.55 (3H), 3.22 (3H), 3.24 - 3.30 (1H), 3.72 (9H), 6.06 - 6.12 (1H), 6.94 (1H), 7.43 (1H), 7.52 (1H), 7.64 (1H), 7.85 (2H), 8.03 (2H), 8.39 (1H). LC-MS (Method 3): m/z: [M+H]+ = 533, R, = 0.94min.
Step b:
4-[4-(N,S-dimethylsulfonimidoyl)phenyl]-2-[morpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
4-[4-(N,S-Dimethylsulfonimidoyl)phenyl]-2-[mo
pyrazol-5-yl]-l,7-naphthyridine (57 mg, 0.11 mmol, 1 eq.) was solubilised in CH2CI2 (1.5 mL) and H20 (1.5 mL). Formic acid (1 mL) was added and the reaction mixture was stirred for lh at rt. The mixture was neutralised with sat. NaHC03 and the aqueous phase was extracted 3 times with CH2CI2. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude material was purified by flash column chromatography (gradient from 100% Hex to 100% EtOAc). The title compound was obtained in 70% yield (46 mg). 1H-NM (400MHz, DMSO-d6): <5 [ppm]: 2.55 (3H), 3.22 (3H), 3.80 (8H), 7.38 (1H), 7.43 (1H), 7.57 (1H), 7.64 (1H), 7.84 (2H), 8.03 (2H), 8.35 (1H), 13.42 (1H). LC-MS (Method 3): m/z: [M+H]+ = 449, t = 0.91min.
Example 6
4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
Under argon, 16 mg (0.019 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 100 mg (0.20 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 116 mg (0.39 mmol) 4- methyl-2-(methylsulfonyl)-5-(4;4;5;5-tetramethyl-l;3;2-dioxaborolan-2-yl)pyridine in 1.4 ml dioxane and 254 mg (0.78 mmol) caesium carbonate. The mixture was stirred at 130 °C for 10 minutes in a microwave oven. After cooling, the reaction mixture was diluted with DCM and filtered using a Whatman filter. The organic phase was concentrated and the crude product (164 mg) was used without further purification.
Step b:
4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
0.31 ml (0.61 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 164 mg crude 4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-
yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 1.0 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na2S04), filtered and concentrated. The residue was purified by preperative HPLC (Autopurifier: basic conditions) to give 31 mg (0.07 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 2.24 (3H), 3.37 (3H), 3.80 (8H), 7.00 (1H), 7.45 (1H), 7.65 (2H), 8.19 (1H), 8.30 (1H), 8.69 (1H), 13.44 (1H).
Example 7
4-(4-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-(4-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 25 mg (0.03 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 391 mg (1.2 mmol) of caesium carbonate were added to a suspension of 154 mg (0.3 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2- yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yltrifluoromethanesulphonate and 169 mg (0.6 mmol) of 4-methylsulphonylphenylboronic acid pinacol ester in 3.0 ml of absolute dioxane. The reaction mixture was stirred at 90°C for 2 h. The mixture was chromatographed directly without work-up [silica gel 60 (12 g, 30 μηι); ethyl acetate (100 ml)]. This gave 110 mg (71% of theory) of 4-(4- methanesu I phonyl phenyl )-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine as a yellow foam. LC-MS (method 1): m/z: [M+H]+ = 520.3, Rt = 3.38 min.
Step b:
4-(4-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 2 ml of (26 mmol) of trifluoroacetic acid were added to 110 mg (0.21 mmol) of 4-(4-methanesu I phonyl phenyl )-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine. After 3 h, LCMS showed complete removal of the protective group. The trifluoroacetic acid was removed using a rotary evaporator and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. 5 ml of methanol were added to the residue. The resulting precipitated solid was filtered off using a frit and then dried. This gave 75 mg (81% of theory) of 4-(4-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine as a yellow solid, m.p. 260-262°C. H NM (400 MHz, DMSO, δ ppm): 3.33 (3H), 3.80 (8H), 7.36 (1H), 7.40 (1H), 7.56 (1H), 7.67 (1H), 7.86 (2H), 8.14 (2H), 8.33 (1H), 13.40 (1H).
Example 8
4-(2-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride Step a:
4-(2-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 30 mg (0.04 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 482 mg (1.48 mmol) of caesium carbonate were added to a suspension of 190 mg (0.37 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 148 mg (0.74 mmol) of 2-methanesulphonylphenylboronic acid in 2.0 ml of absolute dimethylformamide. The reaction mixture was stirred at 90°C for 2 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μηι); chloroform/methanol 95:5 (100 ml)]. This gave 60 mg (31% of theory) of 4-(2-methanesu I phonyl phenyl )-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 520.3, t = 2.92 min.
Step b:
4-(2-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 60 mg (0.12 mmol) of 4- (2-methanesul phonyl phenyl )-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine. After 10 min, the trifluoroacetic acid was distilled off and the residue was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel
60 (12 g, 30 μηη); chloroform/methanol 95:5 (100 ml)]. This gave 20 mg (40% of theory) of methanesu I phonyl phenyl )-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-lH-pyrazol-3-yl]- [l,7]naphthyridine as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 436.2, t = 2.72 min.
Step c:
4-(2-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride
20 mg (0.046 mmol) of 4-(2-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine were dissolved in 3 ml of 2-butanol, and 18 μΙ of trimethylchlorosilane were added. The mixture was stirred in the open vessel at room temperature for 1 h. The solid formed was filtered off with suction and dried. This gave 15 mg (69% of theory) of 4-(2-methane- sulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride as a yellow solid, m.p. 173-175°C. H NMR (400 MHz, CD3OD, δ ppm): 3.05 (3H), 3.87-3.97 (8H), 7.36 (IH), 7.56-7.58 (IH), 7.72 (IH), 7.87 (IH), 7.89-7.95 (2H), 7.99 (IH), 8.19 (IH), 8.29 (IH), 8.29-8.31 (IH). LC-MS (method 1): m/z: [M+H]+ = 436.2, R, = 2.72 min.
Example 9
dimethyl {4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}phosphonate
Step a:
dimethyl (4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}phenyl)phosphonate
Under argon, 12 mg (0.015 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 75 mg (0.15 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 91 mg (0.29 mmo) dimethyl [4-(4A5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]phosphonate in 1.1 ml dioxane and 190 mg (0.58 mmol) caesium carbonate. The mixture was stirred at 110 °C for 150 minutes. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and the residue was purified by column chromatography (ethyl acetate) to give 53 mg (0.10 mmol) of the desired product.
Step b:
dimethyl {4-[2-(morpholin-4-yl -8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}phosphonate
0.11 ml (0.22 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 53 mg
dimethyl (4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7- naphthyridin-4-yl}phenyl)phosphonate in 0.4 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. Aqueous sodium bicarbonate solution was added and the mixture was extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to give 38 mg (0.08 mmol) of the desired product. 1H-N M (400 MHz, CDCIa): δ [ppm] = 3.83 (4H), 3.87 (3H), 3.89 (3H), 3.98 (4H), 7.20 (1H), 7.39 (2H), 7.62 (2H), 7.78 (1H), 8.00 (1H), 8.04 (1H), 8.44 (1H).
Example 10
4-isopropenyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-isopropenyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 24 mg (29 μιτιοΙ) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1: 1, Pd(dppf)CI2) and 286 mg (0.88 mmol) of caesium carbonate were added to a suspension of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 483 mg (1.46 mmol) of tributylisopropenylstannane in 2.0 ml of absolute dioxane. The reaction mixture was stirred at 110°C for 16 h. 20 ml of water were added to the mixture. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (12 g, 30 μητι); chloroform (100 ml)]. This gave 50 mg (42% of theory) of 4-isopropenyl-2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 406.4, Rt = 3.58 min.
Step b:
4-isopropenyl-2-(morpholin-4-yl)- -(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 50 mg (0.12 mmol) of 4- isopropenyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine. The mixture was allowed to stand at room temperature for one hour, the trifluoroacetic acid was then distilled off and the residue was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (12 g, 30 μιη); chloroform/methanol 95:5 (100 ml)]. This gave 30 mg (76% of theory) of 4-isopropenyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine as a yellow solid, m.p. 53-55°C. 1H NM (400 MHz, CDCI3, 5 ppm): 2.17 (3H), 3.70-3.73 (4H), 3.89-3.92 (4H), 5.12 (IH), 5.46 (IH), 7.02 (IH), 7.28 (IH), 7.53 (IH), 7.68 (IH), 8.39 (IH). LC-MS (method 1): m/z: [M+H]+ = 322.3, R, = 2.85 min.
Example 11
2-(morpholin-4-yl)-4-phenyl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
2-(morpholin-4-yl)-4-phenyl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
Under argon, 74 mg (0.09 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 391 mg (1.2 mmol) of caesium carbonate were added to a suspension of 154 mg (0.3 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2- yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 245 mg (1.2 mmol) of phenylboronic acid pinacol ester in 6.0 ml of absolute dioxane. The reaction mixture was stirred at 90°C for 2 h. The mixture was chromatographed directly without work-up [silica gel 60 (12 g, 30 μηη); ethyl acetate (100 ml)]. This gave 47 mg (36% of theory) of 2-(morpholin-4-yl)-4-phenyl-8- [2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 442.3, , = 3.81 min.
Step b:
2-(morpholin-4-yl)-4-phenyl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 47 mg (0.11 mmol) of 2- (morpholin-4-yl)-4-phenyl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine. After 10 min, LCMS showed complete removal of the protective group. The trifluoroacetic acid was removed on a rotary evaporator and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and
then concentrated to dryness. 5 ml of methanol were added to the residue. The resulting precipitated solid was filtered off using a frit and then dried. This gave 30 mg (75% of theory) of 2- (morpholin-4-yl)-4-phenyl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 89-91°C. H NM (400 MHz, CDCI3, δ ppm) : 3.74-3.76 (4H), 3.91-3.93 (4H), 7.14 (1H), 7.31 (1H), 7.41 (1H), 7.45-7.47 (2H), 7.50-7.55 (3H), 7.70 (1H), 8.35 (1H). LC-MS (method 1): m/z: [M+H]+ = 358.3,
Example 12
4-[4-(S-ethylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
4-[4-(ethylsulfanyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- 1,7-naphthyridine
Under argon, 24 mg (0.029 mmol) [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) was added to a mixture of 150 mg (0.29 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 106 mg (0.58 mmol) [4- (ethylsulfanyl)phenyl]boronic acid in 2.1 ml dioxane and 381 mg (1.17 mmol) caesium carbonate. The mixture was stirred at 110 °C for 10 minutes. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and residue was purified by column chromatography (DCM / ethanol 0% - 30%) to give 150 mg (0.03 mmol) of the desired product, containing slight impurities, that was used without further purifications.
Step b:
N-[ethyl(4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}ph sulfan lidene]-2,2,2-trifluoroacetamide
Under an atmosphere of argon, a solution of 49 mg (0.43 mmol) 2,2,2-trifluoroacetamide in 0.16 ml THF was added dropwise to a solution of 27 mg (0.29 mmol) sodium tert.-butoxide in 0.23 ml THF, so that the temperature of the mixture remained below 10 °C. Subsequently, a freshly prepared solution of 53 mg (0.19 mmol) l,3-dibromo-5,5-dimethylhydantoin in 0.23 mL THF was added dropwise to the stirred mixture, so that the temperature of the mixture remained below 10°C. Then the mixture was stirred for 10 minutes at 10 °C. Finally, a solution of 145 mg (0.29 mmol) 4-[4-(ethylsulfanyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 5-yl]-l,7-naphthyridine in 0.23 ml THF was added dropwise to the stirred mixture, so that the temperature of the mixture remained below 10 °C. The mixture was stirred for 90 minutes at 10 °C and then at room temperature overnight. The batch was diluted with 0.6 ml of toluene under cooling and an aqueous solution of 36 mg (0.29 mmol) sodium sulfite in 1.1 mL water was added so that the temperature of the mixture remained below 15 °C. The batch was extracted three times with ethyl acetate. The combined organic phases were washed with an aqueous solution of sodium chloride, filtered using a Whatman filter and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate) to give 33 mg of the desired product. 1H-NM (400 MHz, CDCI3): δ [ppm] = 1.42 (3H), 1.61 (5H), 2.12 (2H), 2.59 (1H), 3.39 (2H), 3.48 (1H), 3.79 (6H), 3.98 (1H), 6.10 (1H), 7.00 (1H), 7.08 (1H), 7.37 (1H), 7.75 (3H), 7.97 (2H), 8.43 (1H).
Step c:
4-[4-(S-ethylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-
pyrazol-5-yl]-l,7-naphthyridine
33 mg (0.054 mmol) N-[ethyl(4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}phenyl)- 4-sulfanylidene]-2;2;2-trifluoroacetamide was dissolved in 1.05 ml methanol. To this solution 0.37 ml water was added. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%). 28 mg (0.046 mmol) Oxone* was added and the mixture was stirred at room temperature for 4 hours. Additional 28 mg (0.046 mmol) Oxone" was added. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%). The batch was stirred at room temperature for 90 minutes. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%) and the batch was stirred at room temperature for 4 days. The batch was filtered and the filtrate was adjusted to pH 6-7 by the addition of IN aqueous hydrogen chloride solution. The mixture was diluted with aqueous sodium chloride solution and extracted with DCM (2x). The combined organic phases were washed with an aqueous solution of sodium sulfite (10%), filtered using a Whatman filter, and concentrated to give 25 mg crude product that was used without further purification.
Step d:
4-[4-(S-ethylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
0.05 ml (0.11 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 25 mg crude 4-[4-(S-ethylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine in 0.22 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 1.15 (3H), 3.22 (2H), 3.81 (8H), 4.34 (1H), 7.36 (1H), 7.44 (1H), 7.56 (1H), 7.65 (1H), 7.81 (2H), 8.08 (2H), 8.35 (1H), 13.43 (1H).
Example 13
3-[(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S- methylsulphoximide
Step a:
3-[(-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H^yrazol-3-yl]-[l,7]naphthyridine-4- yl]phenyl-/V-ethoxycarbonyl-S-methylsulphoximide
H3
Under argon, 48 mg (0.06 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 761 mg (2.34 mmol) of caesium carbonate were added to a suspension of 300 mg (0.58 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 413 mg (1.17 mmol) of pinacol ester in 7.5 ml of absolute dioxane. The reaction mixture was stirred at 100°C for 3 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μιη); ethyl acetate (100 ml)]. This gave 270 mg (78% of theory) of 3-[(-2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-W-ethoxycarbonyl-S- methylsulphoximide as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 591.3, t = 3.42 min.
Step b:
3-[(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S- methylsulphoximide
260 mg (0.44 mmol) of 3-[(-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide were dissolved in 10 ml of ethanol, and 5 ml of (10 mmol) of 2N hydrochloric acid were added. After 1 h, LCMS showed complete removal of the protective group. Ethanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (25 g, 30 μιη); ethyl acetate (100 ml)]. This gave 160 mg (72% of theory) of 3-[(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-W- ethoxycarbonyl-S-methylsulphoximide as a yellow solid, m.p. 115-117°C. H NM (400 MHz, DMSO-d5): δ [ppm] = 1.09-1.13 (3H), 3.57 (3H), 3.81 (8H), 3.98-4.00 (2H), 7.34-7.35 (1H), 7.42 (1H), 7.56 (1H), 7.65 (1H), 7.91-7.96 (1H), 7.98-7.99 (1H), 8.10-8.33 (2H), 8.33-8.34 (1H), 13.40 (1H). LC-MS (method 1): m/z: [M+H]+ = 507.3, R, = 2.93 min.
Example 14
4-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine Step a:
4-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
Under argon, 12 mg (0.015 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) was added to a mixture of 75 mg (0.15 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 65 mg (0.29 mmol) 1- methyl-4-(4;4;5;5-tetramethyl-l;3;2-dioxaborolan-2-yl)-l;2;3;6-tetrahydropyridine in 1.1 ml dioxane and 190 mg (0.58 mmol) caesium carbonate. The mixture was stirred at 110 °C for 150 minutes. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and the crude product (142 mg) was used without further purification.
Step b:
4-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
0.36 ml (0.71 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 142 mg crude 4-(l-methyl-l;2;3;6-tetrahydropyridin-4-yl)-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 1.4 ml methanol and the reaction mixture was stirred at
room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC (Autopurifier: basic conditions) to give 22 mg (0.06 mmol) of the desired product. ^-NM (400 MHz, CDCI3): δ [ppm] = 2.51 (3H), 2.59 (2H), 2.78 (2H), 3.23 (2H), 3.76 (4H), 3.96 (4H), 5.89 (1H), 7.07 (1H), 7.31 (1H), 7.57 (1H), 7.73 (1H), 8.43 (1H), 12.99 (1H).
Example 15
4-(3-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
4-(3-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 24 mg (0.03 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 381 mg (1.17 mmol) of caesium carbonate were added to a suspension of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 165 mg (0.58 mmol) of 2-(3-methanesulphonylphenyl)-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane in 5.0 ml of absolute dioxane. The reaction mixture was stirred at 90°C for 16 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μητι); chloroform/methanol 95:5 (100 ml)]. This gave 80 mg (53% of theory) of 4-(3-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 520.3, R, = 3.33 min.
Step b:
4-(3-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 80 mg (0.15 mmol) of 4- (3-methanesulphonyl phenyl )-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine. After one hour of stirring at room temperature, the trifluoroacetic acid was distilled off and the residue was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (12 g, 30 μιη); chloroform/methanol 90:10 (100 ml)]. This gave 30 mg (45% of theory) of 4-(3-methanesulphonylphenyl)-2-(morpholin-4-yl)-8-(2H-pyrazol-3- yl)-[l,7]naphthyridine as a yellow solid, m.p. 255-257°C. :H NM (400 MHz, DMSO, δ ppm): 3.30 (3H), 3.81 (8H), 7.36 (IH), 7.43 (IH), 7.56 (IH), 7.64 (IH), 7.86-7.95 (2H), 8.10-8.13 (2H), 8.35 (IH), 13.41 (IH). LC-MS (method 1): m/z: [M+H]+ = 436.2, R, = 2.80 min.
Example 16
4-[5-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[5-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
Under argon, 16 mg (0.019 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 100 mg (0.20 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 116 mg (0.39 mmol) 3- methyl-2-(methylsulfonyl)-5-(4;4;5;5-tetramethyl-l;3;2-dioxaborolan-2-yl)pyridine in 1.4 ml dioxane and 254 mg (0.78 mmol) caesium carbonate. The mixture was stirred at 130 °C for 10 minutes in a microwave oven. After cooling, the reaction mixture was diluted with DCM and filtered using a Whatman filter. The organic phase was concentrated and the crude product (119 mg) was used without further purification.
Step b:
4-[5-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
0.22 ml (0.45 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 119 mg crude 4-[5-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 1.0 ml methanol and the reaction mixture was stirred at
room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na2S04), filtered and concentrated. The residue was purified by preperative HPLC (Autopurifier: basic conditions) to give 7 mg (0.016 mmol) of the desired product. :H-NMR (400 MHz, DMSO-d6): δ [ppm] = 2.73 (3H), 3.48 (3H), 3.81 (8H), 7.41 (2H), 7.66 (2H), 8.22 (IH), 8.35 (1H), 8.73 (IH), 13.44 (IH).
Example 17
2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(l,2,3,6-tetrahydropyridin-4-yl)-l,7-naphthyridine
Step a:
2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-4-(l,2,3,6- tetrahydropyridin-4-yl)-l,7-naphth ridine
Under argon, 12 mg (0.015 mmol) [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) was added to a mixture of 75 mg (0.15 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 71 mg (0.29 mmol) 4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine hydrochloride (1:1) in 1.1 ml dioxane and 285 mg (0.88 mmol) caesium carbonate. The mixture was stirred at 110 °C for 4 hours. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 16 mg (0.04 mmol) of the desired product. 1H-NMR (400 MHz, CDCI3): δ [ppm] = 1.76 (5H), 2.09 (2H), 2.52 (3H), 3.23 (2H), 3.47 (IH), 3.69 (5H), 3.83 (4H), 3.98 (IH), 5.93 (IH), 6.03 (IH), 6.95 (IH), 6.97 (IH), 7.64 (IH), 7.72 (1H), 8.43 (IH).
Step b:
2-(morpholin-4-yl)-8-(lH-pyrazol-5- -4-(l,2,3,6-tetrahydropyridin-4-yl)-l,7-naphthyridin
0.04 ml (0.08 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 16 mg (0.036 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-4-( 1,2,3,6- tetrahydropyridin-4-yl)-l,7-naphthyridine in 0.17 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to give 11 mg (0.030 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 2.32 (2H), 2.98 (2H), 3.42 (2H), 3.67 (1H), 3.76 (8H), 5.90 (1H), 7.29 (1H), 7.36 (1H), 7.63 (1H), 7.67 (1H), 8.35 (1H), 13.30 (1H).
Example 18
4-cyclopropyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-cyclopropyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 80 mg (0.1 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 635 mg (2.0 mmol) of caesium carbonate were added to a suspension of 250 mg (0.49 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 84 mg (0.97 mmol) of 2-cyclopropyl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane in 5 ml of absolute dioxane. The reaction mixture was stirred at 110°C for 4 h. The mixture was chromatographed directly without work-up [silica gel 60 (40 g, 30 μιτι); chloroform/methanol (1:1, 100 ml)]. This gave 150 mg (76% of theory) of 4-cyclopropyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 406.3, t = 3.53 min.
Step b:
4-cyclopropyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 150 mg (0.37 mmol) of 4-cyclopropyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine. After 1 h, LCMS showed complete removal of the protective group. The trifluoroacetic acid was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. 5 ml of methanol were added to the residue, resulting in the precipitation of a solid. The latter was filtered off and dried. This gave 30 mg (25% of theory) of 4- cyclopropyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 211- 214°C. H NMR (400 MHz, DMSO): δ [ppm] = 0.92-0.96 (2H), 1.10-1.14 (2H), 2.42-2.44 (1H), 3.72- 3.73 (4H), 3.77-3.78 (4H), 7.08 (1H), 7.36 (1H), 7.61 (1H), 7.99-8.00 (1H), 8.40-8.42 (1H), 13.34 (1H). LC-MS (method 1): m/z: [M+H]+ = 322.3, t = 2.68 min.
Example 19
3-[(2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S-methylsulphoximide
120 mg (0.24 mmol) of 3-[(2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide were suspended in 8 ml of sodium methoxide (33%), and the mixture was stirred at 60°C for 30 min. For work-up, 20 ml of water were added and the mixture was then extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated. This gave 100 mg (97% of theory) 3-[(2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine-4-yl]phenyl-S-methylsulphoximide as a yellow solid, m.p. 227-229°C. 1H NM (400 MHz, CDCIa-ds): δ [ppm] = 3.22 (3H), 3.79-3.81 (4H), 3.94-3.96 (4H), 7.20 (1H), 7.30-7.32 (1H), 7.35-7.36 (1H), 7.73-7.76 (3H), 8.18-8.20 (2H), 8.40-8.41 (1H). LC-MS (method 1): m/z: [M+H]+ = 435.3, Rt = 2.63 min.
Example 20
4-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride
Step a:
4-methyl-2-(morpholin-4-yl)-8-[2-(tetrah dropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
Under argon, 91 mg (0.11 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 241 mg (0.74 mmol) of caesium carbonate were added to a suspension of 190 mg (0.37 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-
2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 44 mg (0.74 mmol) of methylboronic acid in 2.5 ml of absolute dioxane. The reaction mixture was stirred at 90°C for 2 h. The mixture was chromatographed directly without work-up [silica gel 60 (40 g, 30 μιη); chloroform/methanol (95:5, 100 ml)]. This gave 120 mg (86% of theory) of 4-methyl-2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 380.3, t = 3.23 min.
Step b:
4-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 2 ml of (26 mmol) of trifluoroacetic acid were added to 120 mg (0.32 mmol) of 4-methyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine. After 1 h, LCMS showed complete removal of the protective group. The trifluoroacetic acid was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (12 g, 30 μιη); chloroform (100 ml)]. This gave 45 mg (48% of theory) of 4-methyl-2-(morpholin-4-yl)-8-(lH- pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid. After brief exposure to air, this solid became discoloured. For this reason, the compound was converted into the corresponding hydrochloride. LC-MS (method 1): m/z: [M+H]+ = 296.3, R, = 2.53 min.
Step c:
4-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride
45 mg (0.15 mmol) of 4-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine were dissolved in 4.0 ml of 2-butanol, and 58 μΙ (0.46 mmol) of trimethylchlorosilane were added. The reaction solution was stirred at room temperature for 1 h. The precipitated solid was filtered off and then dried. This gave 45 mg (89% of theory) of 4-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3- yl)-[l,7]naphthyridine hydrochloride as a yellow solid, m.p. 164-166°C. :H NM (400 MHz, DMSO, 5 ppm): 2.69 (3H), 3.81-3.86 (8H), 7.55 (1H), 7.82 (1H), 8.11-8.14 (2H), 8.38 (1H). LC-MS (method 1): m/z: [M+H]+ = 296.3, R, = 2.51 min. Example 21
4-[2-(methylsulfonyl)-l,3-thiazol-4-yl]-2-(morpholm
Step a:
4-[2-(methylsulfonyl)-l,3-thiazol-4-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
Under argon, 16 mg (0.019 mmol) [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 100 mg (0.20 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 113 mg (0.39 mmol) 2-
(methylsulfonyl)-4-(4;4;5;5-tetramethyl-l;3;2-dioxaborolan-2-yl)-l;3-thiazole in 1.4 ml dioxane and 254 mg (0.78 mmol) caesium carbonate. The mixture was stirred at 110 °C for 2 hours. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and the crude product (263 mg) was used without further purification.
Step b:
4-[2-(methylsulfonyl)-l,3-thiazo -4-yl]-2-(morpholm
0.58 ml (1.15 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 263 mg crude 4-[2-(methylsulfonyl)-l;3-thiazol-4-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine in 2.3 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC (Autopurifier: acidic conditions) to give 3 mg (0.007 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 3.61 (3H), 3.82 (8H), 7.41 (1H), 7.66 (1H), 7.82 (1H), 7.95 (1H), 8.41 (1H), 8.82 (1H), 13.42 (1H).
Example 22
4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]pyridin-2(lH)-one Step a:
4-(2-methoxypyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate (320 mg, 0.21 mmol), (2-methoxypyridin-4- yl)boronic acid (94 mg, 0,62 mmol), Bis(triphenylphosphin)palladium(ll)chlorid (14 mg, 0,021 mmol), Caesiumcarbonate (235 mg, 0,72 mmol) in Dioxane (4 ml) were heated in a sealed tube in the Microwave at 100° C for 30 minutes. A solution of cone. HCI (10 ml) was added and the reaction was stirred at ambient temperature for 16 hours and at 50°C for another 2 hours. The reaction mixture was filtered through a plug of Celite (1 cm). The Celite was washed with ethyl acetate (50 ml) and methanol (20 ml). The filtrate was dried over Na2S04, the solvent was removed under reduced pressure. The title compound was obtained as crude product and used without further purification in the next step.
Step b:
4-[2-(morpholin-4-yl)-8-(lH-pyrazo -5-yl)-l,7-naphthyridin-4-yl]pyridin-2(lH)-one
Crude 4-(2-methoxypyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine (1.882 g, purity ca. 10%) was added to a solution of concentrated HBr in acetic acid (2 ml) and acetic acid (15 ml) and stirred at 100°C for 2 hours. The reaction was cooled to ambient temperature, dichloromethane (30 ml) and a saturated aqueous solution of NaHC03 (50 ml) was added. The
layers were separated and the aqueous phase was exctracted with dichloromethane (2 x 10 ml). The combined organic layers were dried over Na2S04. The solvent was removed under reduced pressure and the crude product (188 mg) was purified by HPLC chromatography (acidic conditions). The title compound was obtained in 1% yield (1.6 mg). 1H-NM (400 MHz, DMSO): δ [ppm] = 3.80 (8H), 6.33 (1H), 6.50 (1H), 7.41-7.66 (5H), 8.36 (1H), 11.89 (1H), 13.44 (1H).
Example 23
5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]pyridin-2(lH)-one Step a:
4-(6-methoxypyridin-3-yl)-2-(morp -yl)-l,7-naphthyridine
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate (605 mg, 0.39 mmol), (6-methoxypyridin-3- yl)boronic acid (178 mg, 1.17 mmol), Bis(triphenylphosphin)palladium(ll)chlorid (27 mg, 0,039 mmol), Caesiumcarbonate (443 mg, 1.36 mmol) in Dioxane (4 ml) were heated in a sealed tube in the Microwave at 100° C for 30 minutes. A solution of cone. HCI (10 ml) was added and the reaction was stirred at ambient temperature for 16 hours and at 50°C for another 2 hours. The reaction mixture was filtered through a plug of Celite (1 cm). The Celite was washed with ethyl acetate (50 ml) and methanol (20 ml). The filtrate was dried over Na2S04, the solvent was removed under reduced pressure. The title compound was obtained as crude product and used without further purification in the next step.
Step b:
5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]pyridin-2(lH)-one
Crude 4-(6-methoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine (1.344 g, purity ca. 10%) was added to a solution of concentrated HBr in acetic acid (2 ml) and acetic acid (15 ml) and stirred at 100°C for 2 hours. The reaction was cooled to ambient temperature, dichloromethane (30 ml) and a saturated aqueous solution of NaHCC (50 ml) was added. The layers were separated and the aqueous phase was exctracted with dichloromethane (2 x 10 ml). The combined organic layers were dried over NazSCu. The solvent was removed under reduced pressure and the crude product (188 mg) was purified by HPLC chromatography (acidic conditions). The title compound was obtained in 2% yield (2.3 mg). 1H-NM (400 MHz, DMSO): δ [ppm] = 3.79 (8H), 6.51 (1H), 7.40 (1H), 7.48 (1H), 7.51 (1H), 7.64-7.70 (3H), 8.36 (1H), 12.10 (1H), 13.40 (1H).
Example 24
4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
4-[2-fluoro-4-(methylsulfanyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
Under argon, 24 mg (0.029 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 150 mg (0.29 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 108 mg (0.58 mmol) [2- fluoro-4-(methylsulfanyl)phenyl]boronic acid in 2.1 ml dioxane and 381 mg (1.17 mmol) caesium carbonate. The mixture was stirred at 110 °C for 2 hours. After cooling, the reaction mixture was diluted with ethyl acetat and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and concentrated. The residue was purified by column chromatography (hexane / ethyl acetate 20% - 70%) to give 126 mg (0.25 mmol) of the desired product.
Step b:
4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
Under argon, 2 mg (0.006 mmol) tetrapropylammonium perruthenate (TPAP) and 14 mg (0.127 mmol) N-metylmorpholine-N-oxide (NMO) were added to a solution of 64 mg (0.127 mmol) 4-[2- fluoro-4-(methylsulfanyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridine in 1.4 mL DCM and 1.4 mL acetonitrile at 0°C. The mixture was stirred for 4 hours at 0°C. Additional 14 mg (0.127 mmol) N-metylmorpholine-N-oxide (NMO) was added and the mixture was stirred at 0°C for 7 hours and then for 40 minutes at 10°C. Finally, the batch was concentrated to give 81 mg crude product that was used without further purification.
Step c:
4-[2-fluoro-4-(methylsulfonyl)ph -pyrazol-5-yl)-l,7-naphthyridine
0.17 ml (0.35 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 81 mg crude 4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine in 0.7 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (Na2S04), filtered and concentrated. The residue was purified by preperative HPLC (Autopurifier: acidic conditions) to give 18 mg (0.04 mmol) of the desired product. ^-NM (400 MHz, DMSO): δ [ppm] = 3.40 (3H), 3.80 (8H), 7.20 (1H), 7.44 (1H), 7.70 (2H), 7.88 (1H), 8.00 (1H), 8.06 (1H), 8.33 (1H), 13.55 (1H).
Example 25
2-(morpholin-4-yl)-4-{4-[S-(propan-2-yl)sulfonimidoyl]phenyl}-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-(morpholin-4-yl)-4-[4-(propan-2-ylsulfanyl)phenyl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
Under argon, 16 mg (0.019 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) was added to a mixture of 100 mg (0.20 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 76 mg (0.39 mmol) [4- (propan-2-ylsulfanyl)phenyl]boronic acid in 1.4 ml dioxane and 253 mg (0.78 mmol) caesium carbonate. The mixture was stirred at 110 °C for 2 hours. After cooling, the reaction mixture was diluted with ethyl acetate and an aqueous solution of sodium chloride. The mixture was extracted with ethyl acetate (2x) and the combined organic phases were filtered using a Whatman filter. The organic phase was concentrated and residue was purified by column chromatography (hexane / ethyl acetate 20% - 80%) to give 74 mg (0.14 mmol) of the desired product, containing slight impurities, that was used without further purifications.
Step b:
2,2,2-trifluoro-N-[(4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}phenyl)(propan-2-yl)-A4-sulfanylidene]acetamide
H3C→
CH3
Under an atmosphere of argon, a solution of 39 mg (0.35 mmol) 2,2,2-trifluoroacetamide in 0.13 ml THF was added dropwise to a solution of 22 mg (0.23 mmol) sodium tert.-butoxide in 0.19 ml THF, so that the temperature of the mixture remained below 10 °C. Subsequently, a freshly prepared solution of 43 mg (0.15 mmol) l,3-dibromo-5,5-dimethylhydantoin in 0.19 ml THF was added dropwise to the stirred mixture, so that the temperature of the mixture remained below 10°C. Then the mixture was stirred for 10 minutes at 10 °C. Finally, a solution of 120 mg (0.23 mmol) 2-(morpholin-4-yl)-4-[4-(propan-2-ylsulfanyl)phenyl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine in 0.23 ml THF was added dropwise to the stirred mixture, so that the temperature of the mixture remained below 10 °C. The mixture was stirred for 80 minutes at 10 °C and then at room temperature overnight. The batch was diluted with 0.5 ml toluene under cooling and an aqueous solution of 29 mg (0.23 mmol) sodium sulfite in 0.9 ml water was added so that the temperature of the mixture remained below 15 °C. The batch was extracted three times with ethyl acetate. The combined organic phases were washed with an aqueous solution of sodium chloride, filtered using a Whatman filter and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate) to give 28 mg of the desired product containing slight impurities.
Step c:
4-[4-(S-isopropylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
28 mg (0.035 mmol) 2;2;2-trifluoro-N-[(4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl}phenyl)(propan-2-yl)- 4-sulfanylidene]acetamide was dissolved in 0.87 ml methanol. To this solution 0.31 ml water was added. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%). 23 mg (0.038 mmol) Oxone* was added and the mixture was stirred at room temperature for 4 hours. Additional amount 23 mg (0.038 mmol) Oxone" was added. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%). The batch was stirred at room temperature for 90 minutes. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%) and the batch was stirred at room temperature for 4 days. The batch was filtered and the filtrate was adjusted to pH 6-7 by the addition of IN aqueous hydrogen chloride solution. The mixture was diluted with aqueous sodium chloride solution and extracted with DCM (2x). The combined organic phases were washed with an aqueous solution of sodium sulfite (10%), filtered using a Whatman filter, and concentrated to give 21 mg crude product that was used without further purification.
Step d:
2-(morpholin-4-yl)-4-{4-[S-(propan-2-yl)sulfonimidoyl]phenyl}-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
0.04 ml (0.11 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 21 mg crude 2-(morpholin-4-yl)-4-{4-[S-(propan-2-yl)sulfonimidoyl]phenyl}-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 0.18 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC (Autopurifier: basic conditions) to give 4 mg (0.01 mmol) of the desired product.1H-NM (400 MHz, DMSO-d6): δ [ppm] = 1.22 (6H), 3.35 (1H), 3.81 (8H), 4.30 (1H), 7.36 (1H), 7.44 (1H), 7.57 (1H), 7.65 (1H), 7.82 (2H), 8.05 (2H), 8.35 (1H), 13.43 (1H).
Example 26
4-(4-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine
Step a:
4-(4-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7]naphthyridine
Under argon, 120 mg (227 μιηοΙ) of 2-((R)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7] naphthyridin-4-yl trifluoromethanesulphonate, 76 mg (0.38 mmol) of 4- (methanesulphonyl)phenylboronic acid, 18 mg (22.7 μιηοΙ) of [l,l'-bis(diphenylphosphino)- ferrocene]dichloropalladium(ll) x dichloromethane and 296 mg (0.91 mmol) of caesium carbonate were weighed out and dissolved in 1.5 ml of absolute 1,4-dioxane. The mixture was degassed three times and stirred at 90°C for 2 h. The course of the reaction was monitored by LC/MS. Since conversion was incomplete, another 52 mg of 4-(methanesulphonyl)phenylboronic acid, 18 mg of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) x dichloromethane and 296 mg of caesium carbonate were added to the reaction solution and the mixture was stirred at 90°C for 20 h. Under reduced pressure, the mixture was concentrated to dryness. The residue was chromatographed [silica gel 60 (40 g, 50 μιη); dichloromethane/methanol 98:2 to 95:5]. 79 mg (65% of theory) of 4-(4-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine were obtained as a yellow solid. H NM (400 MHZ, CDCI3): δ [ppm] = 1.34 (3H), 1.48-1.74 (3H), 2.08-2.11 (2H), 2.56 (1H), 3.19 (3H), 3.34 (1H), 3.46 (1H), 3.59 (1H), 3.71-3.84 (3H), 3.94 (1H), 4.02-4.24 (2H), 4.44 (1H), 6.08 (1H), 6.98 (1H), 7.01 (1H), 7.69-7.72 (3H), 8.14 (2H), 8.40 (1H). LC-MS (method 1): R, = 3.46 min; MS (ESI/APCIpos) m/z = 534.3 [M+H]+. Step b:
4-(4-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine
79 mg (0.15 mmol) of 4-(4-methanesulphonylphenyl)-2-((R)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 5 ml of methanol, 1 ml of 2N hydrochloric acid (2 mmol) was added and the mixture was stirred at room temperature for 1 h. After 1 h, LC/MS showed complete removal of the protective group. The methanol was removed under reduced pressure and the residue was adjusted to pH = 7 using saturated sodium bicarbonate solution. The aqueous phase was extracted five times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated to dryness under reduced pressure. The residue was washed twice with in each case 4 ml of methanol, filtered off and dried. This gave 44 mg (66% of theory) of 4-(4- methanesu I phonyl phenyl )-2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid. H NM (400 MHz, DMSO-d5): δ [ppm] = 1.31 (3H), 3.33 (3H), 3.32-3.40 (IH), 3.57 (IH), 3.72 (IH), 3.83 (IH), 4.05 (IH), 4.24 (IH), 4.66 (IH), 7.35 (IH), 7.43 (IH), 7.50 (IH), 7.61 (IH), 7.87 (2H), 8.13 (2H), 8.33 (IH), 13.4 (IH). LC-MS (method 1): R, = 2.88 min; MS (ESI/APCIpos) m/z = 450.2 [M+H]+.
Example 27
2-((/?)-3-methylmorpholin-4-yl)-4-phenyl-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
2-((ff)-3-methylmorpholin-4-yl)-4-phenyl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 120 mg (227 μιηοΙ) of 2-((R)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate, 46 mg (0.38 mmol) of benzeneboronic acid, 18 mg (0.0227 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) x dichloromethane and 296 mg (0.91 mmol) of caesium carbonate were weighed out and dissolved in 1.5 ml of absolute 1,4-dioxane. The mixture was degassed three times and stirred at 90°C for 1 h. The course of the reaction was monitored by LC/MS. The mixture was concentrated to dryness under reduced pressure. The residue was chromatographed [silica gel 60 (40 g, 50 μητι); dichloromethane/methanol 98:2 to 95:5]. This gave 90 mg (87% of theory) of 2-((/?)-3-methylmorpholin-4-yl)-4-phenyl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine as a yellow solid. 1H NM (400 MHz, CDCI3): δ [ppm] = 1.33 (3H), 1.48-1.51 (1H), 1.62-1.77 (2H), 2.07-2.10 (2H), 2.56 (1H), 3.32 (1H), 3.46 (1H), 3.58 (1H), 3.69-3.83 (2H), 3.94-3.98 (1H), 4.03-4.52 (3H), 6.05 (1H), 6.97 (1H), 7.02 (1H), 7.47-7.56 (6H), 7.71 (1H), 8.38 (1H). LC-MS (method 1): R, = 3.89 min; MS (ESI/APCIpos) m/z = 456.3 [M+H]+.
Step b:
2-((/?)-3-methylmorpholin-4-yl)-4-phenyl-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine
90 mg (0.20 mmol) of 2-((/?)-3-methylmorpholin-4-yl)-4-phenyl-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 5 ml of methanol, 1 ml of 2N hydrochloric acid
(2 mmol) was added and the mixture was stirred at room temperature for 1 h. After 1 h, LC/MS showed complete removal of the protective group. The methanol was removed under reduced pressure and the residue was adjusted to pH = 7 using saturated sodium bicarbonate solution. The aqueous phase was extracted five times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then, under reduced pressure, concentrated to dryness. The residue was chromatographed twice [silica gel 60 (25 g, 30 μιη); dichloromethane/methanol 96:4]. This gave 52 mg (71% of theory) of 2-((/?)-3-methylmorpholin- 4-yl)-4-phenyl-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine as an orange solid. 1H NM (400 MHz, CDCIa): δ [ppm] = 1.46 (3H), 3.57 (1H), 3.72 (1H), 3.84-3.94 (2H), 4.04 (1H), 4.17 (1H), 4.46 (1H), 7.14 (1H), 7.32 (1H), 7.43 (1H), 7.47-7.58 (5H), 7.72 (1H), 8.38 (1H). 13C NMR (101 MHz, CDCI3): δ [ppm] = 13.6, 40.6, 48.6, 66.7, 71.1, 106.3, 113.5, 117.8, 126.9, 120.8, 129.0, 129.2, 137.2, 140.1, 140.4, 140.5, 143.0 144.7, 149.9, 156.8. LC-MS (method 1): R, = 3.32 min; MS (ESI/APCIpos) m/z = 372.2 [M+H]+. Example 28
4-(3-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine
Step a:
4-(3-methanesulphonylphenyl)-2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7]naphthyridine
Under argon, 120 mg (227 μιτιοΙ) of 2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl trifluoromethanesulphonate, 76 mg (0.38 mmol) of 3- (methanesulphonyl)phenylboronic acid, 18 mg (22.7 μιτιοΙ) of [l,l'-bis(diphenylphosphino)- ferrocene]dichloropalladium(ll) x dichloromethane and 296 mg (0.91 mmol) of caesium carbonate
were weighed out and dissolved in 1.5 ml of absolute 1,4-dioxane. The mixture was degassed three times and stirred at 90°C for 90 min. The course of the reaction was monitored by LC/MS. Under reduced pressure, the mixture was concentrated to dryness. The residue was chromatographed [silica gel 60 (25 g, 30 μιη); dichloromethane/methanol 98:2]. This gave 72 mg (60% of theory) of 4-(3-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow solid. 1H NM (400 MHz, CDCIa): δ [ppm] = 1.32-1.37 (3H), 1.49-1.69 (1H), 1.69 (2H), 2.09 (2H), 2.55 (1H), 2.68 (3H), 3.27- 3.39 (1H), 3.47 (1H), 3.59 (1H); 3.77 (2H), 3.94-4.48 (4H), 6.10 (1H), 6.93-6.95 (1H), 7.02-7.08 (1H), 7.20-7.25 (1H), 7.42 (1H), 7.71-7.79 (3H), 8.32-8.35 (2H). LC-MS (method 1): Rt = 3.43 min; MS (ESI/APCIpos) m/z = 534.3 [M+H]+.
Step b:
4-(3-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine
72 mg (0.13 mmol) of 4-(3-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 5 ml of methanol, 1 ml of 2N hydrochloric acid (2 mmol) was added and the mixture was stirred at room temperature for 1 h. After 1 h, LC/MS showed complete removal of the protective group. The methanol was removed under reduced pressure and the residue was adjusted to pH = 7 using saturated sodium bicarbonate solution. The aqueous phase was extracted five times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then, under reduced pressure, concentrated to dryness. The residue was chromatographed twice [silica gel 60 (25 g, 30 μιη); dichloromethane/methanol 96:4]. This gave 37 mg (61% of theory) of 4-(3-methanesulphonylphenyl)-2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine as an orange solid. :H NMR (400 MHz, CDCI3): δ [ppm] = 1.46 (3H), 2.66 (3H), 3.58 (1H), 3.72 (1H), 3.83-3.92 (2H), 4.04-4.20 (2H), 4.39 (1H), 6.91 (1H), 7.33-7.37 (2H), 7.42 (1H),
7.73-7.80 (3H), 8.33 (2H). LC-MS (method 1): , = 2.80 min; MS (ESI/APCIpos) m/z = 450.2 [M+H]
Example 29
4 yclopropyl-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]-naphthyridine Step a:
4-cyclopropyl-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridin
Under argon, 82 mg (0.1 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 652 mg (2.0 mmol) of caesium carbonate were added to a suspension of 264 mg (0.5 mmol) of 2-[(3/?)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 86 mg (1 mmol) of 2-cyclopropyl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane in 5 ml of absolute dioxane. The reaction mixture was stirred at 110°C for 4 h. Without work-up, the mixture was chromatographed directly [Puri-Flash, silica gel 60 (25 g, 30 μιη); ethyl acetate (100 ml)]. This gave 100 mg (48% of theory) of 4-cyclopropyl-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2- yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow solid. 13C NMR (101 MHz, CDCI3-d5): δ [ppm] = 6.9, 7.0, 12.5, 13.5, 22.8, 25.0, 30.0, 39.4, 39.7, 47.1, 47.7, 66.9, 67.0, 67.6, 71.1, 84.8, 108.8, 110.2, 116.6, 128.0, 128.1, 138.5, 138.6, 139.0, 139.1, 140.3, 141.7, 148.2, 149.6, 156.6, 156.7.
Step b:
4-cyclopropyl-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]-naphthyridine
100 mg (0.24 mmol) of 4-cyclopropyl-2-((R)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 5 ml of methanol, and 1 ml (2 mmol) of 2N hydrochloric acid was added. After 1 h, LCMS showed complete removal of the protective group. The methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [Puri- Flash, silica gel 60 (12 g, 30 μηι); ethyl acetate (100 ml)]. This gave 70 mg (88% of theory) of 4- cyclopropyl-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 74-76°C. :H NM (400 MHz, CDCI3): δ [ppm] = 0.78-0.82 (2H), 1.14-1.17 (2H), 1.38-1.40 (3H), 2.24-2.28 (1H), 3.46-3.52 (1H), 3.64-3.71 (1H), 3.80-3.96 (3H), 4.11-4.15 (1H), 4.37-4.39 (1H), 6.86 (1H), 7.26-7.26 (1H), 7.68-7.69 (1H), 7.81-7.83 (1H), 8.44-8.45 (1H). Example 30
4-[2-((ff)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S- methylsulphoximide
Step a:
4-[2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S-methylsulphoximide
Under argon, 48 mg (0.06 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 761 mg (2.34 mmol) of caesium carbonate were added to a suspension of 308 mg (0.58 mmol) of 2-((R)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 413 mg (1.17 mmol) of pinacol ester in 7.5 ml of absolute dioxane. The reaction mixture was stirred at 90°C for 2 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μηη); ethyl acetate (100 ml)]. This gave 245 mg (69% of theory) of 4-[(2-(morpholin-4-yl)- 8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S- methylsulphoximide as a yellow foam. LC-MS (method 1): m/z: [M+H]+ = 605.3, Rt = 3.52 min.
Step b:
4-[2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-^-methylsulphoximide
240 mg (0.40 mmol) of 4-[2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol- 3-yl]-[l,7]naphthyridine-4-yl]phenyl-/\/-ethoxycarbonyl-S-methylsulphoximide were dissolved in 10 ml of ethanol, and 4 ml of (8 mmol) of 2N hydrochloric acid were added. After 1 h, LCMS showed complete removal of the protective group. Ethanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. This gave 200 mg (97% of theory) of 2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine-4-carbonitrile as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 521.3, t = 3.00 min.
Step c:
4-[2-((ff)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S-
170 mg (0.33 mmol) of 4-[2-((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine- 4-yl]phenyl-S-methylsulphoximide were suspended in 5 ml of sodium methoxide (33%), and the mixture was stirred at 60°C for 30 min. For work-up, 20 ml of water were added and the mixture was then extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated. The solid formed was triturated with 5 ml of methanol, filtered off and dried. This gave 88 mg (57% of theory) of 4-[2- ((/?)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S- methylsulphoximide as a yellow solid, m.p. 233-236°C. 1H NM (400 MHz, DMSO-de): δ [ppm] = 1.30-1.32 (3H), 3.17 (3H), 3.54 (IH), 3.55-3.57 (IH), 3.70-3.73 (IH), 3.81-3.84 (IH), 4.22- 4.25 (IH), 4.35 (IH), 7.35-7.36 (IH), 7.42 (IH), 7.48 (IH), 7.65 (IH), 7.80-7.82 (2H), 8.12-8.14 (2H), 8.33-8.34 (IH), 13.40 (IH). LC-MS (method 1): m/z: [M+H]+ = 449.3, t = 2.69 min.
Example 31
3-[2-((ff)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S- methylsulphoximide
Step a:
3-[2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phen l-/V-ethoxycarbonyl-S-methylsulphoximide
Under argon, 48 mg (0.06 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 761 mg (2.34 mmol) of caesium carbonate were added to a suspension of 308 mg (0.58 mmol) of 2-((/?)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and
413 mg (1.17 mmol) of pinacol ester in 7.5 ml of absolute dioxane. The reaction mixture was stirred at 90°C for 2 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μηι); ethyl acetate (100 ml)]. This gave 289 mg (82% of theory) of 3-[2-((/?)-3- methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 605.3, t = 3.56 min.
Step b:
4-[2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S-methylsulphoximide
280 mg (0.46 mmol) of 3-[2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-
3- yl]-[l;7]naphthyridine-4-yl]phenyl-/V-ethoxycarbonyl-S-methylsulphoximide were dissolved in 10 ml of ethanol, and 4 ml of (10 mmol) of 2N hydrochloric acid were added. After 1 h, LCMS showed complete removal of the protective group. Ethanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (25 g, 30 μιη); ethyl acetate (100 ml)]. This gave 220 mg (91% of theory) of 2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-
4- carbonitrile as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 521.3, t = 3.04 min.
Step c:
3-[2-((ff)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S- methylsulphoximide
210 mg (0.40 mmol) of 4-[2-((R)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-
3- yl]-[l,7]naphthyridine-4-yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide were suspended in 5 ml of sodium methoxide (33%), and the mixture was stirred at 60°C for 30 min. For work-up, 20 ml of water were added and the mixture was then extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated. This gave 165 mg (91% of theory) of 3-[2-((/?)-3-methylmorpholin-4-yl)-8-(2H- pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S-methylsulphoximide as a yellow solid, m.p. 79- 81°C. H NM (400 MHz, DMSO-de): δ [ppm] = 1.30-1.32 (3H), 3.18 (3H), 3.57-3.58 (IH), 3.71-3.75 (IH), 3.82-3.85 (IH), 4.03-4.06 (IH), 4.21-4.24 (IH), 4.34 (IH), 4.67-4.68 (IH), 7.35-7.36 (IH), 7.42 (IH), 7.48 (IH), 7.65 (IH), 7.80-7.82 (2H), 8.12-8.14 (2H), 8.33-8.34 (IH), 13.40 (IH). LC-MS (method 1): m/z: [M+H]+ = 449.3, R, = 2.69 min.
Example 32
4-methanesulphonyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Step a:
4- methanesulphonyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
A solution of 500 mg (1.25 mmol) of 4-chloro-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7] naphthyridine, 140 mg (1.38 mmol) of sodium methanesulphinate, 45 mg (0.13 mmol) of copper(ll) trifluoromethanesulphonate and 29 mg (0.25 mmol) of (±)-trans-l,2- diaminocyclohexane in 5 ml of dimethyl sulphoxide was stirred at 100°C for 16 h. 20 ml of water were added to the reaction mixture. The resulting precipitated solid was filtered off. The solid was purified by column chromatography [Puri-Flash, silica gel 60 (40 g, 30 μιη), dichloromethane/methanol 1:1 (300 ml)]. In this manner, 4-methanesulphonyl-2-(morpholin-4- yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine was obtained as a yellow solid in a yield of 300 mg (54% of theory). LC-MS (method 1): m/z: [M+H]+ = 444.3, , = 3.24 min.
Step b:
4-methanesulphonyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
300 mg (0.67 mmol) of 4-methanesulphonyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7] naphthyridine were dissolved in 5 ml of methanol, and 1 ml (4 mmol) of 2N hydrochloric acid was added. After 1 h, LCMS showed complete removal of the protective group. Methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium
sulphate and then concentrated to dryness. The solid residue was triturated with 5 ml of methanol, filtered off and dried. This gave 146 mg (60% of theory) of 4-methanesulphonyl-2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridine as a yellow solid, m.p. 271-273°C. :H NM (400 MHz, DMSO, δ ppm): 3.48 (3H), 3.80 (8H), 7.35 (1H), 7.65 (1H), 7.93 (1H), 8.14-8.16 (1H), 8.49-8.50 (1H), 13.43 (1H). LC-MS (method 1): m/z: [M+H]+ = 360.2,
Example 33
2-[(3R)-3-methylmorpholin-4-yl]-4-(methylsulfonyl)-8-(lH^yrazol-5-yl)-l,7-naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(methylsulfonyl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 5-yl]-l,7-naphthyridine
4-Chloro-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine (50 mg, 0.12 mmol, 1 eq.) was solubil ised in DMF (4 mL). Methanesulfinic acid sodium salt (25 mg, 0.24 mmol, 2 eq.) and DMAP (1.5 mg, 0.012 mmol, 0.1 eq.) were added. The reaction was stirred for 16h at 120°C. After cooling to rt, the reaction mixture was concentrated under reduced pressure and the crude was purified by flash column chromatography (gradient 100% hexane to 100% EtOAc). The desired product was obtained in 74% yield (46 mg). 1H-NMR (400MHz, DMSO-d5): δ [ppm]: 1.24 (3H), 1.39 - 1.65 (3H), 1.89 - 2.03 (2H), 2.34 - 2.43 (1H), 3.20 - 3.29 (1H), 3.41 - 3.54 (5H), 3.58 - 3.73 (2H), 3.77 (1H), 3.94 - 4.01 (1H), 4.12 (1H), 4.45 - 4.56 (1H), 5.97 - 6.08 (1H), 6.89 (1H), 7.64 (1H), 7.84 (1H), 8.19 (1H), 8.54 (1H). LC-MS (Method 3): m/z: [M+H]+ = 458, R, = 1.01 min.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(methylsulfonyl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
2-[(3 )-3-Methylmorpholin-4-yl]-4-(me
yl]-l,7-naphthyridine (38 mg, 0.084 mmol, 1 eq.) was solubilised in CH2CI2 (1.5 mL) and H20 (1 mL). Formic acid was added (1 mL) and the reaction was stirred for 2h at rt. The mixture was then quenched with sat. NaHCC>3 and the aqueous phase was extracted three times with CH 2CI 2. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography (gradient from 100% hex to 100% EtOAc to EtOAc/EtOH : 8/2). The desired compound was obtained in 85% yield. 1H-NMR (400MHz, DMSO- d5): δ [ppm] : 1.32 (3H), 3.36 - 3.46 (1H), 3.49 (3H), 3.57 (1H), 3.71 (1H), 3.84 (1H), 4.06 (1H), 4.17 (1H), 4.57 - 4.66 (1H), 7.37 (1H), 7.63 - 7.66 (1H), 7.88 (1H), 8.14 (1H), 8.49 (1H), 13.46 (1H). LC- MS (Method 3): m/z: [M+H]+ = 374, R, = 0.81 min.
Example 34
2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4-carbonitrile Step a:
2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- carbonitrile
Under argon, 34 mg (0.029 mmol) of tetrakis(triphenylphosphine)palladium(0) were added to a suspension of 500 mg (0.97 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3- yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 43 mg (0.37 mmol) of zinc cyanide in
5 ml of absolute dimethylformamide. The reaction mixture was stirred at 130°C for 1 h. 30 ml of sodium bicarbonate solution were added to the mixture. The aqueous phase was extracted three times with in each case 40 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was triturated with 10 ml of ethyl acetate, filtered off and then dried. This gave 260 mg (68% of theory) of 2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridine-4-carbonitrile as a colourless solid. LC- MS (method 1): m/z: [M+H]+ = 391.3, t = 3.44 min.
Step b:
2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4-carbonitrile
A drop of water and 2 ml (26 mmol) of trifluoroacetic acid were added to 100 mg (0.26 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridine-4-carbonitrile. After 16 h, LCMS showed complete removal of the protective group. The trifluoroacetic acid was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was triturated with 5 ml of chloroform, filtered off and then dried. This gave 30 mg (38% of theory) of 2-morpholin-4-yl-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine-4-carbonitrile as a yellow solid, m.p. 256-258°C. :H NMR (400 MHz, DMSO): 5 [ppm] = 3.79 (8H), 7.36 (1H), 7.65-7.66 (1H), 7.68-7.69 (1H), 8.28 (1H), 8.49-8.51 (1H), 13.42 (1H). LC-MS (method 1): m/z: [M+H]+ = 306.1, Rt = 2.93 min.
Example 35
2-((ff)-3-methylmorpholin-4-yl)-8-(-2H^yrazol-3-yl]-[l,7]naphthyridine-4-carbonitrile Step a:
2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyra^
4-carbonitrile
Under argon, 4 mg (0.004 mmol) of tetrakis(triphenylphosphine)palladium(0) were added to a suspension of 60 mg (0.114 mmol) of 2-((R)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 14 mg (0.114 mmol) of zinc cyanide in 2 ml of absolute dimethylformamide. The reaction mixture was stirred at 100°C for 15 min. For work-up, a mixture of 25 ml of water and 25 ml of 50 percent strength ammonia solution was added to the mixture. The precipitated solid was filtered off with suction and washed with 10 ml of water. The solid was then dried under reduced pressure. 35 mg (76% of theory) of 2- ((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- carbonitrile were obtained as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 405.3, Rt = 3.53 min.
Step b:
2-((/?)-3-methylmorpholin-4-yl)-8-(- -3-yl]-[l,7]naphthyridine-4^arbonitrile
1 ml (2 mmol) of 2N hydrochloric acid was added to a solution of 35 mg (0.087 mmol) of 2-((/?)-3- methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- carbonitrile in 2 ml of methanol. The solution was stirred at 50°C for 18 h. After 18 h, LCMS showed complete removal of the protective group. Methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution.
A solid precipitated out; this was separated off and washed with 10 ml of water. The solid was then dried under reduced pressure. This gave 18 mg (58% of theory) of 2-((/?)-3-methylmorpholin- 4-yl)-8-(-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-carbonitrile as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 321.2, t = 3.08 min.
Example 36
2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4-carboxamide Step a:
2-morpholin-4-yl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- carboxamide
47 mg (0.85 mmol) of potassium hydroxide in a drop of water were added to a suspension of 300 mg (0.77 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-carbonitrile in 15 ml of isopropanol, and the mixture was stirred at 70°C for 6 h. The solvent was distilled off and the residue was used without further purification for protective group removal. This gave 2-morpholin-4-yl-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3- yl]-[l,7]naphthyridine-4-carboxamide as a yellow solid in a yield of 314 mg (100% of theory). LC- MS (method 1): m/z: [M+H]+ = 409.3, R, = 2.62 min.
Step b:
2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4-carboxamide
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 95 mg (0.23 mmol) of 2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-carboxamide. After 2 h, LCMS showed complete removal of the protective group. The trifluoroacetic acid was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The precipitated solid was filtered off with suction and dried. The product was chromatographed [silica gel 60 (12 g, 30 μιη); chloroform/methanol (1:1, 300 ml)]. This gave 20 mg (25% of theory) of 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4- carboxamide as a yellow solid, m.p. 282-285°C. H NM (400 MHz, DMSO, δ ppm): 3.79 (8H), 7.36 (1H), 7.61 (2H), 7.83-7.84 (1H), 7.89 (1H), 8.23 (1H), 8.37-8.39 (1H), 13.36 (1H).
Example 37
4-methanesulphonylmethyl-2-morpholin-4-yl-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine Step a:
potassium 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine-4-carboxylate
3.3 g (8.45 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]- naphthyridine-4-carbonitrile were suspended in 33 ml of 2-methoxyethanol, 1.4 g (25.4 mmol) of potassium hydroxide in 772 μΙ of water were added and the mixture was stirred at 150°C for 7 h.
Since conversion was still incomplete, the mixture was stirred at 130°C for a further 14 h. For work-up, most of the solvent was removed. The residue was triturated with 10 ml of isopropanol and 50 ml of diethyl ether. The resulting precipitated yellow solid was filtered off and dried under reduced pressure. This gave 2.74 g (72% of theory) of potassium 2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4-carboxylate as a yellow solid. LC- MS (method 1): m/z: [M+H]+ = 410.3, t = 3.03 min.
Step b:
methyl 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- carboxylate
630 mg (1.41 mmol) of potassium 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 5-yl]-[l,7]naphthyridine-4-carboxylate were suspended in 10 ml of tetrahydrofuran, 459 mg (1.41 mmol) of caesium carbonate and 102 μΙ (1.69 mmol) of methyl iodide were added and the mixture was stirred at 80°C for 32 h. For work-up, most of the solvent was removed. 20 ml of water were added to the residue, and the mixture was extracted three times with in each case 30 ml of chloroform. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. This gave 405 mg (68% of theory) of methyl 2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-carboxylate as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 424.4, R, = 3.50 min.
Step c:
{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4- yljmethanol
At 0°C and under an atmosphere of argon, 178 mg (4.68 mmol) of lithium aluminium hydride were added to a solution of 660 mg (1.56 mmol) of methyl 2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4-carboxylate in 16 ml of absolute tetrahydrofuran, and the mixture was stirred at 0°C for 30 min. With ice-cooling, 20 ml of saturated ammonium chloride solution were added to the reaction mixture, and the mixture was then extracted three times with in each case 30 ml of chloroform. The combined organic phases were dried over sodium sulphate and concentrated under reduced pressure. This gave 570 mg (93% of theory) of {2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine-4-yl}methanol as a crude product. The latter consisted of two compounds. According to H NM spectrum, this crude product contained 30% of {2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4-yl}methanol and 70% of a compound having 2 extra mass units. It was not possible to separate the two products by chromatography, and therefore they were used as crude product in the next step. LC-MS (method 1): m/z: [M+H]+ = 396.3, R, = 2.95 min.
Step d:
2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H^yrazol-3-yl]-[l,7]naphthyridine-4-ylmethyl methanesulphonate
Under argon and at 10°C, 56 μΙ (0.72 mmol) of methanesulphonyl chloride were added dropwise to a solution of 260 mg (0.66 mmol) of {2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine-4-yl}methanol and 119 μΙ (0.86 mmol) of triethylamine in 10 ml of absolute tetrahydrofuran, and the mixture was stirred at 10°C for 1 h. The precipitated solid was filtered off and the filtrate was concentrated under reduced pressure. This gave 311 mg (100% of theory) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridine-4- ylmethyl methanesulphonate as a brown solid. This crude product was used without further purification for the next synthesis. LC-MS (method 1): m/z: [M+H]+ = 474.3, t = 3.24 min.
Step e:
4-methanesulphonylmethyl-2-(morpholin-4-yl-)8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Sodium methylsulphinate was added a little at a time to a solution of 311 mg (0.66 mmol) of 2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridine-4-ylmethyl methanesulphonate in 10 ml of absolute dimethyl sulphoxide, and the mixture was then stirred at 120°C for 20 min. The mixture was diluted with 10 ml of water and then extracted three times
with in each case 10 ml of dichloromethane. The combined organic solutions were dried over sodium sulphate and then concentrated under reduced pressure. The residue was chromatographed [Puri-Flash, silica gel 60 (25 g, 30 μιτι); dichloromethane/methanol 95:5]. This gave 80 mg (27% of theory) of 4-methanesulphonylmethyl-2-(morpholin-4-yl-)8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 458.3, t = 2.89 min.
Step f:
4-methanesulphonylmethyl-2-mor -yl)-[l,7]naphthyridine
30 mg (0.07 mmol) of 4-methanesulphonylmethyl-2-(morpholin-4-yl-)8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 1 ml of methanol, and 0.5 ml (1 mmol) of 2N hydrochloric acid was added. After 1 h, LCMS showed complete removal of the protective group. Methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The resulting precipitated solid was filtered off and dried under reduced pressure. This gave 24 mg (98% of theory) of 4- methanesulphonylmethyl-2-morpholin-4-yl-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 272-274T. H NMR (400 MHz, DMSO): δ [ppm] = 3.10 (3H), 3.74-3.81 (8H), 5.00 (2H), 7.36 (1H), 7.64 (2H), 7.94 (1H), 8.40 (3H), 13.31 (1H).
Example 38
[2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]methanol
50 mg (0.126 mmol) of [2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine-4-yl}methanol were dissolved in 1 ml of methanol, and 0.5 ml (1 mmol) of 2N hydrochloric acid was added. After 1 h, LCMS showed complete removal of the protective group. Methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated under reduced pressure. The residue was purified using a Flashmaster chromatography [silica gel 60 (25 g, 30 μιη); dichloromethane/methanol 95:5]. This gave 20 mg (51% of theory) of [2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]-naphthyridine-4-yl]methanol as a yellow solid. H NM (400 MHz, DMSO): δ [ppm] =3.81 (8H), 4.95 (2H), 7.47-7.48 (1H), 7.68 (1H), 7.89-7.92 (2H), 8.35-8.36 (1H), 13.31 (1H). LC-MS (method 1): m/z: [M+H]+ = 312.2, R, = 2.31 min.
Example 39
4-(l-methanesulphonylcyclopropyl)-2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-(l-methanesulphonylcyclopropyl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol- 3-yl)-[l,7]naphthyridine
330 μΙ of 50 percent strength sodium hydroxide solution were added to a solution of 150 mg
(0.328 mmol) of 4-methanesulphonylmethyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H- pyrazol-3-yl]-[l,7]naphthyridine, 28 μΙ (0.319 mmol) of 1,2-dibromoethane and 10 mg (0.032 mmol) of tetrabutylammonium bromide in 960 μΙ of absolute tetrahydrofuran, and the mixture was then stirred at room temperature for 1 h. The colour of the suspension changed from dark-green to dark-brown. Another 28 μΙ (0.319 mmol) of 1,2-dibromoethane, 10 mg (0.032 mmol) of tetrabutylammonium bromide and 330 μΙ of 50 percent strength sodium hydroxide solution were added, and the mixture was stirred at 60°C for 3 h. The mixture was diluted with 10 ml of water and then extracted three times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated under reduced pressure. The residue was purified twice by column chromatography on a Flashmaster [silica gel 60 (2 x 25 g, 30 μιη), dichloromethane/methanol 95:5]. This gave 23 mg (15% of theory) of 4-(l-methanesulphonylcyclopropyl)-2-(morpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid. The solid, which was impure, was used without further purification for the next step. LC-MS (method 1): m/z: [M+H]+ = 484.2, , = 2.75 min.
Step b:
4-(l-methanesulphonylcyclopropyl -2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine
0.5 ml of (1 mmol) of 2N hydrochloric acid was added to a solution of 23 mg (0.048 mmol) of 4-(l- methanesulphonylcyclopropyl)-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl)]- [l,7]naphthyridine in 1 ml of methanol. The solution was stirred at 50°C for 18 h. After 18 h, LCMS showed complete removal of the protective group. Methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and concentrated under reduced pressure. This gave 18 mg (85% of theory) of 4-(l-methanesulphonylcyclopropyl)-2-(morpholin-4-
yl)-8-(2H-pyrazol-3-yl)-[l,7]-naphthyridine as a yellow solid, m.p. 220-234°C. H NM (400 MHz, DMSO): δ [ppm] =1.39-2.09 (4H), 3.06 (3H), 3.79-3.80 (8H), 7.36 (1H), 7.61 (1H), 7.82-7.88 (2H), 8.39-8.41 (1H), 13.36 (1H). LC-MS (method 1): m/z: [M+H]+ = 400.30, R, = 2.21 min. Example 40
4-isopropoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
4-isopropoxy-2-(morpholin-4-yl)-8- 2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin
44 mg (0.31 mmol) of potassium carbonate were added to a solution of 100 mg (0.26 mmol) of 2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-ol and 45 mg (0.26 mmol) of iodopropane in 6 ml of dry acetonitrile (MeCN). The suspension was stirred at 85°C for 7 h. The course of the reaction was monitored by LCMS. The solvent was removed and the residue that remained was chromatographed [silica gel 60 (12 g, 30 μιτι); ethyl acetate (100 ml)]. This gave 90 mg (81% of theory) of 4-isopropoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 424.3, Rt = 3.66 min.
Step b:
4-isopropoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridi
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 80 mg (0.19 mmol) of 4- isopropoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine. After 10 min, LCMS showed complete removal of the protective group. The trifluoroacetic acid was removed under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (12 g, 30 μιη); ethyl acetate (100 ml)]. This gave 40 mg (59% of theory) of 4-isopropoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow foam. m.p. 73-74°C. H NM (400 MHz, CDCI3, δ ppm): 1.48 (6H), 3.64-3.67 (4H), 3.89-3.92 (4H), 4.75-4.78 (1H), 6.37 (1H), 7.23 (1H), 7.67 (1H), 7.71 (1H), 8.38 (1H). LC-MS (method 1): m/z: [M+H]+ = 340.3, t = 2.95 min.
Example 41
2-(morpholin-4-yl)-4-(propan-2-yloxy)-8-(lH-pyrrol-2-yl)-l,7-naphthyridine Step a:
tert-butyl 2-[2-(morpholin-4-yl)-4-(propan-2-yloxy)-l,7-naphthyridin-8-yl]-lH-pyrrole-l- carboxylate
O
H3C-(
CH3
Under argon, 20 mg (0.024 mmol) [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 75 mg (0.24 mmol) 8-chloro-2-(morpholin-4-yl)-4-(propan-2-yloxy)- 1,7-naphthyridine and 57 mg (0.27 mmol) [l-(tert-butoxycarbonyl)-lH-pyrrol-2-yl]boronic acid in 2 ml acetonitrile and 2 ml 2M aqueous solution of potassium carbonate. The mixture was stirred in a microwave oven at 130 °C for 10 minutes. After cooling, DCM was added and the mixture was filtered using a Whatman filter. The organic phase was concentrated and the residue was purified by HPLC separation (Autopurifier: basic conditions) to give 35 mg (0.08 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 0.92 (9H), 1.37 (6H), 3.52 (4H), 3.63 (4H), 5.05 (1H), 6.29 (1H), 6.39 (1H), 6.76 (1H), 7.37 (1H), 7.63 (1H), 8.20 (1H).
Step b:
2-(morpholin-4-yl)-4-(propan-2-ylox )-8-(lH-pyrrol-2-yl)-l,7-naphthyridine
7 μΙ (0.096 mmol) TFA were added to a solution of 9 mg (0.020 mmol) tert-butyl 2-[2-(morpholin- 4-yl)-4-(propan-2-yloxy)-l,7-naphthyridin-8-yl]-lH-pyrrole-l-carboxylate in 2 ml DCM and the reaction mixture was stirred at room temperature for 150 minutes. Additional 7 μΙ (0.096 mmol) TFA was added and the reaction mixture was stirred overnight. Additional 23 μΙ (0.32 mmol) TFA was added and the reaction mixture was stirred for 8 hours. The mixture was basified by addition
of aqueous sodium bicarbonate solution and extracted with DCM (2x). The combined organic phases were filtered using a Whatman filter and concentrated to give 9 mg (0.027 mmol) of the desired product. 1H-NM (400 MHz, CDCI3): δ [ppm] = 1.50 (6H), 3.70 (4H), 3.96 (4H), 4.80 (1H), 6.41 (2H), 7.03 (1H), 7.48 (1H), 7.61 (1H), 8.31 (1H), 11.53 (1H).
Example 42
4-[3-(S-methylsulfonimidoyl)propoxy]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
2,2,2-trifluoro-N-[(3-hydroxypropy idene]acetamide
A mixture of 1.00 g (2.83 mmol) N-[{3-[(benzyloxy)methoxy]propyl}(methyl)oxido- 6- sulfanylidene]-2,2,2-trifluoroacetamide and 0.75 g palladium on charcoal (10%) in 100 ml ethanol was stirred under a hydrogen atmosphere for 90 minutes at 80°C. 0.50 g palladium on charcoal (10%) are added and the mixture is stirred for additional 3 hours under a hydrogen atmosphere at 80°C. After cooling, the reaction mixture was filtered and the filtrate was concentrated to give 0.61 g of the desired product that was used without further purification. 1H-NMR (400 MHz, CDCI3): δ [ppm] = 2.18 (2H), 3.41 (3H), 3.61 (1H), 3.72 (1H), 3.86 (2H).
Step b:
2,2,2-trifluoro-N-{methyl[3-({2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}oxy)propyl]oxido-A6-sulfanylidene}acetamide
A solution of 26 μΙ (0.13 mmol) diisopropyl azodicarboxylate in 0.1 ml THF was added dropwise to a mixture of 50 mg (0.13 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-ol, 28 mg crude 2,2,2-trifluoro-N-[(3-hydroxypropyl)(methyl)oxido- 6- sulfanylidene]acetamide and 34 mg (0.13 mmol) triphenylphosphine in 0.5 ml THF and the batch was stirred at room temperature for 6 hours. 94 mg (0.36 mmol) triphenylphosphine and 71 μΙ (0.36 mmol) diisopropyl azodicarboxylate were added and the mixture was stirred at room temperature overnight. Finally, 34 mg (0.13 mmol) triphenylphosphine and 26 μΙ (0.13 mmol) diisopropyl azodicarboxylate were added and the mixture was stirred for 6 hours before it was concentrated. The residue was purified by column chromatography on silica gel (DCM to DCM / ethanol 15%) to give 34 mg of the product with approximately 70% purity.
Step c:
4-[3-(S-methylsulfonimidoyl)propoxy]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
39 mg (0.29 mmol) potassium carbonate was added to a solution of 34 mg 2,2,2-trifluoro-N- {methyl[3-({2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridin- 4-yl}oxy)propyl]oxido- 6-sulfanylidene}acetamide (purity approximately 70%) in 1.2 ml methanol and the reaction mixture was stirred at room temperature for 90 minutes. Aqueous sodium chloride solution was added and the mixture was extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to give 27 mg of the desired product with a purity of approximately 66%. Step d:
4-[3-(S-methylsulfonimidoyl)propo -2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
0.06 ml (0.12 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 27 mg 4-[3-(S-methylsulfonimidoyl)propoxy]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine (purity approximately 66%) in 0.25 ml methanol and the reaction
mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC (Autopurifier: acidic conditions) to give 3 mg (0.007 mmol) of the desired product. 1H-NM (400 MHz, DMSO-d6): δ [ppm] = 2.32 (2H), 2.99 (3H), 3.31 (2H), 3.75 (4H), 3.80 (4H), 4.41 (2H), 6.90 (1H), 7.38 (1H), 7.62 (1H), 7.81 (1H), 8.35 (1H), 13.37 (1H).
Example 43
4-ethoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
4-ethoxy-2-(morpholin-4-yl)-8-[2-(tetrah dro ran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
44 mg (0.31 mmol) of potassium carbonate were added to a solution of 100 mg (0.26 mmol) of 2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-ol and 21 μΙ (0.26 mmol) of iodoethane in 6 ml of dry acetonitrile (MeCN). The suspension was stirred at 85°C for 2 h. The course of the reaction was monitored by LCMS. The solvent was removed and the residue that remained was reacted further without purification. LC-MS (method 1): m/z: [M+H]+ = 410.3, R, = 3.53 min.
Step b:
4-ethoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
One drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 107 mg (0.26 mmol) of 4-ethoxy-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridine. After 1 h, LCMS showed complete removal of the protective group. The trifluoroacetic acid was removed under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. 5 ml of methanol were added to the residue. The resulting precipitated solid was filtered off and then dried. This gave 25 mg (29% of theory) of 4-ethoxy-2- (morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 173-175°C. :H NM (400 MHz, CDCI3, δ ppm): 1.57-1.61 (3H), 3.70-3.72 (4H), 3.92-3.95 (4H), 4.22-4.27 (2H), 6.41 (1H), 7.25 (2H), 7.70 (1H), 7.75 (1H), 8.42 (1H). LC-MS (method 1): m/z: [M+H]+ = 326.3, R, = 2.81 min.
Example 44
4-methoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-methoxy-2-(morpholin-4-yl)-8- 2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
44 mg (0.31 mmol) of potassium carbonate were added to a solution of 100 mg (0.26 mmol) of 2-
(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-ol and 32 μΙ (0.26 mmol) of methyl iodide in 6 ml of dry acetonitrile. The suspension was stirred at 85°C for 2 h. The course of the reaction was monitored by LCMS. The solvent was removed and the residue that remained was reacted further without purification. LC-MS (method 1): m/z: [M+H]+ = 396.3, t = 3.33 min.
Step b:
4-methoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 103 mg (0.26 mmol) of 4-methoxy-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine. After 10 min, LCMS showed complete removal of the protective group. The trifluoroacetic acid was removed under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was triturated with 5 ml of methanol. The resulting precipitated solid was filtered off and then dried. This gave 30 mg (35% of theory) of 4-methoxy- 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 234-235°C. H NMR (400 MHz, CDCI3, δ ppm): 3.67-3.69 (4H), 3.91-3.93 (4H), 4.01 (3H), 6.36 (1H), 7.25 (1H), 7.68 (2H), 8.40 (1H). LC-MS (method 1): m/z: [M+H]+ = 312.3, R, = 2.60 min.
Example 45
2-methyl-l-{[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]oxy}propan-2-ol
Step a:
2-methyl-l-({2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}oxy)propan-2-ol
87 mg (0.63 mmol) potassium carbonate was added to a mixture of 60 mg (0.16 mmol) 2- (morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridin-4-ol and 102 mg (0.94 mmol) l-chloro-2-methylpropan-2-ol in 5.0 ml ethanol and 0.5 ml water and the mixture was stirred at 70°C for 20 hours. 51 mg (0.47 mmol) l-chloro-2-methylpropan-2-ol and 44 mg (0.32 mmol) potassium carbonate were added and the mixture was stirred for additional 24 hours at 70°C. After cooling, the reaction mixture was diluted with water and extracted with DCM (2x). The combined organic phases were dried (MgS04), filtered and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 17 mg (0.04 mmol) of the desired product.
Step b:
2-methyl-l-{[2-(morpholin-4-yl)-8-( -pyrazol-5-yl)-l,7-naphthyridin-4-yl]oxy}propan-2-ol
0.04 ml (0.08 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 16 mg 2-methyl-l-({2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthy- ridin-4-yl}oxy)propan-2-ol in 0.2 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate
solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to give 5 mg (0.01 mmol) of the desired product. :H-NMR (400 MHz, CDCI3): δ [ppm] = 1.50 (6H), 3.72 (4H), 3.95 (4H), 4.02 (2H), 6.45 (1H), 7.28 (1H), 7.72 (1H), 7.73 (1H), 8.44 (11-1),
Example 46
2-(morpholin-4-yl)-8-(lH-pyrazol-5- -4-(tetrahydrofuran-2-ylmethoxy)-l,7-naphthyridine
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-ol (259 mg, 0.43 mmol), 2-(bromomethyl)tetrahydrofuran (126 mg, 0.68 mmol) and Caesiumcarbonate (181 mg, 0.56 mmol) in DMF (1.63 ml) was heated in a sealed tube in the microwave at 100°C for one hour. The reaction mixture was allowed to cool to ambient temperature, a solution of concentrated aqueous HCI (0.49 ml) was added and the reaction was stirred at this temperature for two hours. The solvent was evaporated under reduced pressure, the residue was taken up in dichloromethane (10 ml) and water (10 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (2x10ml). The combined organic layers were dried over NazSC and the solvent was removed under reduced pressure. The crude product was purified by HPLC chromatography (acidic conditions). The title compound was obtained in 4% yield (7 mg). 1H-NMR (400 MHz, DMSO): δ [ppm] = 1.75-2.15 (4H), 3.73-3.88 (10H), 4.25-4.36 (3H), 6.94 (1H), 7.39 (1H), 7.70 (1H), 7.75 (1H), 8.36 (1H), 13.52 (1H).
Example 47
3-{[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]oxy}dihydrofuran-2(3H)-one
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7- naphthyridin-4-ol (242 mg, 0.40 mmol), 3-bromodihydrofuran-2(3H)-one (99 mg, 0.60 mmol) and Caesiumcarbonate (169 mg, 0.52 mmol) in DMF (2 ml) was heated in a sealed tube in the microwave at 100°C for one hour. The reaction mixture was allowed to cool to ambient temperature, a solution of concentrated aqueous HCI (0.49 ml) was added and the reaction was stirred at this temperature for two hours. The solvent was evaporated under reduced pressure, the residue was taken up in dichloromethane (10 ml) and water (10 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (2x10ml). The combined organic layers were dried over Na2S04 and the solvent was removed under reduced pressure. The crude product was purified by HPLC chromatography (acidic conditions). The title compound was obtained in 4% yield (7 mg). 1H-NM (400 MHz, DMSO): δ [ppm] = 2.91-2.95 (1H), 3.67-3.80 (9H), 4.36 (1H), 4.55 (1H), 5.80 (1H), 7.08 (1H), 7.36 (1H), 7.61 (1H), 7.70 (1H), 8.34 (1H), 13.33 (1H). Example 48
4-[(3-methyl-l,2-oxazol-5-yl)methoxy]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthy- ridin-4-ol (283 mg, 0.47 mmol), 5-(bromomethyl)-3-methyl-l,2-oxazole (123 mg, 0.70 mmol) and
Caesiumcarbonate (197 mg, 0.61 mmol) in DMF (1.78 ml) was heated in a sealed tube in the microwave at 100°C for one hour. The reaction mixture was allowed to cool to ambient temperature, a solution of concentrated aqueous HCI (0.7 ml) was added and the reaction was stirred at this temperature for two hours. The solvent was evaporated under reduced pressure, the residue was taken up in dichloromethane (10 ml) and water (10 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (2x10ml). The combined organic layers were dried over NazSC and the solvent was removed under reduced pressure. The crude product was purified by HPLC chromatography (acidic conditions). The title compound was obtained in 3 % yield (6 mg). 1H-NM (400 MHz, DMSO): δ [ppm] = 2.27 (3H), 3.76 (8H), 5.57 (2H), 6.65 (1H), 7.06 (1H), 7.36 (1H), 7.61 (1H), 7.69 (1H), 8.32 (1H), 13.35 (1H).
Example 49
4-[(5-methyl-l,2-oxazol-3-yl)methoxy]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-ol (264 mg, 0.35 mmol), 3-(bromomethyl)-5-methyl-l,2-oxazole (91 mg, 0.51 mmol) and Caesiumcarbonate (147 mg, 0.45 mmol) in DMF (1.32 ml) was heated in a sealed tube in the microwave at 100°C for one hour. The reaction mixture was allowed to cool to ambient temperature, a solution of concentrated aqueous HCI (0.51 ml) was added and the reaction was stirred at this temperature for two hours. The solvent was evaporated under reduced pressure, the residue was taken up in dichloromethane (10 ml) and water (10 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (2x10ml). The combined organic layers were dried over Na2S04 and the solvent was removed under reduced pressure. The crude product was purified by HPLC chromatography (acidic conditions). The title compound was obtained in 10 mg yield. H-NM (400 MHz, DMSO): δ [ppm] = 2.46 (3H), 3.77 (8H), 5.49 (2H), 6.52 (1H), 7.09 (1H), 7.39 (1H), 7.62 (1H), 7.72 (1H), 8.34 (1H), 13.38 (1H).
Example 50
4-benzyloxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-benzyloxy-2-(morpholin-4-yl)-8- 2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
44 mg (0.31 mmol) of potassium carbonate were added to a solution of 100 mg (0.26 mmol) of 2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naphthyridin-4-ol, 31 μΙ (0.26 mmol) of benzyl bromide and 4 mg (0.024 mmol) of potassium iodide in 6 ml of dry acetonitrile (MeCN). The suspension was stirred at 85°C for 2 h. The course of the reaction was monitored by LCMS. The solvent was removed and the residue that remained was chromatographed [silica gel 60 (12 g, 30 μιη); ethyl acetate (100 ml)]. This gave 90 mg (73% of theory) of 4-benzyloxy-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine as a yellow oil. LC-MS (method 1): m/z: [M+H]+ = 472.3, t = 3.86 min.
Step b:
4-benzyloxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
A drop of water and 1 ml (13 mmol) of trifluoroacetic acid were added to 90 mg (0.19 mmol) of 4- benzyloxy-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7] naphthyridine. After 10 min, LCMS showed complete removal of the protective group. The trifluoroacetic acid was removed under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. 5 ml of methanol were added to the residue. The resulting precipitated solid was filtered off and then dried. This gave 40 mg (54% of theory) of 4-benzyloxy- 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 217-219°C. H NM (400 MHz, CDCI3, 5 ppm) : 3.69-3.71 (t, 4H), 3.92-3.94 (t, 4H), 5.29 (s, 2H), 6.52 (s, 1H), 7.41-7.51 (m, 6H), 7.70 (d, 1H), 7.79 (d, 1H), 8.42 (d, 1H). LC-MS (method 1): m/z: [M+H]+ = 388.3,
Example 51
4-isopropoxy-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-isopropoxy-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
84 mg (0.61 mmol) of potassium carbonate were added to a solution of 200 mg (0.51 mmol) of 2-[(/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4- ol and 101 μΙ (1.01 mmol) of iodopropane in 4 ml of dry acetonitrile. The suspension was stirred at 85°C for 3 h. The course of the reaction was monitored by LCMS. The solvent was removed and the residue that remained was chromatographed [silica gel 60 (25 g, 30 μιη); ethyl acetate (100 ml)]. This gave 60 mg (27% of theory) of 4-isopropoxy-2-((/?)-3-methylmorpholin-4-yl)-8-[2- (tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a yellow oil. LCMS (method 1): m/z: [M+H]+ = 438.4, , = 3.73 min.
Step b:
4-isopropoxy-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
80 mg (0.18 mmol) of 4-isopropoxy-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 2 ml of methanol, and 2 ml (4 mmol) of 2N hydrochloric acid were added. After 1 h, LCMS showed complete removal of the protective group. Ethanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium
sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (25 g, 30 μηι); ethyl acetate (100 ml)]. This gave 45 mg (70% of theory) of 4-isopropoxy-2-((/?)-3- methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid, m.p. 75-77°C. 1H NM (400 MHz, CDCI3): δ [ppm] = 1.38-1.41 (3H), 1.47-1.49 (6H), 3.44-3.51 (1H), 3.65-3.72 (1H), 3.81-3.91 (3H), 4.01-4.15 (1H), 4.30-4.33 (1H), 4.74-4.79 (1H), 6.37 (1H), 7.22 (1H), 7.67-7.68 (1H), 7.70-7.72 (1H), 8.36-8.37 (1H). LC-MS (method 1): m/z: [M+H]+ = 354.4, Rt = 2.92 min.
Example 52
tert-butyl [4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)butyl]carbamate
Step a:
tert-butyl [4-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}oxy)butyl]carbamate
2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyri- din-4-ol (0.41 g, 1.0 mmol, 1 eq.) was solubilized in DMF (12 mL). 4-(Boc-amino)butyl bromide (0.53 g, 2.1 mmol, 2 eq.) and K2C03 (0.72 g, 5.2 mmol, 5 eq.) were added to the mixture. The reaction was stirred at rt for 16 hours. The suspension was diluted with EtOAc and filtered. The organic phase was concentrated under reduced pressure and the crude material purified by flash chromatography (gradient Hex/EtOAc 9/1 to 100% EtOAc). The desired product was obtained in 87% yield (0.52 g). 1H-NMR (400MHz, DMSO-d6): <5 [ppm]: 1.14 - 1.24 (3H), 1.38 (9H), 1.41 - 1.69 (5H), 1.80 - 1.90 (2H), 1.99 (2H), 2.30 - 2.42 (1H), 3.03 (2H), 3.10 - 3.29 (2H), 3.40 - 3.52 (1H), 3.73
(3H), 3.91 - 3.99 (1H), 4.12 (1H), 4.27 (2H), 4.45 - 4.58 (1H), 6.01 - 6.13 (1H), 6.75 (1H), 6.84 - 6.95 (2H), 7.60 (1H), 7.75 (1H), 8.35 (1H). LC-MS (Method 3): m/z: [M+H]+ = 567, , = 1.31 min.
Step b:
tert-butyl [4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)butyl]carbamate
Tert-butyl [4-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}oxy)butyl]carbamate (20 mg, 0.035 mmol, 1 eq.) was solubilized in CH2CI2 (0.5 mL) and water (0.5 mL). Acetic acid (0.12 mL, 1.8 mmol, 50 eq.) was added. After 2 hours, formic acid (0.10 mL, 2.6 mmol, 75 eq.) was added and the reaction was stirred at rt for 1 hour. The reaction mixture was neutralised by addition of sat. NaHC03 and the aqueous phase was extracted 3 times with CH2CI2. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography (gradient 1/1 Hex/EtOAc to 100% EtOAc to 9/1 EtOAc/MeOH). The desired product was obtained in 68% yield (12 mg). 1H-NMR (400MHz, DMSO-d5): δ [ppm]: 1.20 - 1.30 (4H), 1.37 (9H), 1.57 - 1.67 (2H), 1.80 - 1.89 (2H), 3.03 (2H), 3.56 (1H), 3.71 (1H), 3.83 (1H), 4.05 (1H), 4.15 (1H), 4.27 (2H), 4.56 - 4.65 (1H), 6.81 (1H), 6.89 (1H), 7.37 (1H), 7.60 (1H), 7.71 (1H), 8.32 (1H), 13.37 (1H). LC-MS (Method 3): m/z: [M+H]+ = 483, Rt = 0.98 min.
Example 53
4-methoxy-2-((ff)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
8-chloro-4-methoxy-2-((/?)-3-methylmorpholin-4-yl)-[l,7]naphthyridine
320 mg (2.32 mmol) of potassium carbonate were added to a solution of 540 mg (1.93 mmol) of 8-chloro-2-((/?)-3-methylmorpholin-4-yl)-[l;7]naphthyridin-4-ol and 144 μΙ (2.32 mmol) of iodomethane in 10 ml of acetonitrile. The suspension was stirred at 80°C for 5 h. For work-up, 20 ml of water were added to the mixture. The aqueous phase was extracted three times with in each case 30 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The crude product was separated by column chromatography [Puri-Flash, silica gel 60 (25 g, 30 μιη); ethyl acetate (200 ml)]. This gave 270 mg (48%) of 8-chloro-4-methoxy-2-(( )-3-methylmorpholin-4-yl)-[l;7]naphthyridine as a yellow oil. LCMS (method 1): m/z: [M+H]+ = 294.3, R, = 3.43 min.
Step b:
4-methoxy-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
Under argon, 145 mg (0.18 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1) and 1.15 g (3.54 mmol) of caesium carbonate were added to a suspension of 260 mg (0.89 mmol) of 8-chloro-4-methoxy-2-((/?)-3-methylmorpholin-4-yl)- [l,7]naphthyridine and 369 mg (1.33 mmol) of l-(tetrahydropyran-2-yl)-5-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolane-2-yl)-lH-pyrazole in 12 ml of absolute 1,4-dioxane. The reaction mixture was stirred at 95°C for 6 h. The brown reaction solution was purified via column chromatography
[silica gel 60 (30 g); ethyl acetate (200 ml)]. In this manner, 360 mg (99% of theory) of 4-methoxy- 2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine were isolated as a yellow solid. LCMS (method 1): m/z: [M+H]+ = 410.3, t = 3.46 min.
Step c:
4-methoxy-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
360 mg (0.88 mmol) of 4-isopropoxy-2-((/?)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)- 2H-pyrazol-3-yl]-[l,7]naphthyridine were dissolved in 10 ml of methanol, and 2 ml (4 mmol) of 2N hydrochloric acid were added. After 1 h, LCMS showed complete removal of the protective group. The methanol was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. 5 ml of ethyl acetate were added to the residue. The resulting precipitated solid was filtered off and dried. This gave 120 mg (42% of theory) of 4-methoxy-2-((/?)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine and 100 mg (35% of theory) of slightly contaminated product as a beige solid, m.p. 193-195°C. :H NMR (400 MHz, DMSO): δ [ppm] = 1.27-1.29 (3H), 3.31-3.32 (1H), 3.56-3.57 (1H), 3.70-3.73 (1H), 3.82- 3.85 (1H), 3.85-4.06 (1H), 4.04 (3H), 4.15-4.17 (1H), 4.61-4.63 (1H), 6.82 (1H), 7.37 (1H), 7.61 (1H), 7.70-7.71 (1H), 8.32-8.33 (1H), 13.36 (1H).
Example 54
tert-butyl [3-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)propyl]carbamate Step a:
tert-butyl [3-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}oxy)propyl]carbamate
2-[(3 )-3-Methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphth din-4-ol (0.37 g, 0.93 mmol, 1 eq.) was solubilized in DMF (6 mL). N-Boc-3-chloropropylamine (0.36 g, 1.9 mmol, 2 eq.) and K2C03 (0.64 g, 4.7 mmol, 5 eq.) were added to the mixture. The reaction was stirred at 120°C for 16 hours. After cooling to rt, the mixture was filtered, the solid was washed with CH2CI2 and the filtrate was concentrated under reduced pressure. The crude material was purified by flash chromatography (gradient 100% Hexane to 100% EtOAc). The desired product was obtained in 70% yield (0.36 g). 1H-NMR (400MHz, DMSO-d5): <5 [ppm] : 1.13 - 1.23 (3H), 1.36 (9H), 1.40 - 1.64 (3H), 1.89 - 2.04 (4H), 2.30 - 2.41 (1H), 3.10 - 3.29 (4H), 3.40 - 3.51 (1H), 3.57 - 3.79 (3H), 3.92 - 3.99 (1H), 4.07 - 4.17 (1H), 4.27 (2H), 4.45 - 4.58 (1H), 6.01 - 6.13 (1H), 6.71 - 6.77 (1H), 6.88 - 6.98 (2H), 7.60 (1H), 7.77 (1H), 8.36 (1H). LC-MS (Method 3): m/z: [M+H]+ = 553 R, = 1.23 min.
Step b:
tert-butyl [3-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)propyl]carbamate
Tert-butyl [3-({2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}oxy)propyl]carbamate (20 mg, 0.036 mmol, 1 eq.) was solubilized in CH2CI2 (0.5 mL) and water (0.5 mL). Formic acid (0.10 mL, 2.7 mmol, 75 eq.) was added and the reaction was stirred at rt for 1 hour. The reaction mixture was neutralised by addition of sat. NaHC03 and the aqueous phase was extracted 3 times with CH2CI2. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The desired product was obtained without further purification in 86% yield (15 mg). 1H-NMR (400MHz, DMSO-d6): <5 [ppm]: 1.26 (3H), 1.36 (9H), 1.93 - 2.02 (2H), 3.18 (2H), 3.25 - 3.30 (1H), 3.55 (1H), 3.70 (1H), 3.82 (1H), 4.05 (1H), 4.15 (1H), 4.27 (2H), 4.55 - 4.63 (1H), 6.80 (1H), 6.95 (1H), 7.37 (1H), 7.61 (1H), 7.73 (1H), 8.33 (1H), 13.37 (1H). LC-MS (Method 3): m/z: [M+H]+ = 469, t = 0.96min.
Example 55
2-({2-[(3R)-3-methylmorpholin-4-yl -8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}oxy)ethanamine
Tert-butyl [2-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}oxy)ethyl]carbamate (0.36 g, 0.67 mmol, 1 eq.) was solubilised in CH2CI2 (4.3 mL) and trifluoroacetic acid (2.6 mL, 33 mmol, 50 eq.) was added. The reaction was stirred for 16h at rt and quenched with sat NaHC03. The aqueous phase was extracted 3 times with EtOAc and the organic phase was washed with H20 and sat. NaCI. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude material was purified by flash column chromatography (gradient hex/EtOAc :7/3 to 100% EtOAc to EtOAc/EtOH:9/l). The combined fractions were concentrated and EtOH was added. The suspension was filtered and the solid was dried under reduced pressure. The desired product was obtained in 11% yield (26 mg). 1H-NMR (400MHz, DMSO-d5): δ [ppm]: 1.26 (3H), 3.24 - 3.31 (1H), 3.55 (1H), 3.67 - 3.78 (3H), 3.83 (1H), 4.05 (1H), 4.17 (1H), 4.32 - 4.41 (3H), 4.57 - 4.67 (1H), 6.85 (1H), 7.37 (1H), 7.60 (1H), 7.75 (1H), 8.33 (1H), 9.77 (1H), 13.37 (1H).
Example 56
tert-butyl [2-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)ethyl]carbamate
Step a:
tert-butyl [2-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}oxy)ethyl]carbamate
2-[(3R)-3-Methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-ol (0.40 g, 1.0 mmol, 1 eq.) was solubilised in DMF (10 mL). K2C03 (0.70 g, 5.0 mmol, 2 eq.) and tert-butyl (2-bromoethyl)carbamate (0.45 g, 2.0 mmol, 2 eq.) were sequentially added. The reaction was stirred for 16 hours at rt. The reaction was then diluted with EtOAc and the suspension was filtered. The filtrate was concentrated under reduced pressure and purified ny flash column chromatography (gradient Hex/EtOAc: 8/2 to hex/EtOAc 1/9). The desired product was obtained in 84% yield (0.46 g). 1H-NMR (400MHz, DMSO-d5): δ [ppm]: 1.19 (3H), 1.32 - 1.49 (11H), 1.49 - 1.64 (IH), 1.89 - 2.04 (2H), 2.30 - 2.40 (IH), 3.10 - 3.30 (2H), 3.40 - 3.51 (3H), 3.73 (3H), 3.90 - 3.99 (IH), 4.09 - 4.18 (IH), 4.19 - 4.23 (2H), 4.47 - 4.59 (IH), 6.01 - 6.13 (IH), 6.78 (IH), 6.92 (IH), 7.21 (IH), 7.60 (IH), 7.88 (IH), 8.34 (IH). LC-MS (Method 3): m/z: [M+H]+ = 539, R, = 1.23 min.
Step b:
tert-butyl [2-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)ethyl]carbamate
Tert-butyl [2-({2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}oxy)ethyl]carbamate (0.10 g, 0.19 mmol, 1 eq.) was solubilsed in CH2CI2 (1.2 mL) and trifluoroacetic acid (0.29 mL, 3.7 mmol, 20 eq.) was added. The reaction was stirred for 1 h at rt and quenched with sat NaHCC The suspension was filtered and the solid was purified by flash column chromatography (gradient from hex/EtOAc: 1/1 to 100% EtOAc to 100% EtOH).The desired product was obtained in 28% yield (24 mg). 1H-NMR (400MHz, DMSO-d5): <5 [ppm] : 1.26 (3H), 1.39 (9H), 3.24 - 3.30 (1H), 3.46 (2H), 3.52 - 3.62 (1H), 3.70 (1H), 3.82 (1H), 3.99 - 4.09 (1H), 4.17 (1H), 4.22 (2H), 4.61 (1H), 6.84 (1H), 7.21 (1H), 7.37 (1H), 7.60 (1H), 7.83 (1H), 8.31 (1H), 13.36 (1H).
Example 57
4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}oxy)butan-l- amine
Tert-butyl [4-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-
l,7-naphthyridin-4-yl}oxy)butyl]carbamate (0.10 g, 0.18 mmol, 1 eq.) was solubilsed in CH2CI2 (1.1 mL) and TFA (0.27 mL, 3.5 mmol, 20 eq.) was added. The reaction was stirred at rt for 30 min and quenched with sat. NaHC03. The suspension was filtered and the solid was dried under reduced pressure. The desired product was obtained without further purification in quantitative yield. 1H- NMR (400MHz, DMSO-d5): δ [ppm]: :H-NMR (400MHz, DMSO-d5): δ [ppm]: 1.27 (3H), 1.73 - 1.84 (2H), 1.88 - 1.98 (2H), 2.86 - 2.95 (2H), 3.56 (1H), 3.71 (1H), 3.84 (1H), 4.02 - 4.10 (1H), 4.15 (1H), 4.30 (2H), 4.61 (1H), 6.82 (1H), 7.37 (1H), 7.57 (1H), 7.61 (2H), 7.71 (1H), 8.33 (1H), 13.36 (1H).
Example 58
2-[(3R,5S)-3,5-dimethylmorpholin-4-yl]-4-isopropoxy-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
8-Chloro-2-[(3R,5S)-3,5-dimethylmorpholin-4-yl]-4-isopropoxy-l,7-naphthyridine (0.10 g, 0.28 mmol, 1 eq.) was solubilised in DME (3 mL). l-(2-Tetrahydropyranyl)-lH-pyrazole-5-boronic acid pinacol ester (0.24 g, 0.84 mmol, 3 eq.), K2C03 (0.11 g, 0.84 mmol, 3 eq.), bis(triphenylphosphin)palladium(ll)chloride (20 mg, 0.030 mmol, 0.1 eq.) and H20 (1.5 mL) were added sequentially. The reaction was heated under microwave irradiation at 130°C for 10 min. The crude reaction mixture was filtered through a silicon filter and concentrated under reduced pressure. The crude mixture was purified by preparative HPLC (H20(HCOOH)/CH3CN : 50:50 to 30:70). The purified product was concentrated under reduced pressure, solubilised in CH2CI2 and washed two times with sat. NaHC03. The organic phase was dried (MgS04) and concentrated under reduced pressure. The desired product was obtained as a solid in 54 % yield (56 mg). 1H- NMR (400MHz, DMSO-d5): δ [ppm]: 1.37 (6H), 1.41 (6H), 3.69 (2H), 3.88 (2H), 4.50 (2H), 5.07 (1H), 6.70 (1H), 7.36 (1H), 7.60 (1H), 7.69 (1H), 8.29 (1H), 13.38 (1H). Example 59
2-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-4-isopropoxy-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
8-Chloro-2-[(3 ,5 )-3,5-dimethylmorpholin-4-yl]-4-isopropoxy-l,7-naphthyridine (40 mg, 0.12 mmol, 1 eq.) ,l-(2-tetrahydropyranyl)-lH-pyrazole-5-boronic acid pinacol ester (50 mg, 0.18 mmol, 1.5 eq.), K2C03 (2 M in H20, 0,18 mL, 0.36 mmol, 3 eq.) and bis(triphenylphosphin)palladium(ll)chloride (8.5 mg, 0.011 mmol, 0.1 eq.) were added sequentially to DME (1.1 mL). The reaction was heated under microwave irradiation at 130°C for lOmin. The reaction mixture was filtered through a silicon filter and concentrated under reduced pressure. The crude mixture was purified by preparative HPLC (H20(HCOOH)/CH3CN : 48:52 to 68:32). The desired product was obtained in 20% yield (9.8 mg). 1H-NMR (400MHz, DMSO-d5): δ [ppm]: 1.26 (6H), 1.41 (6H), 3.67 (2H), 4.11 (2H), 4.22 - 4.31 (2H), 4.99 - 5.09 (1H), 6.83 (1H), 7.44 (1H), 7.61 (1H), 7.73 (1H), 8.36 (1H), 13.28 - 13.56 (1H).
Example 60
2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-l,7-naphthyridine
75 mg (0.20 mmol) of 4-(3,6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine were dissolved in 50 ml of methanol, 50 mg of palladium/carbon (10 percent) were added and the mixture was hydrogenated at 2 bar at room temperature for 3 h. The reaction solution was then filtered through celite and concentrated under reduced pressure. The residue was triturated with methanol, the solid was filtered off and dried under reduced pressure. This gave 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-l,7-naphthyridine in a
yield of 30 mg (40% of theory), m.p. 303-304°C. H NM (400 MHz, DMSO-d5): δ [ppm] = 1.76 (2H), 1.89 (2H), 3.53 (1H), 3.63 (2H), 3.77 (8H), 4.01 (2H), 7.36 (2H), 7.61 (1H), 7.88 (1H), 8.38 (1H), 13.33 (1H). Example 61
2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride
Step a:
2-(morpholin-4-yl)-8-[2-(tetrahydro ran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine
Under argon, 40 mg (0.05 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 635 mg (1.95 mmol) of caesium carbonate were added to a suspension of 250 mg (0.49 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran- 2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridin-4-yl trifluoromethanesulphonate and 205 mg (0.97 mmol) 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester in 5.0 ml of absolute dioxane. The reaction mixture was stirred at 110°C for 4 h. The mixture was chromatographed directly without work-up [silica gel 60 (25 g, 30 μηι); ethyl acetate (100 ml)]. This gave 30 mg (17% of theory) of 2- (morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine as a colourless oil. LC-MS (method 1): m/z: [M+H]+ = 366.3, R, = 3.09 min. Step b:
2-(morpholin-4-yl)-8-(lH-pyrazol-3
A drop of water and 0.5 ml (6.5 mmol) of trifluoroacetic acid were added to 30 mg (0.08 mmol) of 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine. After 1 h,
LCMS showed complete removal of the protective group. The trifluoroacetic acid was distilled off under reduced pressure and the residue that remained was adjusted to pH 7 using sodium bicarbonate solution. The aqueous phase was extracted three times with in each case 20 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then concentrated to dryness. The residue was chromatographed [silica gel 60 (12 g, 30 μιη); chloroform (100 ml)]. This gave 20 mg (87% of theory) of 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine as a yellow solid. Since the latter was still impure, the corresponding hydrochloride was prepared. LC-MS (method 1): m/z: [M+H]+ = 282.3, t = 2.42 min.
Step c:
2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride
20 mg (0.07 mmol) of 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine were dissolved in 3.0 ml of 2-butanol and 28 μΙ (0.21 mmol) of trimethylchlorosilane were added. The reaction solution was stirred at room temperature for 1 h. The precipitated solid was filtered off and then dried. This gave 17 mg (75% of theory) of 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)- [l,7]naphthyridine hydrochloride as a yellow solid, m.p. 151-153°C. H NMR (400 MHz, DMSO): δ [ppm] = 3.80-3.85 (8H), 7.61-7.62 (1H), 7.89-7.91 (1H), 8.11-8.13 (2H), 8.33-8.34 (1H), 8.41-8.43 (1H).
Example 62
4-chloro-2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Step a:
methyl 3-ieri-butoxycarbonylamino-2-chloroisonicotinate
Under argon and at room temperature, 1.92 g (8.7 mmol) of di-ieri-butyl dicarbonate and 244 mg (2 mmol) of 4-dimethylaminopyridine were added to a solution of 1.49 g (8 mmol) of methyl 3- amino-2-chloroisonicotinate in 20 ml of dry tetrahydrofuran. The mixture was stirred at room temperature for 16 h. For work-up, the reaction mixture was adjusted to pH 7 using 2N hydrochloric acid. The resulting precipitated solid was filtered off with suction and washed with 10 ml of water. In this manner, methyl 3-ieri-butoxycarbonylamino-2-chloroisonicotinate was obtained in a yield of 1.2 g (52% of theory) as a colourless solid. This solid was a mixture of the product and the double Boc protected compound. The mixture was used for the next step without further purification.
Step b:
l-(3-amino-2-chloropyridin-4-yl)-3-morpholin-4-yl-propane-l,3-dione
Under argon and at room temperature, 6.76 ml (6.76 mmol) of lithium bis(trimethylsilyl)amide were added dropwise to a solution of 484 μΙ (4.19 mmol) of /V-acetylmorpholine and 1.2 g (4.2 mmol) of methyl 3-tert-butoxycarbonylamino-2-chloroisonicotinate in 10 ml of dry tetrahydrofuran. The mixture was stirred at room temperature for 6 h. For work-up, the reaction mixture was adjusted to pH=l using 2N hydrochloric acid and stirred at room temperature for 16 h. LC-MS showed complete removal of the protective group. The mixture was extracted three times with in each case 50 ml of dichloromethane. The combined organic phases were dried with sodium sulphate and then concentrated to dryness. In this manner, l-(3-amino-2-chloropyridin-4- yl)-3-morpholin-4-yl-propane-l,3-dione was obtained in a yield of 680 mg (57% of theory) as a
yellow solid. :H NM (400 MHz, CDCI3): δ [ppm] = 3.49-3.52 (2H), 3.64-3.74 (6H), 4.08 (s, 2H), 6.73 (s, 2H), 7.57 (d, 1H), 7.75 (d, 1H).
Step c:
l-{3-amino-2-[2-(4-methoxybenzyl)-2H-pyrazol-3-yl]pyridin-4-yl}-3-(morpholin-4-yl)propane-
1,3-dione
Under argon, 207 mg (0.66 mmol) of l-(4-methoxybenzyl)-5-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolane-2-yl)-lH-pyrazole, 195 mg (0.6 mmol) of caesium carbonate, 95 mg (0.33 mmol) of l-(3-amino-2-chloropyridin-4-yl)-3-morpholin-4-ylpropane-l,3-dione and 20 mg (0.02 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1) in 2.5 ml of dioxane were stirred in a microwave vessel at 100°C for 2 h. Without work-up, the residue was purified by column chromatography [Puriflash silica gel 60 (25 g, 30 μηι); ethyl acetate/methanol 1:1, (200 ml)]. In this manner, l-{3-amino-2-[2-(4- methoxybenzyl)-2H-pyrazol-3-yl]pyridin-4-yl}-3-(morpholin-4-yl)propane-l,3-dione was obtained in a yield of 38 mg (26% of theory) as a light-yellow oil. :H NMR (400 MHz, CDCI3): δ [ppm] = 3.48- 3.51 (2H), 3.64-3.68 (6H), 4.09 (2H), 5.37 (2H), 6.43 (2H), 6.55 (1H), 6.69-6.73 (2H), 6.95-6.97 (2H), 7.58-7.62 (2H), 8.09 (1H). Step d:
4-chloro-2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
Under argon, 45 mg (0.1 mmol) of l-{3-amino-2-[2-(4-methoxybenzyl)-2H-pyrazol-3-yl]pyridin-4- yl}-3-(morpholin-4-yl)propane-l,3-dione and 500 μΙ (5.36 mmol) of phosphorus oxychloride were stirred at 120°C for 3 h. Without work-up, the residue was purified by column chromatography [Puriflash silica gel 60 (12 g, 30 μηι); ethyl acetate/methanol 1:1, (100 ml)]. In this manner, 4- chloro-2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine was obtained in a yield of 25 mg (79% of theory) as a yellow solid. H NM (400 MHz, DMSO): δ [ppm] = 3.69-3.79 (8H), 7.36 (1H), 7.64 (1H), 7.78 (1H), 7.85 (1H), 8.45 (1H). LCMS (method 1): m/z: [M+H]+ = 316.3, R, = 3.0 min. Example 63
2-[(3R)-3-methylmorpholin-4-yl]-4-(methylsulfanyl)-8-(lH^yrazol-5-yl)-l,7-naphthyridine
4-Chloro-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine (50 mg, 0.12 mmol, 1 eq.) was solubilised in DMF (3 mL). Sodium methanethiolate (8.5 mg, 0.12 mmol, 1 eq.) was added and the reaction was stirred at 50°C for 2h. Sat. NH4CI was added to the mixture and the aqueous phase was extracted 3 times with CH2CI2. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude mixture was purified by preparative HPLC (H20(HCOOH)/CH3CN : 56:44 to 36:64). The desired product was obtained in 75% yield. 1H-NMR (400MHz, DMSO-d5): δ [ppm] : 1.28 (3H), 2.69 (3H), 3.34 (1H), 3.56 (1H), 3.71 (1H), 3.83 (1H), 4.05 (1H), 4.17 (1H), 4.61 - 4.68 (1H), 7.08 (1H), 7.37 (1H), 7.61 (1H), 7.66 (1H), 8.36 (1H), 13.36 (br. s, 1H).
Example 64
N-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)- -nap
imine 4-oxide
Step a:
N-(2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[(2R)-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridin-4-yl)-l,4A4-oxathian-4-imine 4-oxide
Under argon, 8 mg (0.014 mmol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 7 mg (0.007 mmol) tris(dibenzylideneacetone)dipalladium(0) were added to a mixture of 75 mg (0.142 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate, 25 mg (0.19 mmol) l,4 4-oxathian-4-imine 4-oxide and 69 mg (0.21 mmol) caesium carbonate in 0.67 ml toluene. The mixture was stirred at 110 °C for 3 hours. After cooling, the reaction mixture was diluted with ethyl acetate / THF and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give 113 mg crude product that was used without further purification.
Step b:
N-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}-l,4A4-oxathian-4- imine 4-oxide
0.25 ml (0.51 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 113 mg crude N-(2-[(3 )-3-methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}- l,7-naphthyridin-4-yl)-l,4 4-oxathian-4-imine 4-oxide in 1.0 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 23 mg (0.05 mmol) of the desired product. 1H-NMR (400 MHz, CDCI3): δ [ppm] = 1.43 (3H), 3.43 (2H), 3.51 (IH), 3.61 (2H), 3.70 (IH), 3.85 (IH), 3.92 (2H), 4.14 (3H), 4.30 (2H), 4.38 (IH), 6.97 (IH), 7.26 (IH), 7.72 (IH), 7.89 (IH), 8.43 (IH).
Example 65
4-{[dimethyl(oxido)-A6-sulfanylidene]amino}-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-{[dimethyl(oxido)-A6-sulfanylidene]amino}-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
Under argon, 11 mg (0.019 mmol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 9 mg (0.010 mmol) tris(dibenzylideneacetone)dipalladium(0) were added to a mixture of 100 mg (0.20 mmol) 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridin-4-yl trifluoromethanesulfonate, 24 mg (0.26 mmol) S,S-dimethylsulfoximin and 95 mg (0.29 mmol) caesium carbonate in 0.92 ml toluene. The mixture was stirred at 110 °C for 3 hours. After cooling, the reaction mixture was diluted with ethyl acetate / THF and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give 136 mg crude product that was used without further purification.
Step b:
4-{[dimethyl(oxido)-A6- ■:sulfanylidene]amino}-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
0.34 ml (0.68 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 135 mg crude 4-{[dimethyl(oxido)- 6-sulfanylidene]amino}-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran- 2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 1.4 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preperative HPLC
(Autopurifier: acidic conditions) to give 23 mg (0.06 mmol) of the desired product. 1H-NM (400 MHz, CDCI3): δ [ppm] = 3.39 (6H), 3.70 (4H), 3.94 (4H), 6.93 (1H), 7.25 (1H), 7.72 (1H), 7.82 (1H), 8.43 (1H). Example 66
2-[(3R)-3-methylmorpholin-4-yl]-4-(piperazin-l-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(piperazin-l-yl)-8-[l-(tetrahydro-2H^yran-2-yl)-lH-pyrazol- 5-yl]-l,7-naphthyridine
Under argon, a mixture of 75 mg (0.14 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, and 42 mg (0.48 mmol) piperazine in 0.21 ml acetonitrile was stirred at 70°C for 90 minutes. After cooling, the reaction mixture was diluted with ethyl acetate and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give 91 mg crude product that was used without further purification.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(piperazin-l-yl)-8-(lH^yrazol-5-yl)-l,7-naphthyridine
0.30 ml (0.60 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 120 mg crude 2-[(3 )-3-methylmorpholin-4-yl]-4-(piperazin-l-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine in 1.2 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 27 mg (0.07 mmol) of the desired product. 1H-NMR (400 MHz, CDCI3): δ [ppm] = 1.44 (3H), 3.21 (8H), 3.54 (1H), 3.73 (1H), 3.87 (1H), 3.95 (2H), 4.18 (1H), 4.40 (1H), 6.56 (1H), 7.27 (1H), 7.57 (1H), 7.71 (1H), 8.40 (1H).
Example 67
4-isopropoxy-2-((S)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine Step a:
4-isopropoxy-2-((S)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine
96 mg (0.69 mmol) of potassium carbonate were added to a solution of 380 mg (0.58 mmol) of 2-
[(3S)-3-methylmorpholin-4-yl]-8-(2-tetrahydropyran-2-ylpyrazol-3-yl)-l,7-naphthy and 0.12 ml (1.15 mmol) of 2-iodopropane in 20 ml of acetonitrile. The suspension was stirred in a microwave vessel at 70°C for 16 h. Under reduced pressure, the mixture was concentrated to dryness. The residue was taken up in 50 ml of water and extracted four times with in each case 50 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then, under reduced pressure, concentrated to dryness. The residue was chromatographed [silica gel 60 (40 g, 50 μηι); ethyl acetate 100%]. 139 mg (55% of theory) of 4-isopropoxy-2-((S)-3- methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine were obtained as a beige solid. :H NM (400 MHz, CDCI3): δ [ppm] = 1.30 (3H), 1.48 (m, 1H), 1.49 (6H), 1.56-1.77 (2H), 2.02-2.10 (2H), 2.52 (1H), 3.27 (1H), 3.44 (1H), 3.57 (1H); 3.70-3.82 (2H), 3.93-4.16 (3H), 4.35 (1H), 4.78 (1H), 6.02 (1H), 6.32 (1H); 6.94 (1H), 7.67 (1H), 7.78 (1H), 6.39 (1H). LC-MS (method 1): R, = 3.75 min; MS (ESI/APCIpos) m/z = 438.3 [M+H]+.
Step b:
4-isopropoxy-2-((S)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine
127 mg (0.29 mmol) of (3S)-4-[4-isopropoxy-8-(2-tetrahydropyran-2-ylpyrazol-3-yl)-l,7- naphthyridin-2-yl]-3-methylmorpholine were dissolved in 10 ml of methanol, 1.5 ml of 2N hydrochloric acid (3 mmol) were added and the mixture was stirred at room temperature for 1 h. After 1 h, the LC/MS showed complete removal of the protective group. The methanol was removed under reduced pressure. Saturated sodium bicarbonate solution (pH = 7) was added to the residue. The aqueous phase was extracted five times with in each case 10 ml of dichloromethane. The combined organic phases were dried over sodium sulphate and then, under reduced pressure, concentrated to dryness. This gave 89 mg (87% of theory) of 4-isopropoxy-2- ((S)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine as a yellow solid. :H NMR (400 MHz, CDCI3): δ [ppm] = 1.41 (3H), 1.50 (6H), 3.50 (1H), 3.70 (1H), 3.85 (1H), 3.90 (1H), 3.92 (1H), 4.15 (1H), 4.34 (1H), 4.80 (1H), 6.39 (1H), 7.24 (1H), 7.69 (1H), 7.73 (1H), 8.39 (1H), 13.18
(1H). 13C NM (101 MHz, CDCI3): δ [ppm] = 13.4, 21.6, 21.7, 40.8, 48.9, 66.8, 71.0, 71.7, 91.9, 105.7, 114.3, 123.4, 139.9, 140.0, 140.8, 143.2, 143.9, 158.9, 161.0. LC-MS (method 1): R, = 2.90 min; MS (ESI/APCIpos) m/z = 354.3 [M+H]+.
Example 68
2-(morpholin-4-yl)-4-(propan-2-yloxy)-8-(lH-pyrrol-3-yl)-l,7-naphthyridine
Under argon, 13 mg (0.016 mmol) [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) were added to a mixture of 50 mg (0.16 mmol) 8-chloro-2-(morpholin-4-yl)-4-(propan-2-yloxy)- 1,7-naphthyridine and 34 mg (0.18 mmol) 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrole in 1.5 ml acetonitrile and 1.5 ml 2M aqueous solution of potassium carbonate. The mixture was stirred in a at 130 °C in a microwave oven for 10 minutes. After cooling, DCM was added and the mixture was filtered using a Whatman filter. The organic phase was concentrated and the residue was purified by preparative HPLC separation (Autopurifier: acidic conditions) to give 5 mg (0.01 mmol) of the desired product. :H-NMR (400 MHz, DMSO-d6): δ [ppm] = 1.38 (6H), 3.67 (4H), 3.78 (4H), 5.02 (1H), 6.78 (2H), 6.98 (1H), 7.44 (1H), 8.07 (1H), 8.17 (1H), 10.94 (1H). Example 69
4-(l-ethyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-ethyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.38 mmol) (l-ethyl-lH-pyrazol-5-yl)boronic acid, 15 mg (0.02 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2 ml MeCN and 1 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 min in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-ethyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 104 mg of crude 4-(l-ethyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 2 ml of methanol and 0.2 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried over magnesium sulphate and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 11 mg (0.03 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm] = 1.22 (3H), 1.30 (3H), 3.35 - 3.40 (1H), 3.58 (1H), 3.72 (1H), 3.82 (1H), 3.99 (2H), 4.03 - 4.09 (1H), 4.23 (1H), 4.64 (1H), 6.55 (1H), 7.19 (1H), 7.44 (1H), 7.58 (1H), 7.65 (1H), 7.70 (1H), 8.35 (1H), 13.45 (1H).
Example 70
4-(l-methyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-methyl-lH-imidazol-5-yl)-2-[(3R)-3-methylm^
lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 79 mg (0.38 mmol) l-methyl-5-(4A5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-imidazole, 15 mg (0.02 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2 ml MeCN and 1 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 min in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-methyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 99 mg of crude 4-(l-methyl-lH-imidazol-5-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 2 ml of methanol and 0.2 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried over magnesium sulphate and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.30 (3H), 3.50 - 3.65 (4H), 3.72 (1H), 3.83 (1H), 4.06 (1H), 4.23 (1H), 4.54 - 4.71 (1H), 7.24 (1H), 7.43 (2H), 7.51 (1H), 7.65 (1H), 7.93 (1H), 8.36 (1H), 13.43 (1H).
Example 71
2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l^-naphthyridin-4-yl]aniline
Step a:
2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}aniline
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoro ri6th3n6Sulfon3t6, 52 mg (0.38 mmol)
(2-aminophenyl)boronic acid, 15 mg (0.02 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 h. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-{2-[(3R)^-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]aniline
A solution of 163 mg of crude 2-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}aniline from step a in 7.8 ml of methanol and 0.35 ml of 2N hydrochloric acid was stirred for 90 min at room temperature. The reaction mixture was treated with 2 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 17 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.31 (3H), 3.45 - 3.64 (1H), 3.71 (1H), 3.82 (1H), 3.91 - 4.12 (1H), 4.21 (1H), 4.61 (1H), 4.84 (2H), 6.70 (1H), 6.82 (1H), 7.02 (1H), 7.08 - 7.27 (2H), 7.35 (1H), 7.44 (1H), 7.64 (1H), 8.28 (1H), 13.28 (1H).
Example 72
4-(2,3-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridine
Step a:
4-(2,3-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H^yran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 60 mg (0.38 mmol) (2,3-difluorophenyl)boronic acid, 15 mg (0.02 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 h. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(2,3-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridine
A solution of 133 mg of crude 4-(2,3-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 6.1 ml of methanol and 0.27 ml of 2N hydrochloric acid was stirred for 90 min at room temperature. The reaction mixture was treated with 2 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 20 mg (0.05 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm] = 1.31 (3H), 3.39 (1H), 3.58 (1H), 3.72 (1H), 3.83 (1H), 4.05 (1H), 4.23 (1H), 4.64 (1H), 7.22 (1H), 7.35 - 7.52 (3H), 7.52 - 7.75 (4H), 8.33 (1H), 13.09 (1H).
Example 73
4-[2-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-me
yl)-l,7-naphthyridine
Step a:
4-[2-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrah 2H-pyran-2-yl)-lH-pyrazol-5-y -l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 84 mg (0.28 mmol) 2-methyl-6-(methylsulfonyl)-3-(4,4;5;5-tetramethyl-l;3;2-dioxaborolan-2-yl (pyridine, 12 mg (0.014 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 185 mg (0.57 mmol) of caesium carbonate in 1.0 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 h. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[2-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine
A solution of 152 mg of crude 4-[2-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step a in 1.3 ml of methanol and 0.3 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was treated with 2 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 36 mg (0.08 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.29 (3H), 2.36 (3H), 3.33 - 3.44 (4H), 3.46 - 3.63 (1H),
3.66 - 3.76 (1H), 3.76 - 3.88 (1H), 4.04 (1H), 4.21 (1H), 4.55 - 4.64 (1H), 6.99 (1H), 7.43 (1H), 7.51 - 7.61 (1H), 7.64 (1H), 7.97 - 8.15 (2H), 8.29 (1H), 13.41 (1H).
Example 74
4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[2-fluoro-4-(methylsulfanyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 106 mg (0.57 mmol) [2-fluoro-4-(methylsulfanyl)phenyl]boronic acid, 23 mg (0.028 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 371 mg (1.14 mmol) of caesium carbonate in 2.0 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 150 min. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated. The residue was purified by flash chromatography (gradient Hex/EtOAc 9/1 to 100% EtOAc) to give 96 mg (0.18 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm] = 1.21 (3H), 1.35 - 1.56 (3H), 1.87 - 2.08 (2H), 2.29 - 2.43 (1H), 2.58 (3H), 3.08 - 3.26 (2H), 3.39 - 3.58 (1H), 3.58 - 3.66 (1H), 3.66 - 3.79 (2H), 3.95 (1H), 4.16 ( 1H), 4.47 - 4.58 ( 1H), 6.10 ( 1H), 6.94 ( 1H), 7.23 (1H), 7.26 - 7.32 (1H), 7.35 ( 1H), 7.43 ( 1H), 7.48 ( 1H), 7.62 (1H), 8.34 ( 1H).
Step b:
4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
0=S-CH
II
o
2.7 mg (0.009 mmol) TPAP and 20.7 mg (0.18 mmol) 4-methylmorpholine N-oxide were added to a stirred solution of 92 mg (0.18 mmol) of 4-[2-fluoro-4-(methylsulfanyl)phenyl]-2-[(3R)-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine in 2 ml DCM and 2 ml MeCN at 0°. After 4 h, additional 2.7 mg (0.009 mmol) TPAP was added and the ice bath removed. After 14 h at Rt, additional 2.7 mg (0.009 mmol) TPAP and 20.7 mg (0.18 mmol) 4- methylmorpholine N-oxide were added and the mixture was stirred at room temperatue. After 18 h at Rt, additional 2.7 mg (0.009 mmol) TPAP and 20.7 mg (0.18 mmol) 4-methylmorpholine N- oxide were added and the mixture was stirred at room temperatue. After 16h at Rt, additional 2.7 mg (0.009 mmol) TPAP and 20.7 mg (0.18 mmol) 4-methylmorpholine N-oxide were added and the mixture was stirred at room temperatue. The reaction was filtered using a Whatman filter and concentrated to give the crude product that was used without further purification in the next step.
Step c:
4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 134 mg of crude 4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-[(3 )-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step b in 5.4 ml of methanol and 0.25 ml of 2N hydrochloric acid was stirred for 90 min at room temperature. The reaction mixture was treated with 10 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 23 mg (0.05 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.30 (3H), 3.33 - 3.42 (4H), 3.50 - 3.61 (1H), 3.66 - 3.76 (1H), 3.81 (1H), 3.95 - 4.09 (1H), 4.21 (1H), 4.54 - 4.71 (1H), 7.15 (1H), 7.42 (1H), 7.56 - 7.70 (2H), 7.87 (1H), 7.98 (1H), 8.03 (1H), 8.31 (1H), 13.40 (1H).
Example 75
4-fluoro-2-[2-[(3R)^-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l^-naphthyridin-4-yl]anilin
Step a:
4-fluoro-2-{2-[(3R)^-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}aniline
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 58 mg (0.38 mmol) (2-amino-5-fluorophenyl)boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was
used without further purification in the next step. Step b:
4-fluoro-2-[2-[(3R)^-methylmorpholin-4-yl]-8-(lH^
A solution of 59 mg of crude 4-fluoro-2-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}aniline from step a in 3.0 ml of methanol and 0.12 ml of 2N hydrochloric acid was stirred for 3 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 22 mg (0.05 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.31 (3H), 3.57 (1H), 3.65 - 3.76 (1H), 3.76 - 3.88 (1H), 4.05 (1H), 4.22 (1H), 4.62 (1H), 4.74 (2H), 6.81 (1H), 6.94 (1H), 7.07 (1H), 7.14 (1H), 7.39 (1H), 7.44 (1H), 7.59 - 7.73 (m, 1H), 8.29 (1H), 13.42 (1H).
Example 76
4-(l-benzyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-benzyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmor^
lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.19 mmol) l-benzyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-imidazole, 15 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of cesium carbonate was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 90 minutes. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-benzyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 170 mg of crude 4-(l-benzyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.32 ml of 2N hydrochloric acid was stirred for 3 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then
concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.17 (3H), 3.22 (1H), 3.51 (1H), 3.65 (1H), 3.76 (1H), 3.90 - 4.07 (2H), 4.32 (1H), 5.24 (2H), 6.86 (2H), 7.11 - 7.24 (4H), 7.26 (1H), 7.34 (1H), 7.38 ( 1H), 7.63 (1H), 8.13 (1H), 8.29 ( 1H), 13.40 (1H).
Example 77
4-(2-fluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
4- (2-fluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-
5- yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.38 mmol) (2-fluorophenyl)boronic acid, 15 mg (0.02 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 h. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(2-fluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 126 mg of 4-(2-fluorophenyl)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 6 ml of methanol and 0.27 ml of 2N hydrochloric acid was stirred for 90 min at room temperature. The reaction mixture was treated with 2 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 16 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.31 (3H), 3.39 (1H), 3.58 (1H), 3.64 - 3.77 (1H), 3.82 (1H), 4.05 (1H), 4.23 (1H), 4.65 (1H), 7.15 (1H), 7.39 - 7.69 (7H), 8.32 (1H), 13.33 (1H).
Example 78
2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-l,3-thiazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-l,3-thiazol-5-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoro ri6th3n6Sulfon3t6, 85 mg (0.38 mmol)
2-methyl-5-(4A5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3-thiazole, 15 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 105 mg (0.76 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-l,3-thiazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 183 mg of crude 2-[(3 )-3-methylmorpholin-4-yl]-4-(2-methyl-l,3-thiazol-5-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.8 ml of methanol and 0.44 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 14 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 2.79 (3H), 3.57 (1H), 3.71 (1H), 3.83 (1H), 4.05 (1H), 4.21 (1H), 4.56 - 4.71 (1H), 7.40 (1H), 7.55 (1H), 7.65 (1H), 7.73 (1H), 8.07 (1H), 8.39 (1H), 13.41 (1H).
Example 79
4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine
Step a:
4-[4-methyl-6-(methylsulfonyl)pyridin-3^
2H-pyran-2-yl)-lH-pyrazol-5-yl -l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 84 mg (0.28 mmol) 4-methyl-2-(methylsulfonyl)-5-(4,4;5;5-tetramethyl-l;3;2-dioxaborolan-2-yl (pyridine, 11 mg
(0.014 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 185 mg (0.56 mmol) of caesium carbonate in 1.0 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 h. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine
A solution of 152 mg of 4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step a in 1.3 ml of methanol and 0.32 ml of 2N hydrochloric acid was stirred for 60 min at room temperature. The reaction mixture was treated with 2 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 33 mg (0.07 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.30 (3H), 2.23 (3H), 3.35 (4H), 3.57 (1H), 3.65 - 3.76 (1H), 3.76 - 3.89 (1H), 4.04 (1H), 4.14 - 4.32 (1H), 4.60 (1H), 6.98 (1H), 7.43 (1H), 7.57 (1H), 7.64 (1H), 8.17 (1H), 8.28 (1H), 8.68 (1H), 13.41(1H).
Example 80
4-(l-cyclopropyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-cyclopropyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 57 mg (0.38 mmol) (l-cyclopropyl-lH-pyrazol-5-yl)boronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dixoane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 1 h. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-cyclopropyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- na hthyridine
A solution of 96 mg of crude 4-(l-cyclopropyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.0 ml of methanol and 0.20 ml of 2N hydrochloric acid was stirred for 3 h at room temperature. The reaction mixture was treated with 2 ml of a saturated aqueous sodium bicarboante solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 6 mg (0.02 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 0.74 - 0.83 (2H), 0.91 - 1.02 (2H), 1.30 (3H), 3.39 (1H), 3.52 - 3.64 (2H), 3.73 (1H), 3.83 (1H), 4.06 (1H), 4.23 (1H), 4.60 - 4.71 (1H), 6.59 (1H), 7.28 (1H), 7.43 (1H), 7.53 - 7.79 (3H), 8.36 (1H), 13.01 (1H).
Example 81
4-[2-fluoro-4-(piperazin-l-yl)phenyl]-2-[(3R)^-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[2-fluoro-4-(piperazin-l-yl)phenyl]-2-[(3R)^-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l, -naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 85 mg (0.38 mmol) [2-fluoro-4-(piperazin-l-yl)phenyl]boronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[2-fluoro-4-(piperazin-l-yl)phenyl]-2-[(3R)^-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 106 mg of crude 4-[2-fluoro-4-(piperazin-l-yl)phenyl]-2-[(3 )-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step a in 3.0 ml of methanol and 0.38 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 20 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.29 (3H), 2.78 - 3.01 (m, 4H), 3.20 - 3.43 (m, 5H), 3.57 (1H), 3.72 (1H), 3.82 (1H), 4.04 (1H), 4.20 (1H), 4.62 (1H), 6.81 - 7.03 (2H), 7.25 (1H), 7.30 - 7.49 (3H), 7.65 (1H), 8.25 (1H), 8.32 (1H).
Example 82
2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfonyl)piperazin-l-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfonyl)piperazin-l-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 159 mg (0.97 mmol) 1- (methylsulfonyl)piperazine in 0.42 ml of MeCN was stirred at 70°C for 8 h under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfonyl)piperazin-l-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 267 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfonyl)piperazin-l- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step a in 2.3 ml of methanol and 0.57 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate / THF (1:1) (2x). The combined organic phases were filtered using a Whatman
filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 55 mg (0.12 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.27 (3H), 3.00 (3H), 3.18 - 3.31 (5H), 3.38 - 3.49 (4H), 3.55 (1H), 3.70 (1H), 3.83 (1H), 4.05 (1H), 4.13 (1H), 4.53 - 4.64 (1H), 6.84 (1H), 7.35 (1H), 7.53 - 7.71 (2H), 8.33 (1H), 13.21 (1H).
Example 83
N-(2,2-dimethylpropyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-amine
Step a:
N-(2,2-dimethylpropyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-amine
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 98 mg (0.97 mmol) N,2,2-trimethylpropan-l-amine in 0.42 ml of MeCN was stirred at 70°C for 7 h under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
N-(2,2-dimethylpropyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-amine
A solution of 205 mg of crude N-(2;2-dimethylpropyl)-N-methyl-2-[(3 )-3-methylmorpholin-4-yl]- 8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-amine from step a in 2.0 ml of methanol and 0.50 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate / THF (1:1) (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 47 mg (0.12 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6) : δ [ppm]= 0.90 (9H), 1.23 (3H), 3.09 (3H), 3.16 - 3.31 (2H), 3.36 - 3.42 (1H), 3.56 (1H), 3.63 - 3.78 (1H), 3.82 (1H), 3.92 - 4.18 (2H), 4.49 - 4.61 (1H), 6.99 (1H), 7.34 (1H), 7.60 (1H), 7.73 (1H), 8.30 (1H), 13.36 (1H).
Example 84
(l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l^-naphthyridin-4-yl}piperidm yl)methanol
Step a:
(l-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}piperidin-4-yl)methanol
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 111 mg (0.97 mmol) piperidin-4-ylmethanol in 0.42 ml of MeCN was stirred at 70°C for 3 h under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
(l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5^
yl)methanol
A solution of 345 mg of crude (l-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}piperidin-4-yl)methanol from step a in 3.2 ml of methanol and 0.81 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate / THF (1:1) (2x). The combined organic phases were filtered using a Whatman
filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 37 mg (0.09 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.26 (3H), 1.38 - 1.55 (2H), 1.55 - 1.71 (1H), 1.76 - 1.96 (2H), 2.71 - 2.93 (2H), 3.22 - 3.31 (1H), 3.36 - 3.43 (2H), 3.43 - 3.61 (3H), 3.70 (1H), 3.82 (1H), 4.03 (1H), 4.11 (1H), 4.51 - 4.62 (2H), 6.74 (1H), 7.34 (1H), 7.56 (1H), 7.61 (1H), 8.31 (1H), 13.33 (1H).
Example 85
N-cyclopropyl-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin- 4-amine
Step a:
N-cyclopropyl-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin- -amine
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 69 mg (0.97 mmol) N- methylcyclopropanamine in 0.42 ml of MeCN was stirred at 70°C for 7 h under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
N-cyclopropyl-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin- 4-amine
A solution of 188 mg of crude N-cyclopropyl-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-amine from step a in 1.9 ml of methanol and 0.48 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate / THF (1:1) (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 45 mg (0.12 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.34 - 0.56 (2H), 0.75 - 0.89 (2H), 1.27 (3H), 2.78 - 2.89 (1H), 3.08 (3H), 3.23 - 3.32 (1H), 3.56 (1H), 3.66 - 3.76 (1H), 3.83 (1H), 3.99 - 4.14 (2H), 4.46 - 4.58 (1H), 6.86 (1H), 7.33 (1H), 7.60 (1H), 7.65 (1H), 8.25 (1H), 13.36 (1H).
Example 86
4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-[(3R)-3-m
yl)-l,7-naphthyridine
Step a:
4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-[(3R)-3-m
2H-pyran-2-yl)-lH-pyrazol-5-yl -l,7-naphthyridine
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-
yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluorometha nesulfonate and 119 mg (0.97 mmol) 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazine in 0.42 ml of MeCN was stirred at 70°C for 48 h under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine
A solution of 106 mg of crude 4-(5;6-dihydroimidazo[l;2-a]pyrazin-7(8H)-yl)-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.0 ml of methanol and 0.21 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate / THF (1:1) (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 6 mg (0.01 mmol) of the desired product. 1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.28 (3H), 3.55 (1H), 3.61 - 3.75 (3H), 3.83 (1H), 4.05 (1H), 4.19 (1H), 4.25 - 4.36 (2H), 4.41 - 4.52 (2H), 4.62 (1H), 6.91 (1H), 6.96 (1H), 7.22 (1H), 7.36 (1H), 7.62 (1H), 7.68 (1H), 8.33 (1H), 13.38 (1H).
Example 87
N-(4-fluorophenyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-amine
Step a:
N-(4-fluorophenyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H^yran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-amine
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 121 mg (0.97 mmol) 4- fluoro-N-methylaniline in 0.42 ml of MeCN was stirred at 70°C for 3 h under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
N-(4-fluorophenyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-amine
A solution of 273 mg of crude N-(4-fluorophenyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-amine from step a in 2.5 ml of methanol and 0.63 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate / THF (1:1) (2x). The combined organic phases were filtered using a Whatman
filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 54 mg (0.13 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 3.45 (3H), 3.58 (1H), 3.73 (1H), 3.84 (1H), 4.06 (1H), 4.16 (1H), 4.54 - 4.66 (1H), 6.95 - 7.02 (2H), 7.03 - 7.15 (4H), 7.36 (1H), 7.62 (1H), 8.08 (1H),
13.26 (1H).
Example 88
2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylpyridin^
lntermediate-10 (0.10 g, 0.19 mmol) was solubilised in dioxane (1 ml). 2-Methyl-5- pyridinylboronic acid (52 mg, 0.38 mmol) was added in one portion followed by addition of caesium carbonate (0.25 g, 0.76 mmol) and PdCI2(dppf) in complex with dichloromethane (31 mg, 0.038 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The solid was washed with ethyl acetate and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in dichloromethane and 3N hydrochloric acid was added. The mixture was stirred overnight at rt and then quenched with a saturated aqueous solution of sodium hydrogen carbonate. The aqueous phase was extracted three times with dichloromethane. The organic phase was dried, filtered and concentrated under reduced pressure. The title compound was obtained in 53% yield (39 mg).
1H-NMR (400MHz, DMSO-d5): δ [ppm]= 1.29 (d, 3H), 2.59 (s, 3H), 3.35 - 3.42 (m, 1H), 3.56 (t, 1H), 3.71 (d, 1H), 3.82 (d, 1H), 4.05 (d, 1H), 4.23 (d, 1H), 4.61 - 4.71 (m, 1H), 7.38 (d, 1H), 7.43 (s, 1H), 7.47 (d, 2H), 7.63 (s, 1H), 7.92 (dd, 1H), 8.32 (d, 1H), 8.64 (d, 1H), 13.43 (s, 1H).
Example 89
4-(2-fluoropyridin-3-yl)-2-[(3R)-3-methylmorp^
lntermediate-10 (0.25 g, 0.47 mmol) was solubilised in dioxane (2.5 ml). (2-Fluoropyridin-3- yl)boronic acid (0.20 g, 1.4 mmol) was added in one portion followed by addition of caesium carbonate (0.62 g, 1.90 mmol) and PdCI2(dppf) in complex with dichloromethane (77 mg, 0.094 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The solid was washed with dichloromethane and the filtrate was concentrated under reduced pressure. The crude material was purified by flash column chromatography (hexane/ethyl acetate/ethanol mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (3 ml) and 3N hydrochloric acid (10 ml) was added. The mixture was stirred for 2 hours rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was dried under reduced pressure at 60°C. The title compound was obtained in 90% yield (109 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.30 (d, 3H), 3.29 - 3.41 (m, 1H), 3.51 - 3.61 (m, 1H), 3.67 - 3.75 (m, 1H), 3.78 - 3.86 (m, 1H), 4.00 - 4.09 (m, 1H), 4.17 - 4.26 (m, 1H), 4.59 - 4.68 (m, 1H), 7.17 (dd, 1H), 7.43 (s, 1H), 7.58 - 7.68 (m, 3H), 8.14 - 8.22 (m, 1H), 8.32 (d, 1H), 8.44 - 8.48 (m, 1H), 13.43 (br. s, 1H).
Example 90
4-(2-fluoro-4-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.10 g, 0.19 mmol) was solubilised in dioxane (1 ml). (2-Fluoro-4-methylpyridin- 3-yl)boronic acid (61 mg, 0.38 mmol) was added in one portion followed by addition of caesium carbonate (0.25 g, 0.76 mmol) and PdCI2(dppf) in complex with dichloromethane (31 mg, 0.038 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in dichloromethane and washed with a saturated solution of sodium hydrogen carbonate. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 47% yield (36 mg).
1H-NM (400MHz, CHLOROFORM-d): δ [ppm]= 1.47 (dd, 3H), 2.16 (d, 3H), 3.58 (td, 1H), 3.70 - 3.78 (m, 1H), 3.90 - 3.95 (m, 2H), 4.01 - 4.09 (m, 1H), 4.19 (dd, 1H), 4.37 - 4.46 (m, 1H), 6.94 (d, 1H), 7.13 (d, 1H), 7.26 (d, 1H), 7.32 - 7.35 (m, 1H), 7.74 (d, 1H), 8.27 (d, 1H), 8.37 (d, 1H).
Example 91
2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-lH-pyrrol-2-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.10 g, 0.19 mmol l-methyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrole (79 mg, 0.38 mmol), aq. potassium carbonate (0.29 ml, 2 M) and PdCI2(PPh3)2 (13 mg, 0.019 mmol) were solubilised in dimethoxyethane (5 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in dichloromethane and washed with a saturated solution of sodium hydrogen carbonate. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 53% yield (39 mg). 1H-NM (400MHz, DMSO-de): <5 [ppm]= 1.29 (d, 3H), 3.28 - 3.39 (m, 1H), 3.52 - 3.62 (m, 4H), 3.68 - 3.76 (m, 1H), 3.78 - 3.86 (m, 1H), 4.00 - 4.09 (m, 1H), 4.18 - 4.26 (m, 1H), 4.59 - 4.68 (m, 1H), 6.22 - 6.28 (m, 1H), 6.35 (dd, 1H), 7.07 (dd, 1H), 7.41 (s, 2H), 7.48 (d, 1H), 7.64 (br. s, 1H), 8.34 (d, 1H), 13.41 (br. s, 1H).
Example 92
4-(6-fluoro-5-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol) was solubilised in dioxane (3.2 ml). (6-Fluoro-5- methylpyridin-3-yl)boronic acid (44 mg, 0.28 mmol) was added in one portion followed by addition of caesium carbonate (0.19 g, 0.59 mmol) and PdCI2(dppf) in complex with dichloromethane (11 mg, 0.014 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The crude material was purified by flash column chromatography
(hexane/ethyl acetate mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (1.5 ml) and 3N hydrochloric acid (1.6 ml) was added. The mixture was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The title compound was obtained in 20% yield (11 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.30 (dd, 3H), 2.12 (s, 3H), 3.36 - 3.39 (m, 1H), 3.52 - 3.63 (m, 1H), 3.68 - 3.76 (m, 1H), 3.78 - 3.85 (m, 1H), 4.01 - 4.09 (m, 1H), 4.18 - 4.27 (m, 1H), 4.57 - 4.66 (m, 1H), 7.00 (dd, 1H), 7.33 (s, 1H), 7.40 - 7.45 (m, 1H), 7.51 (d, 1H), 7.65 (d, 1H), 8.17 (d, 1H), 8.29 (d, 1H), 13.42 (br. s, 1H).
Example 93
4-(2-fluoro-6-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol) was solubilised in dioxane (3.2 ml) under argon. (2-Fluoro- 6-methylpyridin-3-yl)boronic acid (44 mg, 0.28 mmol) was added in one portion followed by addition of caesium carbonate (0.19 g, 0.59 mmol) and PdCI2(dppf) in complex with dichloromethane (11 mg, 0.014 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The crude material was purified by flash column chromatography (hexane/ethyl acetate mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (1 ml) and 3N hydrochloric acid (1 ml) was added. The mixture was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was purified by preparative HPLC
(acetonitrile/water/formic acid mixture). The title compound was obtained in 54% yield (19 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.30 (d, 3H), 2.56 (s, 3H), 3.36 - 3.40 (m, IH), 3.52 - 3.61 (m, IH), 3.67 - 3.75 (m, IH), 3.79 - 3.86 (m, IH), 4.00 - 4.07 (m, IH), 4.17 - 4.24 (m, IH), 4.58 - 4.66 (m, IH), 7.18 (dd, IH), 7.41 (d, IH), 7.46 (dd, IH), 7.58 (s, IH), 7.65 (d, IH), 8.04 (dd, IH), 8.32 (d, IH), 13.41 (br. s, IH).
Example 94
4-(6-fluoropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol) was solubilised in dioxane (3.2 ml) under argon. (6- Fluoropyridin-3-yl)boronic acid (40 mg, 0.28 mmol) was added in one portion followed by addition of caesium carbonate (0.19 g, 0.59 mmol) and PdCI2(dppf) in complex with dichloromethane (11 mg, 0.014 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The crude material was purified by flash column chromatography (hexane/ethyl acetate mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (1.4 ml) and 3N hydrochloric acid (1.4 ml) was added. The mixture was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The title compound was obtained in 10% yield (5 mg).
1H-NMR (400MHz, DMSO-d5): δ [ppm]= 1.30 (d, 3H), 3.35 - 3.41 (m, IH), 3.52 - 3.61 (m, IH), 3.67 - 3.75 (m, IH), 3.79 - 3.86 (m, IH), 4.01 - 4.09 (m, IH), 4.19 - 4.28 (m, IH), 4.62 - 4.71 (m, IH), 7.37 (d, IH), 7.39 - 7.46 (m, 2H), 7.55 (s, IH), 7.62 - 7.68 (m, IH), 8.21 - 8.29 (m, IH), 8.34 (d, IH), 8.48 (d, IH), 13.43 (br. s, IH).
Example 95
4-(6-methoxypyridin -yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
4-(6-Fluoropyridin-3-yl)-2-[(3R)-3-methylmorph (10 mg, 0.026 mmol) was solubilised in methanol (3 ml) and the mixture was stirred overnight at 50°C. Sodium methoxide was then added to the mixture (7.1 mg, 0.13 mmol) and the reaction was stirred for additional 18 hours at 50°C. The reaction mixture was cooled to rt and concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture) and the title compound was obtained in 59% yield (6.3 mg).
1H-NMR (400MHz, DMSO-d5): δ [ppm]= 1.30 (d, 3H), 3.34 - 3.40 (m, 1H), 3.50 - 3.62 (m, 1H), 3.68 - 3.75 (m, 1H), 3.79 - 3.86 (m, 1H), 3.96 (s, 3H), 4.01 - 4.09 (m, 1H), 4.19 - 4.28 (m, 1H), 4.61 - 4.71 (m, 1H), 7.04 (d, 1H), 7.42 (d, 2H), 7.47 (s, 1H), 7.64 (br. s, 1H), 7.96 (dd, 1H), 8.33 (d, 1H), 8.40 (d, 1H), 13.41 (br. s, 1H).
Example 96
4-(6-methoxy-5-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
4-(6-fluoro-5-methylpyridin-3-yl)-2-[(3
naphthyridine (13 mg, 0.031 mmol) was solubilised in methanol (3 ml) and the mixture was stirred overnight at 50°C. Sodium methoxide was then added to the mixture (8.3 mg, 0.16 mmol) and the reaction was stirred for additional 18 hours at 50°C. Sodium methoxide was again added (8.3 mg, 0.16 mmol) and the reaction was stirred for 24 hours at 50°C. The reaction mixture was cooled to rt and concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture) and the title compound was obtained in 93% yield (12 mg). 1H-NMR (400MHz, DMSO-d5): δ [ppm]= 1.30 (dd, 3H), 2.04 (s, 3H), 3.34 - 3.40 (m, IH), 3.52 - 3.63 (m, IH), 3.68 - 3.76 (m, IH), 3.77 - 3.85 (m, IH), 3.89 - 3.96 (m, 3H), 4.00 - 4.08 (m, IH), 4.17 - 4.26 (m, IH), 4.56 - 4.67 (m, IH), 6.91 (s, IH), 7.00 - 7.06 (m, IH), 7.39 - 7.47 (m, 2H), 7.64 (br. s, IH), 8.07 (s, IH), 8.29 (d, IH), 13.41 (br. s, IH).
Example 97
4-(6-fluoro-2-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol) was solubilised in dioxane (3.2 ml) under argon. (6-Fluoro- 2-methylpyridin-3-yl)boronic acid (44 mg, 0.28 mmol) was added in one portion followed by addition of caesium carbonate (0.19 g, 0.59 mmol) and PdCI2(dppf) in complex with dichloromethane (11 mg, 0.014 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture) followed by flash column chromatography (hexane/ethyl acetate mixture). The title compound was obtained in 68% yield (41 mg). 1H-NM (400MHz, DMSO-dg): <5 [ppm]= 1.29 (t, 3H), 2.21 (d, 3H), 3.28 - 3.39 (m, 1H), 3.52 - 3.62 (m, 1H), 3.68 - 3.76 (m, 1H), 3.77 - 3.85 (m, 1H), 4.00 - 4.08 (m, 1H), 4.17 - 4.27 (m, 1H), 4.56 - 4.66 (m, 1H), 7.02 (dd, 1H), 7.21 (dd, 1H), 7.44 (br. s., 1H), 7.51 (d, 1H), 7.64 (br. s., 1H), 7.94 (t, 1H), 8.29 (d, 1H), 13.43 (br. s, 1H).
Example 98
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-methyl -(trifluoromethyl)-lH^yrazol-5-yl]-8-(lH-pyrazol- 5-yl)-l,7-naphthyridine
lntermediate-18 (0.060 g, 0.14 mmol) was solubilised in dioxane (3.3 ml) under argon. [1-Methyl- 3-(trifluoromethyl)-lH-pyrazol-5-yl]boronic acid (56 mg, 0.28 mmol) was added in one portion followed by addition of caesium carbonate (0.19 g, 0.58 mmol) and PdCI2(dppf) in complex with dichloromethane (11 mg, 0.014 mmol). The reaction was heated for 4 hours in a sealed tube at 110°C. The reaction was then cooled to rt and filtered. The filtrate was concentrated under reduced pressure and purified by flash column chromatography (hexane/ethyl acetate mixture) followed by preparative TLC (hexane/MTBE mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (1 ml) and 3N hydrochloric acid (2 ml) was added. The mixture was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was dried under reduced pressure at 60°C. The title compound was obtained in 6% yield (4 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.30 (d, 3H), 3.36 - 3.42 (m, 1H), 3.52 - 3.62 (m, 1H), 3.68 - 3.75 (m, 1H), 3.79 - 3.87 (m, 4H), 4.01 - 4.09 (m, 1H), 4.19 - 4.27 (m, 1H), 4.59 - 4.68 (m, 1H), 7.13 (s, 1H), 7.25 (d, 1H), 7.43 (br. s, 1H), 7.65 (br. s, 1H), 7.72 (s, 1H), 8.36 (d, 1H), 13.45 (br. s, 1H).
Example 99
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-2-t^
lntermediate-10 (0.075 g, 0.14 mmol), (3-methylthiophen-2-yl)boronic acid (40 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh3)2 (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and 3M hydrochloric acid (2 ml) was added. The reaction was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was dried under reduced pressure at 60°C. The title compound was obtained in 66% yield (38 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.29 (d, 3H), 2.09 (s, 3H), 3.28 - 3.39 (m, 1H), 3.51 - 3.62 (m, 1H), 3.67 - 3.75 (m, 1H), 3.78 - 3.85 (m, 1H), 3.99 - 4.08 (m, 1H), 4.15 - 4.25 (m, 1H), 4.58 - 4.67 (m, 1H), 7.16 (d, 1H), 7.32 (d, 1H), 7.41 (d, 1H), 7.46 (s, 1H), 7.64 (d, 1H), 7.73 (d, 1H), 8.34 (d, 1H), 13.35 (br. s, 1H).
Example 100
2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-2-thienyl)-8-(lH^yrazol-5-yl)-l^-naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol), (5-methylthiophen-2-yl)boronic acid (40 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and 3M hydrochloric acid (2 ml) was added. The reaction was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was dried under reduced pressure at 60°C. The title compound was obtained in 67% yield (39 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.28 (d, 3H), 2.57 (d, 3H), 3.28 - 3.39 (m, 1H), 3.51 - 3.61 (m, 1H), 3.67 - 3.75 (m, 1H), 3.78 - 3.85 (m, 1H), 4.00 - 4.08 (m, 1H), 4.15 - 4.23 (m, 1H), 4.58 - 4.67 (m, 1H), 7.02 (dd, 1H), 7.34 - 7.45 (m, 3H), 7.63 (s, 1H), 7.86 (d, 1H), 8.38 (d, 1H), 13.40 (br. s, 1H).
Example 101
2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methyl-3-thienyl)-8-(lH^yrazol-5-yl)-l,7-naphthyridin
lntermediate-10 (0.075 g, 0.14 mmol), (4-methylthiophen-3-yl)boronic acid (40 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh3)2 (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in dichloromethane (2 ml) and 3M hydrochloric acid (2 ml) was added. The reaction was stirred overnight at rt and then basified with a 3M sodium hydroxide solution and extracted three times with dichloromethane. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 76% yield (45 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.29 (d, 3H), 2.03 (d, 3H), 3.33 (s, IH), 3.51 - 3.62 (m, IH), 3.67 - 3.75 (m, IH), 3.77 - 3.84 (m, IH), 4.00 - 4.08 (m, IH), 4.17 - 4.26 (m, IH), 4.57 - 4.67 (m, IH), 7.17 (d, IH), 7.37 - 7.47 (m, 3H), 7.64 (d, IH), 7.68 (d, IH), 8.31 (d, IH), 13.40 (br. s, IH).
Example 102
4-(3 hloro-2-thienyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol), (3-chlorothiophen-2-yl)boronic acid (46 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh3)2 (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/ammonium hydroxyde). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and 3M hydrochloric acid (2 ml) was
added. The reaction was stirred overnight at rt and then basified with a 3M sodium hydroxide solution. The suspension was filtered and washed with water. The solid was dried under reduced pressure at 60°C. The title compound was obtained in 4% yield (2 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.29 (d, 3H), 3.34 - 3.39 (m, 1H), 3.52 - 3.62 (m, 1H), 3.68 - 3.75 (m, 1H), 3.78 - 3.85 (m, 1H), 3.99 - 4.08 (m, 1H), 4.16 - 4.25 (m, 1H), 4.58 - 4.67 (m, 1H), 7.28 (d, 1H), 7.35 (d, 1H), 7.40 (s, 1H), 7.58 (s, 1H), 7.65 (s, 1H), 7.98 (d, 1H), 8.36 (d, 1H), 13.41 (br. s, 1H).
Example 103
2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-3-t^
lntermediate-10 (0.10 g, 0.19 mmol), 2-methylthiophene-3-boronic acid pinacol ester (85 mg, 0.38 mmol), aq. potassium carbonate (0.28 ml, 2 M) and PdCI2(PPh3)2 (13 mg, 0.019 mmol) were solubilised in dimethoxyethane (5 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and concentrated hydrochloric acid (1.5 ml) was added. The reaction was stirred overnight at rt and then basified with a saturated solution of sodium hydrogen carbonate and extracted three times with dichloromethane. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 48% yield (37 mg).
1H-NMR (400MHz, DMSO-d5): δ [ppm]= 1.28 (d, 3H), 2.32 (s, 3H), 3.34 - 3.38 (m, 1H), 3.51 - 3.62 (m, 1H), 3.66 - 3.75 (m, 1H), 3.79 (d, 1H), 4.00 - 4.08 (m, 1H), 4.16 - 4.25 (m, 1H), 4.57 - 4.66 (m, 1H), 7.12 (d, 1H), 7.23 (d, 1H), 7.40 (d, 2H), 7.53 (d, 1H), 7.63 (br. s., 1H), 8.31 (d, 1H), 13.41 (br. s,
1H).
Example 104
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(lH-pyrrolo[2,3-b]pyridin
naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lh- pyrrolo[2,3-b]pyridine (69 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was diluted with water and extracted with dichloromethane and the ethyl acetate. The combined organic phases were dried (silicon filter) and concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and concentrated hydrochloric acid (1.5 ml) was added. The reaction was stirred overnight at rt and then basified with a saturated solution of sodium hydrogen carbonate and extracted three times with dichloromethane. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 71% yield (43 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.31 (d, 3H), 3.35 - 3.42 (m, 1H), 3.57 (t, 1H), 3.72 (d, 1H), 3.81 (d, 1H), 4.05 (d, 1H), 4.22 (d, 1H), 4.58 - 4.67 (m, 1H), 6.13 - 6.18 (m, 1H), 7.22 (t, 2H), 7.46 (s, 1H), 7.54 (s, 2H), 7.63 - 7.67 (m, 1H), 8.26 (d, 1H), 8.40 (d, 1H), 11.96 (br. s, 1H), 13.44 (br. s, 1H).
Example 105
4-(3,5-dimethyl-l,2-oxazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-
naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol), 3,5-dimethylisoxazole-4-boronic acid (40 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh3)2 (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was diluted with water and filtered. The solid was purified by preparative HPLC (acetonitrile/water/formic acid). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and concentrated hydrochloric acid (1.5 ml) was added. The reaction was stirred overnight at rt and then basified with a saturated solution of sodium hydrogen carbonate and extracted three times with dichloromethane. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 42% yield (24 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.29 (d, 3H), 2.12 (s, 3H), 2.32 (s, 3H), 3.35 - 3.40 (m, 1H), 3.57 (t, 1H), 3.72 (d, 1H), 3.82 (d, 1H), 4.05 (d, 1H), 4.22 (d, 1H), 4.61 (d, 1H), 7.21 - 7.28 (m, 1H), 7.42 (s, 1H), 7.52 (s, 1H), 7.62 - 7.67 (m, 1H), 8.33 (d, 1H), 13.43 (br. s, 1H).
Example 106
4-(3 hloro-2-methoxypyridin-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol), 3-chloro-2-methoxypyridine-4-boronic acid (53 mg, 0.28 mmol), aq. potassium carbonate (0.21 ml, 2 M) and PdCI2(PPh3)2 (10 mg, 0.019 mmol) were solubilised in dimethoxyethane (4 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was diluted with water and filtered. The solid was purified by preparative HPLC (acetonitrile/water/formic acid). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and concentrated hydrochloric acid (1.5 ml) was added. The reaction was stirred 2 hours at rt and then basified with a saturated solution of sodium hydrogen carbonate and extracted three times with dichloromethane. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 22% yield (14 mg).
1H-NM (400MHz, DMSO-de): <5 [ppm]= 1.25 - 1.33 (m, 3H), 3.34 - 3.40 (m, 1H), 3.52 - 3.61 (m, 1H), 3.67 - 3.74 (m, 1H), 3.78 - 3.85 (m, 1H), 4.04 (s, 4H), 4.16 - 4.24 (m, 1H), 4.55 - 4.64 (m, 1H), 7.01 - 7.06 (m, 1H), 7.18 (d, 1H), 7.42 (s, 1H), 7.51 - 7.55 (m, 1H), 7.61 - 7.67 (m, 1H), 8.25 - 8.34 (m, 2H), 13.42 (br. s, lH).
Example 107
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-l,7- naphthyridine
lntermediate-18 (0.10 g, 0.22 mmol) and 3,6-dihydro-2H-pyran-4-boronic acid pinacolester (95 mg, 0.43 mmol) were solubilised in dioxane (5 ml). Caesium carbonate (0.28 g, 0.87 mmol) and PdC fdppf) in complex with dichloromethane (18 mg, 0.021 mmol) were added sequentially. The reaction was heated for 4 hours in a sealed tube at 110°C. 3,6-Dihydro-2H-pyran-4-boronic acid pinacolester (53 mg, 0.22 mmol) was added and the reaction was stirred for 48 hours at 110°C. The reaction was then cooled to rt, diluted with water and extracted with ethyl acetate. The organic phase was dried (MgS04), filtered and concentrated under reduced pressure. The crude mixture was solubilised in dichloromethane (6 ml) and 1M hydrochloric acid (1.2 ml) was added. The reaction was stirred overnight and basified using a saturated solution of sodium hydrogen carbonate. The reaction mixture was diluted with water and extracted with dichloromethane. The organic phase was washed with brine, dried (MgS04), filtered and concentrated under reduced pressure.The crude material (42 mg) was solubilised in methanol (2 ml) and was hydrogenated in an autoclave (10.5 bar) at rt for 18 hours using 10% Pd/C (20 mg). The reaction mixture was filtered through Celite ® and concentrated under reduced pressure. The crude material was purified by flash chromatography (hexane/ethyl acetate mixture) and the title compound was obtained in 10% yield (11 mg).
1H-NM (400MHz, DMSO-d5): d [ppm]= 1.26 (d, 3H), 1.73 - 1.81 (m, 2H), 1.89 (qd, 2H), 3.33-3.35 (m, IH), 3.50 - 3.58 (m, 2H), 3.59 - 3.67 (m, 2H), 3.70 - 3.75 (m, IH), 3.79 - 3.84 (m, IH), 3.96 - 4.09 (m, 3H), 4.19 (d, IH), 4.60 - 4.70 (m, IH), 7.31 (s, IH), 7.37 (s, IH), 7.60 (s, IH), 7.89 (d, IH), 8.37 (d, IH), 13.36 (br. s., IH).
Example 108
4-(3,6-dihydro-2H-thiopyran-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.30 g, 0.53 mmol), 2-(3,6-dihydro-2H-thiopyran-4-yl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane (0.25 g, 1.1 mmol), aq. potassium carbonate (0.85 ml, 2 M) and PdCI2(PPh3)2 (40 mg, 0.056 mmol) were solubilised in dimethoxyethane (12 ml). The reaction mixture was stirred for 10 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in dichloromethane and washed with a saturated solution of sodium hydrogen carbonate. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 45% yield (100 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.27 (d, 3H), 2.56 - 2.62 (m, 2H), 2.93 (t, 2H), 3.26 - 3.32 (m, 1H), 3.36 - 3.40 (m, 2H), 3.55 (td, 1H), 3.70 (dd, 1H), 3.81 (d, 1H), 4.00 - 4.08 (m, 1H), 4.18 (d, 1H), 4.57 - 4.64 (m, 1H), 6.00 - 6.04 (m, 1H), 7.30 (s, 1H), 7.38 (br. s., 1H), 7.58 (d, 1H), 7.62 (br. s., 1H), 8.34 (d, 1H), 13.38 (br. s., 1H).
Example 109
2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methylpiperidin-l-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.075 g, 0.14 mmol) was solubilised in N-methyl-2-pyrrolidone (2 ml) and 4- methylpiperidine (0.061, 51 mg, 0.50 mmol) was added. The reaction mixture was stirred at 70°C overnight. The mixture was cooled to rt, diluted with ethyl acetate and washed with a half saturated solution of sodium chloride. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude material was purified by preparative HPLC 1H- NM (400MHz, DMSO-d5): δ [ppm]= 0.98 (d, 3H), 1.21 (d, 4H), 1.35 - 1.49 (m, 2H), 1.49 - 1.63 (m, 1H), 1.75 (d, 2H), 2.69 - 2.82 (m, 2H), 3.19 - 3.28 (m, 1H), 3.39 - 3.50 (m, 3H), 3.65 (dd, 1H), 3.77 (d, 1H), 4.03 - 4.10 (m, 1H), 4.52 (dd, 1H), 6.69 (s, 1H), 7.30 (s, 1H), 7.51 (d, 1H), 7.56 (s, 1H), 8.26 (d, 1H), 13.31 (br. s., 1H).
Example 110
4-(l-tert-butyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.1 g, 0.19 mmol), l-tert-butyl-lH-pyrazole-5-boronic acid pinacol ester (95 mg, 0.0.38 mmol), aq. potassium carbonate (0.81 ml, 2 M) and PdCI2(PPh3)2 (13 mg, 0.019 mmol) were solubilised in dimethoxyethane (7 ml). The reaction mixture was stirred for 10 minutes at 130°C
under microwave irradiation. After cooling to rt, the reaction mixture was diluted with dichloromethane and dried by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC (acetonitrile/water/formic acid mixture). The combined fractions were concentrated under reduced pressure, solubilised in methanol (2 ml) and concentrated hydrochloric acid (1 ml) was added. The mixture was stirred for 2 hours at rt and then quenched with a saturated aqueous solution of sodium hydrogen carbonate. The aqueous phase was extracted three times with dichloromethane. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The title compound was obtained in 18% yield (15 mg). 1H-NM (400MHz, DMSO-de): <5 [ppm]= 1.21 - 1.31 (m, 3H), 1.38 (s, 9H), 3.35 - 3.41 (m, 1H), 3.52 - 3.63 (m, 1H), 3.67 - 3.76 (m, 1H), 3.77 - 3.85 (m, 1H), 4.00 - 4.10 (m, 1H), 4.17 - 4.27 (m, 1H), 4.56 - 4.65 (m, 1H), 6.34 - 6.40 (m, 1H), 6.96 (t, 1H), 7.44 (s, 1H), 7.59 - 7.68 (m, 3H), 8.30 - 8.35 (m, 1H), 13.44 (br. s, 1H).
Example 111
2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
lntermediate-10 (0.5 g, 0.95 mmol), l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (415 mg, 1.9 mmol), aq. potassium carbonate (1.4 ml, 2 M) and PdCI2(PPh (67 mg, 0.094 mmol) were solubilised in dimethoxyethane (60 ml). The reaction mixture was stirred for 20 minutes at 130°C under microwave irradiation. After cooling to rt, the reaction mixture was filtered through a silicon filter and concentrated under reduced pressure. The crude material was purified by flash column chromatography (hexane/ethyl acetate/ethanol mixture). The desired fractions were concentrated under reduced pressure and solubilised in cone, sulphuric acid (5 ml).
The mixture was stirred for 3h at rt. The mixture was then poured into ice and basified using solid sodium hydrogen carbonate. The suspension was filtered and the solid was stirred with ethanol at 40°C, filtered and dried under reduced pressure. The title compound was obtained in 78% yield (0.28 g). 1H-NM (400MHz, DMSO-d5): δ [ppm]= 1.30 (d, 3H), 3.30 - 3.40 (m, 1H), 3.51 - 3.62 (m, 1H), 3.68 - 3.77 (m, 4H), 3.79 - 3.86 (m, 1H), 4.01 - 4.09 (m, 1H), 4.18 - 4.28 (m, 1H), 4.60 - 4.69 (m, 1H), 6.59 (d, 1H), 7.27 (d, 1H), 7.42 (s, 1H), 7.60 (s, 1H), 7.63 - 7.69 (m, 2H), 8.35 (d, 1H), 13.42 (br. s, 1H).
Example 112
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-l,2-oxazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-l,2-oxazol-5-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- wlH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 79 mg (0.38 mmol) 3-methyl-5-(4A5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2-oxazole, 15 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-l,2-oxazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 160 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-l,2-oxazol-5-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 6.7 ml of methanol and 0.35 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with a saturated aqueous sodium chloride soltuion and extracted with ethyl acetate (2x). The combined organic phases were dried (MgSC ), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 4 mg (0.01 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 2.40 (3H), 3.37 (1H), 3.51-3.64 (1H), 3.73 (1H), 3.84 (1H), 4.00-4.11 (1H), 4.23 (1H), 4.58-4.72 (1H), 7.22 (1H), 7.36-7.44 (1H), 7.59-7.67 (1H), 7.79 (1H), 7.92 (1H), 8.43 (1H),13.36-13.48 (1H).
Example 113
4-(l-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 90 mg (0.38 mmol) l-ethyl-3-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole, 15 mg (0.019 mmol) of [l;l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 127 mg of crude 4-(l-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 2.5 ml of methanol and 0.26 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman
filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 18 mg (0.04 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.20 (3H), 1.29 (3H), 2.28 (3H), 3.51 - 3.63 (1H), 3.72 (1H), 3.82 (1H), 3.89 (2H), 4.05 (1H), 4.22 (1H), 4.63 (1H), 6.33 (1H), 7.24 ( 1H), 7.43 (1H), 7.54 (1H), 7.64 ( 1H), 8.35 (1H), 13.44 ( 1H).
Example 114
4-(l,4-dimethyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l,4-dimethyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmo
yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.38 mmol) l(l,4-dimethyl-lH-pyrazol-5-yl)boronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-(l,4-dimethyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 102 mg of crude 4-(l;4-dimethyl-lH-pyrazol-5-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 4.2 ml of methanol and 0.22 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 12 mg (0.03 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.30 (3H), 1.88 (3H), 3.49 - 3.69 (4H), 3.69 - 3.76 (1H), 3.82 (1H), 4.06 (1H), 4.25 (1H), 4.64 ( 1H), 7.05 ( 1H), 7.44 ( 1H), 7.50 (1H), 7.58 (1H), 7.65 (1H), 8.35 (1H), 13.44 (1H).
Example 115
4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[(3R)-3-me^
1,7-naphthyridine
Step a:
4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tet
2H-pyran-2-yl)-lH-pyrazol-5-yl -l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-
pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 26 mg (0.14 mmol) [2-methyl-6-(methylsulfanyl)pyridin-3-yl]boronic acid, 11 mg (0.014 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 49 mg (0.36 mmol) of potassium carbonate in 3.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[(3R)-3-m
1,7-naphthyridine
A solution of 119 mg of crude 4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.5 ml of methanol and 0.23 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 15 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 2.24 (3H), 2.55 - 2.63 (3H), 3.49 - 3.64 (1H), 3.72 (1H), 3.82 (1H), 3.98 - 4.13 (1H), 4.22 (1H), 4.61 (1H), 7.05 (1H), 7.32 (1H), 7.37 - 7.53 (2H), 7.53 - 7.70 (2H), 8.30 (1H), 13.42 (1H).
Example 116
4-[2-methyl-6-(S-methylsulfonimidoyl)pyri^
pyrazol-5-yl)-l,7-naphthyridine
Step a:
4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[p^
2H-pyran-2-yl)-lH-pyrazol-5-yl -l,7-naphthyridine
A suspension of 250 mg (0.47 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 87 mg (0.47 mmol) [2-methyl-6-(methylsulfanyl)pyridin-3-yl]boronic acid, 38 mg (0.047 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 164 mg (1.19 mmol) of potassium carbonate in 10.0 ml of MeCN and 3.3 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated. The residue was purified by column chromatography (gradient from 100% Hex to 100% EtOAc) to give 170 mg (0.33 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.15 - 1.35 (3H), 1.46 (2H), 1.52 - 1.69 (1H), 1.88 - 2.07 (2H), 2.25 (3H), 2.30 - 2.45 ( 1H), 2.56 - 2.64 (3H), 3.14 - 3.29 (2H), 3.39 - 3.55 (1H), 3.58 - 3.68
(1H), 3.68 - 3.82 (2H), 3.97 (1H), 4.18 (1H), 4.52 (1H), 6.08 - 6.22 (1H), 6.93 - 7.06 (1H), 7.10 (1H), 7.32 (1H), 7.37 - 7.48 (1H), 7.56 - 7.68 (2H), 8.33 (1H).
Step b:
2,2,2-trifluoro-N-[methyl(6-methyl-5-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}pyridin-2-yl)-A4-sulfanylidene]acetamide
Under an atmosphere of argon, a solution of 43 mg (0.38 mmol) 2,2,2-trifluoroacetamide in 0.20 ml THF was added dropwise to a solution of 24 mg (0.25 mmol) sodium tert.-butoxide in 0.25 ml THF, so that the temperature of the mixture remained below 10 °C. Subsequently, a freshly prepared solution of 47 mg (0.16 mmol) l,3-dibromo-5,5-dimethylhydantoin in 0.25 ml THF was added dropwise to the stirred mixture, so that the temperature of the mixture remained below 10°C. Then the mixture was stirred for 10 minutes at 10 °C. Finally, a solution of 130 mg (0.25 mmol) 4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 0.8 ml THF was added dropwise to the stirred mixture, so that the temperature of the mixture remained below 10 °C. The mixture was stirred for 3 hours at 10 °C and then at room temperature overnight. The batch was diluted with 1.0 ml toluene under cooling and an aqueous solution of 32 mg (0.25 mmol) sodium sulfite in 0.9 ml water was added so that the temperature of the mixture remained below 15 °C. The batch was extracted three times with ethyl acetate. The combined organic phases were washed with an aqueous solution of sodium chloride, filtered using a Whatman filter and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate) to give 28 mg of the desired product containing slight impurities.
Step c:
4-[2-methyl-6-(S-methylsulfonimidoyl)pyridin-3-^
(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
28 mg (0.045 mmol) 2;2;2-trifluoro-N-[methyl(6-methyl-5-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}pyridin-2-yl)- 4- sulfanylidene]acetamide was dissolved in 0.87 ml methanol. To this solution 0.31 ml water was added. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%). 23 mg (0.038 mmol) Oxone" was added and the mixture was stirred at room temperature for 5 hours. Additional amount 23 mg (0.038 mmol) Oxone" was added. The pH was adjusted to 10.5 by addition of an aqueous solution of potassium hydroxide (25%). The batch was stirred at room temperature for 3 hours. The batch was filtered and the filtrate was adjusted to pH 6-7 by the addition of IN aqueous hydrogen chloride solution. The mixture was diluted with aqueous sodium chloride solution and extracted with DCM (2x). The combined organic phases were washed with an aqueous solution of sodium sulfite (10%), filtered using a Whatman filter, and concentrated to give 10 mg crude product that was used without further purification. Step d:
4-[2-methyl-6-(S-methylsulfonimidoyl)pyridin^
pyrazol-5-yl)-l,7-naphthyridine
A solution of 10 mg of crude 4-[2-methyl-6-(S-methylsulfonimidoyl)pyridin-3-yl]-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step c in 1.0 ml of methanol and 0.02 ml of 2N hydrochloric acid was stirred for 2 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 2 mg (0.004 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.23 - 1.40 (3H), 2.22 - 2.41 (3H), 3.25 (3H), 3.38 (1H), 3.46 - 3.65 (1H), 3.72 (1H), 3.82 (1H), 4.05 (1H), 4.13 - 4.32 (1H), 4.53 (1H), 4.62 (1H), 6.91 - 7.11 (1H), 7.46 (1H), 7.58 (1H), 7.66 (1H), 7.99 - 8.17 (2H), 8.31 (1H).
Example 117
2-[(3R)-3-methylmorpholin-4-yl]-4-(l-propyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(l^ropyl-lH-pyrazol-5-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 34 mg (0.14 mmol)
1- propyl-5-(4,4,5,5-tetramethyl-l,3,2Hdioxaborolan-2-yl)-lH-pyrazole, 11 mg (0.014 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 49 mg (0.36 mmol) of potassium carbonate in 3.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2- [(3R)-3-methylmorpholin-4-yl]-4-(l-propyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 110 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-(l-propyl-lH-pyrazol-5-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.4 ml of methanol and 0.23 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 11 mg (0.03 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 0.64 (3H), 1.29 (3H), 1.63 (2H), 3.34 (1H), 3.59 (1H), 3.73 (1H), 3.82 (1H), 3.89 - 4.02 (2H), 4.02 - 4.12 (1H), 4.23 (1H), 4.63 (1H), 6.55 (1H), 7.21 ( 1H), 7.44 (1H), 7.57 (1H), 7.60 - 7.74 (2H), 8.35 (1H), 13.43 (1H).
Example 118
4-(6,7-dihydro-5H^yrrolo[l,2-a]imidazol-3-yl)-2-[(3R)-3-met^
yl)-l,7-naphthyridine
Step a:
4-(6 -dihydro-5H^yrrolo[l,2-a]imidazol-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 57 mg (0.38 mmol) 6,7-dihydro-5H-pyrrolo[l,2-a]imidazol-3-ylboronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(6,7-dihydro-5H^yrrolo[l,2-a]imidazol-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine
A solution of 166 mg of crude 4-(6;7-dihydro-5H-pyrrolo[l;2-a]imidazol-3-yl)-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.2 ml of methanol and 0.34 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 1 mg (0.002 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.19 - 1.42 (3H), 2.54 - 2.71 (2H), 2.81 - 3.00 (2H), 3.58 (1H), 3.73 (1H), 3.84 (1H), 3.97 - 4.15 (3H), 4.21 (1H), 4.63 (1H), 7.29 - 7.51 (3H), 7.64 (1H), 7.78 (1H), 8.37 (1H), 13.42 (1H).
Example 119
4-[l-ethyl-3-(trifluoromethyl)-lH-pyrazol-5-yl]-2-[(3^
yl)-l,7-naphthyridine
Step a:
4-[l-ethyl-3-(trifluoromethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 30 mg (0.14 mmol) [l-ethyl-3-(trifluoromethyl)-lH-pyrazol-5-yl]boronic acid, 11 mg (0.014 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 49 mg (0.36 mmol) of potassium carbonate in 3.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases
were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[l-ethyl-3-(trifluoromethyl)-lH-pyrazo^
yl)-l,7-naphthyridine
A solution of 118 mg of crude 4-[l-ethyl-3-(trifluoromethyl)-lH-pyrazol-5-yl]-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.2 ml of methanol and 0.22 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 1 mg (0.002 mmol) of the desired product.
H-NMR (400MHZ, DMSO-d6): δ [ppm]= 1.11 - 1.38 (6H), 3.36 (1H), 3.58 (1H), 3.72 (1H), 3.83 (1H), 4.07 (3H), 4.24 (1H), 4.64 (1H), 7.10 (1H), 7.17 (1H), 7.36 - 7.48 (1H), 7.66 (1H), 7.72 (1H), 8.36 (1H), 13.40 (1H).
Example 120
methyl 5-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}-lH- py rro le-2-ca rboxy late
Step a:
1-tert-butyl 2-methyl 5-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl}-lH-pyrrole-l,2-dicarboxylate
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 38 mg (0.14 mmol) [l-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-lH-pyrrol-2-yl]boronic acid, 11 mg (0.014 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 49 mg (0.36 mmol) of potassium carbonate in 3.0 ml of MeCN and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave reactor. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
methyl 5-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin
pyrrole-2-carboxylate
A solution of 115 mg of crude 1-tert-butyl 2-methyl 5-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}-lH-pyrrole-l,2-dicarboxylate
from step a in 5.5 ml of methanol and 0.23 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.32 (3H), 3.36 - 3.44 (1H), 3.52 - 3.65 (1H), 3.72 (1H), 3.78 - 3.93 (4H), 3.99 - 4.16 (1H), 4.24 (1H), 4.66 (1H), 6.72 (1H), 7.03 (1H), 7.39 (1H), 7.49 - 7.59 (1H), 7.59 - 7.70 (1H), 7.84 (1H), 8.38 (1H), 12.60 (1H), 13.40 (1H).
Example 121
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-4-(l,2-thiazol-5-yl)-1 -naphthyridine Step a:
2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H^yran-2-yl)-lH-pyrazol-5-yl]-4-(l,2-thiazol- 5-yl)-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 80 mg (0.38 mmol) 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2-thiazole, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 247 mg (0.76 mmol) of ceasium carbonate in 1.3 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
A solution of 155 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-4-(l,2-thiazol-5-yl)-l,7-naphthyridine from step a in 1.5 ml of methanol and 0.39 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.31 (3H), 3.40 (1H), 3.57 (1H), 3.72 (1H), 3.83 (1H), 4.05 (1H), 4.17 - 4.34 (1H), 4.59 - 4.83 (1H), 7.41 (1H), 7.57 - 7.75 (3H), 7.89 (1H), 8.40 (1H), 8.80 (1H), 13.39 (1H).
Example 122
N,N-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4- yljaniline
Step a:
N,N-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}aniline
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 63 mg (0.38 mmol) [2-(dimethylamino)phenyl]boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of ceasium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
N,N-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridin-4- yljaniline
A solution of 180 mg of crude N,N-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}aniline from step a in 1.7 ml of methanol and 0.42 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 40 mg (0.10 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.28 (3H), 2.45 (6H), 3.60 (1H), 3.70 - 3.78 (1H), 3.78 - 3.86 (1H), 3.97 - 4.12 (1H), 4.21 (1H), 4.59 (1H), 7.03 - 7.19 (2H), 7.19 - 7.29 (2H), 7.36 - 7.54 (3H), 7.64 (1H), 8.25 (1H), 13.40 (1H).
Example 123
4-(2,4-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridine Step a:
4-(2,4-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H^yran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 60 mg (0.38 mmol) (2,4-difluorophenyl)boronic acid, 15 mg (0.019 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 247 mg (0.76 mmol) of ceasium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 90 minutes. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(2,4-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 126 mg of crude 4-(2,4-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-
(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.7 ml of methanol and 0.26 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 12 mg (0.03 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 3.38 (1H), 3.57 (1H), 3.68 - 3.75 (1H), 3.82 (1H), 4.05 (1H), 4.22 (1H), 4.64 (1H), 7.17 (1H), 7.31 - 7.38 (1H), 7.42 (1H), 7.49 - 7.58 (2H), 7.60 - 7.70 (2H), 8.32 (1H), 13.18 (1H).
Example 124
4-(l-isopropyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-isopropyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 58 mg (0.38 mmol) (l-isopropyl-lH-pyrazol-5-yl)boronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of ceasium carbonate in 2.0 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 60 minutes. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-isopropyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 126 mg of crude 4-(l-isopropyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 4.0 ml of methanol and 0.20 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 14 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.32 (9H), 3.59 (1H), 3.72 (1H), 3.82 (1H), 4.06 (1H), 4.13 - 4.31 (2H), 4.52 - 4.74 (1H), 6.51 (1H), 7.14 (1H), 7.43 (1H), 7.54 (1H), 7.66 (1H), 7.71 (1H), 8.35 (1H), 13.43 (1H).
Example 125
ethyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate
Step a:
ethyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}phosphinate
A mixture of 250 mg (0.47 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.47 mmol) ethyl methylphosphinate, 2 mg (0.009 mmol) palladium(ll) acetate, 6 mg (0.01 mmol) of 1,1'- bis(diphenylphosphino)ferrocene and 0.11 ml (0.62 mmol) of ethyldiisopropylamine in 2.1 ml of DMF and 0.24 ml 1,2-dimethoxyethane was degased with argon. Under argon, the reaction mixture was stirred at room temperature for 10 minutes and then at 110°C overnight. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The aqueous phase was saturated with solid sodium chloride and extracted with a mixture of THF and ethyl acetet (1:1). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
ethyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate
A solution of 310 mg of crude ethyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}phosphinate from step a in 2.9 ml of methanol and 0.75 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted
with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 15 mg of an apparent salt of the desired product. The material was taken up in 13 ml of ethyl acetate and 2 ml of saturated aqueous sodium chloride solution and the mixture was stirred for 15 minutes. The mixture was filtered using a Whatman filter and concentrated to give 8 mg (0.02 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.18 - 1.28 (3H), 1.28 - 1.37 (3H), 1.81 - 1.97 (3H), 3.58 (1H), 3.72 (1H), 3.85 (1H), 3.88 - 3.98 (1H), 4.00 - 4.12 (2H), 4.12 - 4.21 (1H), 4.60 (1H), 7.37 (1H), 7.65 (1H), 7.80 (1H), 8.11 (1H), 8.33 - 8.51 (1H), 13.45 (1H).
Example 126
4-{[diethyl(oxido)- 6-sulfanylidene]amino}-2-[(^^
1,7-naphthyridine
Step a:
4-{[diethyl(oxido)-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-na hthyridine
Under argon, 8 mg (0.014 mmol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 7 mg (0.007 mmol) tris(dibenzylideneacetone)dipalladium(0) were added to a mixture of 75 mg (0.142 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate, 22 mg (0.19 mmol) (S-ethylsulfonimidoyl)ethane and 69 mg (0.21 mmol) caesium carbonate in 0.67 ml toluene. The mixture was stirred at 110 °C for 3 hours. After cooling, the reaction mixture was diluted with ethyl acetate and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give the crude product that was used without further purification.
Step b:
4-{[diethyl(oxido)- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazo 1,7-naphthyridine
0.14 ml (0.29 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 71 mg crude 4-{[diethyl(oxido)- 6-sulfanylidene]amino}-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 3.2 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 25 mg (0.06 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.25 (3H), 1.29 - 1.40 (6H), 3.20 - 3.31 (1H), 3.48 - 3.67 (5H), 3.71 (1H), 3.83 (1H), 3.94 - 4.14 (2H), 4.39 (1H), 6.84 (s, 1H), 7.34 (1H), 7.60 (1H), 7.88 (1H), 8.29 (1H), 13.35 (1H).
Example 127
isobutyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate
Step a:
isobutyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}phosphinate
A mixture of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 26 mg (0.19 mmol) methylphosphonic acid isobutylester, 1 mg (0.004 mmol) palladium(ll) acetate, 2 mg (0.004 mmol) of l,l'-bis(diphenylphosphino)ferrocene and 0.01 ml (0.25 mmol) of ethyldiisopropylamine in 0.9 ml of DMF and 0.1 ml 1,2-dimethoxyethane was degased with argon. Under argon, the reaction mixture was stirred at room temperature for 10 minutes and then at 110°C overnight. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The aqueous phase was saturated with solid sodium chloride and extracted with a mixture of THF and ethyl acetet (1:1). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
isobutyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate
A solution of 135 mg of crude isobutyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahyd 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}phosphinate from step a in 1.2 ml
methanol and 0.3 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 26 mg (0.06 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 0.88 (6H), 1.31 (3H), 1.90 (3H), 3.30 - 3.45 (1H), 3.52 - 3.64 (2H), 3.72 (1H), 3.76 - 3.91 (2H), 4.07 (1H), 4.11 - 4.27 (2H), 4.47 - 4.71 (1H), 7.37 (1H), 7.64 (1H), 7.79 (1H), 8.10 (1H), 8.44 (1H), 13.41 (1H).
Example 128
2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}propan-2-ol Step a:
methyl 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine-4-carboxylate
In an autoclave, a mixture of 2527 mg (4.79 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 203 mg (0.48 mmol) l,3-bis(diphenylphosphino)propane, 108 mg (0.48 mmol) palladium(ll) acetate and 1.3 ml triethylamine (9.6 mmol) in 34 ml of DMF and 18 ml of methanol was purged with carbon monoxide at room temperature. The autoclave was pressured with carbonmonoxide to 16.5 bar and the mixture was stirred at room temperature for 30 minutes. The autoclave was depressurized and then pressured with carbon monoxide to 20.9 bar. The mixture was stirred at 80°C for 20 hours. The autoclave was depressurized and after cooling, the mixture was diluted with water and extracted with ethyl acetate (2x). The combined organic phases were dried (Na2S04), filtered and concentrated. The residue was purified by column chromatography (gradient from 100% Hex to 100% EtOAc) to give 1537 mg (3.51 mmol) of the desired product. :H-NMR (400M HZ, DMSO-d6): δ [ppm]= 1.22 (3H), 1.35 - 1.52 (2H), 1.52 - 1.72 (1H), 1.82 - 2.05
(2H), 2.28 - 2.45 (1H), 3.14 - 3.31 (2H), 3.43 - 3.57 (1H), 3.57 - 3.85 (3H), 3.91 - 4.05 (4H), 4.12 (1H), 4.40 - 4.61 (1H), 5.90 - 6.18 (1H), 6.89 (1H), 7.59 - 7.68 (1H), 7.86 (1H), 8.19 (1H), 8.47 (1H).
Step b:
2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}propan-2-ol
0.23 ml (0.69 mmol) of a 3.0 M solution of methylmagnesium bromide in diethylether was added dropwise to a stirred solution of 100 mg (0.23 mmol) methyl 2-[(3 )-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4-carboxylate in 3.8 ml of THF at 0°C. The mixture was stirred at 0°C for 30 minutes and then the icebath was removed and the mixture was stirred at room temperature for 150 minutes. The mixture was diluted with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step c:
2-{2-[(3R)-3-methylmorpholin-4-yl]- -(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}propan-2-ol
A solution of 91 mg of crude 2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}propan-2-ol from step b in 1.8 ml of methanol and 0.21 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The
residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 14 mg (0.04 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.28 (3H), 1.69 (6H), 3.57 (1H), 3.72 (1H), 3.84 (1H), 4.06 (1H), 4.09 - 4.18 (1H), 4.58 (1H), 5.59 (1H), 7.35 (1H), 7.42 (1H), 7.61 (1H), 8.26 - 8.38 (2H), 13.35 (1H).
Example 129
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}pentan-3-ol Step a:
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}pentan-3-ol
0.46 ml (1.37 mmol) of a 3.0 M solution of ethylmagnesium bromide in diethylether was added dropwise to a stirred solution of 200 mg (0.46 mmol) methyl 2-[(3R)-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4-carboxylate in 7.7 ml of THF at 0°C. The mixture was stirred at 0°C for 30 minutes and then the icebath was removed and the mixture was stirred at room temperature for 150 minutes. The mixture was diluted with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}pentan-3-ol
A solution of 211 mg of crude 3-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}pentan-3-ol from step a in 5.0 ml of methanol and 0.45 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 6 mg (0.02 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.66 (6H), 1.26 (3H), 1.84 - 2.07 (2H), 2.17 (2H), 3.59 (1H), 3.75 (1H), 3.84 (1H), 3.99 - 4.15 (2H), 4.51 (1H), 5.17 (1H), 7.35 (1H), 7.53 (1H), 7.61 (1H), 8.11 (1H), 8.31 (1H), 13.34 (1H).
Example 130
4-(5 hloropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridm Step a:
4-(5 hloropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 45 mg (0.28 mmol) (5-chloropyridin-3-yl)boronic acid, 11 mg (0.014 mmol) of [Ι, -
bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 185 mg (0.57 mmol) of caesium carbonate in 1.0 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 90 minutes. After cooling the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
A solution of 120 mg of crude 4-(5-chloropyridin-3-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.0 ml of methanol and 0.24 ml of 2N hydrochloric acid was stirred for 2 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 8 mg (0.02 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.31 (3H), 3.36 - 3.41 (1H), 3.57 (1H), 3.72 (1H), 3.84 (1H), 4.06 (1H), 4.25 (1H), 4.55 - 4.77 (1H), 7.38 (1H), 7.43 (1H), 7.59 (1H), 7.66 (1H), 8.26 (1H), 8.35 (1H), 8.75 (1H), 8.83 (1H), 13.34 (1H).
Example 131
5-fluoro-2-{2-[(3R)^-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridin-4-yl}anilin Step a:
5-fluoro-2-{2-[(3R)^-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-
l,7-naphthyridin-4-yl}aniline
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 90 mg (0.38 mmol) 5-fluoro-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
A solution of 147 mg of crude 5-fluoro-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}aniline from step a in 5.8 ml of methanol and 0.30 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction
mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 14 mg (0.03 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.31 (3H), 3.48 - 3.65 (1H), 3.66 - 3.77 (1H), 3.82 (1H), 4.05 (1H), 4.15 - 4.30 (1H), 4.50 - 4.73 (1H), 5.20 (2H), 6.37 - 6.54 (1H), 6.58 (1H), 7.04 (1H), 7.14 (1H), 7.35 (1H), 7.44 (1H), 7.64 (1H), 8.28 (1H), 13.41 (1H).
Example 132
4-[2-fluoro-3-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[2-fluoro-3-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l, -naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 57 mg (0.19 mmol) 2-[2-fluoro-3-(methylsulfonyl)phenyl]-4,4,5,5-tetramethyl-l,3,2-dioxaborolane, 15 mg (0.019 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 2.0 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 90 minutes. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[2-fluoro-3-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 105 mg of crude 4-[2-fluoro-3-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.19 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 14 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.32 (3H), 3.36 - 3.44 (4H), 3.58 (1H), 3.72 (1H), 3.83 (1H), 4.05 (1H), 4.23 (1H), 4.65 (1H), 7.18 (1H), 7.44 (1H), 7.52 - 7.82 (3H), 7.90 - 8.02 (1H), 8.02 - 8.16 (1H), 8.34 (11-1), 13.43 (1H).
Example 133
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(oxetan-3-yl)-lH-pyrazol-5-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(oxetan-3-yl)-lH-pyrazol-5-yl]-8-[l-(tetrahydro-2H-pyran- 2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 94 mg (0.38 mmol) l-(oxetan-3-yl)-5-(4A5;5-tetramethyl-l;3;2-dioxaborolan-2-yl)-lH-pyrazole; 15 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(oxetan-3-yl)-lH-pyrazol-5-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 119 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(oxetan-3-yl)-lH-pyrazol-5-yl]- 8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.24 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier:
acidic conditions) to give 11 mg (0.03 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.19 - 1.39 (3H), 3.57 (1H), 3.72 (1H), 3.83 (1H), 4.06 (1H), 4.21 (1H), 4.62 (1H), 4.73 (2H), 5.00 (2H), 5.25 - 5.44 (1H), 6.65 (1H), 7.09 (1H), 7.43 (1H), 7.48 (1H), 7.58 - 7.71 (1H), 7.88 (1H), 8.26 - 8.40 (1H), 13.45 (1H).
Example 134
4-[2-fluoro-4-(pyrrolidin-l-yl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[2-fluoro-4-(pyrrolidin-l-yl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l, -naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 79 mg (0.38 mmol) [2-fluoro-4-(pyrrolidin-l-yl)phenyl]boronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[2-fluoro-4-(pyrrolidin-l-yl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-
naphthyridine
A solution of 180 mg of crude 4-[2-fluoro-4-(pyrrolidin-l-yl)phenyl]-2-[(3R)-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.5 ml of methanol and 0.38 ml of 2N hydrochloric acid was stirred for 1 hours at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 44 mg (0.10 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 1.96 - 2.07 (4H), 3.27 - 3.33 (4H), 3.58 (1H),
3.72 (1H), 3.82 (1H), 4.05 (1H), 4.14 - 4.25 (1H), 4.56 - 4.70 (1H), 6.47 - 6.58 (2H), 7.24 - 7.48 (4H), 7.64 (1H), 8.31 (1H), 13.41 (1H).
Example 135
4-[3-(methoxymethyl)-5-methyl-l,2-oxazol-4-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol- 5-yl)-l,7-naphthyridine
Step a:
4-[3-(methoxymethyl)-5-methyl-l,2-oxazol-4-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 24 mg (0.14 mmol) [3-(methoxymethyl)-5-methyl-l,2-oxazol-4-yl]boronic acid, 11 mg (0.014 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 49 mg (0.36 mmol) of potassium carbonate in 3.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[3-(methoxymethyl)-5-methyl-l,2-oxazol-4-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol- 5-yl)-l,7-naphthyridine
A solution of 111 mg of crude 4-[3-(methoxymethyl)-5-methyl-l,2-oxazol-4-yl]-2-[(3R)-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.22 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier:
basic conditions) to give 11 mg (0.02 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.25 - 1.36 (3H), 2.34 (3H), 3.09 (3H), 3.37 (1H), 3.59 (1H), 3.73 (1H), 3.83 (1H), 4.07 (1H), 4.20 (1H), 4.37 (1H), 4.50 (1H), 4.54 - 4.64 ( 1H), 7.29 (1H), 7.41 (1H), 7.55 (1H), 7.65 (1H), 8.34 (1H), 13.14 (1H).
Example 136
2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-l,3,4-oxadiazol-2-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine-4-carbohydrazi
0.06 ml (1.14 mmol) hydrazine hydrate was added to a solution of 50 mg (0.11 mmol) of methyl 2- [(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridine-4-carboxylate in 2 ml of ethanol and the mixture was stirred at 100 °C for 5 hours. The mixture was concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-l,3,4-oxadiazol-2-yl)-8-[l-(tetrahydro-2H^yran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
0.03 ml (0.34 mmol) trifluoroacetic acid was added to a solution of crude 2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4- carbohydrazide from step a in 1.5 ml of trimethyl orthoacetate. The mixture was stirred at 95°C for 60 minutes. After cooling the reaction mixture was concentrated to give the crude product that was used without further purification in the next step.
Step c:
2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-l,3,4-oxadiazol-2-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 47 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-l,3,4-oxadiazol-2-yl)-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step b in 3.0 ml of methanol and 0.10 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.31 (3H), 2.63 - 2.82 (3H), 3.37 - 3.46 (1H), 3.59 (1H), 3.74 (1H), 3.85 (1H), 4.08 (1H), 4.21 (1H), 4.65 (1H), 7.40 (1H), 7.66 ( 1H), 7.96 (1H), 8.49 (1H), 8.62 (1H), 13.45 (1H).
Example 137
N-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-1 -naphthyridin-4-yl}tetrahydro-^ lA4-thiophen-l-imine 1-oxide
Step a:
N-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}tetrahydro-lH-lA4-thio hen-l-imine 1-oxide
Under argon, 8 mg (0.014 mmol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 7 mg (0.007 mmol) tris(dibenzylideneacetone)dipalladium(0) were added to a mixture of 75 mg (0.142 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate, 22 mg (0.19 mmol) tetrahydro-lH-l 4-thiophen-l- imine 1-oxide and 69 mg (0.21 mmol) caesium carbonate in 0.67 ml toluene. The mixture was stirred at 110 °C for 3 hours. After cooling, the reaction mixture was diluted with ethyl acetate and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give the crude product that was used without further purification.
Step b:
N-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}tetrahydro-lH- lA4-thiophen-l-imine 1-oxide
0.15 ml (0.29 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 72 mg crude N-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}tetrahydro-lH-l 4-thiophen-l-imine 1-oxide in 3.3 ml methanol and the reaction mixture was stirred at room temperature for 1 hour. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 26 mg (0.06 mmol) of the desired product.
H-NMR (400M HZ, DMSO-d6): δ [ppm]= 1.26 (3H), 2.07 - 2.24 (2H), 2.24 - 2.37 (2H), 3.18 - 3.30 (1H), 3.44 - 3.69 (5H), 3.72 (1H), 3.83 (1H), 3.95 - 4.13 (2H), 4.44 (1H), 6.67 (1H), 7.35 (1H), 7.60 (1H), 7.89 (1H), 8.29 (1H), 13.36 (1H).
Example 138
4-{[(4-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, mixture of 2 diastereoisomers
Step a:
4-{[(4-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
Under argon, 8 mg (0.014 mmol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 7 mg (0.007 mmol) tris(dibenzylideneacetone)dipalladium(0) were added to a mixture of 75 mg (0.142 mmol) 2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7- naphthyridin-4-yl trifluoromethanesulfonate, 32 mg (0.19 mmol) l-fluoro-4-(S- methylsulfonimidoyl)benzene and 69 mg (0.21 mmol) caesium carbonate in 0.67 ml toluene. The mixture was stirred at 110 °C for 3 hours. After cooling, the reaction mixture was diluted with ethyl acetate and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give the crude product that was used without further purification.
Step b:
4-{[(4-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, mixture of 2 diastereoisomers
0.23 ml (0.29 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 125 mg crude 4-{[(4-fluorophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3 )-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine in 5.1 ml methanol and the reaction mixture was stirred at room temperature for 90 minutes. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 24 mg (0.05 mmol) of the desired product as a mixture of 2 stereoisomers.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.82 (3H), 1.16 (3H), 3.00 - 3.17 (2H), 3.41 - 3.55 (2H), 3.55 - 3.67 (2H), 3.67 - 3.78 (8H), 3.78 - 3.92 (2H), 3.98 (3H), 4.14 (1H), 6.44 (1H), 6.56 (1H), 7.28 (2H), 7.49 (4H), 7.56 (2H), 7.92 - 8.17 (6H), 8.33 (2H), 13.29 (2H).
Example 139
4-{[(2-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, mixture of 2 diastereoisomers
Step a:
4-{[(2-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH- razol-5-yl]-l,7-naphthyridine
Under argon, 8 mg (0.014 mmol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 7 mg (0.007 mmol) tris(dibenzylideneacetone)dipalladium(0) were added to a mixture of 75 mg (0.142 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl trifluoromethanesulfonate, 32 mg (0.19 mmol) l-fluoro-2-(S- methylsulfonimidoyl)benzene and 69 mg (0.21 mmol) caesium carbonate in 0.67 ml toluene. The mixture was stirred at 110 °C for 3 hours. After cooling, the reaction mixture was diluted with
ethyl acetate and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated to give the crude product that was used without further purification. Step b:
4-{[(2-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, mixture of 2 diastereoisomers
0.20 ml (0.29 mmol) 2N aqueous solution of hydrogen chloride was added to a solution of 110 mg crude 4-{[(2-fluorophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3 )-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine in 4.5 ml methanol and the reaction mixture was stirred at room temperature for 90 minutes. The mixture was basified by addition of an aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 28 mg (0.06 mmol) of the desired product as a mixture of 2 stereoisomers.
!H-NM (400MHZ, DMSO-d6): δ [ppm]= 0.82 (3H), 1.15 (3H), 2.99 - 3.17 (2H), 3.46 (2H), 3.57 (1H), 3.60 - 3.67 (1H), 3.71 (2H), 3.74 - 3.92 (8H), 3.92 - 4.06 (3H), 4.12 ( 1H), 6.47 (1H), 6.52 (1H), 7.27 (2H), 7.38 - 7.54 (4H), 7.56 (2H), 7.73 - 7.84 (2H), 7.91 - 7.96 (2H), 8.11 (1H), 8.11 (1H), 8.27 - 8.34 (2H), 13.28 (2H).
Examples 140 and 141
4-{[(2-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, diastereoisomer 1
4-{[(2-fluorophenyl)(methyl)oxido-A6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8-
(lH-pyrazol-5-yl)-l,7-naphthyridine, diasteroisomer 2
The mixture of 2 steroisomers from example 139 was separated into the single stereoisomers using preparative chiral HPLC:
Example 142
4-(dimethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-(dimethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 35 mg (0.32 mmol) dimethylphosphinoxide, 33 mg (0.028 mmol tetrakis(triphenylphosphine)palladium(0) and 0.06 ml (0.43 mmol) of triethylamine in 0.9 ml of acetonitrile was degased with argon. Under argon, the reaction mixture was stirred at 90°C for 3 hours. After cooling the reaction mixture was diluted with ethyl acetate and washed with aqueous chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(dimethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 210 mg of crude 4-(dimethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 2.1 ml of methanol and 0.53 ml of 2N hydrochloric acid was stirred for 10 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 13 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 1.94 (3H), 1.90 (3H), 3.36 - 3.43 (1H), 3.57 (1H), 3.72 (1H), 3.85 (1H), 4.07 (1H), 4.18 (1H), 4.55 - 4.71 (1H), 7.37 (1H), 7.54 - 7.74 (2H), 8.32 - 8.51 (2H), 13.40 (1H).
Example 143
4-(diethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-(diethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 32 mg (0.28 mmol) diethylphosphane oxide, 1.3 mg (0.006 mmol) palladium(ll) acetate, 3.5 mg (0.006 mmol) of 1,1'- bis(diphenylphosphino)ferrocene and 0.06 ml (0.37 mmol) of ethyldiisopropylamine in 1.2 ml of DMF and 0.14 ml 1,2-dimethoxyethane was degased with argon. Under argon, the reaction mixture was stirred at room temperature for 10 minutes and then at 110°C overnight. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The aqueous phase was saturated with solid sodium chloride and extracted with a mixture of THF and ethyl acetet (1:1). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-(diethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 190 mg of crude 4-(diethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.8 ml of methanol and 0.45 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 25 mg (0.06 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.89 - 1.12 (6H), 1.18 - 1.35 (3H), 2.09 - 2.31 (4H), 3.59 (1H), 3.74 (1H), 3.84 (1H), 4.07 (1H), 4.18 (1H), 4.62 (1H), 7.37 (1H), 7.54 - 7.81 (2H), 8.39 (1H), 8.50 (1H), 13.40 (1H).
Example 144
ethyl isobutyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate
Step a:
ethyl isobutyl{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}phosphinate
A mixture of 250 mg (0.47 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 71 mg (0.47 mmol) ethyl (2- methylpropyl)phosphinate, 2.1 mg (0.009 mmol) palladium(ll) acetate, 5.8 mg (0.01 mmol) of l,l'-bis(diphenylphosphino)ferrocene and 0.11 ml (0.62 mmol) of ethyldiisopropylamine in 2.1 ml of DMF and 0.24 ml 1,2-dimethoxyethane was degased with argon. Under argon, the reaction mixture was stirred at room temperature for 10 minutes and then at 110°C overnight. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The aqueous phase
was saturated with solid sodium chloride and extracted with a mixture of THF and ethyl acetet (1:1). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
ethyl isobutyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate
A solution of 456 mg of crude ethyl isobutyl{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}phosphinate from step a in 3.9 ml of methanol and 1.0 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 29 mg (0.07 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.79 - 0.96 (3H), 1.03 (3H), 1.13 - 1.42 (6H), 1.90 - 2.19 (4H), 3.59 (1H), 3.73 (1H), 3.79 - 3.93 (2H), 3.97 - 4.27 (3H), 4.42 - 4.72 (1H), 7.38 (1H), 7.64 (1H), 7.81 (1H), 8.10 (1H), 8.45 (1H), 13.42 (1H).
Example 145
2-[(3R)-3-methylmorpholin-4-yl]-4-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(morpholin-4-yl)-8-[l-(tetrahydro-2H^yran-2-yl)-lH^yrazoU 5-yl]-l,7-naphthyridine
A mixture of 50 mg (0.095 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 28 mg (0.32 mmol) morpholine in 0.14 ml of MeCN was stirred at 70°C for 150 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and THF and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 45 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-(morpholin-4-yl)-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridinel from step a in 0.45 ml of methanol and 0.11 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 16 mg (0.04 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.25 (3H), 3.07 - 3.23 (4H), 3.54 (1H), 3.69 (1H), 3.77 - 3.91 (5H), 3.98 - 4.07 (1H), 4.11 (1H), 4.57 (1H), 6.77 (1H), 7.33 (1H), 7.59 (1H), 7.63 (1H), 8.29
(1H), 13.33 (1H).
Example 146
4-(l-isobutyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-isobutyl-lH^yrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 36 mg (0.14 mmol) l-isobutyl-5-(4A5;5-tetramethyl-l;3;2-dioxaborolan-2-yl)-lH-pyrazole; 11 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 49 mg (0.36 mmol) of potassium carbonate in 3.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-isobutyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 105 mg of crude 4-(l-isobutyl-lH-pyrazol-5-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.21 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgSC ), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 8 mg (0.02 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.64 (6H), 1.16 - 1.36 (3H), 1.82 - 2.04 (1H), 3.50 - 3.67 (1H), 3.69 - 3.96 (4H), 3.98 - 4.14 (1H), 4.23 (1H), 4.62 (1H), 6.56 (1H), 7.23 (1H), 7.44 (1H), 7.57 (1H), 7.65 (1H), 7.71 (1H), 8.36 (1H), 13.43 ( 1H).
Example 147
4-[5-fluoro-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-m
1,7-naphthyridine
Step a:
4-[5-fluoro-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahyd 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 86 mg (0.28 mmol)
3- fluoro-2-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine, 12 mg (0.014 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 185 mg (0.57 mmol) of caesium carbonate in 1.0 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4- [5-fluoro-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)^ 1,7-naphthyridine
A solution of 118 mg of crude 4-[5-fluoro-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.0 ml of methanol and 0.25 ml of 2N hydrochloric acid was stirred for 1 hours at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 1 mg (0.002 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.27- 1.33 (3H), 3.45 - 3.63 (5H), 3.71 (1H), 3.83 (1H), 4.05 (1H), 4.23 (1H), 4.65 (1H), 7.33 - 7.54 (2H), 7.64 (2H), 8.34 (1H), 8.43 (1H), 8.80 (1H), 13.42 (1H).
Example 148
4-[(3R)-3-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-[(3R)-3-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H^yran-2-yl)-lH-pyrazol- 5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluorometha nesulfonate and 100 mg (0.99 mmol) (3R)-3- methylmorpholine in 0.43 ml of MeCN was stirred at 70°C overnight under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[(3R)-3-methylmorpholin-4-yl]-2- razol-5-yl)-l,7-naphthyridine
A solution of 190 mg of crude 4-[(3R)-3-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.9 ml of methanol and 0.47 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then
concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 18 mg (0.05 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 0.93 (3H), 2.82 (1H), 3.38 - 3.47 (1H), 3.54 (1H), 3.65 - 3.86 (10H), 3.91 (1H), 3.98 (1H), 6.96 (1H), 7.36 (1H), 7.61 (1H), 7.71 (1H), 8.33 (1H), 13.35 (1H).
Example 149
2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methyl-lH^yrazol-5-yl)-8-[l-(tetrahydro-2H^yran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 48 mg (0.38 mmol)
1- isobutyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole, 15 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
2- [(3R)-3-methylmorpholin-4-yl]-4-(4-methyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 111 mg of crude 2-[(3 )-3-methylmorpholin-4-yl]-4-(4-methyl-lH-pyrazol-5-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.0 ml of methanol and 0.24 ml of 2N hydrochloric acid was stirred for 60 minutes at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgSC ), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 12 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.30 (3H), 2.07 (3H), 3.59 (1H), 3.73 (1H), 3.83 (1H), 4.06 (1H), 4.20 (1H), 4.62 (1H), 7.25 - 7.52 (2H), 7.64 (2H), 7.76 (1H), 8.34 (1H), 13.11 (1H), 13.41 (1H).
Example 150
4-[2-fluoro-5-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[2-fluoro-5-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l, -naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoro ri6th3n6Sulfon3t6, 83 mg (0.38 mmol)
[2-fluoro-5-(methylsulfonyl)phenyl]boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-[2-fluoro-5-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 83 mg of crude 4-[2-fluoro-5-(methylsulfonyl)phenyl]-2-[(3 )-3-methylmorpholin-4- yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.15 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgSC ), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 29 mg (0.06 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.32 (3H), 3.37 (1H), 3.35 (3H), 3.58 (1H), 3.72 (1H), 4.05 (1H), 4.21 (1H), 4.65 (1H), 7.17 (1H), 7.45 (1H), 7.65 (2H), 7.77 (1H), 8.07 - 8.28 (2H), 8.33 (1H),
13.45 (1H).
Example 151
4-[4-(isopropylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-
naphthyridine
4-[4-(isopropylsulfonyl)phenyl]-2-[(3R)-3-methylm^
naphthyridine was isolated as a side product in minor amounts in the preparation of example 25. 1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.25 (6H), 3.55 (1H), 3.81 (8H), 7.38 (1H), 7.44 (1H), 7.59 (1H), 7.65 (1H), 7.74 - 7.94 (2H), 7.95 - 8.15 (2H), 8.35 (1H), 13.43 (1H).
Example 152
4-(6-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholm
Step a:
4-(6-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H^yran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.38 mmol) (6-fluoropyridin-2-yl)boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with
argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(6-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridm
A solution of 92 mg of crude 4-(6-fluoropyridin-2-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.19 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 12 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.31 (3H), 3.35 - 3.42 (1H), 3.58 (1H), 3.73 (1H), 3.84 (1H), 4.06 (1H), 4.16 - 4.29 (1H), 4.59 - 4.75 (1H), 7.37 - 7.46 (2H), 7.59 - 7.67 (2H), 7.72 (1H), 7.82 (1H), 8.26 (1H), 8.36 (1H), 13.43 (1H).
Example 153
4-(l-ethyl-lH-imidazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(l-ethyl-lH-imidazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 83 mg (0.38 mmol) l-ethyl-4-(4A5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-imidazole, 15 mg (0.019 mmol) of [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(l-ethyl-lH-imidazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 130 mg of crude 4-(l-ethyl-lH-imidazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.28 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction
mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 12 mg (0.03 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.29 (3H), 1.46 (3H), 3.51 - 3.64 (1H), 3.74 (1H), 3.85 (1H), 3.99 - 4.26 (4H), 4.62 (1H), 7.38 (1H), 7.51 - 7.73 (2H), 7.88 - 8.00 (1H), 8.09 (1H), 8.36 (1H), 8.61 (1H), 13.38 (1H).
Example 154
l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l^-naphthyridin-4-yl}prolinamide Step a:
l-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}prolinamide
A mixture of 150 mg (0.28 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 110 mg (0.97 mmol) prolinamide in 0.42 ml of MeCN was stirred at 70°C for 3 hours under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}prolinamide
A solution of 233 mg of crude l-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}prolinamide from step a in 2.2 ml of methanol and 0.55 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 18 mg (0.05 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.16 - 1.32 (3H), 1.82 - 2.10 (3H), 2.28 - 2.36 (1H), 3.24 (1H), 3.45 - 3.61 (1H), 3.68 (2H), 3.82 (1H), 4.01 - 4.21 (3H), 4.26 - 4.52 (2H), 6.20 (1H), 7.16 (1H), 7.31 (1H), 7.58 (1H), 7.66 (1H), 7.87 (1H), 8.21 (1H), 13.36 (1H).
Example 155
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}pyridin-2-amm Step a:
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}pyridin-2-amine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 42 mg (0.19 mmol) 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-amine, 15 mg (0.019 mmol) of [1,1'-
bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.5 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 90 minutes. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
3-{2-[(3R)-3-methylmorpholin-4-yl]- -(lH^yrazol-5-yl)-l,7-naphthyridin-4-yl}pyridin-2-am
A solution of 76 mg of crude 3-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}pyridin-2-amine from step a in 3.0 ml of methanol and 0.16 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgSC ), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 7 mg (0.02 mmol) of the desired product. !H-NM (400MHZ, DMSO-d6): δ [ppm]= 1.31 (3H), 3.57 ( 1H), 3.71 (1H), 3.82 (1H), 4.06 (1H), 4.21 (1H), 4.57 - 4.67 (1H), 5.71 (2H), 6.72 (1H), 7.12 (1H), 7.29 - 7.54 (3H), 7.64 (1H), 8.11 ( 1H), 8.29 (1H), 13.42 (1H).
Example 156
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-[l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl]- 1,7-naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-4-[l-(2,2,2- trifluoroethyl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 74 mg (0.38 mmol) [l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl]boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 247 mg (0.76 mmol) of caesium carbonate in 2.0 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 1 hour. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-[l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl]- 1,7-naphthyridine
A solution of 107 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-4-[l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.20 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (MgS04), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 7
mg (0.02 mmol) of the desired product.
!H-NM (400MHZ, CDCI3): δ [ppm]= 1.48 (3H), 3.61 (1H), 3.68 - 3.81 (1H), 3.81 - 4.00 (2H), 4.05 ( 1H), 4.20 (1H), 4.50 (1H), 4.89 (2H), 6.79 (1H), 7.33 (1H), 7.42 (1H), 7.67 - 7.79 (2H), 8.08 (1H), 8.47 (1H).
Example 157
l-methyl-4-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}piperazin-2-one
Step a:
l-methyl-4-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}piperazin-2-one
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 150 mg (0.99 mmol) 1- methylpiperazin-2-one hydrochloride and 0.28 ml (1.99 mmol) of triethylamine in 0.43 ml of MeCN was stirred at 70°C overnight under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
l-methyl-4-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}piperazin-2-one
A solution of 207 mg of crude l-methyl-4-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}piperazin-2-one from step a in 2.0 ml of methanol and 0.50 ml of 2N hydrochloric acid was stirred for 1 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 11 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 2.96 (3H), 3.49 (2H), 3.61 (2H), 3.76 (8H), 3.86 (2H), 6.84 (1H), 7.35 (1H), 7.47 - 7.75 (2H), 8.33 (1H), 13.36 (1H).
Example 158 and 159
4- [l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
4-[l-(2-fluoroethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(lH-pyrazol-5-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-
5- yl]-l,7-naphthyridine
A suspension of 200 mg (0.38 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-
pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 136 mg (0.76 mmol) 5-(5,5-dimethyl-l,3,2-dioxaborinan-2-yl)-lH-pyrazole, 31 mg (0.038 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 131 mg (0.95 mmol) of potassium carbonate in 3.9 ml of acetonitrile and 2.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was purified by column chromatography on silica gel (hexane / ethylacetate 40% to ethyl acetate) to give 134 mg of the desired product containing slight impurities.
Step b:
4-[l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
4-[l-(2-fluoroethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2- -lH-pyrazol-5-yl]-l,7-naphthyridine
A mixture of 45 mg (0.10 mmol) 2-[(3 )-3-methylmorpholin-4-yl]-4-(lH-pyrazol-5-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a, 35 mg (0.20 mmol) of l-fluoro-2-iodoethane and 66 mg (0.20 mmol) of caesium carbonate in 1.0 ml DMF was stirred at 50°C for 3 hours. After cooling, the mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution and aqueous sodium bicarbonate solution. The organic phase was filtered using a Whatman filter and concentrated to dryness to give a mixture of the crude products 4-[l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine and 4-[l-(2-fluoroethyl)-lH-pyrazol-5-yl]-2- [(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine that was used without further purification.
Step c:
4-[l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
4-[l-(2-fluoroethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 55 mg of a crude misture of 4-[l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3 )-3- methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine and 4- [l-(2-fluoroethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step b in 0.5 ml of methanol and 0.13 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with an aqueous solution of sodium bicarbonate and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 12 mg (0.03 mmol) of 4-[l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine (example 158) and 2 mg (0.005 mmol) of 4-[l-(2-fluoroethyl)-lH-pyrazol-5- yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine (example 159).
Example 158
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.21 - 1.37 3H), 3.59 (1H), 3.74 (1H), 3.85 (1H), 4.07 (1H), 4.22 (1H), 4.59 (1H), 4.62 - 4.72 (2H), 4.83 (1H), 4.95 (1H), 7.03 (1H), 7.40 (1H), 7.64 (2H), 7.84 - 8.13 (1H), 8.39 (1H), 8.47 - 8.58 (1H), 13.40 (1H).
Example 159
:H-NMR (400MHZ, DMSO-d6): δ [ppm]= 1.29 (3H), 3.58 ( 1H), 3.72 (1H), 3.82 (1H), 4.06 (1H), 4.21 (1H), 4.25 - 4.39 (2H), 4.53 - 4.68 (2H), 4.72 (1H), 6.60 (1H), 7.23 (1H), 7.42 (1H), 7.53 ( 1H), 7.65
(1H), 7.77 (1H), 8.29 - 8.36 (1H), 13.32 (1H).
Example 160
2-(3-{2-[(3R)^-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}-lH-pyrazol-l- yl)ethanol
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-{l-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-lH-pyrazol-3-yl}-8- [l-(tetrahydro-2H-pyran-2- -lH-pyrazol-5-yl]-l,7-naphthyridine
A mixture of 45 mg (0.10 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-4-(lH-pyrazol-5-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine, 25 mg (0.12 mmol) of 2-(2- bromoethoxy)tetrahydro-2H-pyran and 39 mg (0.12 mmol) of caesium carbonate in 0.2 ml DMF was stirred at 70°C for 7 hours. After cooling, the mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and concentrated to dryness to give a mixture of the crude products that was used without further purification.
Step b:
2-(3-{2-[(3R)^-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}-lH-pyrazol-l- yl)ethanol
A solution of 52 mg crude 2-[(3 )-3-methylmorpholin-4-yl]-4-{l-[2-(tetrahydro-2H-pyran-2- yloxy)ethyl]-lH-pyrazol-3-yl}-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step a in 0.8 ml of methanol and 0.21 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with an aqueous solution of sodium bicarbonate and extracted with ethyl acetate and THF (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 11 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.29 (3H), 3.35-3.41 (1H), 3.53-3.63 (1H), 3.70-3.79 (1H), 3.85 (3H), 4.00-4.10 (1H), 4.17-4.24 (1H), 4.31 (2H), 4.63-4.73 (1H), 5.00 (1H), 6.98 (1H), 7.40 (1H), 7.62 (2H),7.94 (1H), 8.38 (1H), 8.56 (1H), 13.41 (1H).
Example 161
2-methyl-l-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}-lH- pyrazol-l-yl)propan-2-ol
Step a:
2-methyl-l-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}-lH-pyrazol-l-yl)propan-2-ol
In a closed vessel under argon, a mixture of 50 mg (0.11 mmol) 2-[(3 )-3-methylmorpholin-4-yl]- 4-(lH-pyrazol-5-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine; 16 mg (0.22 mmol) of 2,2-dimethyloxirane and 23 mg (0.17 mmol) of potassium carbonate in 0.5 ml DMF was stirred at 130°C in a microwave oven for 10 minutes. After cooling, 31 mg (0.29 mmol) of 2,2- dimethyloxirane was added and the mixture was stirred at 130°C in a microwave oven for 10 minutes.After cooling, the mixture was diluted with ethyl acetate and washed with water. The organic phase was filtered using a Whatman filter and concentrated to dryness to give a mixture of the crude products that was used without further purification.
Step b:
2-methyl-l-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin pyrazol-l-yl)propan-2-ol
A solution of 30 mg crude 2-methyl-l-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}-lH-pyrazol-l-yl)propan-2-ol from step a in 1.5 ml of methanol and 0.06 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with an aqueous solution of sodium bicarbonate and extracted with ethyl acetate and THF (2x). The combined organic phases were filtered using a
Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 8 mg (0.02 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.17 (6H), 1.30 (3H), 3.50 - 3.67 (1H), 3.74 (1H), 3.85 (1H), 3.99 - 4.15 (1H), 4.15 - 4.40 (3H), 4.68 (1H), 4.81 (1H), 7.00 (1H), 7.40 ( 1H), 7.54 - 7.70 (2H), 7.89 (1H), 8.37 (1H), 8.56 (1H), 13.40 (1H).
Example 162
4- [(2R)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-[(2R)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H^yran-2-yl)-lH-pyrazol-
5- yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 103 mg (1.02 mmol) (2R)-2- methylmorpholine hydrochloride and 0.14 ml (1.02 mmol) trimethylamine in 0.5 ml of MeCN was stirred at 70°C overnight under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[(2R)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 178 mg of crude 4-[(2R)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 8.6 ml of methanol and 0.38 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 64 mg (0.17 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.16 (3H), 2.57 - 2.69 (1H), 2.87 (1H), 3.32 - 3.41 (2H), 3.71 (4H), 3.77 (4H), 3.81 - 3.97 (3H), 6.81 (1H), 7.33 (1H), 7.59 (1H), 7.63 (1H), 8.31 (1H), 13.32
(1H).
Example 163
4-(5-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholm
Step a:
4-(5-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H^yran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53mg (0.38 mmol)
(5-fluoropyridin-2-yl)boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 150 minutes. After cooling the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-(5-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridm
A solution of 106 mg of crude 4-(5-fluoropyridin-2-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.22 ml of 2N hydrochloric acid was stirred for 2 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 3 mg (0.01 mmol) of the desired product.
H-NMR (400MHZ, CDCI3): δ [ppm]= 1.26 - 1.39 (3H), 3.53 - 3.65 (2H), 3.73 (1H), 3.84 (1H), 4.06 (1H), 4.24 (1H), 4.67 (1H), 7.42 (1H), 7.44 - 7.53 (1H), 7.60 (1H), 7.62 - 7.67 (1H), 7.68 - 7.74 (1H), 7.87 - 8.13 (2H), 8.28 - 8.44 (1H), 8.84 ( 1H), 13.20 (1H).
Example 164
2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylpyridin-2-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyrW Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylp^
pyrazol-5-yl]-l,7-naphthyridin
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 52 mg (0.38 mmol) (6-methylpyridin-2-yl)boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylpyridin-2-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyrW
A solution of 113 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylpyridin-2-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 5.4 ml of methanol and 0.24 ml of 2N hydrochloric acid was stirred for 2 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The
organic phase was filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 4 mg (0.01 mmol) of the desired product.
!H-NM (400MHZ, CDCI3): δ [ppm]= 1.30 (3H), 2.57 - 2.63 (3H), 3.53 - 3.64 (1H), 3.73 (1H), 3.80 - 3.89 (1H), 4.06 (1H), 4.22 (1H), 4.66 (1H), 7.44 (2H), 7.55 (1H), 7.58 - 7.68 (2H), 7.72 (1H), 7.93 (1H), 8.33 (1H), 13.42 ( 1H).
Example 165
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methylpyridin-2-yl)-8-(lH-pyrazol-5-yl)-l^-naphthyn Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methylpyridin-2-yl)^
pyrazol-5-yl]-l,7-naphthyridin
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 52 mg (0.38 mmol) (3-methylpyridin-2-yl)boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, PdfdppfJC ) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methylpyridin-2-yl)-8-(lH-pyrazol-5-yl)-l^-naphthyrid
A solution of 113 mg of crude 2-[(3 )-3-methylmorpholin-4-yl]-4-(3-methylpyridin-2-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 4.3 ml of methanol and 0.19 ml of 2N hydrochloric acid was stirred for 2 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 4 mg (0.01 mmol) of the desired product.
1H-NMR (400MHz, CDCI3): δ [ppm]= 1.29 (d, 3H), 2.13 (s, 3H), 3.57 (d, 1H), 3.67 - 3.79 (m, 1H), 3.79 - 3.90 (m, 1H), 4.05 (d, 1H), 4.15 - 4.30 (m, 2H), 4.61 (1H), 6.96 (1H), 7.38 - 7.57 (3H), 7.65 (1H), 7.89 (1H), 8.27 (1H), 8.59 (1H), 13.43 (1H).
Example 166
N-(2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}phenyl)acetamide
Step a:
N-(2-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}phenyl)acetamide
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-
pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 68 mg (0.38 mmol) (2-acetamidophenyl)boronic acid, 15 mg (0.019 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 7 hours. After cooling the reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
N-(2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}phenyl)acetamide
A solution of 164 mg of crude N-(2-{2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}phenyl)acetamide from step a in 1.5 ml of methanol and 0.37 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 11 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, CDCI3): δ [ppm]= 1.32 (3H), 1.71 (3H), 3.50 - 3.64 (1H), 3.64 - 3.78 (1H), 3.78 - 3.92 (1H), 4.07 (1H), 4.23 (1H), 4.59 (1H), 7.02 (1H), 7.20 - 7.47 (4H), 7.47 - 7.60 (1H), 7.65 (1H), 7.74 (1H), 8.24 (1H), 9.16 (1H), 12.82 (1H).
Example 167
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridin-4-yl}pyridin-2-ol Step a:
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}pyridin-2-ol
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.38 mmol) (2-hydroxypyridin-3-yl)boronic acid, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridin-4-yl}pyridin-2-ol
A solution of 96 mg of crude 3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}pyridin-2-ol from step a in 5.1 ml of methanol and 0.20 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The
residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 2 mg (0.005 mmol) of the desired product.
!H-NM (400MHZ, CDCI3): δ [ppm]= 1.30 (3H), 3.57 (1H), 3.71 (1H), 3.82 ( 1H), 4.04 (1H), 4.18 (1H), 4.62 (1H), 6.39 (1H), 7.27 (1H), 7.40 (2H), 7.50 - 7.75 (3H), 8.28 (1H), 12.05 (1H), 13.39 (1H).
Example 168
2-(3-{2-[(3R)^-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridin-4-yl}phenyl)propan-
2-ol
Step a:
2-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}phenyl)propan-2-ol
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 53 mg (0.38 mmol) (2-hydroxypyridin-3-yl)boronic acid, 15 mg (0.019 mmol) of [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 247 mg (0.76 mmol) of caesium carbonate in 1.4 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 2 hours. After cooling the reaction mixture was diluted aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}phenyl)propan- 2-ol
A solution of 96 mg of crude 2-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}phenyl)propan-2-ol from step a in 5.1 ml of methanol and 0.20 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 2 mg (0.005 mmol) of the desired product.
1H-NMR (400MHz, CDCI3): δ [ppm]= 1.30 (3H), 3.57 (1H), 3.71 (1H), 3.82 (1H), 4.04 (1H), 4.18 (1H), 4.62 (1H), 6.39 (1H), 7.27 (1H), 7.40 (2H), 7.50 - 7.75 (3H), 8.28 (1H), 12.05 (1H), 13.39 (1H).
Example 169
4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 122 mg (0.99 mmol) 5,6,7,8- tetrahydroimidazo[l,2-a]pyrazine in 0.4 ml of MeCN was stirred at 70°C for 90 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 200 mg of crude 4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-(morpholin-4-yl)-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.9 ml of methanol and 0.47 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 5 mg (0.01 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 3.66 (2H), 3.72 - 3.87 (8H), 4.27 - 4.40 (2H), 4.47 (2H), 6.85 - 7.05 (2H), 7.23 (1H), 7.36 (1H), 7.62 (1H), 7.68 (1H), 8.34 (1H), 13.37 (1H).
Example 170
4-[(2S)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-[(2S)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-
5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 103 mg (1.02 mmol) (2S)-2- methylmorpholine in 0.5 ml of MeCN was stirred at 70°C overnight under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-[(2S)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 146 mg of crude 4-[(2S)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 7.0 ml of methanol and 0.31 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 62 mg (0.16 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.16 (3H), 2.57 - 2.69 (1H), 2.87 (1H), 3.32 - 3.41 (2H),
3.71 (4H), 3.77 (4H), 3.81 - 3.97 (3H), 6.81 (1H), 7.33 (1H), 7.59 (1H), 7.63 (1H), 8.31 (1H), 13.32
(1H).
Example 171
4-[(trans)-2-methylcyclopropyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-[(trans)-2-methylcyclopropyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 69 mg (0.38 mmol) trans-l-methyl-cyclopropyl-2-boronic ester, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[(trans)-2-methylcyclopropyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 113 mg of crude 4-[(trans)-2-methylcyclopropyl]-2-[(3 )-3-methylmorpholin-4-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 3.0 ml of methanol and 0.26 ml of 2N hydrochloric acid was stirred for 3 hours at room temperature. The reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgSC ), filtered and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 8mg (0.02 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.86 - 0.94 (1H), 1.19 - 1.28 (5H), 1.28 - 1.34 (3H), 2.14 - 2.24 (1H), 3.22 - 3.32 (1H), 3.54 (1H), 3.69 (1H), 3.81 (1H), 4.03 (1H), 4.09 - 4.24 (1H), 4.49 - 4.77 (1H), 7.00 (1H), 7.37 (1H), 7.61 (1H), 7.93 (1H), 8.41 (1H), 13.38 (1H).
Example 172
4-(difluoromethoxy)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-(difluoromethoxy)-2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin
A mixture of 100 mg (0.25 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-ol, 66 mg (0.51 mmol) chlorodifluoroacetic acid and 42 mg (0.30 mmol) of potassium carbonate in 0.9 ml of DMF and 0.9 ml water was degased with argon. Under argon, the reaction mixture was stirred at 120°C for 90 minutes. After cooling the reaction
mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-(difluoromethoxy)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 71 mg of crude 4-(difluoromethoxy)-2-[(3 )-3-methylmorpholin-4-yl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 0.7 ml of methanol and 0.18 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with aqueous bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 7 mg (0.02 mmol) of the desired product.
H-NMR (400MHZ, DMSO-d6): δ [ppm]= 1.29 (3H), 3.56 ( 1H), 3.66 - 3.79 (1H), 3.84 (1H), 4.05 (1H), 4.15 (d, 1H), 4.58 (1H), 7.16 (1H), 7.39 (1H), 7.62 ( 1H), 7.66 - 7.74 (2H), 8.40 (1H), 13.40 (1H).
Example 173
2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]propan-2-ol
Step a:
2-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H^yran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4- yl}propan-2-ol
0.24 ml (0.71 mmol) of a 3.0 M solution of methylmagnesium bromide in diethylether was added dropwise to a stirred solution of 100 mg (0.24 mmol) methyl 2-(morpholin-4-yl)-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine-4-carboxylate in 4.0 ml of THF at 0°C. The mixture was stirred at 0°C for 30 minutes and then the icebath was removed and the mixture was stirred at room temperature overnight. The mixture was diluted with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-[2-(morpholin-4-yl)-8-(lH-pyrazol- -yl)-l,7-naphthyridin-4-yl]propan-2-ol
A solution of 80 mg of crude 2-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}propan-2-ol from step a in 2.0 ml of methanol and 0.19 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were dried (MgS04), filtered and concentrated to dryness to give 34 mg (0.09 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.69 (6H), 3.73 (4H), 3.77 - 3.93 (4H), 5.60 (1H), 7.35 (1H), 7.46 (1H), 7.61 (1H), 8.28 - 8.45 (2H), 13.35 (1H).
Example 174
2-(morpholin-4-yl)-4-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
2-(morpholin-4-yl)-4-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 153 mg (1.02 mmol) 3-oxa-8- azabicyclo[3.2.1]octane hydrochloride (1:1) and 0.14 ml (1,02 mmol) triethylamine in 0.5 ml of MeCN was stirred at 70°C for 72 hours under argon. After cooling the reaction mixture was diluted with DCM and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-(morpholin-4-yl)-4-(3-oxa-8-azabi -pyrazol-5-yl)-l,7-naphthyridine
A solution of 152 mg of crude 2-(morpholin-4-yl)-4-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 7.2 ml of methanol and 0.32 ml of 2N hydrochloric acid was stirred overnight at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then
concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 12 mg (0.03 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.92 (3H), 3.58 - 3.72 (6H), 3.72 - 3.86 (4H), 3.94 (2H), 4.15 (2H), 6.70 (1H), 7.34 (1H), 7.60 (1H), 7.71 (1H), 8.31 (1H), 13.34 (1H).
Example 175
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(pyrrolidin-l-yl)-l,7-naphthyridine Step a:
2-[(3R)-3-methylmorpholin-4-yl]-4-(pyrrolidin-l-y
5-yl]-l,7-naphthyridine
A mixture of 75 mg (0.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 35 mg (0.50 mmol) pyrrolidine in 0.21 ml of MeCN was stirred at 70°C for 90 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-4-(pyrrolidin-l-yl)-1 -naphthyridine
A solution of 10 mg of crude 2-[(3R)-3-methylmorpholin-4-yl]-4-(pyrrolidin-l-yl)-8-[l-(tetrahydro-
2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 0.5 ml of methanol and 0.02 ml of 2N hydrochloric acid was stirred overnight at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 2 mg (0.005 mmol) of the desired product.
1H-NM (400MHz, CDCI3): δ [ppm] = 1.47 (3H), 2.20 (4H), 3.55 (1H), 3.66 - 3.94 (7H), 4.04 (1H), 4.16 - 4.37 (2H), 5.75 (1H), 7.12 (1H), 7.77 (1H), 7.90 (1H), 8.53 (1H). Example 176
4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]piperazin-2-one
Step a:
4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4- yl}piperazin-2-one
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 99 mg (0.99 mmol) piperazin-2- one in 0.4 ml of MeCN was stirred at 70°C for 3 hours under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
rpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]piperazin-2-one
A solution of 182 mg of crude 4-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 5-yl]-l,7-naphthyridin-4-yl}piperazin-2-one from step a in 1.8 ml of methanol and 0.45 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 32 mg (0.08 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 3.39 - 3.45 (2H), 3.45 - 3.55 (2H), 3.64 - 3.88 (10H), 6.84 (1H), 7.35 (1H), 7.63 (2H), 8.11 (1H), 8.32 (1H), 13.36 (1H).
Example 177
4-(dimethylphosphoryl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
4-(dimethylphosphoryl)-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- 1,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 36 mg (0.33 mmol) dimethylphosphinoxide, 34 mg (0.029 mmol tetrakis(triphenylphosphine)palladium(0) and 0.06 ml (0.44 mmol) of triethylamine in 0.9 ml of acetonitrile was degased with argon. Under argon,
the reaction mixture was stirred at 90°C for 3 hours. After cooling the reaction mixture was diluted with ethyl acetate and washed with aqueous chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(dimethylphosphoryl)-2-(morph )-l,7-naphthyridine
A solution of 210 mg of crude 4-(dimethylphosphoryl)-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 2.2 ml of methanol and 0.55 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 21 mg (0.06 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.88 (3H), 1.92 (3H), 3.78 (8H), 7.35 (1H), 7.55 - 7.79 (2H), 8.33 - 8.51 (2H), 13.37 (1H).
Example 178
4-[(trans)-2,5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin Step a:
4-[(trans)-2,5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 113 mg (0.99 mmol) (trans)- 2,5-dimethylpiperazine in 0.4 ml of MeCN was stirred at 70°C for 3 hours under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-[(trans)-2,5-dimethylpiperazin-l- -2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin
A solution of 117 mg of crude 4-[(trans)-2,5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.1 ml of methanol and 0.28 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 3 mg (0.008 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 0.81 - 0.95 (3H), 0.95 - 1.06 (3H), 2.24 - 2.40 (1H), 2.63 -
2.75 (1H), 3.02 - 3.21 (4H), 3.67 - 3.77 (4H), 3.77 - 3.85 (4H), 7.12 (1H), 7.36 (1H), 7.62 (1H), 7.79 (1H), 8.24 (1H), 8.36 (1H).
Example 179
4-[(cis)-3,5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridm Step a:
4-[(cis)-3,5-dimethylpiperazin-l-yl]-2-(morpholin^
pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 113 mg (0.99 mmol) (cis)-2,6- dimethylpiperazine in 0.4 ml of MeCN was stirred at 70°C for 90 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-[(cis)-3,5-dimethylpiperazin-l-yl]- -(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 189 mg of crude 4-[(cis)-3,5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 1.8 ml of methanol and 0.46 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 51 mg (0.13 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.03 (6H), 2.30 - 2.42 (2H), 2.94 - 3.16 (2H), 3.35 (2H), 3.63 - 3.74 (4H), 3.74 - 3.87 (4H), 6.75 (1H), 7.34 (1H), 7.59 (2H), 8.28 - 8.35 (1H), 13.33 (1H).
Example 180
l-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyri
Step a:
l-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H^yran-2-yl)-lH^yrazol-5-yl]-l,7-naphthyridin-4-yl^ (trifluoromethyl)azetidin-3-ol
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 182 mg (1.02 mmol) 3- (trifluoromethyl)azetidin-3-ol hydrochloride (1:1) and 0.14 ml (1.02 mmol) trimethylamine in 0.5 ml of MeCN was stirred at 70°C for 90 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
l-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]-3-(trifluoromethyl)azetidin
A solution of 156 mg of crude l-{2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 5-yl]-l,7-naphthyridin-4-yl}-3-(trifluoromethyl)azetidin-3-ol from step a in 7.0 ml of methanol and 0.31 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 6 mg (0.02 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 3.53 - 3.71 (4H), 3.71 - 3.84 (4H), 4.30 (2H), 4.64 (2H), 6.23 (1H), 7.30 (1H), 7.47 (1H), 7.54 - 7.68 (2H), 8.22 (1H), 13.33 (1H).
Example 181
methyl hydrogen {4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl]phenyl}phosphonate
A mixture of 33 mg (0.07 mmol) of dimethyl {4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-yl]phenyl}phosphonate and 0.14 ml (0.28 mmol) aqueous 2N sodium hydroxide solution in 0.14 ml of MeOH was stirred at 70°C for 4 hours. The pH was adjusted to 6 by the
addition of aqueous sodium bicarbonate solution and the mixture was extracted with THF (3x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 1 mg (0.002 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 3.56-3.63 (8H), 3.80 (3H), 7.40 (1H), 7.41 (1H), 7.52 (1H), 7.65 (1H), 7.69 (2H), 7.89 (3H), 8.33 (1H)
Example 182
4-(4-methylpiperazin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
Step a:
4-(4-methylpiperazin-l-yl)-2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- 1,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate and 100 mg (0.99 mmol) 1- methylpiperazine in 0.4 ml of MeCN was stirred at 70°C for 90 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[(3aR,6aS)-tetrahydro-lH-furo[3,4-c]pyrrol-5(3H)-yl]- 1,7-naphthyridine
A solution of 204 mg of crude 2-(morpholin-4-yl)-4-[(3a ;6aS)-tetrahydro-lH-furo[3;4-c]pyrrol- 5(3H)-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthyridine from step a in 2.0 ml of methanol and 0.51 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 7 mg (0.02 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 2.30 (3H), 2.61 (4H), 3.18 (4H), 3.62 - 3.75 (4H), 3.78 (4H), 6.81 (1H), 7.35 (1H), 7.53 - 7.69 (2H), 8.32 (1H), 13.35 (1H).
Example 183
2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[(3aR,6aS)-tetrahydro-lH-furo[3,4-c]pyrrol-5(3H)-yl]- 1,7-naphthyridine
Step a:
2-(morpholin-4-yl)-4-[(3aR,6aS)-tetrahydro-lH-furo[3,4-c]pyrrol-5(3H)-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-
pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 153 mg (1.00 mmol) (3a ,6aS)- hexahydro-lH-furo[3,4-c]pyrrole hydrochloride and 0.14 ml (1.00 mol) of triethylamine in 0.4 ml of MeCN was stirred at 70°C for 3 hours under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
4-(4-methylpiperazin-l-yl)-2-(morp -yl)-l,7-naphthyridine
A solution of 176 mg of crude 2-(morpholin-4-yl)-4-[(3aR,6aS)-tetrahydro-lH-furo[3,4-c]pyrrol- 5(3H)-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 8.2 ml of methanol and 0.37 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 13 mg (0.03 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 2.30 (3H), 2.61 (4H), 3.18 (4H), 3.62 - 3.75 (4H), 3.78 (4H), 6.81 (1H), 7.35 (1H), 7.53 - 7.69 (2H), 8.32 (1H), 13.35 (1H).
Example 184
4-(3-methoxy-3-methylazetidin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine Step a:
4-(3-methoxy-3-methylazetidin-l-yl)-2-(morpholin-4-yl^
pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 137 mg (0.99 mmol) 3-methoxy-3- methylazetidine hydrochloride and 0.28 ml (1.99 mmol) trimethylamine in 0.4 ml of MeCN was stirred at 70°C for 90 minutes under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
4-(3-methoxy-3-methylazetidin-l-y -2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
A solution of 225 mg of crude 4-(3-methoxy-3-methylazetidin-l-yl)-2-(morpholin-4-yl)-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 2.3 ml of methanol and 0.56 ml of 2N hydrochloric acid was stirred for 1 hour at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 3 mg (0.01 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.52 (3H), 3.25 (3H), 3.59 - 3.71 (4H), 3.71 - 3.85 (4H),
4.17 (2H), 4.27 (2H), 6.11 (1H), 7.31 (1H), 7.59 (1H), 7.65 (1H), 8.22 (1H), 13.36 (1H).
Example 185
2-(morpholin-4-yl)-4-[(lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-(morpholin-4-yl)-4-[(lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
A mixture of 150 mg (0.29 mmol) of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH- pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 139 mg (1.00 mmol) (lS,4S)-2-oxa- 5-azabicyclo[2.2.1]heptane hydrochloride and 0.14 ml (1.02 mmol) trimethylamine in 0.4 ml of MeCN was stirred at 70°C overnight under argon. After cooling the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The organic phase was filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step.
Step b:
2-(morpholin-4-yl)-4-[(lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
A solution of 172 mg of crude 2-(morpholin-4-yl)-4-[(lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-8- [l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine from step a in 8.3 ml of methanol and 0.37 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and then concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 39 mg (0.10 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.91 (1H), 2.03 (1H), 3.38 (1H), 3.56 - 3.72 (4H), 3.72 - 3.86 (5H), 3.89 - 4.14 (2H), 4.64 (1H), 4.78 (1H), 6.44 (1H), 7.29 (1H), 7.58 (1H), 7.70 (1H), 8.20 (1H), 13.32 (1H).
Example 186
2-[(3R)-3-methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7- naphthyridin-4-ol
A suspension of 2310 mg (8.3 mmol) of 8-chloro-2-(3-methylmorpholin-4-yl)-l,7-naphthyridin-4- ol, 3000 mg (12.4 mmol) (l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)boronic acid, 1348 mg (1.7 mmol) of [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 4251 mg (13.0 mmol) of caesium carbonate in 69 ml of dioxane was degased with argon. Under argon, the reaction mixture was stirred at 110°C for 1 hour. After cooling the reaction mixture was diluted with agqueous sodium chloride solution and extracted with ethyl acetate (3x). The combined organic phases were filtered using a Whatman filter and then concentrated. The residue was purified by column chromatography (gradient from 100% Hex to 100% EtOAc) to give 1710 mg (3.9 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= -0.35 - -0.27 (9H), 0.47 - 0.61 (2H), 1.18 (3H), 3.06 - 3.29 (3H), 3.46 (1H), 3.63 (1H), 3.74 (1H), 3.95 (2H), 4.32 (1H), 5.81 (1H), 5.88 (1H), 6.59 (1H), 6.98 (1H),
7.63 (1H), 7.78 (1H), 8.32 (1H), 11.49 (1H).
Step b:
2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7- naphthyridin-4-yl trifluoromethanesulfonate
A mixture of 1710 mg (3.9 mmol) 2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2- (trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7-naphthyridin-4-ol, 1549 mg (4.3 mmol) 1,1,1- trifluoro-N-phenyl-N-[(trifluoromethyl)sulfonyl]methanesulfonamide and 1.35 ml (7.7 mmol) of Ν,Ν-diisopropyethylamin in 22 ml of DCM was stirred at room temperature for 2 hours. The mixture was concentrated and the residue was purified by column chromatography (gradient from 100% Hex to hexane / EtOAc 50%) to give 1870 mg (3.3 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= -0.37 (9H), 0.43 - 0.64 (2H), 1.23 (3H), 3.13 - 3.30 (3H), 3.49 (1H), 3.64 (1H), 3.79 (1H), 3.96 - 4.03 (1H), 4.14 (1H), 4.48 (1H), 5.82 (1H), 5.89 (1H), 7.05 (1H), 7.64 (1H), 7.68 (1H), 7.76 (1H), 8.54 (1H).
Step c:
methyl 2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5- yl)-l,7-naphthyridine-4-carbox late
In an autoclave, a mixture of 1800 mg (3.14 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-
(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl trifluoromethanesulfonate, 133 mg (0.31 mmol) l,3-bis(diphenylphosphino)propane, 70 mg (0.31 mmol) palladium(ll) acetate and 0.9 ml triethylamine (6.3 mmol) in 22 ml of DMF and 12 ml of methanol was purged with carbon monoxide at room temperature. The autoclave was pressured with carbonmonoxide to 13.7 bar and the mixture was stirred at room temperature for 30 minutes. The autoclave was depressurized and then pressured with carbon monoxide to 16.1 bar. The mixture was stirred at 80°C for 24 hours. The autoclave was depressurized and after cooling, the mixture was diluted with ethyl acetate and washed with aqueous sodium chloride solution. The organic phase was dried (NazSC ), filtered and concentrated. The residue was purified by column chromatography (gradient from 100% Hex to 100% EtOAc) to give 720 mg (1.49 mmol) of the desired product.
1H-NM (400MHz, DMSO-d6): δ [ppm]= -0.48 - -0.30 (9H), 0.42 - 0.61 (2H), 1.22 (3H), 3.20 (3H), 3.48 (1H), 3.54 - 3.68 (1H), 3.75 (1H), 3.88 - 4.05 (4H), 4.10 (1H), 4.50 (1H), 5.78 (1H), 5.85 (1H), 6.96 (1H), 7.66 (1H), 7.87 (1H), 8.19 (1H), 8.46 (1H). Step d:
{2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7- naphthyridin-4-yl}methanol
3.0 ml (3.00 mmol) of a 1M solution of DIBAL in toluene was added to a solution of 720 mg (1.49 mmol) of methyl 2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH- pyrazol-5-yl)-l,7-naphthyridine-4-carboxylate in 17 ml of dry THF at room temperature and the mixture was stirred at 70 °C for 4 hours. After cooling, the mixture was diluted with 25 ml of a saturated solution of ammonium chloride and stirred at room temperature overnight. The mixture was diluted with ethyl acetate and filtered using a Whatman filter. The organic phase was concentrated and the residue was purified by column chromatography (gradient from 100% Hex to 100% EtOAc) to give 405 mg (0.89 mmol) of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= -0.37 - -0.25 (9H), 0.39 - 0.62 (2H), 1.13 - 1.31 (3H), 3.12 - 3.28 (3H), 3.48 (1H), 3.63 (1H), 3.77 (1H), 3.98 (1H), 4.11 (1H), 4.47 (1H), 4.93 (2H), 5.65 (1H), 5.80
(1H), 5.86 (1H), 6.96 (1H), 7.45 (1H), 7.64 (1H), 7.72 (1H), 8.38 (1H). Step e:
4-(chloromethyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH- pyrazol-5-yl)-l,7-naphthyridine and
4-(chlorometh l)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine
0.05 ml (0.66 mmol) thiony chloride was added to a stirred solution of {2-[(3R)-3- methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l;7-naphthyridin- 4-yl}methanol in 33 ml of dry DMF at 0 °C. The mixture was stirred at 5 °C for 1 hour. Toluene was added and the mixture was concentrated to give a crude mixture of 4-(chloromethyl)-2-[(3R)-3- methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7-naphthyridine and 4-(chloromethyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine. Step f:
2-[(3R)-3-methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(l-{[2- (trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7-naphthyridine and
2-[(3R)-3-methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
0.56 ml (1.71 mmol) of an aqueous solution of sodium methanethiolate (21%) was added to 184 mg of a crude mixture of 4-(chloromethyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-
(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7-naphthyridine and 4-(chloromethyl)-2-[(3R)-3- methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine from step e in 4.3 ml of acetone at roomtemperature. The mixture was stirred at room temperature for 150 minutes before it was diluted with ethyl acetate and washed with an aqueous solution of sodium chloride. The organic phase was filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 33 mg (0.07 mmol) 2-[(3R)-3- methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH- pyrazol-5-yl)-l,7-naphthyridine and 32 mg (0.09 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-4- [(methylsulfanyl)methyl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine.
2-[(3R)-3-methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(l-{[2- (trimethylsilyl)ethoxy] methyl }-lH-pyrazol-5-yl)-l,7-naphthyridine:
:H-NMR (400MHZ, DMSO-d6): δ [ppm]= -0.14 - 0.02 (9H), 0.86 (2H), 1.24 (3H), 2.02 (3H), 3.26 (1H), 3.53 (1H), 3.60 (2H), 3.64 - 3.73 (1H), 3.77 (1H), 3.91 - 4.05 (1H), 4.10 (2H), 4.18 (1H), 4.53 (1H), 5.50 (2H), 7.17 (1H), 7.39 (1H), 7.81 (1H), 7.95 (1H), 8.35 (1H).
2-[(3 )-3-methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine:
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.20 - 1.36 (3H), 2.02 (3H), 3.32 (1H), 3.52 - 3.67 (1H), 3.73 (1H), 3.84 (1H), 3.96 - 4.23 (4H), 4.55 (1H), 7.38 (1H), 7.47 (1H), 7.62 (1H), 7.83 (1H), 8.37 (1H), 13.38 (1H).
Example 187
N,N-dimethyl-5-[2-(morpholin-4-yl)- -(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]pyridin-2-am
Example 187 was prepared using Automated Medicinal Chemistry (see examples 346-437).
However, initial purity was not sufficient for testing and therefore the sample had to be purified by a second preparative HPLC (Autopurifier: basic conditions) to give 1 mg (0.002 mmol) of the
desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 3.13 (6H), 3.80 (8H), 6.83 (1H), 7.31 - 7.49 (2H), 7.53 (1H), 7.64 (1H), 7.77 (1H), 8.18 - 8.39 (2H), 13.42 (1H).
Example 188
4-(2-methylpyridin-4-yl)-2-(morph l)-l,7-naphthyridine
Example 187 was prepared using Automated Medicinal Chemistry (see examples 346-437).
However, initial purity was not sufficient for testing and therefore the sample had to be purified by a second preparative HPLC (Autopurifier: basic conditions) to give 0.7 mg (0.002 mmol) of the desired product.
:H-NMR (400MHz, DMSO-d6): δ [ppm]= 2.60 (3H), 3.80 (8H), 7.40 (2H), 7.43 (1H), 7.48 (1H), 7.54 (1H), 7.65 (1H), 8.34 (1H), 8.64 (1H), 13.44 (1H). Example 189
l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}cyclohexanol Step a:
l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l,7- naphthyridin-4-yl}cyclohexanol
0.23 ml (0.12 mmol) of a solution of 0.5M pentamethylenebis(magnesium bromide) in THF was
added to a solution of 56 mg (0.12 mmol) methyl 2-[(3 )-3-methylmorpholin-4-yl]-8-(l-{[2- (trimethylsilyl)ethoxy]methyl}-lH-pyrazol-5-yl)-l;7-naphthyridine-4-carboxylate in 3.0 ml of THF at 0°C under argon. The mixture was stirred at 0°C for 30 minutes and then 1 hour at room temperature. Additional 0.12 ml (0.06 mmol) of the solution of 0.5M
pentamethylenebis(magnesium bromide) in THF was added and the mixture was stirred for 150 minutes at room temperature. The mixture was diluted with aqueous ammonium chloride solution and extracted with ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by column chromatography (gradient from 100% Hex hexane / EtOAc 50%) to give 26 mg (0.05 mmol) the desired product.
Step b:
l-{2-[(3R)-3-methylmorpholin-4-yl]- -(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}cyclohexanol
0.04 ml (0.08 mmol) of a 2N aqueous hydrogen chloride solution was added to a solution of 20 mg (0.038 mmol) of l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH- pyrazol-5-yl)-l,7-naphthyridin-4-yl}cyclohexanol from step a in 0.4 ml of dioxane. The mixture was stirred at room temperature for 7 hours. The mixture was diluted with aqueous sodium chloride solution and extracted with ethyl acetat (2x) and DCM (lx). The combined organic phases were filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (Autopurifier: basic conditions) to give 4 mg (0.01 mmol)of the desired product.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.25 (3H), 1.41 - 1.57 (2H), 1.57 - 1.68 (1H), 1.70 - 1.84 (1H), 1.96 - 2.11 (2H), 3.31 (1H), 3.56 (1H), 3.71 (1H), 3.82 (1H), 4.05 (1H), 4.12 (1H), 4.53 (1H), 4.89 - 5.01 (2H), 5.09 - 5.29 (1H), 5.61 (1H), 5.77 (1H), 7.36 (1H), 7.49 (1H), 7.60 (1H), 7.77 (1H), 8.34 (1H), 13.36 (1H).
Example 190
5-fluoro-2-{2-[(3R)^-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l,7-naphthyridin-4-yl}anilin Step a:
2-fluoro-6-{2-[(3R)^-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}aniline
A suspension of 100 mg (0.19 mmol) of 2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifl uoromethanesulfonate, 90 mg (0.38 mmol) 2-fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline, 15 mg (0.019 mmol) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (1:1, Pd(dppf)CI2) and 65 mg (0.47 mmol) of potassium carbonate in 2.0 ml of acetonitrile and 1.0 ml water was degased with argon. Under argon, the reaction mixture was stirred at 130°C for 10 minutes in a microwave oven. After cooling the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with ethyl acetate (2x). The combinded organic phases were filtered using a Whatman filter and then concentrated to give the crude product that was used without further purification in the next step. Step b:
A solution of 156 mg of crude 2-fluoro-6-{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl}aniline from step a in 5.8 ml of methanol and 0.30 ml of 2N hydrochloric acid was stirred for 90 minutes at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with
ethyl acetate (2x). The combined organic phases were filtered using a Whatman filter and concentrated to dryness. The residue was purified by preparative HPLC (Autopurifier: acidic conditions) to give 2 mg (0.005 mmol) of the desired product.
:H-NMR (400MHZ, DMSO-d6): δ [ppm]= 1.22 - 1.40 (3H), 3.51 - 3.64 (1H), 3.71 ( 1H), 3.82 (1H), 4.05 (1H), 4.21 (1H), 4.54 - 4.70 (1H), 4.89 (2H), 6.62 - 6.76 (1H), 6.90 (1H), 6.97 - 7.26 (2H), 7.39 (1H), 7.44 (1H), 7.55 - 7.74 (1H), 8.28 (1H), 13.42 (1H).
Example 191
(methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}oxido- 6- sulfanylidene)cyanamide
Step a:
4-[4-(methylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-{l-[(2)-tetrahydro-2H^yran-2-yl]-lH- pyrazol-5-yl}-l,7-naphthyridine
4-[(2-(Morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l,7]naphthyridine-4- yl]phenyl-W-ethoxycarbonyl-S-methylsulphoximide (1.00 g, 1.52 mmol) was solubilised in a solution of NaOMe (30% solution in MeOH, 25 mL). the reaction was stirred at 60°C for 3h. The reaction mixture was concentrated under reduced pressure and diluted with DCM and H20. The aqueous phase was extracted two times with DCM. The combined organic phases were washed with brine, dried (silicon filter) and concentrated under reduced pressure. The titled compound was obtain in quantitative yield without further purification.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1.40 - 1.66 (m, 3H), 1.99 (br. s., 2H), 2.30 - 2.47 (m, 1H), 3.17 (s, 3H), 3.22 - 3.30 (m, 1H), 3.72 (s, 8H), 4.35 (s, 1H), 5.75 (s, 1H), 6.06 - 6.12 (m, 1H), 6.93 (d, 1H), 7.41 (d, 1H), 7.50 (s, 1H), 7.64 (d, 1H), 7.82 (d, 2H), 8.13 (d, 2H), 8.38 (d, 1H). Step b:
(methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}oxido- 6- sulfanylidene)cyanamide
4-[4-(Methylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-{l-[(2)-tetrahydro-2H-pyran
pyrazol-5-yl}-l,7-naphthyridine (200 mg, 0.39 mmol) was solubilised in DCM (6 mL). DMAP (51 mg, 0,42 mmol) and BrCN (82 mg, 0.77 mmol, 3M solution) were added sequentially. The reaction was stirred at rt for 16h. The reaction mixture was concentrated under reduced pressure and diluted with MeOH. The suspension was filtered, washed with MeOH and dried under reduced pressure. The crude solid (74 mg) was then solubilized in DCM (2 mL) and 3M HCI (1.5 mL) was added. The reaction was stirred for lh at rt. The reaction was quenched by addition of sat. bicarbonate and the solid was filtered and dried. The title compound was obtained without further purification in (60 mg).
1H-NM (400MHz, DMSO-d5): δ [ppm]= 3.76 - 3.85 (m, 11H), 7.33 (d, 1H), 7.43 (br. s, 1H), 7.60 - 7.68 (m, 2H), 8.00 (d, 2H), 8.26 (d, 2H), 8.36 (d, 1H), 13.42 (br. s, 1H).
Example 192 l-ethyl-3-(methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}oxido- 6-sulfanylidene)urea
Step a: (methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}oxido- 6- sulfanylidene)cyanamide
4-[4-(Methylsulfonimidoyl)phenyl]-2-(m^
pyrazol-5-yl}-l,7-naphthyridine (100 mg, 0.19 mmol) was solubilised in DCM (6 mL). Triethylamine (39 mg, 0.39 mmol) and ethyl isocyanate (27 mg, 0. 39 mmol) were added. The reaction was stirred for 16h at rt and triethylamine (195 mg, 3.89 mmol) and ethyl isocyanate (135 mg, 1.95 mmol) were added. The reaction was stirred for 16h at rt and concentrated under reduced pressure. The crude material was solubilized in DMF (6 mL) and triethylamine (195 mg, 3.89 mmol) and ethyl isocyanate (135 mg, 1.95 mmol) were added. The reaction was stirred for 48h at 60°C. The reaction was diluted with water and extracted with DCM. The organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude material was purified by flash chromatography (100% Hexane to 100% AcOEt to 20% MeOH). The titled compound was obtained in 78% yield (93 mg). 1H-NM (400MHz, DMSO-d6): δ [ppm]= 0.99 (t, 3H), 1.40 - 1.66 (m, 3H), 1.99 (s, 2H), 2.34 - 2.45 (m, 1H), 2.90 - 3.04 (m, 2H), 3.23 - 3.29 (m, 1H), 3.45 (s, 3H), 3.72 (s, 9H), 6.09 (dd, 1H), 6.94 (d, 1H), 7.00 (t, 1H), 7.41 (d, 1H), 7.53 (s, 1H), 7.64 (d, 1H), 7.87 (d, 2H), 8.11 (d, 2H), 8.39 (d, lH).
Step b: l-ethyl-3-(methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}oxido 6-sulfanylidene)urea
(Methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridm^
sulfanylidenejcyanamide (93 mg, 46 mmol) was solubilized in DCM (3 mL) and 3M HCI (2 mL) was added. The reaction was stirred 16h at rt and then quenched with sat NaHC03. The aqueous phase was extracted with DCM and the organic phase was dried (silicon filter) and concentrated under reduced pressure. The crude material was purified by flash column chromatography (100% Hexane to 100% AcOEt to 20% MeOH) and the titled compound was obtained in 85% yield (68 mg). 1H-NM (400MHz, DMSO-d6): δ [ppm]= 0.99 (t, 3H), 2.90 - 3.03 (m, 2H), 3.45 (s, 3H), 3.80 (s, 8H), 7.00 (t, 1H), 7.35 (d, 1H), 7.43 (br. s, 1H), 7.57 (s, 1H), 7.65 (br. s, 1H), 7.86 (d, 2H), 8.11 (d, 2H), 8.35 (d, 1H), 13.37 - 13.47 (m, 1H).
Example 193
3-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-l^-naphthyridin-4-yl}oxy)propan-l- amine
Tert-butyl [3-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]- l,7-naphthyridin-4-yl}oxy)propyl]carbamate (80 mg, 0.15 mmol) was solubilised in DCM (2 mL) and TFA (0,22 mL, 2.9 mmol) was added. The reaction was stirred 2h at rt and quenched with sat. NaHC03. The aqueous phase was extracted with DCM and the organic phase was dried (silicon
filter) and concentrated under reduced pressure.
The crude material was purified by preparative HPLC (ACN/H20/formic acid system). The titled compound was obtained in 18% yield (10 mg). 1H-NM (400MHz, DMSO-d6): δ [ppm]= 1.27 (d, 3H), 2.11 (quin, 2H), 2.99 (t, 2H), 3.30 (dt, 1H), 3.56 (dt, 1H), 3.72 (dd, 1H), 3.83 (d, 1H), 4.05 (dd, 1H), 4.15 (d, 1H), 4.36 (t, 2H), 4.56 - 4.64 (m, 1H), 6.82 (s, 1H), 7.36 (d, 1H), 7.61 (d, 1H), 7.75 (d, 1H), 8.30 - 8.41 (m, 2H).
Example 194
4-(4-cyclopropyl-lH-l,2,3-triazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a:
4-(cyclopropylethynyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[tetrahydro-2H-pyran-2-yl]-lH- pyrazol-5-yl}-l,7-naphthyridine
2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridin-4-yl trifluoromethanesulfonate (150 mg, 284 μιτιοΙ), copper(l) iodide (5.53 mg, 98 % purity, 28.4 μιτιοΙ) and triethylamine (790 μΙ, 5.7 mmol) were dissolved in acetonitrile (4.0 mL). The reaction mixture was degassed with Argon. Ethynylcyclopropane (74 μΙ, 98 % purity, 850 μιτιοΙ) and : Bis(triphenylphosphin)palladium(ll)chlorid (8.15 mg, 98 % purity, 11.4 μιτιοΙ) were added sequentially and the reaction was stirred for 16h at 45°C. The reaction was then filtered and concentrated under reduced pressure. The residue was dissolved in DCM and water and the aqueous phase was extracted 3x with DCM. The combined organic layers were dried (silicone filter) and concentrated under reduced pressure. The crude material was purified by flash column chromatography (Hex/EtOAc mixture) and the title compound was obtained in 87% yield (110 mg).
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.90 - 0.98 (m, 2H), 1.01 - 1.08 (m, 2H), 1.15 - 1.22 (m, 3H), 1.39 - 1.50 (m, 2H), 1.52 - 1.65 (m, 1H), 1.72 - 1.81 (m, 1H), 1.94 - 2.01 (m, 2H), 2.31 - 2.39 (m,
1H), 3.11 - 3.30 (m, 2H), 3.40 - 3.51 (m, 1H), 3.56 - 3.64 (m, 1H), 3.65 - 3.77 (m, 2H), 3.90 - 3.98 (m, 1H), 4.07 - 4.16 (m, 1H), 4.42 - 4.53 (m, 1H), 6.07 (ddd, 1H), 6.92 (dd, 1H), 7.53 (d, 1H), 7.62 (d, 1H), 7.80 (d, lH), 8.44 (d, 1H). Step b:
4-(4-cyclopropyl-lH-l,2,3-triazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
4-(cyclopropylethynyl)-2-[(3 )-3-methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran-2 pyrazol-5-yl}-l,7-naphthyridine (70.0 mg, 158 μιτιοΙ) was solubilised in tert. Butanol (1.8 mL) and water (1.8 mL). Sodium azide (10.3 mg, 158 μιτιοΙ) was added and the mixture was strirred for 5 min. at rt. Copper(ll) sulphate hydrate (19.7 mg, 78.9 μιτιοΙ) and (+)-sodium L-ascorbate (15.6 mg, 78.9 μητιοΙ) were added and the mixture was strirred for 16h at 100°C.
The reaction was then cooled to rt , diluted with DCM and washed with H20. The organic phase was dried and concentrated under reduced pressure. The crude material was purified by preparative HPLC (H20/CAN/formic acid mixture). The title compound was obtained in 1% yield (1 mg).
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 0.82 - 0.89 (m, 2H), 0.94 - 1.00 (m, 2H), 1.22 - 1.29 (m, 1H), 1.31 (d, 3H), 1.89 - 1.99 (m, 1H), 3.52 - 3.65 (m, 2H), 3.71 - 3.77 (m, 1H), 3.81 - 3.86 (m, 1H), 4.07 (dd, 1H), 4.17 - 4.24 (m, 1H), 4.56 - 4.64 (m, 1H), 7.42 (s, 1H), 7.61 (s, 1H), 7.65 (s, 1H), 7.77 (d, 1H), 8.37 (d, 1H), 13.44 (br. s., 1H).
The following compounds of Table 1 were prepared according to Scheme 3 and in analogy to example 54.
Table 1
The following compounds of Table 2 were prepared according to Scheme 4 and in analogy to examples 63, 70, 85 and 107.
Table 2
2H), 1.14 - 1.20
3.68 - 3.75 (m, IH), IH), 4.60 - 4.69 (m, 7.97 (d, IH), 8.36
(d, 6H), 3.29 - - 3.87 (m, IH), 2H), 7.39 (s, IH), - 8.41 (m, 2H),
- 3.40 (m, IH), IH), 4.02 - 4.08 (m, 7.57 (s, IH), 7.64 8.85 (s, IH),
(s, 9H), 3.34 - (dd, IH), 4.21 (s, IH), 7.86 (d, IH).
(d, 3H), 2.12 (d, (m, IH), 3.78 (s, 4.53 - 4.67 (m, 8.31 (d, IH), 13.41
3.28 -3.38 (m, IH),
4H), 4.17 (d, IH), IH), 7.63 (br. s.,
- 3.40 (m, IH), (dd, IH), 4.21 (s, IH), 7.45 (s, IH), (d, IH), 13.37 (br.
(t, 3H), 3.33 - - 3.88 (m, IH), - 4.70 (m, IH), (s, IH), 8.35 - 8.40
- 3.32 (m, IH), - 4.08 (m, IH), (t, IH), 7.31 (s, 8.34 (d, IH), 13.12
(d, 6H), 3.27 - (dd, IH), 4.21 (d, IH), 7.86 (d,
The following compounds of Table 3 were prepared according to Scheme 6 and in analogy to example 126.
Table 3
Exa Structure NMR
mpl
Name
e
Example 281
3-methyl-2-{2-[(3R)-3-methylmorpholin-4
ol
Step a:
2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[(2R)-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridine-4-carboxylic acid
Methyl 2-[(3 )-3-methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}- l,7-naphthyridine-4-carboxylate (1.10 g, 2.51 mmol) was solubilized in THF (11 mL) and methanol (5 mL9). NaOH solution (2.8 ml, 1.0 M, 2.8 mmol) was added and the mixture was stirred for 10 min at rt. The solvent was removed under reduced pressure and the aqueous phase was acidified to pH 5 using 1M HCI. The aquoueous solution was lyophilised and the title compound was obtained without further purification in 99% yield (1.10 g).
1H-NMR (400MHz, DMSO-d6): d [ppm]= 1.18 (dd, 3H), 1.37 - 1.49 (m, 2H), 1.51 - 1.64 (m, 1H), 1.88 - 2.03 (m, 2H), 2.29 - 2.40 (m, 1H), 3.09 - 3.19 (m, 1H), 3.19 - 3.28 (m, 1H), 3.41 - 3.51 (m, 1H), 3.58 - 3.65 (m, 1H), 3.66 - 3.78 (m, 2H), 3.89 - 4.00 (m, 1H), 4.06 (t, 1H), 4.36 - 4.51 (m, 1H), 5.92 -
6.08 (m, 1H), 6.84 (dd, 1H), 7.48 (d, 1H), 7.60 (s, 1H), 8.32 (d, 1H), 8.46 - 8.53 (m, 1H).
Step b:
N-methoxy-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[(2R)-tetrahydro-2H-pyran-2-yl]-lH- pyrazol-5-yl}-l,7-naphthyridine-4-carboxamide
N-methoxymethanamine hydrochloride (1:1) (861 mg, 8.83 mmol) was solubilized in DMF (20 mL). N,N-Diisopropylethylamin (3.1 ml, 18 mmol) and HATU (2.52 g, 6.62 mmol) were added and the mixture stirred for 10 min at rt. 2-[(3 )-3-Methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran- 2-yl]-lH-pyrazol-5-yl}-l,7-naphthyridine-4-carboxylic acid (1.10 g, 85 % purity, 2.21 mmol) was then added and the mixture stirred 16h at rt. N,N-Diisopropylethylamin (3.1 ml, 18 mmol) and HATU (2.52 g, 6.62 mmol) were added again and the reaction stirred for 16h at rt.Water was added and the mixture was stirred for 10 min. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with half sat. NaCI-solution. The organic layer was dried over a silicone filter and concentrated under reduced pressure. The crude material was purified by flash column chromatograpy ( from Hx/EtOAc: 0-100% to 100% EtOAc to EtOAc/EtOH: 0-20%) and the title compound was obtained in quantitative yield.
1H-NMR (400MHz, DMSO-d6): d [ppm]= 1.19 - 1.25 (m, 3H), 1.41 - 1.54 (m, 2H), 1.54 - 1.66 (m, 1H), 1.92 - 1.99 (m, 2H), 2.69 (s, 2H), 3.15 - 3.32 (m, 2H), 3.42 (br. s., 3H), 3.50 (br. s., 3H), 3.60 - 3.72 (m, 2H), 3.72 - 3.80 (m, 1H), 3.93 - 4.01 (m, 1H), 4.12 - 4.22 (m, 1H), 4.46 - 4.57 (m, 1H), 6.04 - 6.17 (m, 1H), 6.97 (dd, 1H), 7.44 (d, 1H), 7.58 - 7.67 (m, 2H), 8.41 (d, 1H).
Step c:
l-(2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[(2R)-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridin-4-yl)ethanone
N-methoxy-N-methyl-2-[(3 )-3-methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran pyrazol-5-yl}-l,7-naphthyridine-4-carboxamide (710 mg, 1.52 mmol) was solubilized in THF and cooled to 0°C. Methylmagnesium bromide (1.5 ml, 3.0 M, 4.6 mmol)was added dropwise and the reaction was stirred at 0°C for 30 min. and 1.5 h at rt. Methylmagnesium bromide (1.5 ml, 3.0 M, 4.6 mmol) was added again and the reaction was stirred for 16h. The reaction was quenched with sat. NH4CI and extracted with DCM. The organic phase was filtred and concentrated under reduced pressure. The title compound was used without further purification.
1H-NMR (400MHz, DMSO-d6): d [ppm]= 1.23 (dd, 3H), 1.40 - 1.48 (m, 2H), 1.53 - 1.64 (m, 1H), 1.95 - 2.00 (m, 1H), 2.32 - 2.40 (m, 1H), 2.69 (s, 3H), 2.78 (s, 2H), 3.19 - 3.30 (m, 2H), 3.64 - 3.73 (m, 2H), 3.75 - 3.81 (m, 1H), 3.95 - 4.02 (m, 1H), 4.14 - 4.21 (m, 1H), 4.55 - 4.63 (m, 1H), 5.97 - 6.07 (m, 1H), 6.88 (dd, 1H), 7.63 (t, 1H), 7.85 (d, 1H), 7.95 (d, 1H), 8.42 (d, 1H).
Step d:
3-methyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^^
ol
l-(2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[(2R)-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridin-4-yl)ethanone (33.0 mg, 78.3 μιηοΙ) was solubilized in THF (2.0 mL) and the mixture was cooled to 0°C. Chloro(propan-2-yl)magnesium (120 μΙ, 2.0 M, 230 μιηοΙ) was added dropwise. The mixture was stirred at 0°C 0.5h and 1.5h at rt. The reaction mixture was quenched with water and of 3M aq. HCI (0.5 mL) was added. The mixture was stirred for 16h at rt. The reaction was quenched with NaHCC and extracted with DCM. The organic phase was dried over a silicone filter and concentrated under reduced pressure. The crude material was purified by preparative HPLC
(ACN/H2O/NH4OH mixture) and the title compound was obtained in 27% yield (9 mg).
1H-NM (400MHz, DMSO-d6): δ [ppm]= 0.75 - 0.89 (m, 6H), 1.26 (d, 3H), 1.63 (d, 3H), 3.59 (t, 1H), 3.71 - 3.78 (m, 1H), 3.80 - 3.88 (m, 1H), 4.03 - 4.16 (m, 2H), 4.50 - 4.60 (m, 1H), 5.39 (d, 1H), 7.35 (s, 1H), 7.43 (s, 1H), 7.60 (s, 1H), 8.27 - 8.32 (m, 2H), 13.34 (br. s., 1H).
Example 282
l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}-l-(tetrahydro-2H pyran-4-yl)ethanol
l-(2-[(3R)-3-methylmorpholin-4-yl]-8-{l-[(2R)-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridin-4-yl)ethanone (33.0 mg, 78.3 μιτιοΙ) was solubilized in THF (2.0 mL) and the mixture was cooled to 0°C. Chloro(tetrahydro-2H-pyran-4-yl)magnesium (1.4 ml, 0.50 M, 710 μιτιοΙ) was added dropwise. The mixture was stirred at 0°C 0.5h and 1.5h at rt. The mixture was cooled to 0°C and chloro(tetrahydro-2H-pyran-4-yl)magnesium (1.4 ml, 0.50 M, 710 μιτιοΙ) was again added. The reaction was stirred at 0°C for 30 min and 45 at rt. The reaction mnixture was quenched with water and of 3M aq. HCI (0.5 mL) was added. The mixture was stirred for 72h at rt. The reaction was quenched with NaHC03 and extracted with DCM. The organic phase was dried over a silicone filter and concentrated under reduced pressure. The crude material was purified by preparative HPLC (ACN/H2O/N H4OH mixture) and the title compound was obtained in 23% yield (25 mg). 1H-NMR (400MHz, DMSO-d6): d [ppm]= 1.25 (d, 4H), 1.34 - 1.45 (m, 2H), 1.45 - 1.56 (m, 1H), 1.64 - 1.68 (m, 3H), 2.24 - 2.35 (m, 1H), 3.06 - 3.24 (m, 2H), 3.26 - 3.32 (m, 1H), 3.57 (t, 1H), 3.69 - 3.90 (m, 5H), 4.02 - 4.14 (m, 2H), 4.48 - 4.58 (m, 1H), 5.48 (d, 1H), 7.33 (br. s., 1H), 7.45 (d, 1H), 7.60 (s, 1H), 8.24 - 8.34 (m, 2H), 13.33 (br. s., 1H). Example 283
3,3-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}butan-2-ol
l-(2-[(3 )-3-methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl^ naphthyridin-4-yl)ethanone (33.0 mg, 78.3 μιτιοΙ) was solubilized in THF (2.0 mL) and the mixture was cooled to 0°C. tert-butyl(chloro)magnesium (710 μΙ, 1.0 M, 710 μmol) was added dropwise. The mixture was stirred at 0°C 0.5h and 1.5h at rt. The reaction mixture was quenched with water and of 3M aq. HCI (0.5 mL) was added. The mixture was stirred for 72h at rt. The reaction was quenched with NaHC03 and extracted with DCM. The organic phase was dried over a silicone filter and concentrated under reduced pressure. The crude material was purified by preparative HPLC (ACN/H2O/N H4OH mixture) and the title compound was obtained in 24% yield (25 mg).
1H-NMR (400MHz, DMSO-d6): d [ppm]= 0.94 (s, 9H), 1.14 - 1.30 (m, 3H), 1.70 (s, 3H), 3.19 - 3.31 (m, 1H), 3.58 (t, 1H), 3.67 - 3.75 (m, 1H), 3.75 - 3.86 (m, 1H), 3.98 - 4.17 (m, 2H), 4.53 (br. s., 1H), 5.59 (s, 1H), 7.10 (br. s., 1H), 7.31 (br. s., 1H), 7.58 (s, 1H), 8.26 (d, 1H), 8.92 (br. s., 1H), 13.30 (br. s., 1H).
Example 284
2-{2-[(3R)-3-methylmorpholin-4-yl]- -(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}hexan-2-ol
l-(2-[(3 )-3-methylmorpholin-4-yl]-8-{l-[(2 )-tetrahydro-2H-pyran-2-yl]-lH-pyrazol-5-yl}-l,7- naphthyridin-4-yl)ethanone (33.0 mg, 78.3 μιτιοΙ) was solubilized in THF (2.0 mL) and the mixture was cooled to 0°C. Butyl(chloro)magnesium (360 μΙ, 2.0 M, 710 μιτιοΙ) was added dropwise. The mixture was stirred at 0°C 0.5h and 1.5h at rt. The reaction mixture was quenched with water and
of 3M aq. HCI (0.5 mL) was added. The mixture was stirred for 72h at rt. The reaction was quenched with NaHC03 and extracted with DCM. The organic phase was dried over a silicone filter and concentrated under reduced pressure. The crude material was purified by preparative HPLC (ACN/H2O/NH4OH mixture) and the title compound was obtained in 7% yield (7 mg).
1H-NM (400MHz, DMSO-d6): d [ppm]= 0.77 (td, 3H), 0.97 - 1.08 (m, 1H), 1.12 - 1.22 (m, 3H), 1.27 (d, 4H), 1.68 (d, 3H), 1.87 - 2.00 (m, 1H), 2.02 - 2.14 (m, 1H), 3.58 (t, 1H), 3.73 (d, 1H), 3.84 (d, 1H), 4.01 - 4.16 (m, 2H), 4.55 (d, 1H), 5.47 (d, 1H), 7.35 (s, 1H), 7.47 (d, 1H), 7.61 (s, 1H), 8.22 (dd, 1H), 8.32 (d, 1H), 13.35 (br. s., 1H).
Example 285
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-3-yl)-l,7-naphthyridine-4-carboxamide Step a
2-((ff)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H^yrazol-3-yl]-[l,7]naphthyridi 4-carboxamide
2-((R)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine-4-carbonitrile (1.5g, 3.882 mmol) were suspended in 2-methoxyethanol (15 ml). Then KOH (0.653 g, 11.645 mmol) in water (367 μΙ) were added and the reaction was stirred at 150°C for 7 hours and at 130°C for 14 hours. The solvent was removed by distillation under reduced pressure and the residue was crystallized from a mixture of isopropanol (5 ml) and diethylether (25 ml). The title compound was obtained by filtration as a yellow solid in 6% yield (95 mg). LC-MS (method 1): m/z: [M+H]+ = 423.2, Rt = 3.01 min. Step b
2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-3-yl)-l,7-naphthyridine-4-carboxamide
To 2-(( )-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[l;7]naph^ ridine-4-carboxamide (95 mg, 0.22 mmol) was added a drop of water and trifluoroacetic acid (1 ml, 13 mmol). After 2 hours LCMS indicated the complete removal of the protective group. The trifluoroacetic acid was removed under reduced pressure and the residue was adjusted to pH 7 by addition of aq. NaHC03 solution. The aqueous layer was extracted with a mixture of dichloromethane / isopropanol (10 :1, 5 x). The combined organic layers were dried over sodium sulfate and the solvent was evaporated. The residue was purified in a flashmaster chromatography (25 g of silica gel 60, 30 μΜ) with chloroform / methanol 90 :10 as eluent. The title compound was obtained in 19% yield (14 mg) as a yellow solid. Melting point: 145-147 °C. 1H-NMR (400 MHz, CD3OD): δ [ppm] =1.40-1.41 (m, 3H), 3.49-3.52 (m, IH), 3.65-3.71 (m, IH), 3.82-3.91 (m, 2H), 4.10-4.18 (m, 2H), 4.60-4.61 (m, IH), 7.34 (s, IH), 7.56 (s, IH), 7.67 (s, IH), 7.86-7.87 (m, IH), 8.37-8.38 (m, IH). LC-MS (method 1): m/z: [M+H]+ = 339.2, t = 2.23 min. Example 286
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(methylsulfonyl)cyclopropyl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
Step a
{2-((R)-3-methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl}methanol
a solution of methyl-2-((/?)-3-Methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3- [l,7]naphthyridine-4-carboxylate (190.5 mg, 0.435 mmol) in absolute THF (19 ml) was added
diisobutylaluminium hydride solution (1M in toluene, 871 μΙ, 0.871 mmol) under argon at ambient temperature and the reaction was stirred for 1.5 hours at 80°C. The reaction mixture was cooled with ice, a saturated aqueous ammonium chloride solution (20 ml) was added and the aqueous layer was extracted with ethyl acetate (3 x 30 ml). The combined organic layers were dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was purified in a Flashmaster chromatography (silica gel 60, 30 μΜ) using chloroform / methanol 98 : 2 as eluent. The title compound was obtained in 66 % yield (118 mg). LC-MS (method 1): m/z: [M+H]+ = 410.3,
Step b
{2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7- naphthyridin-4-yl}methyl methanesulfonate
To a solution of {2-((R)-3-Methylmorpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine-4-yl}methanol (118 mg, 0.288 mmol) and trimethylamine (52 μΙ, 0.375 mmol) in absolute THF (5 ml) was added dropwise under argon at 0°C methansulfonyl chloride (25 μΙ, 0.317 mmol) and the reaction was allowed to stir for one hour at 0°C. With intervals of two hours additional methansulfonyl chloride (3 x 25 μΙ, 0.317 mmol) were added and the reaction was allowed to stir for another 16 hours at ambient temperature. After addition of another portion of methansulfonyl chloride (25 μΙ, 0.317 mmol) the reaction was stirred at 40°C for two hours. The reaction mixture was filtered and the filtrate was evaporated. The title compound was obtained in quantitative yield (219 mg) and used without further purification in the next step. LC-MS (method 1): m/z: [M+H]+ = 488.2, Rt = 3.32 min. Step c
2-[(3R)-3-methylmorpholin-4-yl]-4-[(methylsulfonyl)methyl]-8-[l-(tetrahydro-2H^yran-2-yl)- lH-pyrazol-5-yl]-l,7-naphthyridine
To a solution of {2-[(3 )-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}methyl methanesulfonate (219 mg, 0.45 mmol) in absolute DMSO (2 ml) was added portionwise sodium methylsulfinate (161 mg, 1.572 mmol) and the reaction was allowed to stir at 120°C for 20 minutes. The reaction was diluted with water (10 ml) and extracted with dichloromethane (3 x 10 ml).The combined organic layers were dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by Puri-Flash chromatography (25 g of silica gel 60, 30 μιη) using dichloromethane / methanol 95 : 5 as eluent. The title compound was obtained in 40% yield (84 mg) as a yellow solid. LC-MS (method 1): m/z: [M+H]+ = 472.3, Rt = 3.06 min.
Step d
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(methylsulfonyl)cyclopropyl]-8-[l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-5-yl]-l,7-naphthyridine
To a solution of 2-[(3R)-3-methylmorpholin-4-yl]-4-[(methylsulfonyl)methyl]-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine (84 mg, 0.178 mmol), 1,2-dibromoethane (15 μΙ, 0.178 mmol) and tetrabutylammoniumbromide (6 mg, 0.018 mmol) in absolute THF (1.68 ml) was added a NaOH solution (50% in water, 185 μΙ) and the reaction was stirred at ambient temperature for one hour. The suspension changed its color to dark green / dark brown. Additional 1,2-dibromoethane (15 μΙ, 0.178 mmol), tetrabutylammoniumbromide (6 mg, 0.018 mmol) and NaOH solution (50% in water, 185 μΙ) were added and the reaction was stirred at 60°C
for 5 hours. The reaction was diluted with water (10 ml) and extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was purified in a Flashmaster chromatography (25 g of silica gel 60, 30 μιη) using dichloromethane / methanol 95 : 5 as eluent. The title compound was obtained in 28% yield (25 mg) as yellow solid. The product was used in the next step without further purification. LC-MS (method 1): m/z: [M+H]+ = 498.3, t = 3.27 min.
Step e
2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(methylsulfonyl)cyclopropyl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
To a solution of 2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(methylsulfonyl)cyclopropyl]-8-[l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridine (25 mg, 0.05 mmol) in methanol (2 ml) was added HCI (2N in water). The reaction was stirred for 18 hours at 50°C. The LCMS indicated complete removal of the protective group. Methanol was removed under reduced pressure and the pH value of the residue was adjusted to seven by addition of aqueous NaHC03 solution. The aqueous layer was extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over sodium sulfate and the solvent was removed under reduced pressure. The title compound was obtained in 73% yield (16 mg) as a yellow solid. Melting point: 240-248 °C. 1H-NMR (400 MHz, CDCI3): δ [ppm] =0.06-0.09 (m, 3H), 0.83-089 (m, 1H), 1.22-1.53 (m, 1H), 1.97-2.36 (m, 2H), 2.86 (s, 3H), 3.51-3.58 (m, 1H), 3.67-3.75 (m, 1H), 3.83-3.88 (m, 1H), 3.91-3,95 (m, 1H), 3.98-4.03 (m, 1H), 4.16-4.20 (m, 1H), 4.39-4.46 (m, 1H), 7.32 (s, 1H), 7.45 (s, 1H), 7.71 (s, 1H), 7.82-7.83 (m, 1H), 8.48-8.49 (m, 1H). LC-MS (method 1): m/z: [M+H]+ = 414.2, Rt = 2.65 min.
Example 287
2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)-l,7-naphthyridine
A mixture of 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7- naphthyridin-4-ol (75 mg, 0.1 mmol), 4-(bromomethyl)tetrahydro-2H-pyran (26.4 mg, 147.5 μιτιοΙ) and cesiumcarbonate (41.6 mg, 127.8 μΜ) in DMF (0.6 ml) was heated in a microwave reactor at 100°C for one hour. The reaction mixture was cooled to ambient temperature and cone. HCI (0.13 ml) was added slowly (gas evolution). The reaction was stirred at ambient temperature for 14 hours. The solvent was evaporated and the residue was extracted with dichloromethane (10 ml) and water (10 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 10 ml). The combined organic layers were dried over sodium sulfate and the solvent was removed under reduced pressure. The title compound was obtained after HPLC separation in 3 % yield (1 mg). 1H-NM (400 MHz, CD2CI2, selected peaks): δ [ppm] = 1.86 (m, 2H), 3.52 (m, 2H), 3.64 (m, 1H), 3.77 (m, 4H), 3.95 (m, 4H), 4.07 (m, 4H), 6.51 (s, 1H), 7.26 (d, 1H), 7.67 (d, 1H), 7.79 (d, 1H), 8.42 (d, 1H).
Example 288
N,N-dimethyl-3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]benzamid
H
To a solution of [3-(dimethylcarbamoyl)phenyl]boronic acid (530 μΙ, 0.57 M, 300 μιτιοΙ) in 0.52 mL DMF was added 2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-
[l,7]naphthyridin-4-yl-trifluoromethanesulphonate (1.0 ml, 0.15 M, 150 μιτιοΙ; lntermediate-3) 1 mL DMF, aqueous sodium carbonate solution (200 μΙ, 2.3 M, 450 μιτιοΙ) and 1,1'- bis(diphenylphosphino)ferrocenedichloropalladium(ll) (400 μΙ, 0.038 M in DMF, 15 μιτιοΙ). The reaction mixture was shaked at 90°C for 12 h.
To the crude reaction mixture aqueous hydrochloric acid (240 μΙ, 1.9 M, 470 μιτιοΙ) was added a the corresponding mixture was shaked over night at room temperature.
The reaction mixture was purified by preparative HPLC to give 22 mg of the product as solid material.
LC-MS Method 4: t = 0.75 min; MS (ESIpos) m/z = 429 [M+H]+.
The following examples (Table 4) were prepared in analogy to example 288:
Table 4
The examples in the following table (Table 5) were prepared in analogy to this procedure:
To 2-5 eq of boronic acid derivative were added 0.15 mmol 2-(morpholin-4-yl)-8-[l-(tetrahydro- 2H-pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate (0.25 M in NMP, 600 μί), 30 μηιοΙ l;l'-BIS(DIPHENYLPHOSPHINO)FERROCENE]DICHLOROPALLADIUM(ll) (0.04 M in NMP, 750 μί) and 0.45 mmol potassium carbonate (1 M in water, 450 μί) and the mixture was heated in a microwave oven at 110°C for 5 hours. After cooling, 0.9 mmol HCI (2M in water, 450 μΐ) were added and the mixture was heated in a microwave oven for 10 hours at 50°C. After cooling, the mixture was filtered, washed with NMP and subjected to preparative HPLC to yield the target product.
LC-MS Method 4
Table 5
The examples in the following table (Table 6) were prepared in analogy to this procedure:
To 2-5 eq of amine derivative were added 0.15 mmol 2-(morpholin-4-yl)-8-[l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-5-yl]-l,7-naphthyridin-4-yl trifluoromethanesulfonate (0.25 M in N MP, 600 μΐ) and the mixture was heated at 70°C overnight. After cooling, 1.5 mmol HCI (2M in water, 750 μΐ) were added and the mixture was heated overnight at 50°C. After cooling, the mixture was subjected to preparative H PLC to yield the target product.
LC-MS Method 4 Table 6
Retention LC-MS
Example Structure Name time m/z
[min] [M+H]+
2-(morpholin-4-yl)-4-(piperidin-l- yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine
408 0.83 365.4
0
The title compounds described in the example section were tested in selected biological assays one or more times. When tested more than once, data are reported as either average values or as median values, wherein
•the average value, also referred to as the arithmetic mean value, represents the sum of the
values obtained divided by the number of times tested, and
•the median value represents the middle number of the group of values when ranked in ascending or descending order. If the number of values in the data set is odd, the median is the middle value. If the number of values in the data set is even, the median is the arithmetic mean of the two middle values.
Examples were synthesized one or more times. When synthesized more than once, data from biological assays represent average values or median values calculated utilizing data sets obtained from testing of one or more synthetic batch.
Expression of ATR/ATRIP in HEK 293-6E cells: The cDNAs encoding the protein sequences of full-length human AT sequence (Q13535) with an N-terminally fused Flag tag as well as the full-length human ATRIP (Q8WXE1) were optimized for expression in eukaryotic cells and synthesized by the GeneArt Technology at Life Technologies. Both cDNAs also encoded att-site sequences at the 5'and 3' ends for subcloning into the following destination vectors using the Gateway Technology: pD-MamA (an in-house derivate of the vector pEAK from EdgeBioSystems but with a human CMV promotor) which provides a N-terminal fusion of a GST-tag to the integrated gene of interest; pD-MamB (an in-house derivative of pTT5 from NRCC, Y. Durocher) which provides a N-terminal fusion of a STREP II -tag to the integrated gene. The cDNAs of ATR and ATR-DN were cloned into pD-MamA and the ATRIP-FL into pD-MamB. The cDNA sequence of codon-optimized ATR including a GST tag is described in SEQ ID No. 1 of the attached sequence listing, its corresponding protein sequence in SEQ ID No. 3.
The cDNA sequence of codon-optimized ATRIP including a STREP II tag is described in SEQ ID No. 2, its corresponding protein sequence in SEQ ID No. 4.
Coexpression of ATR and ATRIP by transient transfection in HEK293-6E cells:
For transient transfection of HEK293-6E suspension cells a Biostat Cultibag Bioreactor with 5 L culture volume (starting volume) in a 20 L culture bag was used. The cells were cultured in F17 Medium (Gibco, Invitrogen, Cat# 05-0092DK) with the following supplements Pluronic F68 (10 mL/L of 10% solution, Gibco # 24040), Gluta-Max (20ml of lOOx solution/L, L-Alanyl-Glutamine (200mM, Invitrogen #25030), G418 (final concentration 25ng/ml, PAA #P02-012). The applied culture conditions were 37°C, rocking ratel8 rpm, pH 7.0, p02 55 %. At the day of transfection the cell culture had reached a cell density of 1.6 x 106 cells/mL and a viability of 99 %. For preparation of the transfection solution to 500 mL F17 medium (without the supplements) 4 mg of the ATR
encoding plasmid, 1 mg of the ATRIP encoding plasmid and 10 mg PEI (Polyethylenimin, linear, Polysciences # 23966, as 1 mg/mL stock solution) were subsequently added, carefully mixed and incubated at room temperature for 15 min. This transfection solution was then added to the 5 L cell culture in the culture bag. This cell culture was incubated for 5 h and afterwards 5 L of F17 medium with the mentioned supplements were added and the rocking rate increased to 19 rpm. 48 h after transfection the cells were harvested by centrifugation (30 min., lOOOg, 15 °C) and the cell pellets stored at -80 °C.
Purification:
Purification of the ATR (Flag-Tag)/ATRIP(Strep-Tag) complex was achieved by affinity chromatography using anti-FLAG-resin (Sigma, #A220).
Cells were harvested by centrifugation (4000xg) and lysed in buffer A (50mM Tris-HCI pH 7,5; 150mM NaCI, 5% Glycerol, ImM Na3V04, ImM NaF, lOmM β-glycerophosphate, l% Tween 20; 0,1% NP40; Complete with EDTA) for lh at 4°C. The supernatant (20.000xg) was than bound to Flag-Agarose and eluted after several washing steps using Buffer B (50mM Tris-HCI pH7.4; 150mM NaCI; 10% Glycerin, 200μg/ml Flag Peptides from Sigma, #F3290). Elution fractions were aliquoted and shock frozen using liquid nitrogen. The final concentration of ATR in the final preparation was 250μg/ml calculated densitrometrically using BSA as a standard in a Coomassie stained gel. The yield of copurified ATRIP was far below a 1:1 ratio compared to ATR but was essential for ATR activity.
Tracer A:
3^6'-bis(dimethylamino)-N-(4-{[2-(lH-indol-4-yl)-6-(morp
3-oxo-3H-spiro[2-benzofuran-l,9'-xanthene]-5-carboxamide
Step a: tert-butyl (4-{[2-(lH-indol-4-yl)-6-(morpholin-4-yl)pyrimidin-4-yl]amino}butyl)carbamate
The starting material 4-[4-chloro-6-(morpholin-4-yl)pyrimidin-2-yl]-lH-indole was synthesized according to the literature (WO2008/125833). A solution of 4-[4-chloro-6-(morpholin-4- yl)pyrimidin-2-yl]-lH-indole (980 mg, 3.11 mmol), diisopropylethylamine (805 mg, 1.09 ml, 6.23 mmol) and N-BOC-l,4-diaminobutane (879 mg, 4.67 mmol) in l-methyl-2-pyrrolidinone (24.5 ml) was stirred overnight at 150°C. The mixture was allowed to cool to ambient temperature. Ethyl acetate (50 ml) and brine (50 ml) were added, the layers were separated and the organic layer was washed with brine (3x 50 ml). The organic layer was dried over sodium sulphate and the solvent was removed under reduced pressure. The title compound was obtained as crude mixture (purity 40%, 2.37g) and used without further purification in the next step.
Step b:
N-[2-(lH-indol-4-yl)-6-(morpholin-4-yl)pyrimidin-4-yl]butane-l,4-diamine
Tert-butyl (4-{[2-(lH-indol-4-yl)-6-(morpholin-4-yl)pyrimidin-4-yl]amino}butyl)carbamate (2.37 g, 2.03 mmol) was dissolved in HCI / dioxane (4M, 20 ml) and stirred at ambient temperature for 10 minutes. Ethyl acetate (50 ml) and water (50 ml) were added and the phases separated. By addition of aqueous NaOH (2N, 50 ml) the pH of the aqueous layer was basified and extracted with ethyl acetate (2 x 50 ml). The combined organic layers were dried over sodium sulphate and the solvent was removed under reduced pressure. The title compound was obtained in 77% yield (770 mg) and used without further purification in the next step.
Step c:
3^6'-bis(dimethylamino)-N-(4-{[2-(lH-indol-4-yl)-6-(morp
3-oxo-3H-spiro[2-benzofuran-l,9'-xanthene]-6-carboxamide and
3^6'-bis(dimethylamino)-N-(4-{[2-(lH-indol-4-yl)-6-(morp
3-oxo-3H-spiro[2-benzofuran-l,9'-xanthene]-5-carboxamide
Isomer 2
N-[2-(lH-indol-4-yl)-6-(morpholin-4-yl)pyrimidin-4-yl]butane-l;4-diamine (70 mg, 0.14 mmol) was dissolved in DMF (3 mL). DIPEA (74 μΙ, 0.43 mmol, 3 eq.) and a mixture of commercially available 5-carboxytetramethylrhodamine N-succinimidyl ester and 6-carboxytetramethylrhodamine N- succinimidyl ester (75 mg, 0.14 mmol, 1 eq.) were added sequentially. The mixture was stirred for 15 minutes at ambient temperature and concentrated under reduced pressure. The two title compounds were separated by preparative HPLC (H20(NH4OH)/CH3CN : 85:15 to 45:55).
Isomer 1 was obtained in 22 % yield (25 mg). 1H-NM (300 MHz, DMSO-d6): <5 [ppm]: 1.56 (4H),
2.92 (12H), 3.49 (4H), 3.69 (4H), 5.53 (1H), 6.48 (6H), 6.74 (1H), 7.06 (1H), 7.33 (2H), 7.43 (1H), 7.63 (1H), 8.03 (2H), 8.15 (1H), 8.71 (1H), 11.11 (1H).
Isomer 2 was obtained in 34 % yield (31 mg). H-NM (400 MHz, DMSO-d5): δ [ppm]: 1.67 (4H),
2.93 (12H), 3.38 (4H), 3.52 (4H), 3.71 (4H), 5.58 (1H), 6.47 (6H), 6.80 (1H), 7.09 (1H), 7.28 (1H),
7.36 (2H), 7.44 (1H), 8.02 (1H), 8.22 (1H), 8.44 (1H), 8.83 (1H).
Isomer 2 was used as ligand for the AT binding assay which is described infra.
Tracer B:
3^6'-bis(dimethylamino)-N-[4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-yl}oxy)butyl]-3-oxo-3H-spiro[2-benzofuran-l,9'-xanthene]-5 arboxamide
Step a: tert-butyl [4-({2-[(3R)-3-methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl]-l,7-naphthyridin-4-yl}oxy)butyl]carbamate
2-[(3R)-3-Methylmorpholin-4-yl]-8-[l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl]-l;7-naphthy- ridin-4-ol (0.41 g, 1.0 mmol, 1 eq.) was solubilized in DMF (12 mL). 4-(Boc-amino)butyl bromide (0.53 g, 2.1 mmol, 2 eq.) and K2C03 (0.72 g, 5.2 mmol, 5 eq.) were added to the mixture. The reaction was stirred at ambient temperature for 16 hours. The suspension was diluted with EtOAc and filtered. The organic phase was concentrated under reduced pressure and the crude material purified by flash chromatography (gradient Hex/EtOAc 9/1 to 100% EtOAc). The desired product was obtained in 87% yield (0.52 g). 1H-NMR (400MHz, DMSO-d5): δ [ppm] : 1.14 - 1.24 (m, 3H), 1.38 (s, 9H), 1.41 - 1.69 (m, 5H), 1.80 - 1.90 (m, 2H), 1.99 (s, 2H), 2.30 - 2.42 (m, 1H), 3.03 (q, 2H), 3.10 - 3.29 (m, 2H), 3.40 - 3.52 (m, 1H), 3.73 (d, 3H), 3.91 - 3.99 (m, 1H), 4.12 (t, 1H), 4.27 (t, 2H), 4.45 - 4.58 (m, 1H), 6.01 - 6.13 (m, 1H), 6.75 (d, 1H), 6.84 - 6.95 (m, 2H), 7.60 (s, 1H), 7.75 (d, 1H), 8.35 (d, 1H). LC-MS (Method A): m/z: [M+H]+ = 567, R, = 1.31 min.
Step b:
4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH^yrazol-5-yl)-1 -naphthyridin-4-yl}oxy)butan-l- amine
4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naph
(0.10 g, 0.18 mmol, 1 eq.) was solubilized in CH2CI2 (1.1 mL) and TFA was added (0.27 mL, 3.5 mmol, 20 eq.). The reaction was stirred at ambient temperature for 30 minutes. The mixture was then quenched with saturated NaHC03 solution and the suspension was filtered. The solid was dried under reduced pressure and the desired compound was obtained without further purification in quantitative yield. 1H-NMR (400MHz, DMSO-d5): δ [ppm] : 1.27 (d, 3H), 1.73 - 1.84 (m, 2H), 1.88 - 1.97 (m, 2H), 2.92 (s, 2H), 3.49 - 3.61 (m, 1H), 3.65 - 3.74 (m, 1H), 3.80 - 3.87 (m, 1H), 4.02 - 4.09 (m, 1H), 4.11 - 4.19 (m, 1H), 4.30 (s, 2H), 4.56 - 4.65 (m, 1H), 6.82 (s, 1H), 7.34 - 7.40 (m, 1H), 7.50 - 7.65 (m, 4H), 7.71 (d, 1H), 8.33 (d, 1H), 13.31 - 13.41 (m, 1H).
Step c: 3^6'-bis(dimethylamino)-N-[4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridin-4-yl}oxy)butyl]-3-oxo-3H-spiro[2-benzofuran-l,9'-xanthene]-5-carboxamide
4-({2-[(3R)-3-Methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyri^
(18 mg, 0.047 mmol, 1 eq.) was solubilized in DMF (ImL). DIPEA (25 μΐ, 0.14 mmol, 3 eq.) and a mixture of commercially available 5-carboxytetramethylrhodamine N-succinimidyl ester and 6- carboxytetramethylrhodamine N-succinimidyl ester (25 mg, 0.047 mmol, 1 eq.) were added sequentially. The reaction was stirred for 15 minutes at ambient temperature and concentrated under reduced pressure. The crude product was purified by preparative HPLC (H20(NH4OH)/CH3CN : 85:15 to 45:55) and the desired compound was obtained in 49% yield (18 mg). 1H-NMR (400MHz, DMSO-d5): δ [ppm] : 1.26 (d, 3H), 1.79 - 1.88 (m, 2H), 1.92 - 2.02 (m, 2H), 2.94 (s, 12H), 3.46 (q, 2H), 3.52 - 3.60 (m, 1H), 3.67 - 3.73 (m, 1H), 3.82 (d, 1H), 4.01 - 4.07 (m, 1H), 4.12 - 4.19 (m, 1H), 4.34 (t, 2H), 4.56 - 4.64 (m, 1H), 6.44 - 6.53 (m, 6H), 6.83 (s, 1H), 7.32 (d, 1H), 7.37 (br. s., 1H), 7.61 (s, 1H), 7.73 (d, 1H), 8.24 (dd, 1H), 8.32 (d, 1H), 8.46 (s, 1H), 8.88 (t, 1H), 13.36 (br. s., 1H).
1. Binding assay ATR
To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described above. Furthermore, a fluorescently labelled compound (either tracer A or B as described above) was used as a tracer molecule.
Detection of the binding event of the tracer was achieved by time-resolved fluorescence energ
transfer (TR-FRET). We used an anti-GST-Terbium antibody (CisBio) that binds to the GST-tag at the N-terminus of ATR-kinase. Excitation of Terbium with 337 nm light results in emission of fluorescent light with 545 nm. In case a tetrameric complex has formed (antiGST-Tb + GST-ATR + Strp2-ATRIP + tracer), part of the energy will be transferred from the Terbium to the fluorophore that itself emits light of 570 nm. Displacement of the fluorescent tracer by a test compound leads to a reduction of the TR-FRET-signal.
For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (MTP, Greiner Bio-One, Frickenhausen, Germany). To prepare the ATR-working solution, ATR/ATRIP stock solution was diluted in assay buffer [50mM HEPES (pH 7.0), lOmM MgCI2, ImM DTT, 0.01% (w/v) Igepal, 0.01% (w/v) BSA] to 4.2nM protein concentration (concentration may vary from lot to lot of protein preparation). AntiGST-Tb antibody was diluted to 4.2 nM. The ATR-working solution was incubated for 30 min at 22°C prior to dispensing to pre-form the complex of antiGST-Tb + GST-ATR + ATRIP. Then, 3 μΙ of the ATR-working solution were added to the test compound and the mixture was incubated for 10 min at 22°C to allow pre-binding of the test compounds to ATR/ATRIP. Then, 2 μΙ of a 100 nM solution of either tracer A or B in assay buffer were added to the ATR-working solution. The resulting mixture was incubated for 30 min at 22°C. The measurement of the TR-FRET signal was performed in a standard HTRF-compatible MTP reader instrument (e.g. BMG Pherastar) by recording the fluorescence emissions at 545 nm and 570 nm after excitation at 337-350 nm. The ratio between emission at 570 nm divided by emission at 545 nm was calculated to give the well ratio. The experimental data (well ratios) were normalised by the following way: positive control contained ATR-working solution plus either tracer A or B solution (= 0 % inhibition), the negative control contained all components except GST-ATR/ATRIP (= 100 % inhibition). Usually the compounds were tested on the same MTP in 11 different concentrations in the range of 20 μΜ to 0.1 nM (20 μΜ, 5.9 μΜ, 1.7 μΜ, 0.51 μΜ, 0.15 μΜ, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM). The dilution series were prepared separately before the assay on the level of the 100 fold concentrated solutions in DMSO by serial 1:3.4 dilutions in duplicate values for each concentration. IC5o values were calculated by a 4 parameter fit using standard software (GraphPad prism or equivalent).
Table 7: ATR binding
Example No ATR binding (tracer A) ATR binding (tracer B)
ICso [M] ICso [M]
1 3,68 E-8 2,39 E-8
2 9,52 E-8 3,83 E-8
3 5,69 E-8 3,87 E-8
4 6,17 E-8 4,35 E-8
5 6,43 E-8 3,41 E-8
6 6,86 E-8
7 5,87 E-8 2,65 E-8
8 1,18 E-7 6,92 E-8
9 1,20 E-7 1,27 E-7
10 1,26 E-7 4,39 E-8
11 1,35 E-7 8,68 E-8
12 1,35 E-7 4,72 E-8
13 1,41 E-7 1,04 E-7
14 1,62 E-7 7,99 E-8
15 1,63 E-7 1,74 E-7
16 1,73 E-7
17 1,85 E-7 1,17 E-7
18 2,28 E-7 7,51 E-8
19 2,93 E-7 1,81 E-7
20 8,16 E-7 3,20 E-7
21 1,90 E-7
22 4,65 E-7
23 4,43 E-7
24 3,82 E-8 2,07 E-8
25 1,10 E-7 7,51 E-8
26 1,56 E-8 6,36 E-9
27 1,72 E-8 1,09 E-8
28 1,76 E-8 8,40 E-9
29 2,15 E-8 9,23 E-9
30 2,28 E-8 9,48 E-9
31 8,66 E-8 4,51 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
32 8,47 E-8 3,67 E-8
33 1,98 E-8 1,03 E-8
34 3,57 E-7 5,36 E-7
35 1,22 E-7 7,55 E-8
36 1,50 E-6
37 1,70 E-7 1,27 E-7
38 5,02 E-7 4,05 E-7
39 6,01 E-8 3,53 E-8
40 1,25 E-7 9,90 E-8
41 3,39 E-7 2,30 E-7
42 4,84 E-7 5,33 E-7
43 4,93 E-7 2,58 E-7
44 5,43 E-7 3,27 E-7
45 2,93 E-7
46 2,62 E-7
47 1,39 E-6
48 1,61 E-7
49 2,00 E-7
50 4,10 E-7 5,14 E-7
51 3,80 E-8 2,33 E-8
52 1,01 E-7 7,89 E-8
53 1,92 E-7 6,35 E-8
54 2,88 E-7 1,29 E-7
55 1,62 E-7
56 7,51 E-7 3,24 E-7
57 2,30 E-7
58 4,13 E-7 6,15 E-7
59 7,30 E-7 1,25 E-6
60 2,41 E-8 1,57 E-8
61 7,09 E-7 5,03 E-7
62 9,97 E-7 7,07 E-7
63 8,07 E-8 3,07 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
64 2,74 E-8
65 3,35 E-7 2,76 E-7
66 8,72 E-8
67 1,00 E-6 1,27 E-6
68 5,89 E-7 4,72 E-7
69 5,34 E-9
70 5,17 E-9
71 5,65 E-9
72 6,33 E-9
73 6,71 E-9
74 7,10 E-9
75 6,97 E-9
76 8,91 E-9
77 8,92 E-9
78 1,10 E-8
79 1,20 E-8
80 1,21 E-8
81 1,43 E-8
82 4,90 E-9
83 5,38 E-9
84 6,60 E-9
85 1,19 E-8
86 1,09 E-8
87 8,71 E-9
88 1,53 E-8
89 8,11 E-9
90 1,06 E-8
91 1,00 E-8
92 1,37 E-8
93 1,09 E-8
94 1,37 E-8
95 1,13 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
96 1,27 E-8
97 1,39 E-8
98 1,31 E-8
99 6,38 E-9
100 1,65 E-8
101 1,13 E-8
102 1,23 E-8
103 1,01 E-8
104 1,41 E-8
105 8,67 E-9
106 1,31 E-8
107 1,37 E-8
108 1,15 E-8
109 9,14 E-9
110 1,35 E-8
111 7,24 E-9
112 4.74 E-9
113 5.71 E-9
114 7.35 E-9
115 7.44 E-9
116 9.51 E-9
117 8.16 E-9
118 1.01 E-8
119 1.17 E-8
120 1.31 E-8
121 1.74 E-8
122 1.94 E-8
123 2.13 E-8
124 1.36 E-8
125 1.72 E-8
126 2.15 E-8
127 2.55 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
128 3.26 E-8
129 3.53 E-8
130 2.16 E-8
131 2.31 E-8
132 2.37 E-8
133 2.70 E-8
134 3.43 E-8
135 3.29 E-8
136 3.58 E-8
137 2.60 E-8
138 2.90 E-8
139 4.17 E-8
140 7.65 E-8
141 3.86 E-7
142 4.41 E-8
143 2.77 E-8
144 7.51 E-8
145 1.82 E-8
146 3.57 E-8
147 4.54 E-8
148 4.79 E-8
149 4.84 E-8
150 5.03 E-8
151 5.12 E-8 2.32 E-8
152 5.18 E-8
153 5.47 E-8
154 5.50 E-8
155 6.33 E-8
156 8.01 E-8
157 9.18 E-8
158 1.35 E-8
159 1.65 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
160 3.72 E-8
161 6.26 E-8
162 1.00 E-7
163 1.07 E-7
164 1.61 E-7
165 2.24 E-7
166 3.65 E-7
167 4.08 E-7
168 5.30 E-7
169 1.15 E-7
170 1.68 E-7
171 9.47 E-8
172 8.28 E-8
173 2.05 E-7
174 2.13 E-7
175 2.21 E-7
176 2.23 E-7
177 2.50 E-7
178 3.77 E-7
179 4.54 E-7
180 4.87 E-7
181 5.39 E-7
182 6.32 E-7
183 6.49 E-7
184 7.63 E-7
185 8.52 E-7
186 6.74 E-8
187 9.68 E-8
188 2.51 E-7
189 2.14 E-8
190 9.50 E-9
191 4.41 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
192 1.15 E-7
193 2.45 E-7
194 3.76 E-8
195 7.14 E-8
196 7.26 E-8
197 7.24 E-8
198 2.93 E-7
199 1.38 E-7
200 8.69 E-8
201 4.00 E-8
202 7.83 E-8
203 1.13 E-8
204 6.76 E-9
205 4.93 E-8
206 4.04 E-7
207 5.42 E-7
208 1.16 E-6
209 3.85 E-7
210 2.31 E-7
211 5.47 E-7
212 >2.00 E-5
213 5.35 E-8
214 1.76 E-7
215 3.17 E-7
216 8.44 E-8
217 8.02 E-7
218 1.18 E-8
219 1.32 E-7
220 3.24 E-8
221 1.96 E-7
222 5.02 E-8
223 1.24 E-7
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
224 5.21 E-8
225 4.47 E-7
226 1.14 E-6
227 7.55 E-8
228 3.01 E-8
229 2.84 E-8
230 3.17 E-8
232 3.91 E-8
233 4.20 E-8
234 2.92 E-8
235 2.13 E-8
236 2.82 E-8
237 1.82 E-8
238 3.45 E-8
239 2.03 E-8
240 3.00 E-8
241 4.06 E-9
242 9.59 E-8
243 3.65 E-8
244 1.59 E-7
245 3.20 E-8
246 6.80 E-8
247 2.16 E-8
248 2.41 E-8
249 1.37 E-8
250 6.62 E-9
251 2.75 E-8
252 6.45 E-9
253 3.37 E-8
254 4.48 E-8
255 4.27 E-8
256 5.62 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
257 5.88 E-8
258 7.66 E-9
259 1.71 E-8
260 2.81 E-8
261 2.92 E-8
262 4.22 E-8
263 1.93 E-8
264 2.55 E-8
265 7.46 E-8
266 8.31 E-9
267 1.01 E-6
268 1.93 E-8
269 1.27 E-8
270 3.37 E-8
271 4.16 E-8
272 2.13 E-8
273 1.40 E-8
274 6.27 E-8
275 3.04 E-7
276 2.37 E-7
277 7.82 E-8
278 2.69 E-8
279 2.93 E-7
280 4.68 E-8
281 1.36 E-8
282 1.27 E-8
283 3.37 E-8
284 4.16 E-8
285 5.09 E-7
286 1.45 E-8
287 6.75 E-7 4.61 E-7
288 3.45 E-7
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
289 2.99 E-6
290 1.19 E-6
291 8.37 E-8
292 1.08 E-7
293 3.28 E-7
294 3.72 E-8
295 1.13 E-7
296 7.68 E-8
297 1.19 E-7
298 5.92 E-8
299 5.52 E-8
300 1.81 E-7
301 2.16 E-8
302 1.88 E-7
303 8.61 E-8
304 5.72 E-8
305 1.33 E-7
306 8.23 E-8
307 1.89 E-7
308 1.31 E-7
309 1.46 E-7
310 9.77 E-8
311 3.76 E-7
312 2.37 E-8
313 2.90 E-8
314 6.79 E-8
316 5.32 E-8
317 6.65 E-8
318 3.06 E-8
319 3.25 E-7
320 4.68 E-8
321 4.44 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
322 8.09 E-8
324 7.77 E-8
325 3.44 E-8
326 7.32 E-8
327 1.77 E-8
328 2.96 E-7
329 1.69 E-7
330 9.13 E-8
331 3.76 E-7
332 6.81 E-8
333 2.53 E-8
334 5.81 E-8
335 6.62 E-8
336 1.20 E-7
337 2.84 E-8
338 1.03 E-7
339 8.96 E-8
340 3.35 E-8
341 2.64 E-8
342 2.77 E-6
343 1.98 E-8
344 1.74 E-7
345 5.56 E-8
346 1.40 E-7
347 2.41 E-7
348 5.53 E-8
349 1.19 E-7
350 1.62 E-7
351 1.54 E-7
352 1.75 E-7
353 2.42 E-7
354 8.47 E-8
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
355 4.84 E-7
356 7.95 E-8
357 5.35 E-8
358 4.64 E-8
359 8.55 E-8
360 9.38 E-8
361 5.22 E-8
362 2.95 E-7
363 1.91 E-7
364 5.64 E-8
365 1.03 E-7
366 5.21 E-8
367 2.15 E-7
368 3.95 E-6
369 1.15 E-7
370 3.50 E-8
371 1.22 E-7
372 1.34 E-7
373 3.81 E-8
374 1.36 E-7
375 8.94 E-7
376 3.57 E-7
377 2.99 E-6
378 9.27 E-8
379 6.98 E-8
380 1.46 E-6
381 1.21 E-7
382 1.99 E-7
383 2.39 E-7
384 8.92 E-8
385 8.51 E-8
386 1.73 E-7
Example No ATR binding (tracer A) ATR binding (tracer B) ICso [M] ICso [M]
387 2.18 E-7
388 7.91 E-8
389 2.66 E-8
390 6.63 E-7
391 1.76 E-7
392 4.43 E-8
393 4.15 E-8
394 1.19 E-7
395 1.49 E-7
396 1.74 E-7
397 9.55 E-8
398 1.20 E-7
399 6.18 E-7
400 3.00 E-7
401 8.75 E-8
402 2.99 E-7
403 1.94 E-7
404 4.24 E-7
405 4.19 E-7
406 3.64 E-7
407 3.09 E-7
408 6.51 E-8
409 1.39 E-7
410 1.53 E-7
412 1.62 E-7
413 2.79 E-7
414 9.08 E-8
415 3.27 E-8
416 2.51 E-7
417 1.07 E-6
418 9.41 E-8
419 1.18 E-7
Example No ATR binding (tracer A) ATR binding (tracer B)
ICso [M] ICso [M]
420 6.02 E-7
421 1.79 E-6
422 2.24 E-6
423 8.39 E-8
424 2.41 E-7
425 1.00 E-6
426 1.59 E-7
427 1.12 E-7
428 6.98 E-8
429 4.48 E-8
430 6.13 E-8
431 3.47 E-8
432 2.04 E-6
433 4.16 E-8
434 3.18 E-8
435 6.51 E-8
436 2.40 E-8
437 1.18 E-7
2. ATR activity assay
ATR kinase phosphorylates a biotinylated peptide derived from Radl7 (sequence: biotin-PEG2- ASELPASQPQPFS-amide, produced by Biosyntan GmbH, Berlin). The assay measures the amount of phosphorylated peptide by time-resolved fluorescence (TR-FRET). Streptavidin-XL665 (Cisbio, reference #610SAXLB), an anti-Radl7-phospho-serine 645 specific antibody (available from either Imgenex/Biomol , reference #IMG-6386A, or from Lifespan, reference #LS-C43028) and antiRabbit-lgG-Europium (Perkin Elmer, reference #AD0083) are employed to specifically detect phosphorylated biotin-peptide, but not non-phosphorylated peptide. Excitation of Europium with 337 nm light results in emission of fluorescent light with 620 nm. In case a tetrameric detection complex has formed, part of the energy will be transferred to the Streptavidin-XL665 fluorophor that itself emits light of 665 nm. Unphosphorylated peptide does not give rise to light emission at 665nm, because no FRET-competent detection complex can be formed.
For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (MTP, Greiner Bio-One, Frickenhausen, Germany). To prepare the ATR-working solution, ATR/ATRIP stock solution (expression and purification: see above) was diluted in assay buffer [50mM HEPES (pH 7.0), lOmM MgCI2, ImM dithiothreitol (DTT), 0.01% (w(v) Igepal, 0.2% (w/v) bovine gamma globulin (BGG)] to ΙΟηΜ protein concentration (concentration may vary from lot to lot of protein preparation). A substrate working solution was prepared by diluting the biotinylated Radl7 peptide to 0.5μΜ together with ATP to 20μΜ in assay buffer. A stop/detection working solution was prepared containing 50mM Hepes pH 7.0, 0.15 % (w/v) bovine serum albumin (BSA), 150mM EDTA, 200nM Streptavidin- XL665, 2.5nM anti phospho Radl7-pS645 (IMG-6386A) and 1.5 nM anti-Rabbit-lgG-Eu. The amount of the antibodies is dependent on the batch used and was optimized by variation the activity of the batch. All solutions were kept at 20°C. First, 2.5 μΙ of ATR-working solution were dispensed into the wells of the MTP containing the test compounds. After 10 minutes preincubation to allow binding of the compounds to ATR, 2.5 μΙ of substrate working solution was dispensed to the wells. After 180 minutes, 5 μΙ of stop/detection solution were dispensed into the wells. The resulting mixture was incubated for 60 min at 20°C. The measurement of the TR-FRET signal was performed in a standard HTRF-compatible MTP reader instruments (e.g. BMG
Pherastar or Perkin Elmer ViewLux) by recording the fluorescence emissions at 620 nm and 665 nm after excitation at 337-350 nm. The ratio between emission at 665 nm divided by emission at 620 nm was calculated to give the well ratio. The experimental data (well ratios) were normalised by the following way: positive control was composed of ATR-working solution + substrate solution (= 0 % inhibition), the negative control contains the same reagents, but ATR-working solution is replaced by assay buffer (= 100 % inhibition). Usually the compounds were tested on the same MTP in 11 different concentrations in the range of 20 μΜ to 0.1 nM (20 μΜ, 5.9 μΜ, 1.7 μΜ, 0.51 μΜ, 0.15 μΜ, 44 ηΜ, 13 ηΜ, 3.8 ηΜ, 1.1 ηΜ, 0.33 nM and 0.1 nM) The dilution series were prepared separately before the assay on the level of the 100 fold concentrated solutions in DMSO by serial 1:3.4 dilutions in duplicate values for each concentration. IC5o values were calculated by a 4 parameter fit using with standard software (GraphPad prism or equivalent).
3. Proliferation assay Human tumour cells (Table 8) were originally obtained from the American Type Culture Collection (ATCC), the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, German Collection of Microorganisms and Cell Cultures), or Epo GmbH Berlin.
Adherently growing cells (HeLa, HeLa-MaTu-AD , HT-144, Lovo, HT-29, NCI-H460, DU145, Caco2, B16F10) were plated out in a density of 1500-4000 cells/measurement point, depending on the rate of growth of the cell line, in a 96-well multititre plate in 200 μΙ of growth medium
(DMEM/HAMS F12, 2 mM L-glutamine, 10% foetal calf serum). After 24 hours, the cells of one plate (zero plate) were dyed with crystal violet (see below), whereas the medium of the other plates was replaced with fresh culture medium (200 μΙ) to which the test substances were added in various concentrations (0 μΜ, and also in the range of 0.001-10 μΜ; the final concentration of the solvent dimethyl sulphoxide was 0.1 or 0.5%). The cells were incubated for 4 days in the presence of the test substances. Cell proliferation was determined by staining the cells with crystal violet: the cells were fixed at room temperature for 15 min by adding 20 μΙ/measurement point of an 11% strength glutaraldehyde solution. After washing the fixed cells three times with water, the plates were dried at room temperature. The cells were stained by adding 100 μΙ/measurement point of a 0.1% strength crystal violet solution (pH adjusted to pH 3 by adding acetic acid). After washing the cells three times with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μΙ/measurement point of a 10% strength acetic acid solution. Absorbance was determined photometrically at a wavelength of 595 nm. The percentage change in cell growth was calculated by normalizing the measured values to the absorbance values of the zero plate (=0%) and the absorbance of the untreated (0 μΜ) cells (=100%). The IC50 values were determined by means of a four parameter fit. Cells growing in suspension (GRANTA-519, Jeko-1) were plated out in a cell density of 2000-4000 cells/measurement point, depending on the rate of growth of the cell line, in a black-walled, clear-bottom 96-well multititre plate in 100 μΙ of growth medium (DMEM/HAMS F12, 2 mM L- glutamine, 10% foetal calf serum). After 24 hours, cell density was determined in one plate (zero plate) by adding 60 μΙ/measurement point of CTG solution (Promega Cell Titer-Glo solution (catalogue numbers G755B and G756B)), subsequent incubation for 2 min followed by 10 min shaking (in the dark) and measurement of luminescence (VICTOR V, Perkin Elmer).
For the test plates, the test substances were prepared in various concentrations (0 μΜ, and also in the range of 0.001-10 μΜ; the final concentration of the solvent dimethyl sulphoxide was 0.1 or 0.5%) as 3x concentrated solutions in fresh growth medium. Aliquots of 50 μΙ each were added to the cell suspensions and the cells were incubated for 4 days in the presence of the test substances. Subsequently, cell density was determined using CTG solution as described above and IC50 values were calculated by means of a four parameter fit.
The substances were investigated in the following cell l ines, which, by way of example, represent the specified indications (Table 8).
Table 8: List of the cell lines investigated in the proliferation assays.
The results of the proliferation assays demonstrate the efficacy of test compounds in the human tumour cells investigated. These data suggest a possible use of the test compounds in the tumour types investigated.
Table 9: Inhibition of proliferation of HeLa, HeLa-MaTu-ADR, NCI-H460, DU 145, Caco-2 and
B16F10 cells by compounds according to the present invention, determined as described above. All IC5o (inhibitory concentration at 50% of maximal effect) values are indicated in M, "n.t." means that the compounds have not been tested in the respective assay.
Φ: Example Number
©: Inhibition of HeLa cell proliferation
©: Inhibition of HeLa-MaTu-ADR cell proliferation
©: Inhibition of NCI-H460 cell proliferation
©: Inhibition of DU 145 cell proliferation
©: Inhibition of Caco-2 cell proliferation
®: Inhibition of B16F10 cell proliferation
Table 9: Inhibition of proliferation
© © © © © © ©
3 2,77 E-6
5 > 3,00 E-6 6,41 E-7 3,68 E-7 2,19 E-6 2,98 E-6
6 1,49 E-6
7 1,33 E-6 2,31 E-6 1,02 E-6 1,59 E-6 5,95 E-6 2,98 E-6
> 1,00 E-5
8,97 E-6
8 2,26 E-6 > 3,00 E-6 9,09 E-7 2,05 E-6 > 3,00 E-6 > 3,00 E-6
9 1,01 E-6
10 4,96 E-7 1,30 E-6 4,47 E-7 8,27 E-7 1,46 E-6 2,98 E-6
11 > 1,00 E-5
3,05 E-6
2,28 E-6
14 1,99 E-6
15 1,41 E-6 > 3,00 E-6 5,28 E-7 8,17 E-7 1,72 E-6 > 3,00 E-6
24 3,41 E-6 3,78 E-7 1,35 E-6 8,33 E-7 3,65 E-6
26 2,96 E-7 > 1,00 E-6 5,86 E-7 7,25 E-7 > 1,00 E-6 > 1,00 E-6
27 3,55 E-7
28 3,16 E-7
29 3,94 E-7 4,98 E-7 2,43 E-7 2,91 E-7 5,77 E-7 1,58 E-6
30 5,12 E-7 > 3,00 E-6 2,93 E-7 3,25 E-7 2,89 E-6 1,37 E-6
31 1,25 E-6 > 3,00 E-6 6,85 E-7 1,11 E-6 > 3,00 E-6 > 3,00 E-6
32 1,56 E-6 > 3,00 E-6 > 3,00 E-6 1,84 E-6 > 3,00 E-6 > 3,00 E-6
1,95 E-6
> 3,00 E-6 2,69 E-7 1,01 E-6 6,53 E-7 1,08 E-6
1,02 E-6 > 3,00 E-6 1,63 E-6 2,39 E-6 4,99 E-6 > 3,00 E-6
5,08 E-6
1,05 E-6 4,00 E-7 8,37 E-7
2,72 E-6 2,26 E-6 6,72 E-7 1,15 E-6 1,97 E-6 2,82 E-6
> 3,00 E-6
3,88 E-6
1,01 E-6 > 1,00 E-5 2,01 E-6 4,45 E-6 7,69 E-6 > 1,00 E-5
> 1,00 E-5
> 1,00 E-5
1,23 E-6 1,80 E-6 3,91 E-7 8,95 E-7 2,93 E-6 > 3,00 E-6
1,41 E-6
6,98 E-6 3,74 E-7 1,56 E-6 5,51 E-7 6,32 E-6 > 3,00 E-6 > 3,00 E-6 > 3,00 E-6
9,98 E-7 2,17 E-6 6,91 E-7 7,30 E-7 1,98 E-6 > 3,00 E-6
1,64 E-7 > 3,00 E-6 > 3,00 E-6 > 3,00 E-6 < 3,00 E-8 1,31 E-7
1,13 E-6 > 3,00 E-6 2,29 E-7 > 3,00 E-6 2,18 E-5
> 3,00 E-6
1,53 E-6 3,08 E-7 9,15 E-7 1,54 E-6 2,19 E-6
1,17 E-6 9,23 E-8 5,06 E-7 8,44 E-7 8,76 E-7
8,90 E-6 1,27 E-7 7,26 E-7 3,35 E-6 2,98 E-6 > 3,00 E-6 > 3,00 E-6
1,91 E-7
2,01 E-7
1,67 E-7
2,00 E-7
1,81 E-7 1,79 E-6 5,90 E-8 7,48 E-7 6,31 E-7 6,04 E-7
2,03 E-7 > 1,00 E-6 > 1,00 E-6 > 1,00 E-6 > 1,00 E-6 > 1,00 E-6
2,71 E-7
9,68 E-7
77 2,54 E-7
78 6,55 E-7
79 3,03 E-7 2,30 E-6 9,37 E-8 6,56 E-7 8,68 E-7 1,06 E-6
80 1,87 E-7
81 2,45 E-7
82 5,29 E-7
83 3,31 E-7
84 1,30 E-7
85 4,38 E-7
87 5,43 E-7
88 1,57 E-7 2,91 E-7 8,17 E-8 1,04 E-7 2,86 E-7 4,98 E-7
89 1,42 E-7
90 9,20 E-8
91 1,08 E-7
92 1,17 E-7
93 1,79 E-7
94 2,68 E-7
95 2,11 E-7
96 1,69 E-7
97 2,52 E-7
98 4,40 E-7
99 4,00 E-7
100 9,50 E-7
101 3,41 E-7
102 6,04 E-7
103 3,74 E-7
104 4,99 E-7
105 1,00 E-6
106 4,34 E-7
107 3,06 E-7
108 4,56 E-7
109 2,98 E-7
110 2,06 E-7
111 1,56 E-7 2,26 E-7 6,50 E-8 1,10 E-7 2,37 E-7 7,11 E-7
112 9,95 E-8
113 1,22 E-7
114 1,77 E-7
115 1,99 E-7
116 2,84 E-7
117 2,25 E-7
118 1,71 E-7
119 4,25 E-7
120 3,54 E-7
121 3,52 E-7
122 7,06 E-7
123 4,31 E-7
124 1,56 E-7
125 7,05 E-7 > 3.00 E-6 5.61 E-7 7.12 E-7 > 3.00 E-6 > 3.00 E-6
> 3.00 E-6 5.41 E-7 7.64 E-7 2.63 E-6 > 3.00 E-6
126 1,70 E-7 5,95 E-7 8,84 E-8 9,40 E-8 3,40 E-7 9,06 E-7
127 5,78 E-7
128 7,70 E-7
129 6,86 E-7
130 3,74 E-7
131 3,49 E-7
132 5,07 E-7
133 1,07 E-6
134 1,53 E-6
135 1,82 E-6
136 5,75 E-7
137 3,83 E-7 7,91 E-7 1,53 E-7 1,46 E-7 5,49 E-7 7,79 E-7
138 6,19 E-7
139 1,37 E-6
142 1,59 E-6
143 5,43 E-7
144 > 3,00 E-6
145 2,48 E-7 5,22 E-7 9,06 E-8 3,05 E-8 4,92 E-7 1,09 E-6
146 1,11 E-6
147 9,53 E-7
148 8,05 E-7
151 9,21 E-7 2,15 E-6 6,73 E-7 1,90 E-6 2,05 E-6 2,13 E-6
152 6,71 E-7
153 7,59 E-7
155 9,59 E-7
156
157 8,72 E-7 > 3.00 E-6 > 3.00 E-6 > 3.00 E-6 > 3.00 E-6 > 3.00 E-6
> 3.00 E-6 > 3.00 E-6 > 3.00 E-6 > 3.00 E-6 > 3.00 E-6
158 3,28 E-7
159 6,16 E-8
160 4,51 E-7
161 5,88 E-7
162 1,22 E-6
169 7,31 E-7 > 3.00 E-6 2.62 E-6 2.82 E-6 > 3.00 E-6 > 3.00 E-6
> 3.00 E-6 5.62 E-7 5.91 E-7 > 3.00 E-6 > 3.00 E-6
170 2,41 E-6
172 2,10 E-6
173 > 3,00 E-6
176 2,52 E-6
177 > 3,00 E-6
178 > 3,00 E-6
179 > 3,00 E-6
185 > 3,00 E-6
186 7,89 E-7
189 1,01 E-6
190 3,34 E-7
191 2,12 E-6
194 8,92 E-7
195 3,01 E-6
196 1,02 E-6 > 3,00 E-6 2,91 E-7 1,44 E-7 8,69 E-7 1,47 E-6
197 1,01 E-6 > 3,00 E-6 5,16 E-7 1,29 E-7 > 3,00 E-6 2,96 E-6
198 > 3,00 E-6
199 8,57 E-7 9,65 E-7 3,20 E-7 2,44 E-7 7,08 E-7 > 1,00 E-6
200 1,96 E-6
201 > 3,00 E-6
202 1,53 E-6
203 9,98 E-7
204 5,68 E-7
205 6,72 E-7 1,49 E-6 2,19 E-7 6,52 E-7 1,24 E-6 1,70 E-6
213 > 3.00 E-6
214 > 3.00 E-6
215 > 3.00 E-6
216 1.01 E-6 > 3.00 E-6 1.11 E-6 1.66 E-6 > 3.00 E-6 > 3.00 E-6
> 3.00 E-6 1.02 E-6 1.33 E-6 > 3.00 E-6 > 3.00 E-6
218 3,00 E-7
219 2,98 E-6
220 6,04 E-7 9,93 E-7 3,03 E-7 3,34 E-7 > 1,00 E-6 > 1,00 E-6
221 > 3,00 E-6
222 9,75 E-7
227 1,94 E-6
228 2,25 E-7 5,94 E-7 2,33 E-7 3,13 E-7 6,37 E-7 2,60 E-6
229 4,47 E-7
230 3,80 E-7
232 3,41 E-7
233 1,80 E-7
234 1,21 E-6
235 9,50 E-7
236 7,92 E-7
237 5,28 E-7
238 1,18 E-6
239 1,13 E-6
241 1,71 E-7
242 8,11 E-7
243 3,60 E-7
245 3,43 E-7
246 2,84 E-6
247 2,28 E-7
248 4,51 E-7
249 4,09 E-7
250 1,16 E-7
251 8,00 E-7
252 2,22 E-7
253 5,58 E-7
254 3,12 E-7
255 4,58 E-7
258 2,63 E-7
259 4,97 E-7
260 4,85 E-7
261 4,20 E-7
262 4,71 E-7
263 3,32 E-7
264 1,98 E-7
266 1,54 E-7
267 2,97 E-6
268 4,15 E-7
269 4,05 E-7
270 5,65 E-7
271 1,33 E-6
272 6,48 E-7
273 9,99 E-7
274 6,10 E-7
277 4,01 E-7
278 1,68 E-7
280 4,17 E-7
281 2,59 E-7
282 1,18 E-6
283 1,46 E-7
284 8,52 E-7
286 2,93 E-7 8,82 E-7 7,56 E-8 4,86 E-8 5,29 E-7 5,86 E-7
291 1,52 E-6
292 2,64 E-6
294 2,45 E-6
296 2,74 E-6
298 2,44 E-6
299 > 3,00 E-6
301 2,82 E-6
303 > 3,00 E-6
304 > 3,00 E-6
306 > 3,00 E-6
310 > 3,00 E-6
312 > 3,00 E-6
313 2,54 E-6
314 > 3,00 E-6
316 > 3,00 E-6
317 2,98 E-6
318 2,00 E-6
320 > 3,00 E-6
321 > 3,00 E-6
322 > 3,00 E-6
323 2,22 E-6
324 2,42 E-6
325 9,99 E-7
326 2,92 E-6
327 1,89 E-6
330 > 3,00 E-6
332 > 3,00 E-6
333 > 3,00 E-6
334 > 3,00 E-6
335 2,96 E-6
337 1,71 E-6
339 > 3,00 E-6
340 2,95 E-6
341 1,59 E-6
343 1,71 E-6
345 > 3,00 E-6
348 6,13 E-7 9,40 E-7 3,99 E-7 5,18 E-7 8,22 E-7 2,22 E-6
349 > 3,00 E-6
350 > 3,00 E-6
351 3,00 E-6
4. Phospho-H2AX assay
Phospho-Serl39 Histone H2AX (also known as EH2AX, UniProtKB/Swiss-Prot P16104) represents an cellular early marker for DNA damage response. In particular, H2AX gets phosphorylated by AT upon DNA replication stress. HT-29 human colorectal adenoadenocarcinoma cells, originally obtained from the DSMZ, were plated out in a density of 12000 cells/measurement point a black- walled, clear-bottom 96-well multititre plate in 100 μΙ of growth medium (DMEM/HAMS F12, 2 mM L-glutamine, 10% foetal calf serum). After 24 hours, the test substances were added in various concentrations (0 μΜ, and also in the range of 0.001-10 μΜ in quadruplicates; the final concentration of the solvent dimethyl sulphoxide was 0.1%) followed by addition of a hydroxyurea solution to achieve a finale concentration of 2.5 mM and a final assay volume of 200 μΐ. One control plate was left untreated and further processed in parallel. The cells were incubated for 30 min at 37°C. Subsequently,the growth medium was carefully evaporated and the cells were fixed with 50 μΙ/weW of ice-cold methanol for 15 min. The cells were washed once with 100 μΙ/weW of PBS, followed by incubation with 50 μΙ/weW of blocking buffer (Liqor, 927-40000) for 1 h at room temperature. Subsequently, the cells were incubated with 50 μΙ/weW of anti- phospho-H2AX (Ser 139) antibody (Merck Millipore, clone JBW301, 05-636) diluted 1:500 in blocking buffer for 1 h at room temperature (or over night at 4°C). The cells were washed three time with 100 μΙ/weW of PBS, followed by incubation with 50 μΙ/weW of a 1:500 diluted solution of Alexa Fluor 488 conjugated donkey anti-mouse IgG antibody (Life Technologies, A-21202) in TBST for 1 h at room temperature and protected from light. After the cells were washed three time with 100 μΙ/weW of PBS, the wells were filled with 100 μΐ of PBS and fluorescence was determined using an Acumen laser scanning cytometer (TTP Labtech). The percentage change in hydroxy urea induced phospho-H2AX content was calculated by normalizing the measured values to the fluorescence values of untreated control wells (=0%) and the fl uorescence of the hydroxy urea control wells without test compounds (0 μΜ, =100%). The IC5o values were determined by means of a four parameter fit.
5. Caco-2 Permeation Assay
Caco-2 cells (purchased from DSMZ Braunschweig, Germany) were seeded at a density of 4.5 x 104 cell per well on 24 well insert plates, 0.4 μιη pore size, and grown for 15 days in DMEM medium supplemented with 10% fetal bovine serum, 1% GlutaMAX (lOOx, GIBCO), 100 U/ml penicillin, 100μg/ml streptomycin (GIBCO) and 1% non essential amino acids (100 x). Cells were maintained at 37oC in a humified 5% C02 atmosphere. Medium was changed every 2-3 day.
Before running the permeation assay, the culture medium was replaced by a FCS-free hepes- carbonate transport puffer (pH 7.2) For assessment of monolayer integrity the transepithelial electrical resistance (TEE ) was measured. Test compounds were predissolved in DMSO and added either to the apical or basolateral compartment in final concentration of 2 μΜ. Before and after 2h incubation at 37oC samples were taken from both compartments. Analysis of compound content was done after precipitation with methanol by LC/MS/MS analysis. Permeability (Papp) was calculated in the apical to basolateral (A - B) and basolateral to apical (B - A) directions. The apparent permeability was calculated using following equation :
Papp = (Vr/Po)(l/S)(P2/t) Where Vr is the volume of medium in the receiver chamber, Po is the measured peak area of the test drug in the donor chamber at t=o, S the surface area of the monolayer, P2 is the measured peak area of the test drug in the acceptor chamber after 2h of incubation, and t is the incubation time. The efflux ratio basolateral (B) to apical (A) was calculated by dividing the Papp B-A by the Papp A-B. In addition the compound recovery was calculated. As assay control reference compounds were analyzed in parallel.
Claims (1)
- 1. A compound of general formula (I)(I) in which:R1 represents a group selected from:wherein * indicates the point of attachment of said group with the rest of the molecule; represents hydrogen, halogen, -NR7R8, CN, Ci-C6-alkyl, Ci-C6-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C6-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloal kenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)N R7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10,-SiR10R R12, -(PO)(OR7)2, -(PO)(OR7)R10 or -(PO)(R10)2,wherein each Ci-C6-alkyl, Ci-C6-alkoxy, 3- to 10-membered heterocycloal koxy, C2-C6- alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-C5-alkyl optionally substituted with hydroxyl or phenyl, Ci-C5- haloalkyl, Ci-C6-alkoxy, C3-C5-cycloal kyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, NR8(CO)OR7, -NR8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)NR7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl; wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl;R3, R4 represent, independently from each other, hydrogen or methyl;R7, R8 represent, independently from each other, hydrogen, Ci-C5-alkyl, C3-C5-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen; orR7 and R8together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci-C5-alkyl, Ci-C5-haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13;R10 represents Ci-C4-alkyl; orR9 and R10together, in case of -N=(SO)R9R10 group, represent a 5- to 8-memberedheterocycloalkyl group;R represents hydrogen, Ci-C4-alkyl, -(CO)OR7, -(CO)NR7R8 or CN;R12 represents hydrogen or Ci-C -alkyl;R13 represents halogen, OH, -NR7R8, CN, N02, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy, Ci-C6- haloalkoxy, C2-C6-alkenyl, C3-C6-cycloalkyl, -(CO)OR7 or -(CO)NR7R8; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.2. The compound according to claim 1, in which R1 represents a group selected from:wherein * indicates the point of attachment of said group with the rest of the molecule;R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloal kenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)N R7R8,-(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10,-SiR10R R12, -(PO)(OR7)2, -(PO)(OR7)R10 or -(PO)(R10)2,wherein each Ci-C6-alkyl, Ci-C6-alkoxy, 3- to 10-membered heterocycloal koxy, C2-C6- alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-Ce-alkyl, 3- to 6-membered heterocycloalkyl, 4- to 6- membered heterocycloalkenyl phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10,-N R8(CO)OR7, -N R8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)NR7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -(PO)(OR7)2,-(PO)(OR7)R10, _(Po)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl; wherein each 4- to 10-membered heterocycloal kenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl;R3, R4 represent, independently from each other, hydrogen or methyl;R7, R8 represent, independently from each other, hydrogen or Ci-C6-alkyl; or R7 and R8 together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci-Ce-alkyl, Ci-C5-haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S; R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13;R10 represents Ci-C4-alkyl; orR9 and R10 together, in case of -N=(SO)R9R10 group, represent a 5- to 8-memberedheterocycloalkyl group; R represents hydrogen, Ci-C4-alkyl, -(CO)OR7, -(CO)NR7R8 or CN; 12 represents hydrogen or Ci-C4-alkyl;R13 represents halogen, OH, -NR7R8, CN, N02, Ci-Ce-alkyl, Ci-C6-haloalkyl, Ci-Ce-alkoxy, Ci-C6- haloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, -(CO)OR7 or -(CO)N R7R8.3. The compound according to claim 1, which is selected from the group of:4- [(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]--naphthyridine-4-yl]phenyl-N-ethoxycarbonyl-5- methylsulphoximide4-[(2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S- methylsulphoximide4-[6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(3,6-dihydro-2H-pyran-4-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-3-yl)-[l;7]naphthyridine4-[4-(N,S-dimethylsulfonimidoyl)phenyl]-2-[morpholin-4-yl]-8-( lH-pyrazol-5-yl)-l,7- naphthyridine4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(4-methanesu Iphonyl phenyl )-2-(morpholin-4-yl)-8-( lH-pyrazol-3-yl)-[l,7]-naphthyridine4-(2-methanesu Iphonyl phenyl )-2-(morpholin-4-yl)-8-( lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloridedimethyl {4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}phosphonate 4-isopropenyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl )-[l,7]naphthyridine2- (morpholin-4-yl)-4-phenyl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine4-[4-(S-ethylsulfonimidoyl)phenyl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine3- [(2-(morpholin-4-yl)-8-[2H-pyrazol-3-yl]-[l,7]naphthyridine-4-yl]phenyl-N-ethoxycarbonyl-S- methylsulphoximide4- (l-methyl-l;2;3;6-tetrahydropyridin-4-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7- naphthyridine4-(3-methanesu Iphonyl phenyl )-2-(morpholin-4-yl)-8-( lH-pyrazol-3-yl)-[l,7]naphthyridine4-[5-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine 2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(l,2^4-cyclopropyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l;7]naphthyridine3- [(2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine-4-yl]phenyl-S- methylsulphoximide4-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine hydrochloride4- [2-(methylsulfonyl)-l;3-thiazol-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin4- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridin-2(lH)-one5- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridin-2(lH)-one4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-(morpholin-4-yl)-4-{4-[S-(propan-2-yl)sulfonimidoyl]phenyl}-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(4-methanesulphonyl phenyl )-2-((R)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)- [l,7]naphthyridine2-(( )-3-methylmorpholin-4-yl)-4-phenyl-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine4-(3-methanesulphonyl phenyl )-2-((R)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine4-cyclopropyl-2-((R)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l;7]-naphthyridine4-[2-((R)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l;7]naphthyridine-4-yl]phenyl-S- methylsulphoximide3-[2-((R)-3-methylmorpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l;7]naphthyridine-4-yl]phenyl-S- methylsulphoximide4-methanesulphonyl-2-(morpholin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]- [l,7]naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(methylsulfonyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4-carbonitrile2-((R)-3-methylmorpholin-4-yl)-8-(-2H-pyrazol-3-yl]-[l;7]naphthyridine-4-carbonitrile2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine-4-carboxamide4-methanesulphonylmethyl-2-morpholin-4-yl-8-(2H-pyrazol-3-yl)-[l;7]naphthyridine [2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[ 1,7] naphthyridine-4-yl] methanol4-(l-methanesulphonylcyclopropyl)-2-(morpholin-4-yl)-8-(2H-pyrazol-3-yl)-[l,7]naphthyridine4-isopropoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine2-(morpholin-4-yl)-4-(propan-2-yloxy)-8-(lH-pyrrol-2-yl)-l,7-naphthyridine4-[3-(S-methylsulfonimidoyl)propoxy]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-ethoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine4-methoxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine2-methyl-l-{[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]oxy}propan-2-ol2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(tetrahydrofuran-2-ylmethoxy)-l,7-naphthyridine 3-{[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]oxy}dihydrofuran-2(3H)-one4-[(3-methyl-l,2-oxazol-5-yl)methoxy]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[(5-methyl-l,2-oxazol-3-yl)methoxy]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-benzyloxy-2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine4-isopropoxy-2-((R)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine tert-butyl [4-({2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)butyl] carbamate4-methoxy-2-((R)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l,7]naphthyridine tert-butyl [3-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)propyl]carbamate2-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}oxy)ethanamine tert-butyl [2-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}oxy)ethyl] carbamate4-({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}oxy)butan-l- amine2-[(3R;5S)-3;5-dimethylmorpholin-4-yl]-4-isopropoxy-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 2-[(3R;5R)-3;5-dimethylmorpholin-4-yl]-4-isopropoxy-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-l,7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l, 7] naphthyridine hydrochloride4 hloro-2-morpholin-4-yl-8-(lH-pyrazol-3-yl)-[l,7] naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(methylsulfanyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine N-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}-l;4 4-oxathian- 4-imine 4-oxide4-{[dimethyl(oxido)- 6-sulfanylidene]amino}-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(piperazin-l-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-isopropoxy-2-((S)-3-methylmorpholin-4-yl)-8-(lH-pyrazol-3-yl)-[l;7]naphthyridine2-(morpholin-4-yl)-4-(propan-2-yloxy)-8-(lH-pyrrol-3-yl)-l,7-naphthyridine4-(l-ethyl-lH-pyrazol-5-yl)-2-[(3 )-3-methylmorphol in-4-yl]-8-( lH-pyrazol-5-yl)-l,7- naphthyridine4-(l-methyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]aniline4-(2^-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-[2-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine4-[2-fluoro-4-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-fluoro-2-[2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]aniline4-(l-benzyl-lH-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(2-fluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-l,3-thiazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[4-methyl-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine4-(l-cyclopropyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-[2-fluoro-4-(piperazin-l-yl)phenyl]-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfonyl)piperazin-l-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridineN-(2;2-dimethylpropyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridin-4-amine(l-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}piperidin-4- yl)methanolN-cyclopropyl-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin- 4-amine4-(5;6-dihydroimidazo[l;2-a]pyrazin-7(8H)-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol- 5-yl)-l,7-naphthyridineN-(4-fluorophenyl)-N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridin-4-amine2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylpyridin-3-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(2-fluoropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(2-fluoro-4-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-lH-pyrrol-2-yl)-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(6-fluoro-5-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(2-fluoro-6-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(6-fluoropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(6-methoxypyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(6-methoxy-5-methylpyridin-3-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(6-fluoro-2-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl]-8-(lH- pyrazol-5-yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-2-thienyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-2-thienyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methyl-3-thienyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(3-chloro-2-thienyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-3-thienyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(lH-pyrrolo[2;3-b]pyridin-4-yl)-l;7- naphthyridine4-(3;5-dimethyl-l;2-oxazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(3-chloro-2-methoxypyridin-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-l;7- naphthyridine4-(3;6-dihydro-2H-thiopyran-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methylpiperidin-l-yl)-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(l-tert-butyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-l;2-oxazol-5-yl)-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(l-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(l,4-dimethyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[2-methyl-6-(methylsulfanyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine4-[2-methyl-6-(S-methylsulfonimidoyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH- pyrazol-5-yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-propyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4- (6;7-dihydro-5H-pyrrolo[l;2-a]imidazol-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine4-[l-ethyl-3-(trifluoromethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol- 5-yl)-l,7-naphthyridinemethyl 5-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}-lH- pyrrole-2-carboxylate2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(l;2-thiazol-5-yl)-l;7-naphthyridineN;N-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4- yljaniline4-(2;4-difluorophenyl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(l-isopropyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridineethyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate4-{[diethyl(oxido)- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridineisobutyl methyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate 2- {2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}propan-2-ol3- {2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}pentan-3-ol4- (5-chloropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine5- fluoro-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}anN 4-[2-fluoro-3-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(oxetan-3-yl)-lH-pyrazol-5-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-[2-fluoro-4-(pyrrolidin-l-yl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-[3-(methoxymethyl)-5-methyl-l;2-oxazol-4-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH- pyrazol-5-yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methyl-l,3,4-oxadiazol-2-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridineN-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}tetrahydro-lH- l 4-thiophen-l-imine 1-oxide4-{[(4-fluorophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, mixture of 2 diastereoisomers4-{[(2-fluorophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine, mixture of 2 diastereoisomers4-{[(R)(2-fluorophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4- yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine, diastereoisomer4-{[(S)(2-fluorophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]- 8-(lH-pyrazol-5-yl)-l,7-naphthyridine, diastereoisomer4-(dimethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(diethylphosphoryl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine ethyl isobutyl{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yljphosphinate2-[(3R)-3-methylmorpholin-4-yl]-4-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(l-isobutyl-lH-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-[5-fluoro-6-(methylsulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine4-[(3R)-3-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridin2- [(3 )-3-methylmorpholin-4-yl]-4-(4-methyl-lH-pyrazol-5-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[2-fluoro-5-(methylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-[4-(isopropylsulfonyl)phenyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(6-fluoropyridin-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(l-ethyl-lH-imidazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridinel-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}prolinamide3- {2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}pyridin-2-amine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-[l-(2;2;2-trifluoroethyl)-lH-pyrazol-5- yl]-l,7-naphthyridine1- methyl-4-{2-[(3R)-3-methylmorpholin-4-yl]-8-( lH-pyrazol-5-yl)-l;7-naphthyridin-4- yl}piperazin-2-one4- [l-(2-fluoroethyl)-lH-pyrazol-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[l-(2-fluoroethyl)-lH-pyrazol-5-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}-lH-pyrazol-l- yl)ethanol2- methyl-l-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}-lH- pyrazol-l-yl)propan-2-ol4-[(2R)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridine 4-(5-fluoropyridin-2-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 2-[(3R)-3-methylmorpholin-4-yl]-4-(6-methylpyridin-2-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2- [(3R)-3-methylmorpholin-4-yl]-4-(3-methylpyridin-2-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridmN-(2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}phenyl)acetamide3- {2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}pyridin-2-ol2-(3-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}phenyl)propan-2-ol4- (5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[(2S)-2-methylmorpholin-4-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-[(trans)-2-methylcyclopropyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(difluoromethoxy)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]propan-2-ol2-(morpholin-4-yl)-4-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(pyrrolidin-l-yl)-l;7-naphthyridine 4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]piperazin-2-one4-(dimethylphosphoryl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-[(trans)-2;5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-[(cis)-3;5-dimethylpiperazin-l-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine1- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]-3-(trifluoromethyl)azetidin-3- olmethyl hydrogen {4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl]phenyl}phosphonate4-(4-methylpiperazin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[(3aR;6aS)-tetrahydro-lH-furo[3;4-c]pyrrol-5(3H)-yl]- 1,7-naphthyridine 4-(3-methoxy-3-methylazetidin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin2-(morpholin-4-yl)-4-[(lS,4S)-2-oxa-5-azabicyclo[2.2.1] hept-5-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3 )-3-methylmorpholin-4-yl]-4-[(methylsulfanyl)methyl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridineN,N-dimethyl-5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridin-2-amin 4-(2-methylpyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine1- {2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}cyclohexanol2- fluoro-6-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}anil^(methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-^^sulfanylidene)cyanamide1- ethyl-3-(methyl{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl] phenyl }oxido- 6-sulfanylidene)urea3- ({2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}oxy)propan-l- amine4- (4-cyclopropyl-lH-l,2,3-triazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-ethylsulfinyl-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2- (morpholin-4-yl)-4-[propan-2-ylsulfinyl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[3-(methylsulfonyl)propoxy]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-(morpholin-4-yl)-4-(phenylsulfonyl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2-(morpholin-4-yl)-4-(propan-2-ylsulfonyl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(ethylsulfonyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2-(morpholin-4-yl)-4-(phenylsulfinyl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(methylsulfinyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-oxidotetrahydro-2H-thiopyran-4-yl]-8-(lH-pyrazol-5-yl)- 1,7-naphthyridine 4-(l^-dioxidotetrahydro-2H-thiopyran-4-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5- yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4,8-di(lH-pyrazol-5-yl)-l,7-naphthyridineN;N-dimethyl-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-amine2-(morpholin-4-yl)-4-(phenylsulfanyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-(morpholin-4-yl)-N-(propan-2-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-amine4-(ethylsulfanyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-(morpholin-4-yl)-4-(propan-2-ylsulfanyl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(lH-pyrrol-2-yl)-l;7-naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(lH-pyrrol-3-yl)-l,7-naphthyridine4-[(4-methoxyphenyl)sulfanyl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(5-methyl-lH-pyrazol-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine1- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl] pyrrol idin-2-one4-(l;l-dioxido-l;2-thiazolidin-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphth l-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]piperidin-2-one2- [(3R)-3-methylmorpholin-4-yl]-4-(2-methylpyridin-3-yl)-8-(lH-pyrazol-5-yl)-l,7-naph^2-[(3R)-3-methylmorpholin-4-yl]-4-[2-(propan-2-yloxy)pyridin-3-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(2-methoxypyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(pyridin-4-yl)-l;7-naphthyridine4-[(4-methoxyphenyl)sulfanyl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[3-fluoro-2-(morpholin-4-yl)pyridin-4-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-^yl)-l,7-naphthyridine4-(6-fluoro-5-methylpyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine3- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]-l;3-oxazinan-2-one 3- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]-l;3-oxazolidin-2-one4- (3-methoxypyridin-4-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(2,6-difluoropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(5-chloro-2-fluoropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(3-fluoropyridin-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridm4-(2-chloro-6-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(5;6-dimethylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine4-(5-fluoro-6-methylpyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(5-methylthiophen-3-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(3-methoxythiophen-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(2-chlorothiophen-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(isoquinolin-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(5-chlorothiophen-2-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methylthiophen-2-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(2;5-dimethylthiophen-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-thiopyran-4-yl)-l,7- naphthyridine 2-[(3 )-3-methylmorpholin-4-yl]-4-(l-methyl-l,2,5,6-tetrahydropyridin-3-yl)-8-(lH-pyrazol-5- yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-8-(lH-pyrazol-5- yl)-l,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-methylpiperidin-3-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(l,2,3,6-tetrahydropyridin-4-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-[l-(tetrahydro-2H-pyran-4-yl)-lH- pyrazol-3-yl]-l,7-naphthyridine4-(4,6-difluoropyridin-3-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-lH-pyrazol-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(l,3-dimethyl-lH-pyrazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(l,5-dimethyl-lH-pyrazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(piperidin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-[3-(trifluoromethyl)-lH-pyrazol-4-yl]- 1,7-naphthyridine4-(l-cyclobutyl-lH-pyrazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-(l-cyclopropyl-lH-pyrazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(propan-2-yl)-lH-pyrazol-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine4-[l-(difluoromethyl)-lH-pyrazol-4-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine 4-(l-tert-butyl-lH-pyrazol-4-yl)-2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(l,3,5-trimethyl-lH-pyrazol-4-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl]-8-(lH- pyrazol-5-yl)-l,7-naphthyridine2-(4-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl}-lH-pyrazol-l- yl)ethanol4-(l-ethyl-lH-pyrazol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-methyl-lH-pyrrol-3-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(propan-2-yl)-lH-pyrazol-3-yl]-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-4-(l,2,5-trimethyl-lH-pyrrol-3-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(l-phenyl-lH-pyrazol-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methyl-lH-pyrazol-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-amine2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(2-methylpropyl)-lH-pyrazol-4-yl]-8-(lH-pyrazol-5-yl)- 1,7-naphthyridine2-[(3R)-3-methylmorpholin-4-yl]-4-(lH-pyrazol-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-[(3R)-3-methylmorpholin-4-yl]-4-(l;3-oxazol-2-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(l;3-dimethyl-lH-pyrazol-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(l;5-dimethyl-lH-pyrazol-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(l;3;5-trimethyl-lH-pyrazol-4-yl)-l;7-naphthyridine 4-{[(2-methoxyethyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]- 8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-{[(4-bromophenyl)(oxido)propan-2-yl- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4- yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2- (methyl-N-{2-[(3 )-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl}sulfonimidoyl)phenol4-{[(4-bromophenyl)(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8- (lH-pyrazol-5-yl)-l,7-naphthyridine4-{[tert-butyl(methyl)oxido- 6-sulfanylidene]amino}-2-[(3R)-3-methylmorpholin-4-yl]-8-(lH pyrazol-5-yl)-l,7-naphthyridine formic acid - N-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7^imine 4-oxide (1:1)N-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]hexahydro-l 4-thimine 1-oxide3- methyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}butan 2-ol1- {2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}-l-(tetrahydro^ 2H-pyran-4-yl)ethanol3;3-dimethyl-2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4- yl}butan-2-ol2-{2-[(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl}hexan-2-ol2- [(3R)-3-methylmorpholin-4-yl]-8-(lH-pyrazol-3-yl)-l,7-naphthyridine-4-carboxamide2-[(3R)-3-methylmorpholin-4-yl]-4-[l-(methylsulfonyl)cyclopropyl]-8-(lH-pyrazol-5-yl)-l;7- naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)-l,7-naphthyridine N;N-dimethyl-3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamide{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}(piperidin-l- yl)methanoneN;N-dimethyl-2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamide N-cyclopropyl-4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamide 4-(4-methylpyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(lH-indol-6-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(lH-indol-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine3- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamide4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamideN-methyl-3-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamide4- (3-fluorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(5-chlorothiophen-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(2-methoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[2-(trifluoromethyl)phenyl]-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[4-(trifluoromethyl)phenyl]-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[3-(trifluoromethyl)phenyl]-l;7-naphthyridine 4-(3-chlorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridineN-{3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]phenyl}acetamide 4-(3-methoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(3;5-dimethoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(3-methyl phenyl )-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l,7-naphthyridine4-(4-methoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(furan-2-yl methyl )-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 2;6-dimethyl-4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]phenol 4-(2,3-dimethyl phenyl )-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine {3-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]phenyl}methanol 4-(4-fluorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(4-methyl phenyl )-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l,7-naphthyridine4-(4-chlorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(2-fluoro-3-methoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(2-methylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(2^-dimethoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridineN;N-dimethyl-3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]anilinN;N-dimethyl-2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]anilin N-{2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4- yl] phenyl jmethanesulfonamideN-{4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4- yl] phenyl jmethanesulfonamideN;N-dimethyl-4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]benzamide 2-(morpholin-4-yl)-4-[(lE)-prop-l-en-l-yl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]phenol4-(2-fluorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine{3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]phenyl}(piperidin-l- yl)methanone2-(morpholin-4-yl)-4-[4-(propan-2-yl)phenyl]-8-(lH-pyrazol-5-yl)-l;7-naphthyridineN-cyclopropyl-3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]benzamide 4-(biphenyl-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(2,4-dimethoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(2-chlorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(2;5-dimethylphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 3-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]aniline2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[3-(lH-pyrazol-l-yl)phenyl]-l;7-naphthyridine3- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]phenol4- (2-fluoro-5-methoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 4-(5-fluoro-2-methoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(2,4-difluorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(2,3-difluorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(2,6-dimethoxyphenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]aniline4-(3;5-dichlorophenyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(biphenyl-2-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridine4-(2-chloropyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(l-benzothiophen-2-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridine4-(l-methyl-lH-pyrazol-5-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(quinolin-5-yl)-l,7-naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(pyridin-3-yl)-l,7-naphthyridine4-(2-methoxypyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(5-methylpyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(5-methoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(quinolin-3-yl)-l,7-naphthyridine2-(morpholin-4-yl)-4-[l-(phenylsulfonyl)-lH-indo4-(2-chloropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(6-chloropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine{5-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]thiophen-2-yl}methanol4-(2-fluoropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(6-fluoropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(2-chloro-6-methylpyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(2-methoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(isoquinolin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(3-chloropyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(3-fluoropyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(2;6-difluoropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(l-methyl-lH-pyrazol-4-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridine tert-butyl 5-methoxy-2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]-lH- indole-l-carboxylate2-(morpholin-4-yl)-4-[6-(morpholin-4-yl)pyridin-3-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyrid 4-(4-methylthiophen-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(thiophen-2-yl)-l;7-naphthyridine2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(thiophen-3-yl)-l;7-naphthyridine4-(3-methylthiophen-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin4-(2-chloro-5-methylpyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin 4-(4-methoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(5-chloro-2-methoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine tert-butyl 5-methyl-2-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]-lH-indole-1- carboxylate4-(5-chloro-2-fluoropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 4-(3;5-dimethyl-l;2-oxazol-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(quinolin-8-yl)-l;7-naphthyridine4-(5-methylthiophen-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(6-ethoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4- (2-ethoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(quinolin-6-yl)-l;7-naphthyridine4-(2-chlorothiophen-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine5- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridin-2-amine2-(morpholin-4-yl)-4-(lH-pyrazol-3-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(6-methylpyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(l-methyl-lH-pyrrol-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridin-2-ol4-(5-chloropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-(3-chloro-2-methoxypyridin-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(3-chlorothiophen-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(5-fluoropyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine4-[2-(methylsulfanyl)pyrimidin-5-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridineN-cyclopropyl-5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]pyrimidin-2- amine4-(isoquinolin-5-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridineN-methyl-5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]pyridine-2- carboxamideN-tert-butyl-5-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridine-3- carboxamide4-[5-(methylsulfanyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-(lH-pyrrolo[2;3-b]pyridin-4-yl)-l;7-naphthyridin3- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]pyridin-2-aminemethyl 4-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]thiophene-2- carboxylate4- [2-methoxy-5-(trifluoromethyl)pyridin-3-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7- naphthyridine2-(morpholin-4-yl)-4-[2-(propan-2-yloxy)pyridin-3-yl]-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 4-(5-chloro-6-ethoxypyridin-3-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 4-(l-tert-butyl-lH-pyrazol-4-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine 2-(morpholin-4-yl)-4-(piperidin-l-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridinel-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]piperidin-4-olN-methyl-2-(morpholin-4-yl)-N-phenyl-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-amine{l-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl] pyrrol id in-2-yl}methanol N-methyl-2-(morpholin-4-yl)-N-propyl-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-amine 4-(azepan-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-(3-methylpiperidin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(4-methylpiperidin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine1- [2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]piperidine-3-carboxamide 4-(2;5-dihydro-lH-pyrrol-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridine 4-(3;4-dihydroquinolin-l(2H)-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridm 4-(3;4-dihydroisoquinolin-2(lH)-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyrW 4-(l,3-dihydro-2H-isoindol-2-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine2- (morpholin-4-yl)-8-(lH-pyrazol-5-yl)-4-[l,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl]-l,7- naphthyridinetert-butyl l-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl )-l;7-naphthyridin-4-yl]-prolinateN-methyl-N-(2-methylpropyl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-amineN-(3-fluorophenyl)-N-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-amine4-(l;l-dioxido-l-thia-6-azaspiro[3.3]hept-6-yl)-2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7- naphthyridine4-(3-fluoropiperidin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridineN-(2-fluorophenyl)-N-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-amine l-[2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]-prolinamide{l-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]piperidin-4-yl}methanol4-(4-methoxypiperidin-l-yl)-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridineN-(4-fluorophenyl)-N-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridin-4-amine N-methyl-l-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l;7-naphthyridin-4-yl]-prolinam4-[4-(ethylsulfonyl)piperazin-l-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridine4-[4-(methylsulfonyl)piperazin-l-yl]-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l,7-naphthyridineN-cyclopropyl-N-methyl-2-(morpholin-4-yl)-8-(lH-pyrazol-5-yl)-l;7-naphthyridin-4-amineN-(2,2-dimethylpropyl)-N-methyl-2-(morpholin-4^amine{l-[2-(morpholin-4-yl)-8-( lH-pyrazol-5-yl)-l,7-naphthyridin-4-yl]piperidin-3-yl}methanol4. The compound according to claims 1 or 2 of general formula (lb)(lb) , in which1 represents: wherein * indicates the point of attachment of said group with the rest of the molecule;R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C5-alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloal kenyl, phenyl, heteroaryl, -(CO)OR7, -(CO)N R7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)N R7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10,-SiR10R R12, -(PO)(OR7)2, -(PO)(OR7)R10 or -(PO)(R10)2,wherein each Ci-C5-alkyl, Ci-C5-alkoxy, 3- to 10-membered heterocycloal koxy, C2-C5- alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, -NR7R8, Ci-C5-alkyl optionally substituted with hydroxyl or phenyl, Ci-C5- haloalkyl, Ci-C5-alkoxy, C3-C5-cycloal kyl, 3- to 6-membered heterocycloalkyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, NR8(CO)OR7, -NR8(CO) NR7R8, -(S02)R9, -(SO)R9, -SR9, -(S02)NR7R8, -NR7(S02)R9, -((SO)=NR )R10, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 or with a heteroaryl group which is optionally substituted, one or more times, with Ci-C4-alkyl;wherein each 4- to 10-membered heterocycloal kenyl is optionally substituted, one or more times, indepently from each other, with Ci-C4-alkyl;R3, R4 represent, independently from each other, hydrogen or methyl; R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, C3-C5-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen; orR7 and R8together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from Ci-C6-alkyl, Ci-C6-haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13; R10 represents Ci-C4-alkyl; orR9 and R10together, in case of -N=(SO)R9R10 group, represent a 5- to 8-memberedheterocycloalkyl group;R represents hydrogen, d-C4-alkyl, -(CO)OR7, -(CO)NR7R8 or CN;R12 represents hydrogen or Ci-C -alkyl; R13 represents halogen, OH, -NR7R8, CN, N02, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy, Ci-C6- haloalkoxy, C2-C6-alkenyl, C3-C6-cycloalkyl, -(CO)OR7 or -(CO)N R7R8.5. The compound of general formula (lb) according to claim 4, in which R1 represents: wherein * indicates the point of attachment of said group with the rest of the molecule;R2 represents hydrogen, halogen, -NR7R8, CN, Ci-C6-alkyl, Ci-C -alkoxy, 3- to 10-membered heterocycloalkoxy, C2-C -alkenyl, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, -(CO)NR7R8, -(S02)R9, -(SO)R9,-SR9, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2, wherein each Ci-C5-alkyl, Ci-C4-alkoxy, C3-C5-cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, withhalogen, OH, amino, -N R7R8,Ci-C4-alkyl optionally substituted with hydroxyl or phenyl,Ci-C2-haloalkyl, Ci-C3-alkoxy, C3-C5-cycloalkyl, 3- to 6-membered heterocycloal kyl, phenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, -NR8(CO)OR7, -(S02)R9, -SR9,-N R7(SO2)R9, -((SO)=NR )R10, -(PO)(OR7)2, -(PO)(OR7)R10, or with a heteroaryl group;wherein each 4- to 10-membered heterocycloal kenyl is optionally substituted, one or more times, independently from each other, with methyl;R4 represents hydrogen or methyl;R7, R8 represent, independently from each other, hydrogen, Ci-C6-alkyl, C3-C5-cycloalkyl or phenyl, which phenyl is optionally substituted, one or more times, with halogen; R9 represents Ci-C4-alkyl or phenyl, wherein each Ci-C4-alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R13;R10 represents Ci-C -alkyl; orR9 and R10 together, in case of -N=(SO)R9R10 group, represent a 5- to 8-memberedheterocycloalkyl group; R represents hydrogen, Ci-C -alkyl, -(CO)OR7, -(CO)NR7R8 or CN;R13 represents halogen, OH or Ci-C5-alkoxy.6. The compound of general formula (lb) according to claims 4 or 5, in which R1 represents: wherein * indicates the point of attachment of said group with the rest of the molecule; represents hydrogen, chloro,-amino, propylamino, dimethylamino, methyl(propyl)amino, methyl(2-methyl propyl (amino, 2,2-dimethyl propyl (methyl (amino,cyclopropyl(methyl)amino, methyl(phenyl)amino, CN, methyl, ethyl, propan-2-yl, 3- methylbutan-2-yl, pentan-3-yl, hexan-2-yl, 3,3-dimethylbutan-2-yl, methoxy, ethoxy, propoxy, butoxy, 2-methyl-propan-l-yloxy, propan-2-yloxy,(2-oxotetrahydrofuran-3-yl)oxy, propenyl, cyclopropyl, cyclohexyl, azetidinyl,-pyrrolidinyl,2- oxo-l,3-oxazolidin-2-one, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 2-oxo-pyrrolidin-l-yl, 2-oxo-piperidin-l-yl,3- oxo-piperazin-l-yl, 2-oxo-l,3-oxazinan-3-yl, l-oxidotetrahydro-2H-thiopyran-4-yl, l,l-dioxidotetrahydro-2H-thiopyran-4-yl, l,l-dioxido-l,2-thiazolidin-2-yl,5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl, 3-oxa-8-azabicyclo[3.2.1]oct-8-yl, l,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl,(3a ,6aS)-tetrahydro-lH-furo[3,4-c]pyrrol-5(3H)-yl,(lS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, l,l-dioxido-l-thia-6-azaspiro[3.3]hept-6-yl72.5- dihydro-lH-pyrrol-l-yl, 3,6-dihydro-2H-pyran-4-yl,l,2,5,6-tetrahydropyridin-3-yl, l,2,3,6-tetrahydropyridin-4-yl,3.6- dihydro-2H-thiopyran-4-yl, phenyl, l,3-dihydro-2H-isoindol-2-yl, 3,4-dihydroquinolin- l(2H)-yl, 3,4-dihydroisoquinolin-2(lH)-yl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, 2-oxo-l,2-dihydropyridin-4- yl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, lH-pyrrolo[2,3-b]pyridin-4-yl,6.7- dihydro-5H-pyrrolo[l,2-a]imidazol-3-yl, -(CO)NH2, methylsulfonyl, ethylsulfonyl, propan-2-ylsulfonyl, phenylsulfonyl, methylsulfinyl, ethylsulfinyl, propan-2-ylsulfinyl, phenylsulfinyl, methylsulfanyl, ethylsulfanyl, propan-2-ylsulfanyl, phenylsulfanyl, -N=(SO)dimethyl, -N=(SO)diethyl,wherein * indicates the point of attachment of said group with the rest of the molecule, HPO)(0-methyl)2HPO)(0-ethyl)methyl, -(PO)(0-2-methylpropyl)methyl,-(PO)(0-ethyl)2-methylpropyl, -(PO)dimethyl, -(PO)diethyl,wherein each methyl, ethyl, propan-2-yl, 3-methylbutan-2-yl, pentan-3-yl, hexan-2-yl, 3,3-dimethylbutan-2-yl, methoxy, ethoxy, propoxy, 2-methyl-propan-l-yloxy, butoxy, cyclopropyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,3-oxo-piperazin-l-yl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, indolyl,is optionally substituted, one or more times, independently from each other, with fluoro, chloro, bromo, OH, amino, -NH-cyclopropyl, dimethylamino, methyl, ethyl, propan-l-yl, propan-2-yl, 2-methylpropyl, ieri-butyl, hydroxymethyl, 2-hydroxyethyl, 2-methyl-2-hydroxypropan-l-yl, 2-hydroxypropan-2-yl, benzyl, fluoroethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, isopropoxy, methoxymethyl, cyclopropyl, cyclobutyl , tetrahydrofuranyl, tetrahydropyranyl, phenyl, -(CO)O-methyl, (CO)O-iert-butyl, -(CO)NH2, -(CO)NH-methyl,-(CO)NH-iert-butyl, -(CO)dimethylamino, -(CO)piperidin-l-yl, -(CO)NH-cyclopropyl, -NH(CO)methyl, -NH(CO)0-tert-butyl, methylsulfonyl, ethylsulfonyl, propan-2-ylsulfonyl, phenylsulfonyl, methylsulfanyl, -(S02)NR7R8, NH(S02)methyl,-((SO)=NH)methyl, -((SO)=NH)ethyl, -((SO)=NH)propan-2-yl, -((SO)=N-methyl)methyl, -((SO)=N-(CO)0-ethyl)methyl, -((SO)=N-(CN))methyl, -((SO)=N-(CO)NH-ethyl)methyl, -(PO)(0-methyl)2,-(PO)(OH)(0-methyl) or with furanyl, pyrazolyl,wherein each l,2,5,6-tetrahydropyridin-3-yl, l,2,3,6-tetrahydropyridin-4-yl is optionally substituted, one or more times, independently from each other, with methyl; presents hydrogen or methyl.7. The compound of general formula (lb) according to any one of claims 4 to 6, in which 1 represents: wherein * indicates the point of attachment of said group with the rest of the molecule; represents 2,2-dimethylpropyl (methyl (amino, cyclopropyl( methyl (amino,methyl(phenyl)amino, 3-methylbutan-2-yl, cyclopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidinyl, piperazinyl, 5,6-dihydroimidazo[l,2-a]pyrazin- 7(8H)-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyridinyl, lH-pyrrolo[2,3-b]pyridin-4-yl or 6,7-dihydro-5H-pyrrolo[l,2- a]imidazol-3-yl,wherein each 3-methylbutan-2-yl, cyclopropyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl or pyridinyl is optionally substituted, one or two or three times, independently from each other, withfluoro, chloro, OH, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, hydroxymethyl, benzyl, fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, -(CO)O-methyl, methylsulfonyl, methylsulfanyl, -((SO)=NH)methyl;represents methyl.8. The compound of general formula (lb) according to any one of claims 4 to 7, in which R1 represents: wherein * indicates the point of attachment of said group with the rest of the molecule; represents tetrahydro-2H-thiopyran-4-yl, piperidinyl, 5,6-dihydroimidazo[l,2-a]pyrazin 7(8H)-yl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, pyridinyl or 6,7-dihydro-5H-pyrrolo[l,2- a]imidazol-3-yl, wherein each piperidinyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl or pyridinyl is optionally substituted, one or two times, independently from each other, withfluoro, amino, methyl, ethyl, propan-2-yl, hydroxymethyl, methoxy, cyclopropyl, methylsulfonyl, methylsulfanyl, -((SO)=NH)methyl;represents methyl.compound of general formula (lb) according to any one of claims 4 to 7, in which represents: wherein * indicates the point of attachment of said group with the rest of the molecule;R2 represents 2,2-dimethylpropyl(methyl)amino, cyclopropyl(methyl)amino,methyl(phenyl)amino, 3-methylbutan-2-yl, cyclopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyran-4-yl, piperidin-4-yl, piperazin-l-yl, 5,6-dihydroimidazo[l,2- a]pyrazin-7(8H)-yl, 3,6-dihydro-2H-thiopyran-4-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, 1H- pyrazol-4-yl, thiophen-2-yl, thiophen-3-yl, lH-imidazol-5-yl, l,2-oxazol-5-yl, l,3-thiazol-5- yl, pyridine-3-yl, pyridine-4-yl, lH-pyrrolo[2,3-b]pyridin-4-yl or 6,7-dihydro-5H- pyrrolo[l,2-a]imidazol-3-yl,wherein each 3-methylbutan-2-yl, cyclopropyl, piperidin-4-yl, piperazin-l-yl, phenyl, pyrrol-2-yl, lH-pyrazol-5-yl, lH-pyrazol-4-yl, thiophen-2-yl, thiophen-3-yl, lH-imidazol-5-yl, l,2-oxazol-5-yl, l,3-thiazol-5-yl, pyridine-3-yl or pyridine-4-yl is optionally substituted, one or two or three times, independently from each other, withfluoro, chloro, OH, amino, methyl, ethyl, propan-l-yl, propan-2-yl, ieri-butyl, hydoxymethyl, benzyl, 2-fluoroethyl, trifluoromethyl, methoxy, cyclopropyl, -(CO)O-methyl, methylsulfonyl, methylsulfanyl or -((SO)=NH)methyl;R4 represents methyl.10. The compound of general formula (I) or (lb) according to any one of claims 1 to 9 for use in the treatment or prophylaxis of a disease.11. Use of the compound of general formula (I) or (lb) according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment or prophylaxis of a disease.12. A pharmaceutical composition comprising the com pound of general formula (I) or (lb) according to any one of claims 1 to 9 and one or more pharmaceutically acceptable excipient(s).13. The pharmaceutical composition according to claim 12 for use in the treatment or prophylaxis of a hyperproliferative disease.14. A pharmaceutical combination comprising:one or more active ingredient(s) selected from a compound of general formula (I) or (lb) according to any one of claims 1 to 9, and- one or more active ingredient(s) selected from antihyperproliferative, cytostatic or cytotoxic substances for treatment of cancers.15. A compound of general formula 88 in which 1, R3 and R4 are as defined for the compound of general formula (I) or(l b) according to any one of claims 1 to 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019204125A AU2019204125B2 (en) | 2014-08-04 | 2019-06-13 | 2-(Morpholin-4-yl)-1,7-naphthyridines |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14179692.0 | 2014-08-04 | ||
EP14179692 | 2014-08-04 | ||
EP15159342.3 | 2015-03-17 | ||
EP15159342 | 2015-03-17 | ||
PCT/EP2015/067804 WO2016020320A1 (en) | 2014-08-04 | 2015-08-03 | 2-(morpholin-4-yl)-l,7-naphthyridines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019204125A Division AU2019204125B2 (en) | 2014-08-04 | 2019-06-13 | 2-(Morpholin-4-yl)-1,7-naphthyridines |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015299173A1 true AU2015299173A1 (en) | 2017-02-09 |
AU2015299173B2 AU2015299173B2 (en) | 2019-03-14 |
Family
ID=53762196
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015299173A Active AU2015299173B2 (en) | 2014-08-04 | 2015-08-03 | 2-(morpholin-4-yl)-l,7-naphthyridines |
AU2019204125A Active AU2019204125B2 (en) | 2014-08-04 | 2019-06-13 | 2-(Morpholin-4-yl)-1,7-naphthyridines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019204125A Active AU2019204125B2 (en) | 2014-08-04 | 2019-06-13 | 2-(Morpholin-4-yl)-1,7-naphthyridines |
Country Status (43)
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170076A (en) | 2014-08-04 | 2017-06-26 | Nuevolution As | PIRIMIDIMA DERIVATIVES REPLACED WITH OPTIONALLY CONDENSED HETEROCICLYL USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND SELF-IMMUNITY DISEASES |
TWI700283B (en) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridines |
EP3402795B1 (en) * | 2016-01-14 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
UY37616A (en) | 2017-02-24 | 2018-09-28 | Bayer Ag | COMBINATION OF QUINASA ATR INHIBITORS WITH RADIO SALT-223 |
WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
US20200016283A1 (en) | 2017-02-24 | 2020-01-16 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
JOP20190197A1 (en) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease |
WO2018153973A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors with parp inhibitors |
WO2018153971A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
US10421765B2 (en) | 2017-05-26 | 2019-09-24 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase |
PT3651768T (en) | 2017-07-13 | 2024-03-20 | Univ Texas | Heterocyclic inhibitors of atr kinase |
JOP20200024A1 (en) * | 2017-08-04 | 2020-02-02 | Bayer Ag | Dihydrooxadiazinones |
CA3071760A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
CA3071795A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
EP3668839B1 (en) | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
WO2019057852A1 (en) | 2017-09-22 | 2019-03-28 | Bayer Aktiengesellschaft | Use of kap1 as a biomarker for detecting or monitoring atr inhibition in a subject |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
EP3720973A1 (en) * | 2017-12-08 | 2020-10-14 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
EP3753937B1 (en) | 2018-02-07 | 2024-01-10 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Atr inhibitor and application thereof |
EP3765008B1 (en) * | 2018-03-16 | 2023-06-07 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
MX2021002132A (en) * | 2018-08-24 | 2021-04-28 | Bayer Ag | Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl- 1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine. |
US20210369724A1 (en) * | 2018-10-16 | 2021-12-02 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
JP2022510501A (en) * | 2018-10-30 | 2022-01-26 | リペア セラピューティクス インコーポレイテッド | Compounds, pharmaceutical compositions, and methods of preparing compounds and their use as ATR kinase inhibitors. |
JOP20210215A1 (en) | 2019-02-11 | 2023-01-30 | Bayer Ag | The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease |
CN112142744A (en) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and uses thereof |
CN114174292A (en) * | 2019-07-22 | 2022-03-11 | 修复治疗公司 | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
US20230018728A1 (en) * | 2019-11-21 | 2023-01-19 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof |
EP4072551A4 (en) * | 2019-12-11 | 2023-11-15 | Repare Therapeutics Inc. | Use of atr inhibitors in combination with parp inhibitors |
MX2022007265A (en) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compounds active towards nuclear receptors. |
CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
JP2023532303A (en) * | 2020-07-03 | 2023-07-27 | アンテンジーン・ディスカバリー・リミテッド | ATR inhibitors and uses thereof |
IL299804A (en) * | 2020-07-13 | 2023-03-01 | Beijing Tide Pharmaceutical Co Ltd | Pyrazolopyrimidine compound used as atr kinase inhibitor |
CN112110934B (en) * | 2020-09-23 | 2021-12-07 | 上海应用技术大学 | AZD 9291-based biomarker and preparation method and application thereof |
US20240043419A1 (en) * | 2020-09-27 | 2024-02-08 | Medshine Discovery Inc. | Class of 1,7-naphthyridine compounds and application thereof |
EP4267581A1 (en) * | 2020-12-25 | 2023-11-01 | Impact Therapeutics (Shanghai), Inc | Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof |
CA3219001A1 (en) * | 2021-05-21 | 2022-11-24 | Jiaqi YAO | Pharmaceutically acceptable salt of pyrazoloheteroaryl derivative and crystal form thereof |
IL310412A (en) | 2021-07-27 | 2024-03-01 | Littdd Medicines Ltd | 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof |
AU2022325376A1 (en) * | 2021-08-11 | 2024-02-22 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Naphthyridine derivative as atr inhibitor and method for preparing same |
CN116731011A (en) * | 2022-03-01 | 2023-09-12 | 武汉众诚康健生物医药科技有限公司 | Naphthyridine derivative and application thereof |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
US4008068A (en) * | 1976-03-08 | 1977-02-15 | Velsicol Chemical Corporation | 1-Thiadiazolyl-5-morpholinoimidazolidinones |
AU4007900A (en) | 1999-03-11 | 2000-10-16 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
DE10349423A1 (en) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP5161102B2 (en) * | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | Pyridopyrimidine, pyrazopyrimidine and pyrimidopyrimidine derivatives as mTOR inhibitors |
DE102005062742A1 (en) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases |
EP1803723A1 (en) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
ES2301380B1 (en) * | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF 1,7-NAFTIRIDINE. |
PL2057156T3 (en) * | 2006-08-23 | 2017-08-31 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
AU2009289316A1 (en) * | 2008-09-02 | 2010-03-11 | Novartis Ag | Bicyclic kinase inhibitors |
EP2344490A2 (en) * | 2008-10-03 | 2011-07-20 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k |
EP2370424A1 (en) | 2008-11-10 | 2011-10-05 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US20100144345A1 (en) | 2008-12-09 | 2010-06-10 | Microsoft Corporation | Using called party mobile presence and movement in communication application |
RU2604066C2 (en) | 2008-12-19 | 2016-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Pyrazine derivatives used as atr kinase inhibitors |
TW201028410A (en) * | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2012013082A (en) | 2010-05-12 | 2013-05-09 | Vertex Pharma | 2 -aminopyridine derivatives useful as inhibitors of atr kinase. |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2013526539A (en) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrazines useful as ATR kinase inhibitors |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2013526538A (en) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl Compounds for Use as ATR Inhibitors |
EP2585468A1 (en) * | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
AU2011272862A1 (en) * | 2010-06-30 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
AU2012240030A1 (en) | 2011-04-05 | 2013-10-24 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of TRA kinase |
JP2014517079A (en) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CN103957917A (en) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
EP2751099B1 (en) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
RS56673B1 (en) | 2012-04-05 | 2018-03-30 | Vertex Pharma | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SI3808749T1 (en) | 2012-12-07 | 2023-07-31 | Vertex Pharmaceuticals Incorporated | Pyrazolo(1,5-a)pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
WO2014109414A1 (en) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | Nitrogen-containing heterocylic compound or salt thereof |
JP2016512815A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase |
TWI700283B (en) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridines |
EP3402795B1 (en) * | 2016-01-14 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
WO2018153971A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors |
WO2018153973A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors with parp inhibitors |
WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
UY37616A (en) | 2017-02-24 | 2018-09-28 | Bayer Ag | COMBINATION OF QUINASA ATR INHIBITORS WITH RADIO SALT-223 |
US20200016283A1 (en) | 2017-02-24 | 2020-01-16 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
JOP20190197A1 (en) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
PL3646093T3 (en) | 2017-06-28 | 2022-04-19 | Corning Research & Development Corporation | Multifiber fiber optic connectors, cable assemblies and methods of making the same |
CA3071760A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
EP3720973A1 (en) | 2017-12-08 | 2020-10-14 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
MX2021002132A (en) | 2018-08-24 | 2021-04-28 | Bayer Ag | Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl- 1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine. |
WO2020073034A1 (en) | 2018-10-05 | 2020-04-09 | Isp Investments Llc | Smooth high solids film coating composition comprising water soluble cellulose ether, process for preparing the same |
US20210369724A1 (en) | 2018-10-16 | 2021-12-02 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
JOP20210215A1 (en) | 2019-02-11 | 2023-01-30 | Bayer Ag | The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease |
-
2015
- 2015-07-30 TW TW108109148A patent/TWI700283B/en active
- 2015-07-30 TW TW104124794A patent/TWI656121B/en active
- 2015-08-02 JO JOP/2015/0186A patent/JO3447B1/en active
- 2015-08-03 SG SG11201700750UA patent/SG11201700750UA/en unknown
- 2015-08-03 PT PT157445966T patent/PT3177619T/en unknown
- 2015-08-03 CN CN201580053572.9A patent/CN106795156B/en active Active
- 2015-08-03 CA CA2956992A patent/CA2956992A1/en active Pending
- 2015-08-03 CU CU2017000009A patent/CU24419B1/en unknown
- 2015-08-03 ES ES15744596.6T patent/ES2679625T3/en active Active
- 2015-08-03 NZ NZ765780A patent/NZ765780A/en unknown
- 2015-08-03 PL PL18167649T patent/PL3395818T3/en unknown
- 2015-08-03 ES ES18167649T patent/ES2900599T3/en active Active
- 2015-08-03 HU HUE15744596A patent/HUE038533T2/en unknown
- 2015-08-03 US US15/501,079 patent/US9993484B2/en active Active
- 2015-08-03 CN CN201910654243.XA patent/CN110204544B/en active Active
- 2015-08-03 EP EP15744596.6A patent/EP3177619B1/en active Active
- 2015-08-03 MA MA40523A patent/MA40523B1/en unknown
- 2015-08-03 UA UAA201702047A patent/UA121036C2/en unknown
- 2015-08-03 LT LTEP15744596.6T patent/LT3177619T/en unknown
- 2015-08-03 TN TN2017000027A patent/TN2017000027A1/en unknown
- 2015-08-03 MX MX2017001637A patent/MX2017001637A/en active IP Right Grant
- 2015-08-03 JP JP2017506353A patent/JP6266839B2/en active Active
- 2015-08-03 BR BR112017002221-4A patent/BR112017002221B1/en active IP Right Grant
- 2015-08-03 EA EA201790306A patent/EA031678B1/en not_active IP Right Cessation
- 2015-08-03 RS RS20180844A patent/RS57445B1/en unknown
- 2015-08-03 MY MYPI2017700348A patent/MY192883A/en unknown
- 2015-08-03 EP EP18167649.5A patent/EP3395818B1/en active Active
- 2015-08-03 PL PL15744596T patent/PL3177619T3/en unknown
- 2015-08-03 MX MX2020010333A patent/MX2020010333A/en unknown
- 2015-08-03 HU HUE18167649A patent/HUE056676T2/en unknown
- 2015-08-03 DK DK18167649.5T patent/DK3395818T3/en active
- 2015-08-03 AU AU2015299173A patent/AU2015299173B2/en active Active
- 2015-08-03 RS RS20211453A patent/RS62609B1/en unknown
- 2015-08-03 DK DK15744596.6T patent/DK3177619T3/en active
- 2015-08-03 KR KR1020177005715A patent/KR102180006B1/en active IP Right Grant
- 2015-08-03 UA UAA201909822A patent/UA123928C2/en unknown
- 2015-08-03 PE PE2017000168A patent/PE20170666A1/en unknown
- 2015-08-03 AP AP2017009702A patent/AP2017009702A0/en unknown
- 2015-08-03 KR KR1020207032608A patent/KR102317169B1/en active IP Right Grant
- 2015-08-03 LT LTEP18167649.5T patent/LT3395818T/en unknown
- 2015-08-03 CN CN201910654241.0A patent/CN110256427B/en active Active
- 2015-08-03 EA EA201891861A patent/EA035039B1/en not_active IP Right Cessation
- 2015-08-03 HR HRP20211770TT patent/HRP20211770T1/en unknown
- 2015-08-03 SI SI201530327T patent/SI3177619T1/en unknown
- 2015-08-03 CR CR20170034A patent/CR20170034A/en unknown
- 2015-08-03 WO PCT/EP2015/067804 patent/WO2016020320A1/en active Application Filing
- 2015-08-03 SI SI201531743T patent/SI3395818T1/en unknown
- 2015-08-04 UY UY0001036254A patent/UY36254A/en active IP Right Grant
-
2016
- 2016-05-19 US US15/159,548 patent/US9549932B2/en active Active
-
2017
- 2017-01-22 IL IL250220A patent/IL250220B/en active IP Right Grant
- 2017-02-01 SA SA517380830A patent/SA517380830B1/en unknown
- 2017-02-02 PH PH12017500204A patent/PH12017500204A1/en unknown
- 2017-02-03 EC ECIEPI20177538A patent/ECSP17007538A/en unknown
- 2017-02-03 DO DO2017000038A patent/DOP2017000038A/en unknown
- 2017-02-03 NI NI201700011A patent/NI201700011A/en unknown
- 2017-02-03 CO CONC2017/0001035A patent/CO2017001035A2/en unknown
- 2017-02-03 CL CL2017000287A patent/CL2017000287A1/en unknown
- 2017-12-19 JP JP2017242618A patent/JP6507216B2/en active Active
-
2018
- 2018-05-08 US US15/974,536 patent/US10772893B2/en active Active
- 2018-07-18 HR HRP20181143TT patent/HRP20181143T1/en unknown
- 2018-07-24 CY CY181100768T patent/CY1120673T1/en unknown
-
2019
- 2019-06-13 AU AU2019204125A patent/AU2019204125B2/en active Active
- 2019-08-27 IL IL268969A patent/IL268969B/en active IP Right Grant
-
2020
- 2020-08-21 US US16/999,832 patent/US11529356B2/en active Active
-
2021
- 2021-02-15 ZA ZA2021/01003A patent/ZA202101003B/en unknown
- 2021-04-10 PH PH12021550792A patent/PH12021550792A1/en unknown
- 2021-12-09 CY CY20211101085T patent/CY1124855T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019204125B2 (en) | 2-(Morpholin-4-yl)-1,7-naphthyridines | |
EP3402795B1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
AU2015299173A1 (en) | 2-(morpholin-4-yl)-l,7-naphthyridines | |
EP4188930A1 (en) | Substituted heterocyclic compounds and therapeutic uses thereof | |
NZ728416B2 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines |